0001493152-23-042131.txt : 20231120 0001493152-23-042131.hdr.sgml : 20231120 20231120164421 ACCESSION NUMBER: 0001493152-23-042131 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231120 DATE AS OF CHANGE: 20231120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRESSURE BIOSCIENCES INC CENTRAL INDEX KEY: 0000830656 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 042652826 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38185 FILM NUMBER: 231423326 BUSINESS ADDRESS: STREET 1: 14 NORFOLK AVENUE CITY: SOUTH EASTON STATE: MA ZIP: 02375 BUSINESS PHONE: 5082301828 MAIL ADDRESS: STREET 1: 14 NORFOLK AVENUE CITY: SOUTH EASTON STATE: MA ZIP: 02375 FORMER COMPANY: FORMER CONFORMED NAME: BOSTON BIOMEDICA INC DATE OF NAME CHANGE: 19960812 10-Q 1 form10-q.htm
false --12-31 Q3 0000830656 http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember 0000830656 2023-01-01 2023-09-30 0000830656 2023-11-10 0000830656 2023-09-30 0000830656 2022-12-31 0000830656 us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2022-12-31 0000830656 us-gaap:RelatedPartyMember 2023-09-30 0000830656 us-gaap:RelatedPartyMember 2022-12-31 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesH2ConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesH2ConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2022-12-31 0000830656 2023-07-01 2023-09-30 0000830656 2022-07-01 2022-09-30 0000830656 2022-01-01 2022-09-30 0000830656 2021-12-31 0000830656 2022-09-30 0000830656 us-gaap:PreferredStockMember 2022-12-31 0000830656 us-gaap:CommonStockMember 2022-12-31 0000830656 us-gaap:WarrantMember 2022-12-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000830656 us-gaap:RetainedEarningsMember 2022-12-31 0000830656 us-gaap:PreferredStockMember 2023-03-31 0000830656 us-gaap:CommonStockMember 2023-03-31 0000830656 us-gaap:WarrantMember 2023-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000830656 us-gaap:RetainedEarningsMember 2023-03-31 0000830656 2023-03-31 0000830656 us-gaap:PreferredStockMember 2023-06-30 0000830656 us-gaap:CommonStockMember 2023-06-30 0000830656 us-gaap:WarrantMember 2023-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000830656 us-gaap:RetainedEarningsMember 2023-06-30 0000830656 2023-06-30 0000830656 us-gaap:PreferredStockMember 2021-12-31 0000830656 us-gaap:CommonStockMember 2021-12-31 0000830656 us-gaap:WarrantMember 2021-12-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000830656 us-gaap:RetainedEarningsMember 2021-12-31 0000830656 us-gaap:PreferredStockMember 2022-03-31 0000830656 us-gaap:CommonStockMember 2022-03-31 0000830656 us-gaap:WarrantMember 2022-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000830656 us-gaap:RetainedEarningsMember 2022-03-31 0000830656 2022-03-31 0000830656 us-gaap:PreferredStockMember 2022-06-30 0000830656 us-gaap:CommonStockMember 2022-06-30 0000830656 us-gaap:WarrantMember 2022-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000830656 us-gaap:RetainedEarningsMember 2022-06-30 0000830656 2022-06-30 0000830656 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000830656 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000830656 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000830656 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000830656 2023-01-01 2023-03-31 0000830656 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000830656 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000830656 us-gaap:WarrantMember 2023-04-01 2023-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000830656 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000830656 2023-04-01 2023-06-30 0000830656 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000830656 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000830656 us-gaap:WarrantMember 2023-07-01 2023-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000830656 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000830656 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000830656 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000830656 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000830656 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000830656 2022-01-01 2022-03-31 0000830656 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000830656 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000830656 us-gaap:WarrantMember 2022-04-01 2022-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000830656 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000830656 2022-04-01 2022-06-30 0000830656 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000830656 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000830656 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000830656 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000830656 us-gaap:PreferredStockMember 2023-09-30 0000830656 us-gaap:CommonStockMember 2023-09-30 0000830656 us-gaap:WarrantMember 2023-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000830656 us-gaap:RetainedEarningsMember 2023-09-30 0000830656 us-gaap:PreferredStockMember 2022-09-30 0000830656 us-gaap:CommonStockMember 2022-09-30 0000830656 us-gaap:WarrantMember 2022-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000830656 us-gaap:RetainedEarningsMember 2022-09-30 0000830656 2020-08-30 0000830656 PBIO:NexityGlobalSAMember 2023-01-01 2023-09-30 0000830656 PBIO:NexityGlobalSAMember 2023-09-30 0000830656 srt:MinimumMember 2023-09-30 0000830656 srt:MaximumMember 2023-09-30 0000830656 srt:NorthAmericaMember 2023-07-01 2023-09-30 0000830656 srt:NorthAmericaMember 2022-07-01 2022-09-30 0000830656 srt:NorthAmericaMember 2023-01-01 2023-09-30 0000830656 srt:NorthAmericaMember 2022-01-01 2022-09-30 0000830656 srt:EuropeMember 2023-07-01 2023-09-30 0000830656 srt:EuropeMember 2022-07-01 2022-09-30 0000830656 srt:EuropeMember 2023-01-01 2023-09-30 0000830656 srt:EuropeMember 2022-01-01 2022-09-30 0000830656 srt:AsiaMember 2023-07-01 2023-09-30 0000830656 srt:AsiaMember 2022-07-01 2022-09-30 0000830656 srt:AsiaMember 2023-01-01 2023-09-30 0000830656 srt:AsiaMember 2022-01-01 2022-09-30 0000830656 PBIO:HardwareMember 2023-07-01 2023-09-30 0000830656 PBIO:HardwareMember 2022-07-01 2022-09-30 0000830656 PBIO:HardwareMember 2023-01-01 2023-09-30 0000830656 PBIO:HardwareMember 2022-01-01 2022-09-30 0000830656 PBIO:ConsumablesMember 2023-07-01 2023-09-30 0000830656 PBIO:ConsumablesMember 2022-07-01 2022-09-30 0000830656 PBIO:ConsumablesMember 2023-01-01 2023-09-30 0000830656 PBIO:ConsumablesMember 2022-01-01 2022-09-30 0000830656 PBIO:ContractResearchServicesMember 2023-07-01 2023-09-30 0000830656 PBIO:ContractResearchServicesMember 2022-07-01 2022-09-30 0000830656 PBIO:ContractResearchServicesMember 2023-01-01 2023-09-30 0000830656 PBIO:ContractResearchServicesMember 2022-01-01 2022-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2023-07-01 2023-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2022-07-01 2022-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2023-01-01 2023-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2022-01-01 2022-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2023-07-01 2023-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2022-07-01 2022-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2023-01-01 2023-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2022-01-01 2022-09-30 0000830656 PBIO:AgrochemProductsMember 2023-07-01 2023-09-30 0000830656 PBIO:AgrochemProductsMember 2022-07-01 2022-09-30 0000830656 PBIO:AgrochemProductsMember 2023-01-01 2023-09-30 0000830656 PBIO:AgrochemProductsMember 2022-01-01 2022-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2023-07-01 2023-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2022-07-01 2022-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2023-01-01 2023-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2022-01-01 2022-09-30 0000830656 PBIO:OtherMember 2023-07-01 2023-09-30 0000830656 PBIO:OtherMember 2022-07-01 2022-09-30 0000830656 PBIO:OtherMember 2023-01-01 2023-09-30 0000830656 PBIO:OtherMember 2022-01-01 2022-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2023-07-01 2023-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2022-07-01 2022-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2023-01-01 2023-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2022-01-01 2022-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2023-07-01 2023-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2022-07-01 2022-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2023-01-01 2023-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2022-01-01 2022-09-30 0000830656 PBIO:TwoThousandAndTwentyThreeMember 2023-09-30 0000830656 PBIO:TwoThousandAndTwentyFourMember 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000830656 PBIO:FederalAgenciesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000830656 PBIO:EmployeeStockOptionsMember 2023-01-01 2023-09-30 0000830656 PBIO:EmployeeStockOptionsMember 2022-01-01 2022-09-30 0000830656 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0000830656 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-09-30 0000830656 PBIO:CommonStockWarrantsMember 2023-01-01 2023-09-30 0000830656 PBIO:CommonStockWarrantsMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesHTwoConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesHTwoConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:EmployeesOfficersMember 2023-01-01 2023-09-30 0000830656 PBIO:EmployeesOfficersMember srt:MinimumMember 2023-01-01 2023-09-30 0000830656 PBIO:EmployeesOfficersMember srt:MaximumMember 2023-01-01 2023-09-30 0000830656 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000830656 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000830656 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000830656 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0000830656 us-gaap:EquitySecuritiesMember 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0000830656 us-gaap:FairValueInputsLevel1Member 2023-09-30 0000830656 us-gaap:FairValueInputsLevel2Member 2023-09-30 0000830656 us-gaap:FairValueInputsLevel3Member 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember 2022-12-31 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0000830656 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000830656 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000830656 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000830656 PBIO:CorporateOfficeMember 2023-01-01 2023-09-30 0000830656 PBIO:MedfordLeaseMember 2023-01-01 2023-09-30 0000830656 PBIO:MedfordLeaseMember 2023-09-30 0000830656 PBIO:SparksLeaseMember 2021-08-08 2021-08-09 0000830656 PBIO:SparksLeaseMember 2023-09-30 0000830656 PBIO:BattelleMemorialInstituteMember 2014-01-01 2014-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2015-01-01 2015-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2016-01-01 2016-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2017-01-01 2017-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2018-01-01 2018-12-31 0000830656 PBIO:TargetDiscoveryIncMember 2012-04-01 2012-04-30 0000830656 PBIO:TargetDiscoveryIncMember 2022-01-01 2022-09-30 0000830656 PBIO:TargetDiscoveryIncMember 2023-01-01 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 srt:MinimumMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 srt:MaximumMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 srt:MinimumMember us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 srt:MaximumMember us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 us-gaap:ConvertibleCommonStockMember us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 PBIO:PBIAgrochemIncMember 2023-09-30 0000830656 PBIO:ThreeLendersMember 2023-01-01 2023-09-30 0000830656 PBIO:ThreeLendersMember PBIO:ForbearanceAgreementsMember 2023-01-01 2023-09-30 0000830656 PBIO:FourLendersMember PBIO:ForbearanceAgreementsMember 2023-09-30 0000830656 PBIO:NewLoanMember 2023-09-30 0000830656 PBIO:NewLoanMember 2023-01-01 2023-09-30 0000830656 PBIO:TenLoansMember 2023-01-01 2023-09-30 0000830656 us-gaap:CommonStockMember PBIO:TenLoansMember 2023-01-01 2023-09-30 0000830656 us-gaap:PreferredStockMember PBIO:TenLoansMember 2023-01-01 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember 2023-01-01 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember srt:MinimumMember 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember srt:MaximumMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember 2022-12-31 0000830656 us-gaap:InvestorMember 2023-01-01 2023-09-30 0000830656 us-gaap:InvestorMember 2023-09-30 0000830656 us-gaap:InvestorMember 2022-01-01 2022-12-31 0000830656 us-gaap:InvestorMember 2022-12-31 0000830656 PBIO:OthersMember srt:MinimumMember 2023-01-01 2023-09-30 0000830656 PBIO:OthersMember srt:MaximumMember 2023-01-01 2023-09-30 0000830656 PBIO:OthersMember srt:MinimumMember 2023-09-30 0000830656 PBIO:OthersMember srt:MaximumMember 2023-09-30 0000830656 PBIO:OthersMember 2023-09-30 0000830656 PBIO:OthersMember srt:MinimumMember 2022-01-01 2022-12-31 0000830656 PBIO:OthersMember srt:MaximumMember 2022-01-01 2022-12-31 0000830656 PBIO:OthersMember srt:MinimumMember 2022-12-31 0000830656 PBIO:OthersMember srt:MaximumMember 2022-12-31 0000830656 PBIO:OthersMember 2022-12-31 0000830656 us-gaap:ConvertibleDebtMember PBIO:FiveDayAverageVWAPMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember PBIO:SeriesAAPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtOneMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtTwoMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtThreeMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtFourMember 2023-01-01 2023-09-30 0000830656 srt:ChiefExecutiveOfficerMember 2023-09-30 0000830656 PBIO:NonConvertibleLoansMember 2023-09-30 0000830656 PBIO:NonConvertibleLoansMember 2022-12-31 0000830656 PBIO:MerchantDebtMember 2023-09-30 0000830656 PBIO:MerchantDebtMember 2022-12-31 0000830656 PBIO:SBAMember 2023-09-30 0000830656 PBIO:SBAMember 2022-12-31 0000830656 PBIO:PayrollProtectionProgramMember 2020-12-31 0000830656 PBIO:PaycheckProtectionProgrammeMember 2021-12-31 0000830656 PBIO:MerchantAgreementMember srt:MinimumMember 2023-09-30 0000830656 PBIO:MerchantAgreementMember srt:MaximumMember 2023-09-30 0000830656 PBIO:MerchantAgreementMember 2023-01-01 2023-09-30 0000830656 PBIO:MerchantAgreementMember 2022-01-01 2022-12-31 0000830656 PBIO:OfficersAndDirectorsMember 2023-09-30 0000830656 PBIO:OfficersAndDirectorsMember 2023-01-01 2023-09-30 0000830656 PBIO:OfficersAndDirectorsMember 2022-12-31 0000830656 PBIO:OfficersAndDirectorsMember 2022-01-01 2022-12-31 0000830656 PBIO:OtherRelatedPartiesMember 2023-09-30 0000830656 PBIO:OtherRelatedPartiesMember 2023-01-01 2023-09-30 0000830656 PBIO:OtherRelatedPartiesMember 2022-12-31 0000830656 PBIO:OtherRelatedPartiesMember 2022-01-01 2022-12-31 0000830656 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0000830656 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0000830656 us-gaap:RelatedPartyMember 2023-09-30 0000830656 us-gaap:RelatedPartyMember 2022-12-31 0000830656 us-gaap:RelatedPartyMember srt:MinimumMember 2023-09-30 0000830656 us-gaap:RelatedPartyMember srt:MaximumMember 2023-09-30 0000830656 us-gaap:PreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2023-05-01 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2023-05-01 0000830656 PBIO:SeriesBBPreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBBPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesCCPreferredStockMember 2023-09-30 0000830656 PBIO:SeriesCCPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesBBRestrictedPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesCCRestrictedPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesBBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0000830656 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000830656 PBIO:TwoThousandAndTwentyOneEquityIncentivePlanMember 2021-12-30 0000830656 PBIO:TwoThousandAndTwentyOneEquityIncentivePlanMember 2023-09-30 0000830656 PBIO:UnvestedStockBasedAwardsMember 2023-09-30 0000830656 PBIO:UnvestedStockBasedAwardsMember 2023-01-01 2023-09-30 0000830656 PBIO:StockOptionsMember 2023-09-30 0000830656 PBIO:StockOptionsMember 2023-01-01 2023-09-30 0000830656 PBIO:ExercisableOptionsMember 2023-01-01 2023-09-30 0000830656 us-gaap:WarrantMember 2023-04-13 0000830656 us-gaap:WarrantMember 2023-04-11 2023-04-13 0000830656 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000830656 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000830656 PBIO:AccreditedInvestorAndConsultantsMember 2023-01-01 2023-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember PBIO:CommonStockAndWarrantMember 2023-01-01 2023-09-30 0000830656 PBIO:IssuedForServicesRenderedMember PBIO:CommonStockAndWarrantMember 2023-01-01 2023-09-30 0000830656 PBIO:IssuedForServicesRenderedMember 2023-01-01 2023-09-30 0000830656 PBIO:ConversionOfDebtMember 2023-01-01 2023-09-30 0000830656 PBIO:DebtSettlementMember 2023-01-01 2023-09-30 0000830656 PBIO:LenderMember 2023-09-30 0000830656 PBIO:DividendsPaidInKindMember 2023-01-01 2023-09-30 0000830656 PBIO:ConversionOfDebtMember PBIO:CommonStockAndWarrantMember 2023-01-01 2023-09-30 0000830656 PBIO:DebtExtensionMember 2023-01-01 2023-09-30 0000830656 PBIO:NewCommonStockIssuancesMember 2023-01-01 2023-09-30 0000830656 PBIO:ConversionOfPreferredToCommonStockMember 2023-01-01 2023-09-30 0000830656 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0000830656 PBIO:ConversionOfDebtMember 2022-01-01 2022-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember 2022-01-01 2022-09-30 0000830656 PBIO:IssuedForServicesRenderedMember 2022-01-01 2022-09-30 0000830656 us-gaap:CommonStockMember PBIO:IssuedForServicesRenderedMember 2023-01-01 2023-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000830656 us-gaap:CommonStockMember PBIO:NewConversionDebtMember 2022-01-01 2022-09-30 0000830656 us-gaap:CommonStockMember PBIO:DebtExtensionMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesAAPreferredStockMember PBIO:DebtExtensionMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesAAPreferredStockMember 2022-01-01 2022-09-30 0000830656 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesAJuniorParticipatingPreferredStockMember 2023-09-30 0000830656 PBIO:SeriesAJuniorParticipatingPreferredStockMember 2022-12-31 0000830656 PBIO:SeriesAConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesAConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesBConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesCConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesCConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesEConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesEConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:StockOptionsMember 2022-12-31 0000830656 us-gaap:SubsequentEventMember 2023-11-05 0000830656 us-gaap:SubsequentEventMember srt:MinimumMember 2023-11-05 0000830656 us-gaap:SubsequentEventMember srt:MaximumMember 2023-11-05 0000830656 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2023-10-01 2023-11-05 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-10-01 2023-11-05 0000830656 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember PBIO:TwoThousandTwentyOneEquityPlanMember 2023-10-18 2023-10-18 0000830656 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember PBIO:TwoThousandTwentyOneEquityPlanMember 2023-10-18 0000830656 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2023-10-18 0000830656 PBIO:MrSchumacherMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 PBIO:DrsTingMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 PBIO:LazarevMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 srt:ExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-10-18 0000830656 srt:ExecutiveOfficerMember us-gaap:SubsequentEventMember srt:MinimumMember 2023-10-18 0000830656 srt:ExecutiveOfficerMember us-gaap:SubsequentEventMember srt:MaximumMember 2023-10-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares PBIO:Integer xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2023

 

or

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _____________ to _____________

 

Commission File Number 001-38185

 

PRESSURE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Massachusetts   04-2652826
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

14 Norfolk Avenue

South Easton, Massachusetts

  02375
(Address of principal executive offices)   (Zip Code)

 

(508) 230-1828

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

  Large accelerated filer Accelerated filer
  Non-accelerated Filer Smaller Reporting Company
  Emerging Growth Company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).

 

☐ Yes ☒ No

 

The number of shares outstanding of the Issuer’s common stock as of November 10, 2023 was 21,726,433.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  Page
   
PART I - FINANCIAL INFORMATION 3
   
Item 1. Unaudited Financial Statements 3
   
Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 3
   
Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2023 and 2022 4
   
Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022 5
   
Consolidated Statements of Changes in Stockholders’ Deficit for the Three and Nine Months Ended September 30, 2023 and 2022 7
   
Notes to Unaudited Consolidated Financial Statements 9
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 26
   
Item 3. Quantitative and Qualitative Disclosure About Market Risk 30
   
Item 4. Controls and Procedures 30
   
PART II - OTHER INFORMATION 31
   
Item 1. Legal Proceedings 31
   
Item 1A. Risk Factors 31
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31
   
Item 3. Defaults Upon Senior Securities 32
   
Item 4. Mine Safety Disclosures 32
   
Item 5. Other Information 32
   
Item 6. Exhibits 32
   
SIGNATURES 33

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report2
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   September 30, 2023   December 31, 2022 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $5,263   $3,865 
Accounts receivable   329,263    295,374 
Inventories, net of $905,759 and $982,973 reserve, respectively   467,155    686,383 
Prepaid expenses and other current assets   219,283    257,527 
Total current assets   1,020,964    1,243,149 
Investment in equity securities   77,918    63,638 
Property and equipment, net   91,409    103,351 
Right of use asset operating leases   159,424    282,095 
Intangible assets, net   252,404    317,308 
TOTAL ASSETS  $1,602,119   $2,009,541 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
CURRENT LIABILITIES          
Accounts payable  $1,062,565   $637,238 
Accrued employee compensation   376,760    167,247 
Accrued professional fees and other   2,722,666    2,497,762 
Accrued interest and dividends payable   4,576,350    10,803,983 
Deferred revenue   253,152    58,242 
Convertible debt, net of unamortized debt discounts of $744,393 and $455,517, respectively   18,222,120    17,823,669 
Other debt, net of unamortized discounts of $0 and $0, respectively   2,030,510    1,638,969 
Related party, net of unamortized debt discount of $514 and $7,915, respectively   647,986    634,885 
Right of use operating lease liability   66,259    142,171 
Total current liabilities   29,958,368    34,404,166 
LONG TERM LIABILITIES          
Long term debt   162,522    150,000 
Right of use operating lease liability long term   71,287    139,924 
Deferred revenue   10,645    1,822 
TOTAL LONG TERM LIABILITIES   244,454    291,746 
TOTAL LIABILITIES   30,202,822    34,695,912 
COMMITMENTS AND CONTINGENCIES (Note 4)   -    - 
STOCKHOLDERS’ DEFICIT          
Series D, G, H, H2, J, K, AA, BB, CC Convertible Preferred Stock, $.01 par value (Note 6)   100    1,098 
Common stock, $.01 par value; 100,000,000 shares authorized; 23,399,945 and 13,682,910 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively   234,000    136,829 
Warrants to acquire common stock   35,684,321    31,995,762 
Additional paid-in capital   93,973,646    69,006,145 
Accumulated deficit   (158,492,770)   (133,826,205)
TOTAL STOCKHOLDERS’ DEFICIT   (28,600,703)   (32,686,371)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $1,602,119   $2,009,541 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report3
 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2023   2022   2023   2022 
   For the Three Months Ended
September 30,
   For the Nine Months Ended
September 30,
 
   2023   2022   2023   2022 
Revenue:                    
Products, services, other  $413,009   $144,032   $1,665,412   $1,122,169 
Total revenue   413,009    144,032    1,665,412    1,122,169 
Costs and expenses:                    
Cost of products and services   229,457    126,203    844,684    742,707 
Research and development   288,345    262,370    1,004,437    716,685 
Selling and marketing   157,773    226,526    537,802    422,422 
General and administrative   1,030,243    892,293    5,290,564    2,591,644 
Total operating costs   1,705,818    1,507,392    7,677,487    4,473,458 
Operating loss   (1,292,809)   (1,363,360)   (6,012,075)   (3,351,289)
                     
Other (expense) income:                    
Interest expense, net   (4,338,759)   (2,034,021)   (14,112,098)   (6,448,771)
Unrealized gain (loss) on investment in equity securities   (5,965)   (8,675)   14,280    (8,047)
Gain (loss) on extinguishment of liabilities   -    (1,054,122)   687,591    (1,809,249)
Other income (expense)   7,588    (2,059)   11,820    (904)
Total other expense   (4,337,136)   (3,098,877)   (13,398,407)   (8,266,971)
Net loss   (5,629,945)   (4,462,237)   (19,410,482)   (11,618,260)
Deemed dividends on extension of warrants   -    -    (3,626,950)   - 
Preferred stock dividends   (632,054)   (431,709)   (1,629,133)   (1,295,566)
Net loss attributable to common shareholders  $(6,261,999)  $(4,893,946)  $(24,666,565)  $(12,913,826)
Basic and diluted net loss per share attributable to common shareholders  $(0.29)  $(0.44)  $(1.21)  $(1.24)
Weighted average common shares outstanding used in the basic and diluted net loss per share calculation   21,716,950    11,131,742    20,337,229    10,429,817 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report4
 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   2023   2022 
   For the Nine Months Ended 
   September 30, 
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(19,410,482)  $(11,618,260)
Adjustments to reconcile net loss to net cash used in operating activities:          
(Gain) on extinguishment of debt   (687,591)   (10,000)
Non-cash lease expense   122,671    82,001 
Common stock and warrants issued for interest   3,715,204    2,196,278 
Depreciation and amortization   84,341    67,985 
Accretion of interest and amortization of debt discount   3,213,622    1,777,863 
Loss on extinguishment of accrued liabilities and debt   -    1,809,249 
Common stock and warrants issued for debt extension   1,671,573    - 
Preferred stock issued for debt extension   2,683,600    - 
Stock-based compensation expense   1,706,420    128,984 
(Gain)/Loss on investment in equity securities   (14,280)   8,047 
Common stock and warrants issued for services   1,978,645    367,370 
Preferred stock issued for services   617,200    - 
Changes in operating assets and liabilities:          
Accounts receivable   (33,889)   (11,568)
Inventories   219,228    (238,973)
Prepaid expenses and other assets   38,244    204,141 
Accounts payable   425,327    80,130 
Accrued employee compensation   209,513    104,258 
Operating lease liability   (144,549)   (82,001)
Deferred revenue and other accrued expenses   1,551,380    2,083,239 
Net cash used in operating activities   (2,053,823)   (3,051,257)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of property plant and equipment   (7,495)   (20,754)
Net cash used in investing activities   (7,495)   (20,754)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Sale of common stock for cash   150,000    - 
Proceeds from stock option exercises   81,111    17,443 
Net proceeds from convertible debt   4,336,665    3,428,249 
Net proceeds from non-convertible debt - third party   2,043,681    1,815,000 
Net proceeds from debt - related party   159,186    762,500 
Payments on convertible debt   (2,462,269)   (1,086,946)
Payments on debt - related party   (159,000)   (259,600)
Payments on non-convertible debt   (2,086,658)   (1,506,066)
Net cash provided by financing activities   2,062,716    3,170,580 
           
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   1,398    98,569 
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR   3,865    132,311 
CASH AND CASH EQUIVALENTS AT END OF PERIOD  $5,263   $230,880 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report5
 

 

   2023   2022 
   For the Nine Months Ended 
   September 30, 
   2023   2022 
CASH FLOWS SUPPLEMENTAL INFORMATION          
Interest paid in cash  $1,219,038   $938,451 
NON CASH TRANSACTIONS:          
Early adoption of ASU 2020-06   -    473,027 
Common stock issued with debt   1,293,270    512,593 
Discount from warrants issued with debt   -    93,576 
Common stock issued in lieu of cash for dividend   162,528    306,333 
Preferred stock issued with debt   539,487    - 
Preferred stock dividends   1,629,133    1,295,566 
Conversion of preferred stock for common stock   14,869    44 
Conversion of debt, interest, preferred stock dividend for preferred stock   10,017,212    - 
Conversion of debt and interest into common stock   509,033    350,500 
Conversion of common stock for preferred stock   6,240    - 
Extension of warrants for Series AA preferred stock   3,626,950    - 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report6
 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND SEPTEMBER 30, 2022

(UNAUDITED)

 

   Shares   Amount   Shares   Amount   Warrants   Capital   Deficit   Deficit 
   Combined Preferred Stock   Common Stock   Stock   Additional Paid In   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Warrants   Capital   Deficit   Deficit 
BALANCE, December 31, 2022   109,874   $1,098    13,682,910   $136,829   $31,995,762   $69,006,145   $(133,826,205)  $(32,686,371)
Stock option exercise   -    -    117,552    1,176    -    79,935    -    81,111 
Stock-based compensation   -    -    -    -    -    1,430,244    -    1,430,244 
Series AA Preferred Stock dividend   -    -    -    -    -    -    (431,807)   (431,807)
Issuance of common stock for services   -    -    990,500    9,905    -    1,409,430    -    1,419,335 
Issuance of common stock warrants for services   -    -    -    -    61,609    -    -    61,609 
Conversion of debt and interest for common stock   -    -    203,613    2,036    -    506,997    -    509,033 
Issuance of common stock for dividends paid-in-kind   -    -    73,694    737    -    101,698    -    102,435 
Issuance of common stock for interest paid-in-kind   -    -    1,111,081    11,111    -    1,694,123    -    1,705,234 
Common stock issued for debt extension   -    -    568,200    5,682    -    1,024,257    -    1,029,939 
Stock issued with debt   -    -    783,150    7,832    -    1,079,919    -    1,087,751 
Conversion of preferred stock for common stock   (101,154)   (1,012)   493,540    4,935    -    (3,923)   -    - 
Sale of Common Stock   -    -    40,000    400    -    99,600    -    100,000 
Net loss   -    -    -    -    -    -    (6,857,834)   (6,857,834)
Balance, March 31, 2023   8,720   $86    18,064,240   $180,643   $32,057,371   $76,428,425   $(141,115,846)  $(32,449,321)
Series AA/CC Preferred Stock dividend   -    -    -    -    -    -    (565,272)   (565,272)
Stock-based compensation   -    -    -    -    -    135,554    -    135,554 
Issuance of common stock for services   -    -    147,500    1,475    -    170,925    -    172,400 
Extension of warrants for Series AA Preferred stock   -    -    -    -    3,626,950    -    (3,626,950)   - 
Common stock issued for debt extension   -    -    528,600    5,286    -    486,348    -    491,634 
Conversion of preferred stock for common stock   (44)   -    44,400    444    -    (444)   -    - 
Conversion of debt, accrued interest and accrued dividend for preferred stock   401    4    -    -    -    10,017,208    -    10,017,212 
Conversion of common stock to preferred stock   62    1    (624,000)   (6,240)   -    6,239    -    - 
Issuance of common stock for dividends paid-in-kind   -    -    69,073    690    -    59,403    -    60,093 
Issuance of common stock for interest paid-in-kind   -    -    1,034,000    10,340    -    1,286,106    -    1,296,446 
Stock issued with debt   -    -    302,092    3,021    -    153,653    -    156,674 
Sale of Common Stock   -    -    20,000    200    -    49,800    -    50,000 
Issuance of preferred stock for services   57    1    -    -    -    505,699    -    505,700 
Issuance of Preferred stock for debt extension   185    2    -    -    -    1,396,998    -    1,397,000 
Preferred stock issued with debt   58    1    -    -    -    539,486    -    539,487 
Net loss   -    -    -    -    -    -    (6,922,703)   (6,922,703)
BALANCE, June 30, 2023   9,439   $95    19,585,905   $195,859   $35,684,321   $91,235,400   $(152,230,771)  $(25,115,096)
Stock-based compensation   -    -    -    -    -    140,622    -    140,622 
Series AA/CC Preferred Stock dividend   -    -    -    -    -    -    (632,054)   (632,054)
Issuance of common stock for services   -    -    492,500    4,926    -    320,375    -    325,301 
Common stock issued for debt extension   -    -    250,000    2,500    -    147,500    -    150,000 
Conversion of preferred stock for common stock   (95)   (1)   949,000    9,490    -    (9,489)   -    - 
Issuance of common stock for interest paid-in-kind   -    -    1,949,040    19,490    -    694,034    -    713,524 
Stock issued with debt   -    -    173,500    1,735    -    47,110    -    48,845 
Issuance of preferred stock for services   35    -    -    -    -    111,500    -    111,500 
Issuance of Preferred stock for debt extension   556    6    -    -    -    1,286,594    -    1,286,600 
Net loss   -    -    -    -    -    -    (5,629,945)   (5,629,945)
BALANCE, September 30, 2023   9,935   $100    23,399,945   $234,000   $35,684,321   $93,973,646   $(158,492,770)  $(28,600,703)

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report7
 

 

   Combined Preferred Stock   Common Stock   Stock    Additional Paid In    Accumulated    Total Stockholders’ 
   Shares   Amount   Shares   Amount   Warrants   Capital   Deficit   Deficit 
BALANCE, December 31, 2021   109,878   $1,099    9,120,526   $91,206   $31,715,154   $64,261,048   $(118,277,468)  $(22,208,961)
Early adoption of ASU 2020-06   -    -    -    -    -    (2,728,243)   2,255,216    (473,027)
Stock-based compensation   -    -    -    -    -    64,483    -    64,483 
Series AA Preferred Stock dividend   -    -    -    -    -    -    (432,149)   (432,149)
Issuance of common stock for services   -    -    37,000    370    -    77,330    -    77,700 
Issuance of common stock warrants for services   -    -    -    -    39,761    -    -    39,761 
Warrants issued for debt extension   -    -    -    -    132,537    -    -    132,537 
Common stock issued for debt extension   -    -    214,500    2,145    -    470,755    -    472,900 
Conversion of debt and interest for common stock   -    -    140,200    1,402    -    349,098    -    350,500 
Issuance of common stock for dividends paid-in-kind   -    -    31,810    318    -    63,938    -    64,256 
Issuance of common stock for interest paid-in-kind   -    -    558,100    5,581    -    1,167,877    -    1,173,458 
Stock issued with debt   -    -    92,000    920    -    141,560    -    142,480 
Warrants issued with debt   -    -    -    -    87,436    -    -    87,436 
Net loss   -    -    -    -    -    -    (4,239,685)   (4,239,685)
BALANCE, March 31, 2022   109,878   $1,099    10,194,136   $101,942   $31,974,888   $63,867,846   $(120,694,086)  $(24,748,311)
Stock-based compensation   -    -    -    -    -    32,074    -    32,074 
Stock option exercise   -    -    25,279    253    -    17,190    -    17,443 
Series AA Preferred Stock dividend   -    -    -    -    -    -    (431,708)   (431,708)
Issuance of common stock for services   -    -    40,000    400    -    67,400    -    67,800 
Common stock issued for debt extension   -    -    106,400    1,064    -    190,239    -    191,303 
Conversion of preferred stock for common stock   (4)   (1)   4,400    44    -    (43)   -    - 
Issuance of common stock for dividends paid-in-kind   -    -    86,464    865    -    150,156    -    151,021 
Issuance of common stock for interest paid-in-kind   -    -    224,500    2,245    -    386,270    -    388,515 
Stock issued with debt   -    -    22,000    220    -    35,628    -    35,848 
Net loss   -    -    -    -    -    -    (2,916,338)   (2,916,338)
BALANCE, June 30, 2022   109,874   $1,098    10,703,179   $107,033   $31,974,888   $64,746,760   $(124,042,132)  $(27,212,353)
Stock-based compensation   -    -    -    -    -    32,427    -    32,427 
Issuance of common stock for interest paid-in-kind   -    -    389,500    3,895    -    630,410    -    634,305 
Issuance of common stock for dividends paid-in-kind   -    -    52,032    520    -    90,536    -    91,056 
Issuance of common stock for services   -    -    113,500    1,135    -    166,240         167,375 
Series AA Preferred Stock dividend   -    -    -    -    -    -    (431,709)   (431,709)
Common stock issued for debt extension   -    -    707,900    7,079    -    1,043,396    -    1,050,475 
Warrants issued for services   -    -    -    -    14,734    -    -    14,734 
Stock issued with debt   -    -    254,500    2,545    -    331,720    -    334,265 
Stock warrants issued   -    -    -    -    6,140    -    -    6,140 
Net loss   -    -    -    -    -    -    (4,462,237)   (4,462,237)
BALANCE, September 30, 2022   109,874   $1,098    12,220,611   $122,207   $31,995,762   $67,041,489   $(128,936,078)  $(29,775,522)

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report8
 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(UNAUDITED)

 

1) Business Overview, Liquidity and Management Plans

 

Pressure BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”), (ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)

 

The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion-dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.

 

The UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high-pressure discharge (greater than 20,000 psi) through a dynamically controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company first introduced the UST Platform in May 2022 through participation in several cannabis/health & wellness meetings combined with a free-sample program. Executed agreements were subsequently announced with six CBD companies and one cosmeceutical/skincare company for full commercialization in Q3 202 3. The Company began shipping Nano CBD topical spray on October 2, 2023.

 

The BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.

 

The PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus for PCT is on making, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. We currently have over 350 PCT Systems placed in approximately 250 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific research & clinical laboratories.

 

2) Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows from operationing business since our inception. As of September 30, 2023, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past as described in Notes 5 and 6. In addition, we raised debt and equity capital after September 30, 2023, as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report9
 

 

3) Summary of Significant Accounting Policies

 

Basis of Presentation

 

The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023.

 

Use of Estimates

 

The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.

 

Recent Accounting Pronouncements

 

In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $2,728,243 decrease in additional paid in capital and a $2,255,216 decrease in accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption of ASU 2020-06.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report10
 

 

Revenue Recognition

 

We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, and ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period. We measure and allocate revenue according to ASC 606-10.

 

We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.

 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

 

Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.

 

Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.

 

Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components.

 

Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.

 

We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:

 

  a) The fair value of the asset or service involved is not determinable.
     
  b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange.
     
  c) The transaction lacks commercial substance.

 

We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report11
 

 

We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases.

 

Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.

 

Disaggregation of revenue

 

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

 

In thousands of US dollars ($)  Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Primary geographical markets  2023   2022   2023   2022 
North America  $251   $138   $1,067   $709 
Europe   76    13    130    61 
Asia   86    (7)   468    352 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Major products/services lines  2023   2022   2023   2022 
Hardware  $273   $1   $994   $532 
Consumables   50    49    173    165 
Contract research services   -1    -    35    125 
Sample preparation accessories   31    41    113    93 
Technical support/extended service contracts   34    41    123    94 
                     
Agrochem Products   15    10    181    93 
Shipping and handling   11    2    38    20 
Other   -    -    8    - 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Timing of revenue recognition  2023   2022   2023   2022 
Products transferred at a point in time  $379   $103   $1,506   $903 
Services transferred over time   34    41    159    219 
   $413   $144   $1,665   $1,122 

 

Contract balances

 

In thousands of US dollars ($) 

September 30,

2023

  

December 31,

2022

 
Receivables, which are included in ‘Accounts Receivable’  $329   $295 
Contract liabilities (deferred revenue)   59    60 

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report12
 

 

Transaction price allocated to the remaining performance obligations

 

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

 

In thousands of US dollars ($)  2023   2024   Total 
Extended warranty service  $48   $11   $59 

 

All consideration from contracts with customers is included in the amounts presented above.

 

Contract Costs

 

The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.

 

Concentrations

 

Credit Risk

 

Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.

 

The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.

 

   Three Months Ended
September 30,
   Nine months Ended
September 30,
 
   2023   2022   2023   2022 
Top five customers   80%   42%   49%   31%
Federal agencies   18%   4%   5%   1%

 

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.

 

   September 30,
2023
   December 31,
2022
 
Top five customers   80%   93%
Federal agencies   22%   0%

 

Product Supply

 

In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were:

 

  CNC Machining
  Contract Assembly & Kitting
  Component and Subassembly Design
  Inventory Management
  ISO certification

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report13
 

 

Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location.

 

We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.

 

Investment in Equity Securities

 

As of September 30, 2023, we held 100,250 shares of common stock of Nexity Global SA, (a Polish publicly traded company).

 

We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.

 

As of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $77,918. We recorded $14,280 as an unrealized gain during the nine months ended September 30, 2023 for changes in market value.

 

Computation of Loss per Share

 

Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.

 

The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:

 

   2023   2022   2023   2022 
   For the Three Months Ended September 30,   For the Nine months Ended September 30, 
   2023   2022   2023   2022 
Numerator:                    
Net loss attributable to common shareholders  $(6,261,999)  $(4,893,946)  $(24,666,565)  $(12,913,826)
Denominator for basic and diluted loss per share:                    
Weighted average common stock shares outstanding   21,716,950    11,131,742    20,337,229    10,429,817 
Loss per common share - basic and diluted  $(0.29)  $(0.44)  $(1.21)  $(1.24)

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report14
 

 

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms.

 

   As of September 30, 
   2023   2022 
Stock options   3,420,754    1,307,822 
Convertible debt   7,417,906    6,471,034 
Common stock warrants   15,732,940    16,293,768 
Convertible preferred stock:          
Series D Convertible Preferred Stock   6,250    25,000 
Series G Convertible Preferred Stock   -    26,857 
Series H Convertible Preferred Stock   -    33,334 
Series H2 Convertible Preferred Stock   -    70,000 
Series J Convertible Preferred Stock   -    115,267 
Series K Convertible Preferred Stock   -    229,334 
Series AA Convertible Preferred Stock   8,601,000    8,645,000 
Series BB Convertible Preferred Stock   8,580,000    - 
Series CC Convertible Preferred Stock   4,010,000    - 
    47,768,850    33,217,416 

 

Accounting for Stock-Based Compensation Expense

 

We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.

 

Determining Fair Value of Stock Option Grants

 

The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023:

 

Assumptions  CEO, other Officers and Employees 
Expected life   6.0 (yrs) 
Expected volatility   130.5%
Risk-free interest rate   3.90%
Forfeiture rate   0 to 5.00%
Expected dividend yield   0.0%

 

Valuation and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.

 

Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

 

Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report15
 

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

 

Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 0% to 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense.

 

All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance.

 

The Company recognized stock-based compensation expense of $140,622 and $32,427 for the three months ended September 30, 2023 and 2022, respectively. The company recognized stock-based compensation expense of $1,706,420 and $128,984 for the nine months ended September 30, 2023 and 2022, respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations:

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Cost of sales  $11,183   $2,184   $75,724   $8,694 
Research and development   35,676    9,499    241,585    37,803 
Selling and marketing   17,150    4,583    102,675    18,166 
General and administrative   76,613    16,161    1,286,436    64,321 
Total stock-based compensation expense  $140,622   $32,427   $1,706,420   $128,984 

 

Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.

 

Fair Value Measurements

 

The Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”) as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.

 

The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement.

 

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

 

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023:

 

      

Fair value measurements at

September 30, 2023 using:

 
   September 30, 2023  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities  $77,918   $77,918           -            - 
Total Financial Assets  $77,918   $77,918   $-   $- 

 

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:

 

      

Fair value measurements at

December 31, 2022 using:

 
  

December 31,

2022

  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities   63,638    63,638           -             - 
Total Financial Assets  $63,638   $63,638   $-   $- 

 

4) Commitments and Contingencies

 

Operating Leases

 

The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $7,650 per month, on a lease extension, signed on December 5, 2022, that expires December 31, 2023, for our corporate office. We expanded our space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected in the current payments.

 

We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease required monthly payments of $7,282 subject to annual cost of living increases. The lease shall be automatically extended for additional three years unless either party terminates at least nine months prior to the expiration of the current lease term.

 

The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $221,432 based on the net present value of lease payments discounted using an estimated borrowing rate of 12%.

 

On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term.

 

The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $239,327 based on the net present value of lease payments discounted using an estimated borrowing rate of 12%.

 

Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2023:

 

Year  Total 
October 1 – December 31, 2023  $15,887 
2024   64,393 
2025   66,969 
2026   51,778 
Total future undiscounted lease payments   199,027 
Less imputed interest   (61,481)
Present value of lease liabilities  $137,546 

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report16
 

 

The operating cash flows from the operating leases were $122,671 for the nine months ended September 30, 2023 and $82,001 for the nine months ended September 30, 2022. The weighted-average remaining lease term (years) of the above leases is 2.59 year as of September 30, 2023.

 

Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:

 

Operating Leases  September 30, 2023   December 31, 2022 
Right of use asset  $159,424   $282,095 
Right of use liability, current  $66,259   $142,171 
Right of use liability, long term  $71,287   $139,924 
Total lease liability  $137,546   $282,095 

 

The weighted-average discount rate is 12%.

 

The Company had no financing leases during the nine months ended September 30, 2023 and 2022.

 

The components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:

 

   September 30, 2023   September 30, 2022 
Operating lease cost  $153,290   $152,193 
Short-term lease cost   110,205    123,514 
Total lease cost  $263,495   $275,707 

 

Battelle Memorial Institute

 

In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“Battelle”). The licensed technology is the subject of a patent application filed by Battelle in 2008 and relates to a method and a system for improving the analysis of protein samples, including through an automated system utilizing pressure and a pre-selected agent to obtain a digested sample in a significantly shorter period of time than current methods, while maintaining the integrity of the sample throughout the preparatory process. In addition to royalty payments on net sales on “licensed products,” we are obligated to make minimum royalty payments for each year that we retain the rights outlined in the patent license agreement and we are required to have our first commercial sale of the licensed products within one year following the issuance of the patent covered by the licensed technology. After re-negotiating the terms of the contract in 2013, the minimum annual royalty was $1,200 in 2014 and $2,000 in 2015; the minimum royalties were $3,000 in 2016, $4,000 in 2017 and $5,000 in 2018 and each calendar year thereafter during the term of the agreement.

 

Target Discovery Inc.

 

In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“TDI”), a related party. Under the terms of the agreement, we have been licensed by TDI to manufacture and sell an innovative line of chemicals used in the preparation of tissues for scientific analysis (“TDI reagents”). The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement in 2023 or 2022.

 

In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $1,400 for the use of a lab bench, shared space, and other utilities, and $2,000 per day for technical support services as needed. The agreement requires TDI to pay the Company a minimum royalty fee of $60,000 in 2022 and $60,000 in 2023. For the nine months ended September 30, 2023 and September 30, 2022, the Company reported $55,400 and $65,100, respectively in TDI fees.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report17
 

 

Severance and Change of Control Agreements

 

Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by the Company without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination.

 

Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the occurrence of a change in control, as a disincentive to the control change.

 

5) Debt

 

Convertible Debt

 

On various dates during the nine months ended September 30, 2023, the Company issued convertible notes for net proceeds of approximate total of $4.3 million which contained varied terms and conditions as follows: a) 1-12 month maturity date; b) interest rates of 0-120%; c) convertible to the Company’s common stock at issuance at a fixed rate of $2.50 or at variable conversion rates upon the Company’s up-listing to NASDAQ or NYSE or an event of default. These notes were issued with shares of common stock that were fair valued at issuance date. The aggregate relative fair value of the shares of common stock and preferred stock issued with the notes of $1,832,757  was recorded as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not qualify for derivative accounting treatment on September 30, 2023.

 

For the nine months ended September 30, 2023, deferred financing costs and OID issued with the debt are $648,470  and the Company repaid $2,462,269.

 

The summary of specific terms of the convertible notes and outstanding balances as of September 30, 2023, and December 31, 2022, are listed in the tables below. The convertible notes are from numerous parties and with original issue dates from July 2019 to September 2023 and maturity dates from July 2020 to September 2024. There are approximately $12.3 million of notes that are past due as of September 30, 2023.

 

   September 30, 2023   December 31, 2022 
Holders  Interest
Rate
   Conversion
Price
   Principal   Interest
Rate
   Conversion
Price
   Principal 
Main Investor   10%  $2.50 (1)   $8,586,750    10%  $2.50 (1)  $9,393,150 
Others   0 to 24%  $2.50 (2) or $7.50    10,379,763    0 to 24%  $2.50 (2) or $7.50
   8,886,036 
Totals             -               18,279,186 
Discount             744,393              455,517 
Net            $18,222,120             $17,823,669 

 

Notes:

 

(1)Conversion price of these note is $2.50 except for a note for $189,750, which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25% discount to the 5-day average VWAP of the stock prior to default and $729,100 lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company.
   
(2)Conversion price of these notes is $2.50 but also varies with one or more of these notes having the following conversion adjustment:

 

a.Notes are convertible before maturity at $2.50 per share or mandatorily convertible when the Company up-lists to the NASDAQ at the lower of $2.50 or the up-list price.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report18
 

 

b.Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.
c.Notes are convertible at $2.50 per share except that following an Event of Default the conversion price will be adjusted to 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.
d.Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted at lower of 1) $2.50/share; 2) 30% discount to 5-day VWAP prior to date of default.
e.Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted at lower of 1) $2.50/share; 2) 25% discount to 5-day VWAP prior to date of default.
f.Conversion price is lower of (i) $2.50 or (ii) the price per share that the Company last sold Common Stock after the execution of an anti-dilution protection agreement.
g.Note can be converted at a Voluntary Conversion Price which is the lower of 1) $2.50/share; or 2) purchase price of stock sold by the Company at a price lower than $2.50 except that following an Event of Default, the Holder shall have the right, with no further consent from the Borrower, to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) 70% of the 5-day VWAP prior to conversion.
h.Conversion price is $2.50. If note is in default, it is $1.
i.Notes can be voluntarily converted before maturity at $2.50 per share. Lender retains the option upon an Up-list to convert at the lower of $2.50 or 10% off Up-list price.
j.Notes can be converted at the lesser of $2.5 per share or 25% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of (i) original conversion price or (ii) a 35% discount to the VWAP prior to each conversion date.
k.Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $950,000 as of September 30, 2023 is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion.
l.Some notes can be converted at the lesser of $2.50 per share or 25% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of original conversion price or the product of the VWAP of the common stock for the 5 trading dates immediately prior to the maturity date multiplied by 0.75.

 

For the nine months ended September 30, 2023, the Company recognized amortization expense related to the debt discounts indicated above of $2,621,523. The unamortized debt discounts as of September 30, 2023 related to the convertible notes amounted to $744,393.

 

As of September 30, 2023, the principal balance that is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $352,188.

 

Standstill and Forbearance Agreements

 

In recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. During the nine months ended September 30, 2023, the Company settled one note with total principal of $302,484, leaving one final lender (three notes) with total principal of $272,500 outstanding and incurred interest, penalties and fees of approximately $253,425  in connection with the Standstill and Forbearance Agreements.

 

Convertible Loan Modifications and Extinguishments

 

We refinanced certain convertible loans during the nine months ended September 30, 2023 at substantially the same terms for extensions ranging over a period of two to nine months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report19
 

 

The cash flows of new debt exceeded 10% of the remaining cash flows of the original debt on several loans. During the nine months ended September 30, 2023 we recorded gains on extinguishment of liabilities of approximately $0.7 million  by calculating the difference of the fair value of the new debt and the carrying value of the old debt. During the nine months ended September 30, 2023, the Company extended 17 loans totaling $3,917,898 and increased the principal to $4,067,898.  The Company issued 1,346,800 shares of common stock and 741 shares of preferred stock  for these extensions and increased principal.

 

Other Debt

 

No notes in Other Debt are past due as of September 30, 2023.

 

   September 30, 2023   December 31, 2022 
Holders  Interest Rate   Principal   Interest Rate   Principal 
Non-Convertible   (1)  $1,016,500    (1)  $878,809 
Merchant debt (3)        1,014,010         760,160 
SBA (2)   3.75%   162,522    3.75%   150,000 
Totals        2,193,032        $1,788,969 
Discount        -         - 
Long Term        162,522         150,000 
Short Term       $2,030,510        $1,638,969 

 

Notes:

 

(1)Interest varies from 1% to 10%. The maturity is between being past due and May 2, 2023. As of September 30, 2023, $861,500 of the non-convertible debt is past due.
(2)The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $150,000, accrues interest at 3.75% and requires monthly payments of $731 for principal and interest beginning in December 2022. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the nine months ended September 30, 2023, $14,719 interest was deferred and added to principal on EIDL loan and the Company repaid $2,197 principal on this loan. During the year ended December 31, 2020, the Company borrowed $367,039 (two-year term and 1% interest rate per annum) under the Payroll Protection program (or “2020 PPP”). During the year ended December 31, 2021, the Company borrowed $367,039 through a second Payroll Protection program (or “2021 PPP”) and extended the monthly payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven by the United States and SBA.
(3)During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1% - 100.9% per month. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. The Company’s Chief Executive Officer guarantees the Company’s performance of all representations, warranties, and covenants made by the Company in the Agreement. For loans outstanding on September 30, 2023, the maturity dates ranged from June 26, 2023 to October 15, 2023. For loan outstanding on December 31, 2022, the maturity dates ranged from April 4 to June 6, 2023.

 

Related Party Notes

 

   September 30, 2023   December 31, 2022 
Holders  Interest Rate   Principal   Interest Rate   Principal   Security 
Officers & Directors   -(1)  $522,450    -(1)  $521,950    Unsecured 
Other Related Parties   12%   126,050    12%   120,850    Unsecured 
Totals        648,500         642,800      
Discount        514         7,915      
Net       $647,986        $634,885      

 

Notes:

 

(1)Interest varies from 12% to 120%.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report20
 

 

During the nine months ended September 30, 2023, we received short-term convertible loans of $164,700 with $5,514 OID from related parties and repaid $159,000 of related party loans. These notes bear interest of 12% to 120% and are due upon demand. All related party notes are convertible at $2.50/share.

 

We amortized $592,099  of debt discounts during the nine months ended September 30, 2023 for all non-convertible and related party notes. The total unamortized discount for all non-convertible and related party convertible notes as of September 30, 2023, and December 31, 2022 was $514 and $7,915, respectively.

 

6) Stockholders’ Deficit

 

Preferred Stock

 

We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock, the following is outstanding:

 

   September 30, 2023   December 31, 2022 
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 75 shares issued and outstanding on September 30, 2023, and 300 shares issued and outstanding on December 31, 2022 (Liquidation value of $300,000)  $-   $3 
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 80,570 shares issued and outstanding on December 31, 2022   -    806 
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 10,000 shares issued and outstanding on December 31, 2022   -    100 
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; no shares issued and outstanding on September 30, 2023 and 3,458 shares issued and outstanding on December 31, 2022   -    35 
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 6,880 shares issued and outstanding on December 31, 2022   -    68 
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 8,601 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively   86    86 
Series BB Convertible Preferred Stock, $.01 par value; 1,000 shares authorized; 858 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022   10    - 
Series CC Convertible Preferred Stock, $.01 par value; 2,000 shares authorized; 401 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022   4    - 
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; no shares issued and outstanding on September 30, 2023 and 21 shares issued and outstanding on December 31, 2022   -    - 
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding   -    - 
Series A Convertible Preferred Stock, $.01 par value, 313,960 shares authorized, no shares outstanding   -    - 
Series B Convertible Preferred Stock, $.01 par value, 279,256 shares authorized, no shares outstanding   -    - 
Series C Convertible Preferred Stock, $.01 par value, 88,098 shares authorized, no shares outstanding   -    - 
Series E Convertible Preferred Stock, $.01 par value, 500 shares authorized, no shares outstanding   -    - 
Total Convertible Preferred Shares  $100   $1,098 

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report21
 

 

On May 1, 2023, Pressure Biosciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization (the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 shares of its Preferred Stock as Series BB Convertible Preferred Stock, par value $0.01 per share (the “Series BB Preferred Stock”) and 2,000 shares of Preferred Stock as Series CC Convertible Preferred Stock, par value $0.01 per share (the “Series CC Preferred Stock”). Each of the Certificate of Designation of Series BB Convertible Preferred Stock (the “Series BB COD”) and Certificate of Designation of Series CC Convertible Preferred Stock (the “Series CC COD”) filed with the Amendment set forth the terms and provisions of the Series BB Preferred Stock and Series CC Preferred Stock, respectively.

 

Series BB Preferred Stock

 

Rank. The Series BB Preferred Stock ranks prior to the Company’s common stock, par value $0.01 per share (the “Common Stock”), and subordinate to the Series AA and Series CC Preferred Stock, and to all other classes of classes and series of equity securities of the Company, which by its terms does not rank on a parity with or senior to the Series BB Preferred, and all indebtedness of the Company.

 

Dividends. The holders of shares of the Series BB Preferred Stock are not entitled to receive dividends.

 

Voting Rights. The Series BB Preferred Stock has all of the same voting rights as the Common Stock. Each share of Series BB Preferred Stock. The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held.

 

Voluntary Conversion. The holders of Series BB Preferred Stock have the right to convert its Series BB Preferred Stock into Common Stock at a ratio of 10,000 shares of Common Stock for each share of Series BB Preferred Stock held, subject to adjustment as set forth in Section 4(e) of the Series BB COD.

 

Company Forced Conversion. The Company has the right to cause the conversion of all shares of Series BB Preferred Stock into Common Stock (“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares held by holders of the Series BB Preferred Stock, the Company may effectuate a Forced Conversion if either of the following conditions are satisfied: (i) the VWAP of the Common Stock shall equal or exceed 300% of $2.50 (with such dollar figure to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction that affects the share price of the Common Stock) for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series BB Preferred Stock that are issued pursuant to any exchange of previously issued securities.

 

Series CC Preferred Stock

 

Rank. The Series CC Preferred Stock ranks prior to the Common Stock, pari passu to the Series AA Preferred Stock, and prior to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred Stock (the “Junior Stock”). The Series CC Preferred Stock is subordinate to and ranks junior to all indebtedness of the Company.

 

Quarterly Dividends. The holders of shares of the Series CC Preferred Stock are entitled to receive, out of funds legally available therefor, dividends at an annual rate equal to 8% of the Liquidation Preference Amount (as defined below), calculated on the basis of a 360-day year, consisting of twelve 30-day months, and shall accrue on a daily basis from April 24, 2023. Accrued and unpaid dividends shall compound on a quarterly basis, and shall be, except as set forth in Section 2(b) of the Series CC COD, payable in cash. The first such dividend payment shall be due and payable on April 30, 2023, with subsequent dividend payments due and payable on June 30, September 30, and December 31, 2023. Each year thereafter, dividend payments shall be due and payable on March 31, June 30, September 30, and December 31.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report22
 

 

Junior Stock Dividends. The Company shall not declare or pay any cash dividends on or make any other distributions with respect to or redeem, purchase, or otherwise acquire for consideration, any shares of Junior Stock unless and until all accrued and unpaid dividends on the Series CC Preferred Stock have been paid in full, subject to restrictions as set forth in Section 3(a) of the Series CC COD.

 

Class Voting Rights. So long as more than ten percent (10%) of the Series CC Preferred Stock remain outstanding, the Company shall not, and shall not permit any subsidiary to, without the affirmative vote or consent of the holders of at least 75% of the shares of the Series CC Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting, in which the holders of the Series CC Preferred Stock vote separately as a class: (i) authorize, create, issue or increase the authorized or issued amount of any class or series of stock, including but not limited to the issuance of any more shares of previously authorized Preferred Stock, ranking prior to the Series CC Preferred Stock, with respect to the distribution of assets on liquidation, dissolution or winding up; (ii) amend, alter or repeal the provisions of the Series CC Preferred Stock, whether by merger, consolidation or otherwise, so as to adversely affect any right, preference, privilege or voting power of the Series CC Preferred Stock; (iii) repurchase, redeem or pay dividends on (whether in cash, in kind, or otherwise), shares of Junior Stock; (iv) amend the Articles of Incorporation or By-Laws of the Company so as to affect materially and adversely any right, preference, privilege or voting power of the Series CC Preferred Stock; (v) effect any distribution with respect to Junior Stock or parity stock; (vi) reclassify the Company’s outstanding securities; or (vii) effect a transaction with one or more persons or entities whereby such other persons or entities will own more than the 50% of the outstanding shares of Common Stock following such transaction.

 

General Voting Rights. Except with respect to transactions upon which the Series CC Preferred Stock shall be entitled to vote separately as a class as set forth in “Class Voting Rights” above and except as otherwise required by Massachusetts law, the Series CC Preferred Stock shall have no voting rights. The Common Stock into which the Series CC Preferred Stock is convertible shall, upon issuance, have all of the same voting rights as the Common Stock.

 

Liquidation Preference. In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, the holders of shares of the Series CC Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company whether such assets are capital or surplus of any nature, an amount equal to $25,000.00 per share (the “Liquidation Preference Amount”) of the Series CC Preferred Stock, on a pro rata and pari passu basis with any parity stock (the “Pari Passu Preferred Stock”), together with all accrued but unpaid dividends, before any payment shall be made or any assets distributed to the holders of the Common Stock or any other Junior Stock. If the assets of the Company are not sufficient to pay in full the Liquidation Preference Amount payable to the holders of outstanding shares of the Series CC Preferred Stock and any series of preferred stock or any other class of stock on a parity as to rights on liquidation, dissolution or winding up, with the Series CC Preferred Stock, then all of said assets will be distributed among the holders of the Series CC Preferred Stock, the Pari Passu Preferred Stock and the other classes of stock on a parity with the Series CC Preferred Stock, if any, ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Voluntary Conversion. The holders of Series CC Preferred Stock have the right to convert its Series CC Preferred Stock into a number of fully paid and nonassessable shares of Common Stock (the “Conversion Shares”) equal to the quotient of (i) the Liquidation Preference Amount of the shares of Series CC Preferred Stock being converted thereon divided by (ii) the Conversion Price then in effect as of the date of the delivery by such holder of its notice of election to convert. The “Conversion Price” shall mean $2.50 per share, subject to adjustment under Section 5(e) of the Series CC COD.

 

Company Forced Conversion. The Company has the right to cause the conversion of all shares of Series CC Preferred Stock into Common Stock (“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares held by holders of the Series CC Preferred Stock the Company may effectuate a Forced Conversion if either of the following conditions are satisfied as of the Forced Conversion Effective Date: (i) the VWAP of the Common Stock shall equal or exceed 300% of the Conversion Price for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series CC Preferred Stock that are issued pursuant to any exchange of previously issued securities.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report23
 

 

Conversion Restriction. At no time may a holder of shares of Series CC Preferred Stock convert shares of the Series CC Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 4.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”); provided, however, that a holder may waive the Conversion Restriction by providing the Company with sixty-one (61) days’ notice that such holder is waiving the Conversion Restriction.

 

During the nine months ended September 30, 2023 the Company issued a total of 953 shares of Series BB restricted preferred stock and 401 shares of Series CC restricted preferred stock to accredited investors and consultants, with the following detail:

 

92 shares of Series BB preferred stock with a fair value of $617,200, for services rendered;
741 shares of Series BB preferred stock with a fair value of $2,683,600 for convertible debt extensions;
58 shares of Series BB preferred stock with a fair value of $539,487 and issued with convertible debt;
62 shares of Series BB preferred stock from the conversion of common stock to preferred stock;
95 shares of Series BB preferred stock was converted into common stock;
401 shares of Series CC preferred stock with a fair value of $10,017,212 for the conversion of debt/accrued interest and dividends.

 

Stock Options and Warrants

 

At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Consistent with the Company’s existing 2013 Equity Incentive plan (the “2013 plan”), under the 2021 plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2023, options to acquire 3,420,754 shares were outstanding under these Plans.

 

As of September 30, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $963,322 , which is expected to be recognized over weighted average period of 2.2 years. The aggregate intrinsic value associated with the options outstanding and exercisable as of September 30, 2023, based on the September 30, 2023, closing stock price of $0.20, was $0.00.

 

The following table summarizes information concerning options and warrants outstanding and exercisable:

 

   Stock Options   Warrants         
   Weighted Average   Weighted Average   Total 
   Shares   price per share   Shares   price per share   Shares   Exercisable 
Balance outstanding, December 31, 2022   1,307,822   $0.72    16,278,769   $3.50    17,586,591    17,570,591 
Granted   2,230,484    1.50    100,000    3.50    2,330,484      
Exercised   (117,552)   0.69    -    -    (117,552)     
Expired   -    -    (645,829)   3.50    (645,829)     
Forfeited   -    -    -    -    -      
Balance outstanding, September 30, 2023   3,420,754   $1.23    15,732,940   $3.50    19,153,694    18,289,721 

 

As of September 30, 2023, the 3,420,754 options outstanding have a $1.23 weighted average exercise price and 8.14 years of weighted average remaining life for outstanding options and 7.75 years of weighted average remaining life for exercisable options. Of these options, 2,556,781 are currently exercisable.

 

On April 13, 2023, the Board authorized a 3-year extension of common stock warrants held by Series AA preferred shares holders. Therefore, 8,897,603 warrants were extended with new expiration dates between May 2, 2026 to September 14, 2029. Based on a fair value computation, this extension resulted in net incremental expense of $3,626,950, which was booked as an increase in the value of warrants and an increase of the retained deficit.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report24
 

 

As of September 30, 2023, the warrants outstanding have a $3.50 weighted average exercise price and a 2.42 year weighted average remaining life.

 

Common Stock and Warrant Issuances

 

During the nine months ended September 30, 2023, the Company accrued approximately $3,715,204  in interest expense for these obligations to issue common stock. During the nine months ended September 30, 2022, the Company accrued $634,305 in interest expense for these obligations to issue common stock.

 

During the nine months ended September 30, 2023 the Company issued a total of 9,717,035 shares of restricted common stock and to accredited investors and consultants, with the following detail:

 

  4,094,121 shares of common stock with a fair value of $3,715,204 to lenders for interest paid-in-kind;
  1,630,500 shares with a fair value of $1,917,036 for services rendered;
  203,613 shares with a fair value of $509,033 for conversions of debt principal and interest;
  117,552 shares for stock option exercises (at an exercise price of $0.69 per share);
  142,767 shares with a fair value of $162,528 for dividends paid-in-kind;
  1,258,742 shares with a fair value of $1,293,270 for common stock issued with convertible debt;
  1,346,800 shares with a fair value of $1,671,573 for convertible debt extensions;
  60,000 shares with a fair value of $150,000 for sale of common, and
  1,486,940 shares for the conversion of preferred stock to common stock.

 

During the nine months ended September 30, 2023, the Company issued 100,000 warrants (four-year term at a $3.50 exercise price) to acquire common stock at a fair value of $61,609 to a consultant for professional services.

 

During the nine months ended September 30, 2022, we issued 3,100,085 shares of restricted common stock to accredited investors and consultants, 140,200 shares with a fair value of $350,500 for conversions of debt principal and interest for common stock, 1,172,100 of the shares with a fair value of $2,196,278 were issued for interest paid-in-kind, 190,500 of the shares with a fair value of $312,875 were issued for services rendered,170,306 shares with a fair value of $306,333 for dividends paid-in-kind, 368,500 shares with a fair value $512,593 for new convertible debt issuances, 25,279 shares with a fair value of $17,433 from a stock option exercise, 1,028,800 shares with a fair value of $1,714,678 for debt extension and shareholders converted shares of series AA convertible preferred stock into 4,400 shares of common stock

 

During the nine months ended September 30, 2022, we issued 277,500 warrants (three-year to five-year terms at a $3.50 exercise price) to acquire common stock at a total fair value of $280,608 to a lender in conjunction with the signing of new convertible loans, a vendor for services rendered and for debt extension.

 

7) Subsequent Events

 

From October 1, 2023, through November 10, 2023, the Company issued seven (7) convertible loan with a principal balance of $439,000. The terms of the convertible notes were 15 days to 12 months with interest rates of 10-120% and convertible into the Company’s common stock at a fixed rate of $2.50 per share. In this time the Company also issued 278,500 shares of common stock for new convertible debt loans in the third quarter, 455,350 shares of common stock for accrued interest paid-in-kind, 310,000 shares of common stock for debt extensions, 505,000 shares of common stock from the conversion of Series BB preferred stock, 145,809 shares of common stock for Series AA preferred dividends and 40 Series BB preferred stock for professional services.

 

On October 18, 2023, the Board of Directors (the “Board”) of Pressure BioSciences, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Pressure BioSciences, Inc. 2021 Equity Incentive Plan (the “Plan”). The Plan originally provided that no one person could be granted awards pursuant to the Plan during any one fiscal year to purchase more than 300,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). Pursuant to the amendment, the yearly limit for any one person was raised to 500,000 shares of Common Stock.

 

On the same date, the Board granted a total of 1,500,000 stock options to a number of employees, consultants and the four members of the Board with each option having an exercise price of $0.25 per share. Each award of options expires on October 18, 2033. The options for the members of the Board vest in equal amounts over twelve (12) months. The options for Mr. Schumacher and Drs. Ting and Lazarev were each vested 25% on the date of issuance and 25% of the options vest each year for the next three (3) years.

 

In addition, on the same date, the Board approved the repricing of all outstanding options (including those held by the Board members and the named executive officers) to $0.25. The previous exercise prices of the outstanding stock options held by the Board members and the named executive officers ranged from $0.69 to $1.50.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report25
 

 

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. Such statements include, without limitation, statements regarding:

 

  our need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all;
  our need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient additional financing;
  our belief that we will have sufficient liquidity to finance normal operations for the foreseeable future;
  the options we may pursue in light of our financial condition;
  the potential applications for Ultra Shear Technology (UST);
  the potential applications of the BaroFold high-pressure protein refolding and disaggregation technology
  the amount of cash necessary to operate our business;
  the anticipated uses of grant revenue and the potential for increased grant revenue in future periods;
  our plans and expectations with respect to our continued operations;
  the expected number of Pressure Cycling Technology (“PCT”) and Constant Pressure (“CP”) based units that we believe will be installed and the expected revenues from the sale of consumable products, extended service contracts, and biopharma contract services;
  our belief that PCT has achieved initial market acceptance in the mass spectrometry and other markets;
  the expected development and success of new instrument and consumables product offerings;
  the potential applications for our instrument and consumables product offerings;
  the expected expenses of, and benefits and results from, our research and development efforts;
  the expected benefits and results from our collaboration programs, strategic alliances and joint ventures;
  our expectations of the results of our development activities funded by government research grants;
  the potential size of the market for biological sample preparation, biopharma contract services and Ultra Shear Technology;
  general economic conditions;
  the anticipated future financial performance and business operations of our company;
  our reasons for resources expended in the market for genomic, proteomic, lipidomic and small molecule sample preparation;
  the importance of mass spectrometry as a laboratory tool;
  the advantages of PCT over other current technologies as a method of biological sample preparation and protein characterization in biomarker discovery, forensics, and histology, as well as for other applications;
  the capabilities and benefits of our PCT Sample Preparation System, consumables and other products;
  our belief that laboratory scientists will achieve results comparable with those reported to date by certain research scientists who have published or presented publicly on PCT and our other products and services;
  our ability to retain our core group of scientific, administrative and sales personnel; and
  our ability to expand our customer base in sample preparation and for other applications of PCT, as well as for our other products and services in both the BaroFold and Ultra Shear Technology areas.

 

These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 and in this Report. We qualify all of our forward-looking statements by these cautionary statements.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report26
 

 

Pressure BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”), (ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)

 

The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.

 

The UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high pressure discharge (greater than 20,000 psi) through a dynamically-controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company began early commercial introduction of the UST Platform in May 2022, and executed agreements were subsequently announced with three CBD companies and one cosmeceutical/skincare company for commercialization in Q4 2022.

 

The BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high-pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.

 

The PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus for PCT is on making our, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. We currently have over 350 PCT Systems placed in approximately 225 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific research & clinical laboratories.

 

2023 Key Accomplishments

 

From January 1, 2023 to September 30, 2023, we announced the following key accomplishments:

 

September 22: PBIO’s partner Veterans Service Team increases existing purchase order by 10X for bottles of UltraShear Nano-CBD topical spray, effective immediately.
September 21: PBIO’s fulfillment of UltraShear Nano-CBD orders is underway; customer shipments begin first week of October
September 8: PBIO’s Barofold technology achieves pivotal equipment sale and begins scale-up in service to leading global contract development and manufacturing organization.
August 30: PBIO provides second progress report on UltraShear Nano-CBD Launch: “Drive to 420”.
August 22: PBIO reports Q22023 financial results, provides business update, and offers guidance.
August 9: PBIO reports strongly accelerating UltraShear Nano-CBD orders.
July 26: PBIO and master distributor Canopy CBD Farms announce major increase in sales pipeline.
July 25: PBIO to evaluate Company’s patented UltraShear process to extend shelf-life of fresh produce.
July 17: Company’s UltraShear Nano-CBD commercial roll-out program enters rapid expansion phase 2.
July 10: Company announces Nano-CBD topical spray distribution agreement with Crème de Canna.
July 6: Key academic publication further validates PBIO’s UltraShear platforms’ impact in clean-label foods.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report27
 

 

July 5: PBIO partners with Somalab Int’l for development & distribution of UltraShear-enabled health products.
June 13: PBIO partners with Veterans Service Team to offer exclusive access for VST members to Nano-CBD.
June 1: PBIO expands on six key goals for June 2023 with expected multi-million-dollar growth potential.
May 22: Commercial availability of Best-in-Class Nano-CBD topical spray with lightning-fast action announced.
May 16: PBIO announces Q1 2023 financial results: all-time quarterly record revenue.
May 9: Extended consumer testing strongly validates market transforming speed and dosing efficiency of PBIO’s UltraShear processed nano-THC oral spray.
April 26: PBIO updates rapid progress on potential sales of exclusive THC licenses.
April 21, 2023: PBIO unveils powerful THC market leapfrog opportunity with exclusive licensing of UltraShear nanoemulsion processing platform.
April 18: PBIO announces expansion into strategic manufacturing facilities with premier process tech company.
April 14: PBIO reports Q4 and FY 2022 financial results – offers guidance for a strong 2023.
April 6, 2023: PBIO and NutraLife Biosciences renew partnership for development and distribution of next generation nutraceuticals.
March 28: Company reports fresh sales momentum for PBI Agrochem.
March 22: PBIO receives $1.5 million contract for UltraShear nanoemulsified CBD.
March 1: Company announces the exchange of over $10 million of debt into equity.
February 1: Company receives record order (nearly $600,000) for 16 PCT instruments.
January 27: PBIO and One World Products partner to develop CBD-Nano sports performance/recovery drink.
January 19: Dramatic consumer testing results confirm UltraShear nanoemulsion oral spray delivers first effects and maximization in lightning speed – simple, reliable dosing delivers profoundly improved results.

 

Results of Operations

 

The following disclosure compares the results of operations for the quarter ended September 30, 2023 (“Q2 2023”) with September 30, 2022 (“Q2 2022”) and compares the nine months ended September 30, 2023 with September 30, 2022.

 

Products and Services Revenue

 

We recognized total revenue of $413,009 for Q3 2023 compared to $144,032 for Q3 2022, a 187% increase. For the year-to-date periods ending September 30, 2023 and September 30, 2022, we recognized revenue of $1,665,412 and $1,122,169 respectively, a 48% increase.

 

This increase in revenue was primarily attributable to a $506,828 increase in PCT instrumentation and consumable sales, a $30,295 increase in technical support services and an $87,378 increase in Agrochem products, offset by a decrease of $89,350 in scientific services.

 

Cost of Products and Services

 

The cost of products and services was $229,457 for Q3 2023 compared to $126,203 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022 our cost of products and services were $844,684 and $742,707, respectively. Gross profit margin on products and services increased to 49% in the year-to-date period ended September 30, 2023 from 34% in the same period ended September 30, 2022. The increase in gross profit margin was attributable to $180,670 of Agrochem products sold in 2023 at no cost due to 2022 inventory write-off and a $79,901 instrument non-monetary exchange sale in 2022 was recorded at no profit.

 

Research and Development

 

Research and development expenses were $288,345 for Q3 2023 compared to $262,370 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $1,004,437 and $716,685, respectively, a 40% increase. The reported increase was due to a $71,777 reclass of salaries to COGS for a non-monetary instrument exchange in 2022 and $241,585 of stock-based compensation expense for employee stock options issued in 2023.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report28
 

 

Selling and Marketing

 

Selling and marketing expenses were $157,773 for Q3 2023 compared to $226,526 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $537,802 and $422,422, respectively a 27% increase The reported increase was primarily attributable to the hiring of a Marketing FTE in Q2 2023 and $102,675 of stock-based compensation expense for employee stock options issued in 2023.

 

General and Administrative

 

General and administrative expenses were $1,030,244 for Q3 2023 compared to $892,293 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $5,290,564 and $2,591,644, respectively, a 104% increase. The increase was primarily due to approximately $2.0  million common stock and warrants issued for services, approximately $1.3 million of stock-based compensation expense for employee, BOD and financial consultant stock options issued in 2023, and approximately $132,000 of financial consulting expenses in 2023, offset by an approximately $423,000 decrease in IR expenses.

 

Operating Loss

 

Operating loss was $1,292,809 for Q3 2023 compared to $1,363,360 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, the operating loss was $6,012,075 and $3,551,289 respectively, a 79% increase. This increase was primarily due to $2.0 millions in common stock and warrants issued for services and $1.7 million of stock-based compensation expense for employee, BOD financial consultant stock options issued in 2023, offset by an approximate $423,000 decrease in IR expenses.

 

Interest Expense, net

 

Interest expense was $4,338,759 for Q3 2023 compared to $2,034,021 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $14,112,098 and $6,448,771, respectively, a 119% increase. This increase was attributable to an increase in convertible debt and merchant cash loans, in addition to stock issuances for interest paid in kind and stock issued for debt extensions.

 

Unrealized gain on investment in equity securities

 

Unrealized loss on investments in equity securities was $5,965 for Q3 2023 compared to an unrealized loss of $8,675 for Q3 2022. For the nine months ended September 30, 2023, the unrealized gain on investment in equity securities was $14,280 as compared to an unrealized loss of $8,047 for the nine months ended September 30, 2022. The reported change was attributable to movement in the market price of the Company’s investment in Nexity.

 

Loss on extinguishment of liabilities

 

In connection with debt extensions and forgiveness, we recognized a net gain of $0 for Q3 2023 compared to $1,054,122 of losses for Q3 2022. For the nine months ended September 30, 2023 the recognized net gain of $687,591 as compared to a net loss of $1,809,249 for the nine months ended September 30, 2022. The increase/decline in gains/losses was attributable to decreased extension and forgiveness activity.

 

Net loss attributable to common stockholders

 

Net loss attributable to common stockholders was $6,261,999 ($0.29 per share) for Q3 2023 compared to $4,893,946 ($0.44 per share) for Q3 2022. For the nine months ended September 30, 2023, the net loss attributable to common stock was $24,666,565 ($1.21 per share) as compared to $12,913,826 ($1.24 per share).

 

Liquidity and Financial Condition

 

We have experienced negative cash flows from operations since our inception. As of September 30, 2023, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have substantial doubt regarding our ability to continue as a going concern. As described in Notes 5 and 6 of the accompanying consolidated financial statements, we have been successful in raising debt and equity capital. We received approximately $6.5 million  in net proceeds from loans in the nine months ended September 30, 2023. We have efforts in place to continue to raise cash through debt and equity offerings. (See Note 7 to the financial statements)

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report29
 

 

We will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects.

 

Net cash used in operations for the nine months ended September 30, 2023 was $2,053,823  as compared to $3,051,257 for the nine months ended September 30, 2022.

 

Net cash used in investing activities for the nine months ended September 30, 2023 was $7,495 compared to $20,754 in the nine months ended September 30, 2022.

 

Net cash provided by financing activities for the nine months ended September 30, 2023 was $2,062,716 as compared to $3,170,580 for the nine months ended September 30, 2022.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

This Item 3 is not applicable to us as a smaller reporting company and has been omitted.

 

ITEM 4. CONTROLS AND PROCEDURES

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 filings are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

As of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective.

 

Our conclusion that our disclosure controls and procedures were not effective as of September 30, 2023 is due to the continued presence of the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended December 31, 2022. These material weaknesses are the following:

 

  We identified a lack of sufficient segregation of duties. Specifically, this material weakness is such that the design over these areas relies primarily on detective controls and could be strengthened by adding preventative controls to properly safeguard Company assets.
     
  Management has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training, and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles, particularly as it relates to valuation of warrants and other complex debt /equity transactions. Specifically, this material weakness resulted in audit adjustments to the annual consolidated financial statements and revisions to related disclosures, valuation of warrants and other equity transactions.
     
  Limited policies and procedures that cover recording and reporting of financial transactions.
     
  Lack of multiple levels of review over the financial reporting process

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report30
 

 

We continue to plan to remediate those material weaknesses as follows:

 

  Improve the effectiveness of the accounting group by augmenting our existing resources with additional consultants or employees to assist in the analysis and recording of complex accounting transactions, and to simultaneously achieve desired organizational structuring for improved segregation of duties. We plan to mitigate this identified deficiency by hiring an independent consultant once we generate significantly more revenue or raise significant additional working capital.
     
  Improve expert review and achieve desired segregation procedures by strengthening cross approval of various functions including quarterly internal audit procedures where appropriate once we generate significantly more revenue or raise significantly more working capital.

 

During the period covered by this Report, we implemented and performed additional substantive procedures, such as supervisory review of work papers and consistent use of financial models used in equity valuations, to ensure our consolidated financial statements as of and for the six-month period ended September 30, 2023, are fairly stated in all material respects in accordance with GAAP. We have not, however, been able to fully remediate the material weaknesses due to our limited financial resources. Our remediation efforts are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Except as described above, there have been no changes in our internal controls over financial reporting that occurred during the period ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors

 

Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2022 and, in this Item, 1A. The risks described in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks occur, our business, results of operations, cash flows or financial condition could suffer.

 

There have been no material changes to the risk factors set forth in Item 1A of our 10-K for the year ended December 31, 2022.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Except where noted, all the securities discussed in this Part II, Item 2 were issued in reliance on the exemption under Section 4(a)(2) of the Securities Act.

 

On various dates in the nine months ended September 30, 2023 the Company issued a total of 9,917,035  of its common shares, 953 shares of Series BB preferred stock and 401 shares of Series CC preferred stock as follows:

 

117,552 shares from option exercises;
1,630,500 shares for professional services;
1,346,800 shares for debt extensions;
203,613 shares for conversion of debt and interest;

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report31
 

 

142,767 shares for dividends paid-in-kind;
4,094,121 shares for interest paid-in-kind;
1,258,742 shares for shares issued with debt;
60,000 shares from sale of common shares;
95 shares of Series BB preferred stock was converted to common stock;
92 shares of Series BB preferred stock for professional services;
741 shares of Series BB preferred stock for debt extensions;
58 shares of Series BB preferred stock issued with debt;
401 shares of Series CC preferred stock for conversion of debt/accrued interest and dividends, and
62 shares of Series BB preferred stock for the conversion of common stock.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibits    
     
21.1*  

Securities Issuance and Exchange Agreement

 

31.1*   Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
     
31.2*   Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
     
32.1**   Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
     
32.2**   Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

** In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are furnished and not filed.

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report32
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  PRESSURE BIOSCIENCES, INC.
     
Date: November 20, 2023 By:  /s/ Richard T. Schumacher
    Richard T. Schumacher
    President & Chief Executive Officer
    (Principal Executive Officer and Principal Financial Officer)

 

Pressure BioSciences, Inc.September 30, 2023 10Q Report33

EX-21.1 2 ex21-1.htm

 

Exhibit 21.1

 

SECURITIES Issuance AND EXCHANGE AGREEMENT

 

This Securities Issuance and Exchange Agreement (this “Agreement”) is dated as of February 28, 2023, between Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), and Clayton A. Struve (the “Purchaser”).

 

WHEREAS, the Company has determined that it is in its best interests to issue shares of a newly created series of Preferred Stock (as defined below) to the Purchaser in exchange for (i) all unpaid accrued interest owed to the Purchaser up to February 22, 2023 from his purchase of $9,393,150 of a series of secured convertible promissory notes issued to the Purchaser by the Company from November 15, 2019 up to August 31, 2021; (ii) unpaid accrued Series AA dividends owed to the Purchaser from the purchase issued by the Company from a series of Series AA Preferred Stock from May 2, 2018 up to February 22, 2023; and (iii) the conversion of $1,535,500 of certain secured convertible promissory notes purchased by the Purchaser from the Company, all totaling $10,017,212 (collectively the “Debt”) and decided by the Purchaser to include in this Agreement on Schedule A, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder; and

 

WHEREAS, the Purchaser desires to receive Shares of Preferred Stock (as defined below) in exchange for all Debt, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act and Rule 506 promulgated thereunder.

 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE I.
DEFINITIONS

 

1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:

 

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 144 under the Securities Act.

 

Articles of Amendment” means the Articles of Amendment to the Company’s Restated Articles of Organization, as amended, in the form of Exhibit A attached hereto, that includes a Certificate of Designation setting forth the rights, preferences, powers, privileges, restrictions, qualifications and limitations of the Preferred Stock.

 

Business Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States, or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

1

 

 

Closing” means the approval and issuance of the Shares of Preferred Stock in exchange for the Debt pursuant to Section 2.1.

 

Closing Date” means the date on which the Company completes the issuance of the Shares of Preferred Stock in exchange for the Debt.

 

Common Stock” means the common stock of the Company, par value $.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed into.

 

Conversion Shares” means such shares of Common Stock which, from time to time, have been issued, or may be issuable, upon conversion of the Preferred Stock.

 

Debt” means unpaid accrued interest, unpaid Series AA dividends, and those certain convertible promissory notes owned by the Purchaser and listed on Schedule A.

 

Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

Liens” means a lien, liability, charge, security interest, encumbrance, pledge, right of first refusal, preemptive right or other restriction of any kind, nature or description.

 

Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(a).

 

Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof), or other entity of any kind.

 

Preferred Stock” means the Series CC Convertible Preferred Stock of the Company, $.01 par value, issued or issuable to the Purchaser pursuant to this Agreement with such rights, preferences, powers, privileges, restrictions, qualifications and limitations as are set forth in the Certificate of Designation included in the Articles of Amendment and attached on Schedule B.

 

Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened.

 

Required Approvals” shall have the meaning ascribed to such term in Section 3.1(d).

 

Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.

 

SEC Reports” shall have the meaning ascribed to such term in Section 3.1(f).

 

2

 

 

Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

Shares of Common Stock” shall have the meaning ascribed to such term in Section 2.2(a).

 

“Shares of Preferred Stock” shall have the meaning ascribed to such term in Section 2.2(a).

 

Unpaid Accrued Interestshall mean all earned and unpaid accrued interest owed to the Purchaser from all outstanding convertible loans and Series AA Preferred Stock currently held by the Purchase up until the Closing of this Agreement, see Section 2.2(a).

 

ARTICLE II.
ISSUANCE AND EXCHANGE

 

2.1 Articles of Amendment. On or before the Closing, the Company shall adopt and file with the Secretary of the Commonwealth of Massachusetts the Articles of Amendment.

 

2.2 Purchase, Exchange and Sale.

 

(a) Effective upon the Closing and subject to the terms and conditions set forth herein, (i) the Company hereby issues to the Purchaser that number of shares of Preferred Stock Series CC that represents a number of Common Stock Equivalents (“CSE”) that is the result of the total debt being exchanged (Schedule A) divided by $2.50 (the “Shares of Preferred Stock”), and (ii) the Purchaser hereby assigns, transfers and delivers to the Company all of the Purchaser’s right, title and interest in and to the amount of the Debt, free and clear of all Liens, in exchange for the Shares of Preferred Stock.

 

(b) The Closing and issuance of the Shares of Preferred Stock in exchange for the debt shall take place on February 28, 2023, at the offices of the Company, remotely via the exchange of documents and signatures, or on such other date or at such other location or by such other means as the parties shall mutually agree.

 

2.3 Closing Deliveries.

 

(a) On or prior to the Closing (except as otherwise required below, or agreed to between Company and Purchaser), the Company shall deliver or cause to be delivered to the Purchaser a certificate or certificates registered in the name of the Purchaser representing the Shares of Preferred Stock.

 

(b) On or prior to the Closing (or following the closing, if agreed to between Company and Purchaser), the Purchaser shall deliver or cause to be delivered to the Company an IRS Form W-9 completed with respect to the Purchaser in accordance with the instructions accompanying such form.

 

3

 

 

2.4 Closing Conditions.

 

(a) The obligations of the Company hereunder in connection with the exchange of the Debt and issuance of the Shares of Preferred Stock to the Purchaser at the Closing are subject to the following conditions being met:

 

(i) the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Purchaser contained herein;

 

(ii) all obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed; and

 

(iii) the delivery by the Purchaser of the items set forth in Section 2.3(b) of this Agreement.

 

(b) The obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:

 

(i) the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained herein (except that the representations and warranties of the Company contained herein that are qualified by materiality or Material Adverse Effect shall be true and correct in all respects when made and on the Closing Date);

 

(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; and

 

(iii) the delivery by the Company of the items set forth in Section 2.3(a) of this Agreement.

 

ARTICLE III.REPRESENTATIONS AND WARRANTIES

 

3.1 Representations and Warranties of the Company. The Company hereby makes the following representations and warranties to the Purchaser:

 

(a) Organization and Qualification. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of The Commonwealth of Massachusetts, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. The Company is not in violation or default of any of the provisions of its Restated Articles of Organization, as amended, and bylaws. The Company is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, would not, individually or in the aggregate, have or reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of this Agreement, (ii) a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under this Agreement (any of (i), (ii) or (iii), a “Material Adverse Effect”).

 

4

 

 

(b) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of each of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith other than the Required Approvals. This Agreement has been duly executed and delivered by the Company and constitutes the valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

(c) No Conflicts. The execution, delivery, and performance of this Agreement by the Company and the sale and issuance of the Shares of Preferred Stock do not and will not (i) conflict with or violate any provision of the Company’s Restated Articles of Organization, as amended, or bylaws, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company debt or otherwise) or other understanding to which the Company is a party or by which any property or asset of the Company is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except in the case of each of clauses (ii) and (iii), such as would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.

 

(d) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization, or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery, and performance by the Company of this Agreement, other than (i) the filing of the Articles of Amendment with, and the acceptance of such filing by, the Secretary of the Commonwealth of Massachusetts, (ii) if determined necessary by the Company, the filing of Form D with the Commission and such filings, if any, as are required to be made under applicable state securities laws and (iii) any approvals required under the Company’s Restated Articles of Organization, as amended, as determined by the Company (collectively, the “Required Approvals”).

 

5

 

 

(e) Issuance of Shares of Preferred Stock. The Shares of Preferred Stock are duly authorized and, when issued in accordance with this Agreement, will be duly and validly issued, non-assessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in this Agreement, applicable federal and state securities laws and Liens created by or imposed by the Purchaser. The Conversion Shares have been duly reserved for issuance, and upon issuance in accordance with the terms of the Company’s Restated Articles of Organization, as amended, will be validly issued, non-assessable and free of restrictions on transfer other than restrictions on transfer under this Agreement, applicable federal and state securities laws and Liens created by or imposed by a Purchaser.

 

(f) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

(g) Exchange Act Registration. No Registration has been filed.

 

(h) Private Placement. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the exchange and issuance of the Shares of Preferred Stock by the Company to the Purchaser as contemplated hereby.

 

3.2 Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants as follows:

 

(a) Organization; Authority. The Purchaser has full legal capacity to execute and deliver this Agreement and the documents representing the Debt and to consummate the transactions contemplated by this Agreement and otherwise to carry out his obligations hereunder. This Agreement has been, and the documents the Debt will be, duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

6

 

 

(b) Own Account. The Purchaser understands that the Shares of Preferred Stock are “restricted securities” and have not been registered under the Securities Act or any applicable state or other securities law and is acquiring the Shares of Preferred Stock as principal for his own account and not with a view to or for distributing or reselling such Shares of Preferred Stock or any part thereof in violation of the Securities Act or any applicable state or other securities law, has no present intention of distributing any of such Shares of Preferred Stock in violation of the Securities Act or any applicable state or other securities law, and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares of Preferred Stock (this representation and warranty not limiting the Purchaser’s right to sell the Shares of Preferred Stock or the Conversion Shares in compliance with the Securities Act and any applicable state or other securities laws) in violation of the Securities Act or any applicable state or other securities law.

 

(c) Purchaser Status. At the time the Purchaser was offered the Shares of Preferred Stock, the Purchaser was, on the date hereof he is, and on the Closing Date he will be, an “accredited investor” as defined in Rule 501(a) under the Securities Act.

 

(d) Experience of Such Purchaser. The Purchaser has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares of Preferred Stock and has so evaluated the merits and risks of such investment. The Purchaser understands that the purchase of the Shares of Preferred Stock involves substantial risk. The Purchaser is able to bear the economic risk of an investment in the Shares of Preferred Stock and, at the present time, is able to afford a complete loss of such investment.

 

(e) General Solicitation. The Purchaser is not purchasing the Shares of Preferred Stock as a result of any advertisement, article, notice or other communication regarding the Shares of Preferred Stock published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

 

(f) Provision of Information. The Purchaser has been afforded (i) the opportunity to ask such questions as he has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the Shares of Preferred Stock, the Debt and the finances, operations and business of the Company; and (ii) the opportunity to request such additional information which the Company possesses or can acquire without unreasonable effort or expense. All of the Purchaser’s questions have been answered to his satisfaction and such Purchaser has received all of such requested additional information.

 

7

 

 

(g) Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Purchaser to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank, or other Person with respect to the transactions contemplated by this Agreement.

 

(h) Residency. The residence or principal place of business of the Purchaser is set forth below the Purchaser’s signature on the signature page to this Agreement, and all communications between the Purchaser and the Company regarding the transactions contemplated by this Agreement took place within or from the state of such residence or principal place of business.

 

(i) Ownership of Shares of Common Stock. Not Applicable.

 

(j) Acknowledgement. Such Purchaser acknowledges that the Company has relied upon the representations and warranties of the Purchaser set forth in this Section 3.2 in its determination that no registration under the Securities Act is required for the sale and issuance of the Shares of Preferred Stock by the Company to the Purchaser as contemplated by this Agreement.

 

ARTICLE IV.
OTHER AGREEMENTS OF THE PARTIES

 

4.1 Transfer Restrictions.

 

(a) The Shares of Preferred Stock and the Conversion Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Shares of Preferred Stock and the Conversion Shares other than pursuant to an effective registration statement under the Securities Act or Rule 144, or to the Company, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement.

 

(b) Certificates evidencing the Shares of Preferred Stock and the Conversion Shares will contain the following legend or such other legend as may be reasonably appropriate under the Securities Act so long as is required by this Section 4.1:

 

THE OFFER AND SALE OF THIS SECURITY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, SUCH SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

If the Purchaser or other holder of the Shares of Preferred Stock or the Conversion Shares is not an Affiliate of the Company, certificates evidencing the Shares of Preferred Stock or the Conversion Shares shall not contain any legend (including the legend set forth in Section 4.1(b), (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such securities pursuant to Rule 144, (iii) if such securities are eligible for sale under Rule 144 without limitations, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Securities Exchange Commission). The Company agrees that at such time as such legend is no longer required with respect to such securities under this Section 4.1(b), promptly following the delivery by the Purchaser to the Company or its transfer agent of a certificate representing such securities, it will deliver or cause to be delivered to the Purchaser a certificate representing such securities that is free from all restrictive and other legends.

 

4.2 Reservation of Common Stock. The Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Conversion Shares pursuant to the conversion of the Shares of Preferred Stock.

 

ARTICLE V.
MISCELLANEOUS

 

5.1 Fees and Expenses. Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.

 

5.2 Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

8

 

 

5.3 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile or e-mail at the facsimile number or e-mail address set forth on the signature pages attached hereto prior to 5:30 p.m. (New York City time) on a Business Day, (b) the next Business Day after the date of transmission, if such notice or communication is delivered via facsimile or e-mail at the facsimile number or e-mail address set forth on the signature pages attached hereto on a day that is not a Business Day or later than 5:30 p.m. (New York City time) on any Business Day, (c) the second Business Day following the date of mailing, if sent by internationally recognized overnight courier service for next business day delivery, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

5.4 Amendments; Waivers. No provision of this Agreement may be waived, amended, modified or terminated except in a written instrument signed, by the Company and by the Purchaser. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

5.5 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

 

5.6 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Purchaser may not assign any or all of his rights under this Agreement to any Person without the prior written consent of the Company.

 

5.7 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

9

 

 

5.8 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of The Commonwealth of Massachusetts, without regard to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement, and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees, or agents) shall be commenced exclusively in the state and federal courts sitting in The Commonwealth of Massachusetts. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Boston for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Agreement), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Proceeding is improper or is an inconvenient venue for such Proceeding. The parties hereby waive all rights to a trial by jury.

 

5.9 Execution. This Agreement may be executed in two counterparts, each of which when taken together shall be considered one and the same agreement and shall become effective against the Company and the Purchaser when counterparts have been signed by the Company and the Purchaser and delivered to each other, it being understood that the Company and the Purchaser need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

5.10 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

5.11 Construction. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise this Agreement and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement or any amendments hereto.

 

10

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase and Exchange Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

Pressure BioSciences Inc.

  Address for Notice:

By:

 

Name: Richard T. Schumacher

Title: President and Chief Executive Officer

 

 

14 Norfolk Avenue

South Easton, MA 02375

Facsimile: (508) 580-1829

E-Mail: rschumacher@pressurebiosciences.com

Attention: Richard T. Schumacher

     

Purchaser:

  Address for Notice:
     
    [_____________________]

Name: Accredited Investor

 

 

[_____________________]

Facsimile:

E-Mail:

 

Taxpayer Identification Number: On File at the Company

 

11

 

 

Schedule A

 

Series AA – dividend (8%)        
         
●      Accrued Dividend (May 2, 2018 – Dec 31, 2022)   $ 6,028,158  
●      Accrued Dividend (Jan 1, 2023 – Feb 22, 2023)   $ 197,967  
    $ 6,226,125¹  
Promissory Notes – interest (10%)        
         
●      Accrued Interest (Nov 15, 2019 – Dec 31, 2022)   $ 2,120,306  
●      Accrued Interest (Jan 1, 2023 – Feb 22, 2023)   $ 135,281  
    $ 2,255,587²  
Promissory Notes (“PN”)        
         
●      November 15, 2019   $ 320,000  
●      January 2, 2020   $ 330,000  
●      January 23, 2020   $ 247,500  
●      January 29, 2020   $ 363,000  
●      February 12, 2020   $ 275,000  
    $ 1,535,500³  
         
Total Debt to be Exchanged into Series CC Equity:   $ 10,017,212  
Purchase Price for each share of Preferred Stock Series CC:   $ 25,000.00  
Number of Shares of Series CC Preferred Stock Purchased:     400.6885  
         
No. of Common Stock Equivalents (CSE) from the Series CC:     4,006,885  

 

¹Accrued Series AA Dividends as of February 22, 2023 = $0.00

²Accrued Promissory Note (“PN”) Interest as of February 22, 2023 = $0.00

³PN Principal as of February 22, 2023 = $9,393,150 - $1,535,500 = $7,857,650

 

12

 

 

Schedule B

 

1. Series CC Preferred Stock Designation and Rank.

 

(a) Designation. The designation of such series of the Preferred Stock shall be the Series CC Convertible Preferred Stock, par value $0.01 per share (the “Series CC Preferred Stock”). The maximum number of shares of Series CC Preferred Stock shall be Two Thousand (2,000) shares.

 

(b) Rank. The Series CC Preferred Stock shall rank prior to the common stock, par value $0.01 per share (the “Common Stock”), and to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred Stock (“Junior Stock”). The Series CC Preferred Stock shall be subordinate to and rank junior to all indebtedness of the Company now or hereafter outstanding.

 

2. Dividends.

 

(a) Quarterly Dividends. The holders of shares of the Series CC Preferred Stock shall be entitled to receive, out of funds legally available therefor, dividends at an annual rate equal to 8% of the Liquidation Preference Amount (as defined below), calculated on the basis of a 360-day year, consisting of twelve 30-day months, and shall accrue on a daily basis from February 22, 2023. Accrued and unpaid dividends shall compound on a quarterly basis, and shall be, except as set forth in Section 2(b) below, payable in cash. The first such dividend payment shall be due and payable on March 31, 2023, with subsequent dividend payments due and payable on June 30, September 30, and December 31, 2023. Each year thereafter, dividend payments shall be due and payable on March 31, June 30, September 30, and December 31 (each a “Dividend Payment Date”). All accrued and unpaid dividends, if any, shall be mandatorily paid immediately prior to the earlier to occur of (i) a liquidation, dissolution or winding up (or deemed liquidation, dissolution or winding up under Section 4(b) hereof) of the Company (a “Liquidation”), or (ii) a Voluntary Conversion pursuant to Section 5 hereof (the “Mandatory Dividend Payment Date”).

 

(b) Payment of Dividends. At the option of the Company in compliance with this Section 2(b), the Company may pay dividends on the Series CC Preferred Stock in shares of Common Stock, with each share of Common Stock being valued for this purpose as the VWAP (as hereafter defined) of the Common Stock for the five trading days immediately prior to the Dividend Payment date. In order to pay the dividends in Common Stock, the Company must provide the holders of the Series CC Preferred Stock with at least 10 days’ notice, prior to the Dividend Payment Date, of its election to pay a regularly scheduled dividend in shares of Common Stock (the Company may indicate in such notice that the election contained in such notice shall continue for later periods until revised by a subsequent notice). In the event the Company fails to provide such notice, the dividend shall be payable in cash. Notwithstanding the above, no dividend shall be paid in Common Stock (i) in connection with a Liquidation, (ii) if such payment would cause the limitations on beneficial ownership set forth in Section 7 hereof to be exceeded or (iii) unless the shares of Common Stock received upon such payment shall be freely salable by the recipient pursuant to a then effective registration statement.

 

13

 

 

(c) Junior Stock Dividends. The Company shall not declare or pay any cash dividends on or make any other distributions with respect to or redeem, purchase, or otherwise acquire for consideration, any shares of Junior Stock unless and until all accrued and unpaid dividends on the Series CC Preferred Stock have been paid in full. In all events, Junior Stock dividends shall be subject to the restrictions set forth in Section 3(a) below.

 

3. Voting Rights.

 

(a) Class Voting Rights. The Series CC Preferred Stock shall have the following class voting rights (in addition to the voting rights set forth in Section 3(b) hereof). So long as more than ten percent (10%) of the Series CC Preferred Stock remain outstanding, the Company shall not, and shall not permit any subsidiary to, without the affirmative vote or consent of the holders of at least 75% of the shares of the Series CC Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting, in which the holders of the Series CC Preferred Stock vote separately as a class: (i) authorize, create, issue or increase the authorized or issued amount of any class or series of stock, including but not limited to the issuance of any more shares of previously authorized Preferred Stock, ranking prior to the Series CC Preferred Stock, with respect to the distribution of assets on liquidation, dissolution or winding up; (ii) amend, alter or repeal the provisions of the Series CC Preferred Stock, whether by merger, consolidation or otherwise, so as to adversely affect any right, preference, privilege or voting power of the Series CC Preferred Stock; (iii) repurchase, redeem or pay dividends on (whether in cash, in kind, or otherwise), shares of the Company’s Junior Stock; (iv) amend the Articles of Incorporation or By-Laws of the Company so as to affect materially and adversely any right, preference, privilege or voting power of the Series CC Preferred Stock; (v) effect any distribution with respect to Junior Stock or parity stock; (vi) reclassify the Company’s outstanding securities; or (vii) effect a transaction with one or more persons or entities whereby such other persons or entities will own more than the 50% of the outstanding shares of Common Stock following such transaction (“Change in Control Transaction”).

 

(b) General Voting Rights. Except with respect to transactions upon which the Series CC Preferred Stock shall be entitled to vote separately as a class pursuant to Section 3(a) above and except as otherwise required by Massachusetts law, the Series CC Preferred Stock shall have no voting rights. The Common Stock into which the Series CC Preferred Stock is convertible shall, upon issuance, have all of the same voting rights as other issued and outstanding Common Stock of the Company.

 

14

 

 

4. Liquidation Preference.

 

(a) In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, the holders of shares of the Series CC Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company whether such assets are capital or surplus of any nature, an amount equal to $25,000.00 per share (the “Liquidation Preference Amount”) of the Series CC Preferred Stock, on a pro rata and pari passu basis with any parity stock (the “Pari Passu Preferred Stock”), together with all accrued but unpaid dividends, before any payment shall be made or any assets distributed to the holders of the Common Stock or any other Junior Stock. If the assets of the Company are not sufficient to pay in full the Liquidation Preference Amount payable to the holders of outstanding shares of the Series CC Preferred Stock and any series of preferred stock or any other class of stock on a parity as to rights on liquidation, dissolution or winding up, with the Series CC Preferred Stock, then all of said assets will be distributed among the holders of the Series CC Preferred Stock, the Pari Passu Preferred Stock and the other classes of stock on a parity with the Series CC Preferred Stock, if any, ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full. The liquidation payment with respect to each outstanding fractional share of Series CC Preferred Stock shall be equal to a ratably proportionate amount of the liquidation payment with respect to each outstanding share of Series CC Preferred Stock. All payments for which this Section 4(a) provides shall be in cash, property (valued at its fair market value as determined by an independent appraiser reasonably acceptable to the holders of a majority of the Series CC Preferred Stock) or a combination thereof; provided, however, that no cash shall be paid to holders of Junior Stock unless each holder of the outstanding shares of Series CC Preferred Stock has been paid in cash the full Liquidation Preference Amount to which such holder is entitled as provided herein. After payment of the full Liquidation Preference Amount to which each holder is entitled, such holders of shares of Series CC Preferred Stock will not be entitled to any further participation as such in any distribution of the assets of the Company.

 

Notwithstanding the foregoing, at the option of the holder of Series CC Preferred Shares, such holder may elect to convert the entire Liquidation Preference Amount into shares of Common Stock pursuant to a Voluntary Conversion as set forth in Section 5(a), effective immediately prior to liquidation event.

 

(b) A consolidation or merger of the Company with or into any other corporation or corporations, or a sale or transfer of more than 50% of the assets of the Company, or the effectuation by the Company of a transaction or series of transactions in which more than 50% of the voting shares of the Company is disposed of or conveyed, shall be, at the election of the holders of 75% of the Series CC Preferred Stock, deemed to be a liquidation, dissolution, or winding up within the meaning of this Section 4. In the event of the merger or consolidation of the Company with or into another corporation that is not treated as a liquidation pursuant to this Section 4(b), the Series CC Preferred Stock shall maintain its relative powers, designations and preferences provided for herein and no merger shall result inconsistent therewith.

 

15

 

 

(c) Written notice of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company, stating a payment date and the place where the distributable amounts shall be payable, shall be given by mail, postage prepaid, no less than thirty (30) days prior to the payment date stated therein, to the holders of record of the Series CC Preferred Stock at their respective addresses as the same shall appear on the books of the Company.

 

5. Conversion. The holder of Series CC Preferred Stock shall have the following conversion rights (the “Conversion Rights”):

 

(a) Right to Convert. At any time on or after the Issuance Date, the holder of any such shares of Series CC Preferred Stock may, at such holder’s option, subject to the limitations set forth in Section 7 herein, elect to convert (a “Voluntary Conversion”) all or any portion of the shares of Series CC Preferred Stock held by such person, together with accrued but unpaid dividends thereon, into a number of fully paid and nonassessable shares of Common Stock (the “Conversion Shares”) equal to the quotient of (i) the Liquidation Preference Amount of the shares of Series CC Preferred Stock being converted thereon divided by (ii) the Conversion Price (as defined in Section 5(d) below) then in effect as of the date of the delivery by such holder of its notice of election to convert. The Company shall keep written records of the conversion of the shares of Series CC Preferred Stock converted by each holder. A holder shall be required to deliver the original certificates representing the shares of Series CC Preferred Stock upon complete conversion of the Series CC Preferred Stock.

 

(b) Mechanics of Conversion. The Voluntary Conversion of Series CC Preferred Stock shall be conducted in the following manner:

 

(i) Holder’s Delivery Requirements. To convert Series CC Preferred Stock into full shares of Common Stock on any date (the “Voluntary Conversion Date”), the holder thereof shall (A) transmit by facsimile (or otherwise deliver), for receipt on or prior to 5:00 p.m., New York time on such date, a copy of a fully executed notice of conversion in the form attached hereto as Exhibit I (the “Conversion Notice”), to the Company, and (B) with respect to the final conversion of shares of Series CC Preferred Stock held by any holder, such holder shall surrender to a common carrier for delivery to the Company as soon as practicable following such Conversion Date but in no event later than five (5) business days after such date the original certificates representing the shares of Series CC Preferred Stock being converted (or an indemnification undertaking with respect to such shares in the case of their loss, theft or destruction) (the “Preferred Stock Certificates”).

 

16

 

 

(ii) Company’s Response. Within two (2) business days following the Conversion Notice delivery date (the “Registered Share Delivery Date”), the Company shall transmit the shares of Common Stock to the holder by crediting the account of the holder’s prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and there is an effective registration statement permitting the issuance of the shares to or resale of the shares by the holder. Within three (3) business days following the Conversion Notice delivery date (the “144 Share Delivery Date”), the Company shall transmit the shares of Common Stock to the holder by crediting the account of the holder’s prime broker with The Depository Trust Company through the DWAC system if the Company is then a participant in such system and the shares are eligible for resale by the holders without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery to the holder. In case of conversion under this Section 5 of only a part of the shares of Series CC Preferred Stock represented by a certificate surrendered to the Company, the Company shall issue and deliver a new certificate for the number of shares of Series CC Preferred Stock which have not been converted, upon receipt of the original certificate or certificates representing shares of Series CC Preferred Stock so converted. Until such time as the certificate or certificates representing shares of Series CC Preferred Stock which have been converted are surrendered to the Company and a certificate or certificates representing the Common Stock into which such shares of Series CC Preferred Stock have been converted have been issued and delivered, the certificate or certificates representing the shares of Series CC Preferred Stock which have been converted shall represent the shares of Common Stock into which such shares of Series CC Preferred Stock have been converted. The Company shall pay all documentary, stamp or similar issue or transfer tax due on the issue of shares of Common Stock issuable upon conversion of the Series CC Preferred Stock.

 

(iii) Dispute Resolution. In the case of a dispute as to the arithmetic calculation of the number of shares of Common Stock to be issued upon conversion, the Company shall promptly issue to the holder the number of shares of Common Stock that is not disputed and shall submit the arithmetic calculations to the holder via facsimile as soon as possible, but in no event later than three (3) business days after receipt of such holder’s Conversion Notice. If such holder and the Company are unable to agree upon the arithmetic calculation of the number of shares of Common Stock to be issued upon such conversion within three (3) business day of such disputed arithmetic calculation being submitted to the holder, then the Company shall within three (3) business day submit via facsimile the disputed arithmetic calculation of the number of shares of Common Stock to be issued upon such conversion to the Company’s independent, outside accountant. The Company shall cause the accountant to perform the calculations and notify the Company and the holder of the results no later than seventy-two (72) hours from the time it receives the disputed calculations. Such accountant’s calculation shall be binding upon all parties absent manifest error. The reasonable expenses of such accountant in making such determination shall be paid by the Company, in the event the holder’s calculation was correct, or by the holder, in the event the Company’s calculation was correct, or equally by the Company and the holder in the event that neither the Company’s or the holder’s calculation was correct. The period of time in which the Company is required to effect conversions or redemptions under this Certificate of Designation shall be tolled with respect to the subject conversion or redemption pending resolution of any dispute by the Company made in good faith and in accordance with this Section 5(b)(iii).

 

(iv) Record Holder. The person or persons entitled to receive the shares of Common Stock issuable upon a conversion of the Series CC Preferred Stock shall be treated for all purposes as the record holder or holders of such shares of Common Stock on the Conversion Date.

 

17

 

 

(v) Company’s Failure to Timely Convert. If within three (3) business days of the Company’s receipt of the Conversion Notice (the “Share Delivery Period”) the Company shall fail to issue and deliver to a holder the undisputed number of shares of Common Stock to which such holder is entitled upon such holder’s conversion of the Series CC Preferred Stock (a “Conversion Failure”), in addition to all other available remedies which such holder may pursue, the Company shall pay additional damages to such holder on each business day after such third (3rd) business day that such conversion is not timely effected in an amount equal 0.5% of the product of (A) the sum of the number of shares of Common Stock not issued to the holder on a timely basis pursuant to Section 5(b)(ii) and to which such holder is entitled and (B) the VWAP (as defined below) of the Common Stock on the last possible date which the Company could have issued such Common Stock to such holder without violating Section 5(b)(ii). If the Company fails to pay the additional damages set forth in this Section 5(b)(v) within five (5) business days of the date incurred, then such payment shall bear interest at the rate of 2% per month (prorated for partial months) until such payments are made. “VWAP” means, for any security as of any date, the dollar volume-weighted average price for such security on the principal market or exchange during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If VWAP cannot be calculated for such security on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the holder. If the Company and the holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section 5(b)(iii) above. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period.

 

(c) Company Forced Conversion. The Company shall have the right, subject to satisfaction of the conditions in this Section 5(c), to cause the conversion of all shares of Series CC Preferred Stock into Common Stock (“Forced Conversion”). The Company shall deliver prior written notice to the Holder at least ten (10) business days (“Forced Conversion Notice”) prior to the effective date (the “Forced Conversion Effective Date”) of such Forced Conversion. Following the effectiveness of a registration statement permitting the resale of the Conversion Shares held by holders of the Series CC Preferred Stock the Company may effectuate a Forced Conversion if either of the following conditions are satisfied as of the Forced Conversion Effective Date: (i) the VWAP of the Common Stock shall equal or exceed 300% of the Conversion Price for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series CC Preferred Stock that are issued pursuant to any exchange of previously issued securities.

 

18

 

 

Upon any Forced Conversion, all accrued but unpaid dividends shall be paid and the Company shall transmit the shares of Common Stock to the holder by crediting the account of the holder’s prime broker with The Depository Trust Company through DWAC if the Company is then a participant in such system, and otherwise by physical delivery to the holder. If within three (3) business days of the Forced Conversion Effective Date, the Company shall fail to issue and deliver to a holder the number of shares of Common Stock to which such holder is entitled upon such Forced Conversion, in addition to all other available remedies which such holder may pursue, the Company shall pay additional damages to such holder on each business day after such third (3rd) business day that such conversion is not timely effected in an amount equal 0.5% of the product of (A) the sum of the number of shares of Common Stock not issued to the holder on a timely basis pursuant to Section 5(c) and to which such holder is entitled, and (B) the VWAP of the Common Stock on the last possible date which the Company could have issued such Common Stock to such holder without violating Section 5(c). If the Company fails to pay the additional damages set forth in this Section 5(c) within five (5) business days of the date incurred, then such payment shall bear interest at the rate of 2% per month (prorated for partial months) until such payments are made.

 

If any shares of Series CC Preferred Stock cannot be fully converted into Common Stock of the Company upon a Forced Conversion due to the Conversion Restriction, such shares of Series CC Preferred Stock shall remain unconverted. However, upon such Forced Conversion until such time as the shares of Series CC Preferred Stock are in fact converted into Common Stock, the following rights, preferences, and privileges of the Series CC Preferred Stock shall be of no further force or effect: dividend rights pursuant to Section 2; anti-dilution rights pursuant to Section 5(e)(vi); liquidation preference pursuant to Section 4; and the additional covenants set forth in Section 8.

 

(d) Conversion Price. The term “Conversion Price” shall mean $2.50 per share, subject to adjustment under Section 5(e) hereof.

 

(e) Adjustments of Conversion Price.

 

(i) Adjustments for Stock Splits and Combinations. If the Company shall at any time or from time to time after the Issuance Date, effect a stock split of the outstanding Common Stock, the Conversion Price shall be proportionately decreased. If the Company shall at any time or from time to time after the Issuance Date, combine the outstanding shares of Common Stock, the Conversion Price shall be proportionately increased. Any adjustments under this Section 5(e)(i) shall be effective at the close of business on the date the stock split or combination occurs.

 

19

 

 

(ii) Adjustments for Certain Dividends and Distributions. If the Company shall at any time or from time to time after the Issuance Date, make or issue or set a record date for the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in shares of Common Stock, then, and in each event, the Conversion Price shall be decreased as of the time of such issuance or, in the event such record date shall have been fixed, as of the close of business on such record date, by multiplying, as applicable, the Conversion Price then in effect by a fraction:

 

(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date; and

 

(2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.

 

(iii) Adjustment for Other Dividends and Distributions. If the Company shall at any time or from time to time after the Issuance Date, make or issue or set a record date for the determination of holders of Common Stock entitled to receive a dividend or other distribution payable in securities of the Company other than shares of Common Stock, then, and in each event, an appropriate revision to the applicable Conversion Price shall be made and provision shall be made (by adjustments of the Conversion Price or otherwise) so that the holders of Series CC Preferred Stock shall receive upon conversions thereof, in addition to the number of shares of Common Stock receivable thereon, the number of securities of the Company which they would have received had their Series CC Preferred Stock been converted into Common Stock immediately prior to such event (or the record date for such event, if applicable) and had thereafter, during the period from the date of such event to and including the Conversion Date, retained such securities (together with any distributions payable thereon during such period), giving application to all adjustments called for during such period under this Section 5(e)(iii) with respect to the rights of the holders of the Series CC Preferred Stock.

 

(iv) Adjustments for Reclassification, Exchange or Substitution. If the Common Stock issuable upon conversion of the Series CC Preferred Stock at any time or from time to time after the Issuance Date shall be changed to the same or different number of shares of any class or classes of stock, whether by reclassification, exchange, substitution or otherwise (other than by way of a stock split or combination of shares or stock dividends provided for in Sections 5(e)(i), (ii) and (iii), or a reorganization, merger, consolidation, or sale of assets provided for in Section 5(e)(v)), then, and in each event, an appropriate revision to the Conversion Price shall be made and provisions shall be made (by adjustments of the Conversion Price or otherwise) so that the holder of each share of Series CC Preferred Stock shall have the right thereafter to convert such share of Series CC Preferred Stock into the kind and amount of shares of stock and other securities receivable upon reclassification, exchange, substitution or other change, by holders of the number of shares of Common Stock into which such share of Series CC Preferred Stock might have been converted immediately prior to such reclassification, exchange, substitution or other change, all subject to further adjustment as provided herein.

 

20

 

 

(v) Adjustments for Reorganization, Merger, Consolidation or Sales of Assets. If at any time or from time to time after the Issuance Date there shall be a capital reorganization of the Company (other than by way of a stock split or combination of shares or stock dividends or distributions provided for in Section 5(e)(i), (ii) and (iii), or a reclassification, exchange or substitution of shares provided for in Section 5(e)(iv)), or a merger or consolidation of the Company with or into another corporation, or the sale of all or substantially all of the Company’s properties or assets to any other person that is not deemed a liquidation pursuant to Section 4(b) (an “Organic Change”), then as a part of such Organic Change an appropriate revision to the Conversion Price shall be made and provision shall be made (by adjustments of the Conversion Price or otherwise) so that the holder of each share of Series CC Preferred Stock shall have the right thereafter to convert such share of Series CC Preferred Stock into the kind and amount of shares of stock and other securities or property of the Company or any successor corporation resulting from the Organic Change as the holder would have received as a result of the Organic Change and if the holder had converted its Series CC Preferred Stock into the Company’s Common Stock prior to the Organic Change. In any such case, appropriate adjustment shall be made in the application of the provisions of this Section 5(e)(v) with respect to the rights of the holders of the Series CC Preferred Stock after the Organic Change to the end that the provisions of this Section 5(e)(v) (including any adjustment in the Conversion Price then in effect and the number of shares of stock or other securities deliverable upon conversion of the Series CC Preferred Stock) shall be applied after that event in as nearly an equivalent manner as may be practicable.

 

(vi) Subsequent Equity Sales. If, at any time while shares of Series CC Preferred Stock are outstanding, the Company or any subsidiary, as applicable, sells or grants any option to purchase or sells or grants any right to reprice outstanding securities, or otherwise disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or any security convertible or exchangeable into Common Stock (a “Common Stock Equivalent”), entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then Conversion Price (such lower price, the “Base Conversion Price” and such issuances, collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is lower than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then the Conversion Price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. Notwithstanding the foregoing, no adjustment will be made under this Section in respect of an Exempt Issuance (as hereafter defined). The Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section, indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice, upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance, regardless of whether the Holder accurately refers to the Base Conversion Price in the Notice of Conversion. Notwithstanding the foregoing, if any shares of Series CC Preferred Stock cannot be fully converted into Common Stock of the Company upon a Forced Conversion due to the Conversion Restriction, such shares of Series CC Preferred Stock shall remain unconverted. However, upon such Forced Conversion this Section 5(e)(vi); shall be of no further force or effect in accordance with Section 5(c).

 

21

 

 

(a) For the purposes hereof, an Exempt Issuance shall mean: the issuance of (a) shares of Common Stock or options or other stock based awards to employees, officers or directors and consultants of the Company pursuant to the Company’s stock or option plans existing as of the date hereof, to employees, officers or directors and consultants of the Company pursuant to a written agreement, provided that such shares of Common Stock are not registered and carry no registration rights other than on Form S-8, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the original Issue Date of this Series CC Preferred Stock, provided that such securities have not been amended or has a provision, since the date of this Agreement, to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. An Exempt Issuance shall not include any Change in Control Transaction.

 

(vii) Consideration for Stock. In case any shares of Common Stock or convertible securities other than the Series CC Preferred Stock, or any rights or warrants or options to purchase any such Common Stock or Convertible securities, shall be issued or sold in connection with any merger or consolidation in which the Company is the surviving corporation (other than any consolidation or merger in which the previously outstanding shares of Common Stock of the Company shall be changed to or exchanged for the stock or other securities of another corporation), the amount of consideration therefor shall be deemed to be the fair value, as determined reasonably and in good faith by the Board of Directors of the Company, of such portion of the assets and business of the non-surviving corporation as such Board may determine to be attributable to such shares of Common Stock, Convertible securities , rights or warrants or options, as the case may be.

 

22

 

 

(viii) Record Date. In case the Company shall take record of the holders of its Common Stock or any other Preferred Stock for the purpose of entitling them to subscribe for or purchase Common Stock or Convertible securities, then the date of the issue or sale of the shares of Common Stock shall be deemed to be such record date.

 

(f) No Impairment. The Company shall not, by amendment of its Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith, assist in the carrying out of all the provisions of this Section 5 and in the taking of all such action as may be necessary or appropriate in order to protect the Conversion Rights of the holders of the Series CC Preferred Stock against impairment. In the event a holder shall elect to convert any shares of Series CC Preferred Stock as provided herein, the Company cannot refuse conversion based on any claim that such holder or any one associated or affiliated with such holder has been engaged in any violation of law, unless, an injunction from a court, on notice, restraining and/or enjoining conversion of all or of said shares of Series CC Preferred Stock shall have been issued and the Company posts a surety bond for the benefit of such holder in an amount equal to 130% of the Liquidation Preference Amount of the Series CC Preferred Stock such holder has elected to convert, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds of which shall be payable to such holder in the event it obtains judgment.

 

(g) Certificates as to Adjustments. Upon occurrence of each adjustment or readjustment of the Conversion Price or number of shares of Common Stock issuable upon conversion of the Series CC Preferred Stock pursuant to this Section 5, the Company at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of such Series CC Preferred Stock a certificate setting forth such adjustment and readjustment, showing in detail the facts upon which such adjustment or readjustment is based. The Company shall, upon written request of the holder of such affected Series CC Preferred Stock, at any time, furnish or cause to be furnished to such holder a like certificate setting forth such adjustments and readjustments, the Conversion Price in effect at the time, and the number of shares of Common Stock and the amount, if any, of other securities or property which at the time would be received upon the conversion of a share of such Series CC Preferred Stock. Notwithstanding the foregoing, the Company shall not be obligated to deliver a certificate unless such certificate would reflect an increase or decrease of at least one percent of such adjusted amount.

 

(h) Issue Taxes. The Company shall pay any and all issue and other taxes, excluding federal, state or local income taxes, that may be payable in respect of any issue or delivery of shares of Common Stock on conversion of shares of Series CC Preferred Stock pursuant thereto; provided, however, that the Company shall not be obligated to pay any transfer taxes resulting from any transfer requested by any holder in connection with any such conversion.

 

23

 

 

(i) Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or by facsimile or three (3) business days following being mailed by certified or registered mail, postage prepaid, return-receipt requested, addressed to the holder of record at its address appearing on the books of the Company. The Company will give written notice to each holder of Series CC Preferred Stock at least twenty (20) days prior to the date on which the Company closes its books or takes a record (I) with respect to any dividend or distribution upon the Common Stock, (II) with respect to any pro rata subscription offer to holders of Common Stock or (III) for determining rights to vote with respect to any Organic Change, dissolution, liquidation or winding-up and in no event shall such notice be provided to such holder prior to such information being made known to the public. The Company will also give written notice to each holder of Series CC Preferred Stock at least twenty (20) days prior to the date on which any Organic Change, dissolution, liquidation or winding-up will take place and in no event shall such notice be provided to such holder prior to such information being made known to the public.

 

(j) Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Series CC Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Company shall at its option either (i) pay cash equal to the product of such fraction multiplied by the average of the VWAP of the Common Stock for the five (5) consecutive trading days immediately preceding the Voluntary Conversion Date, or (ii) in lieu of issuing such fractional shares issue one additional whole share to the holder.

 

(k) Reservation of Common Stock. The Company shall, so long as any shares of Series CC Preferred Stock are outstanding, reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of effecting the conversion of the Series CC Preferred Stock, such number of shares of Common Stock as shall from time to time be sufficient to effect the conversion of all of the Series CC Preferred Stock then outstanding; provided that the number of shares of Common Stock so reserved shall at no time be less than 120% of the number of shares of Common Stock for which the shares of Series CC Preferred Stock are at any time convertible (without regard to the limitations on conversion set forth in Section 7 hereof). The initial number of shares of Common Stock reserved for conversions of the Series CC Preferred Stock and each increase in the number of shares so reserved shall be allocated pro rata among the holders of the Series CC Preferred Stock based on the number of shares of Series CC Preferred Stock held by each holder at the time of issuance of the Series CC Preferred Stock or increase in the number of reserved shares, as the case may be. In the event a holder shall sell or otherwise transfer any of such holder’s shares of Series CC Preferred Stock, each transferee shall be allocated a pro rata portion of the number of reserved shares of Common Stock reserved for such transferor. Any shares of Common Stock reserved, and which remain allocated to any person or entity which does not hold any shares of Series CC Preferred Stock, shall be allocated to the remaining holders of Series CC Preferred Stock, pro rata based on the number of shares of Series CC Preferred Stock then held by such holder.

 

24

 

 

(l) Retirement of Series CC Preferred Stock. Conversion of Series CC Preferred Stock shall be deemed to have been effected on the applicable Voluntary Conversion Date or upon the Forced Conversion Effective Date. The Company shall keep written records of the conversion of the shares of Series CC Preferred Stock converted by each holder. A holder shall be required to deliver the original certificates representing the shares of Series CC Preferred Stock upon complete conversion of the Series CC Preferred Stock.

 

(m) Regulatory Compliance. If any shares of Common Stock to be reserved for the purpose of conversion of Series CC Preferred Stock require registration or listing with or approval of any governmental authority, stock exchange or other regulatory body under any federal or state law or regulation or otherwise before such shares may be validly issued or delivered upon conversion, the Company shall, at its sole cost and expense, in good faith and as expeditiously as possible, endeavor to secure such registration, listing or approval, as the case may be.

 

6. No Preemptive Rights. No holder of the Series CC Preferred Stock shall be entitled to rights to subscribe for, purchase or receive any part of any new or additional shares of any class, whether now or hereinafter authorized, or of bonds or debentures, or other evidences of indebtedness convertible into or exchangeable for shares of any class, but all such new or additional shares of any class, or any bond, debentures or other evidences of indebtedness convertible into or exchangeable for shares, may be issued and disposed of by the Board of Directors on such terms and for such consideration (to the extent permitted by law), and to such person or persons as the Board of Directors in their absolute discretion may deem advisable.

 

7. Conversion Restriction.

 

Notwithstanding anything to the contrary set forth in Section 5 of this Certificate of Designation, at no time may a holder of shares of Series CC Preferred Stock convert shares of the Series CC Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 4.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”); provided, however, that upon a holder of Series CC Preferred Stock providing the Company with sixty-one (61) days’ notice (pursuant to Section 5(i) hereof) (the “Waiver Notice”) that such holder would like to waive Section 7 of this Certificate of Designation with regard to any or all shares of Common Stock issuable upon conversion of Series CC Preferred Stock, this Section 7 shall be of no force or effect with regard to those shares of Series CC Preferred Stock referenced in the Waiver Notice.

 

25

 

 

8. Additional Covenants. For as long as there has not been a Forced Conversion, the Company shall not: (i) issue any variable priced equity or variable priced equity linked securities; or (ii) issue any additional shares of preferred or convertible debt that rank in terms of liquidation preference or any other priority senior to the Series CC Preferred Stock, without prior written permission of holder of 75% of the then outstanding shares of Series CC Preferred Stock. In addition, the Company agrees that upon listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq), the Company will not issue any Common Stock or Common Stock equivalents at a price below the initial listing price on any such exchange for a period of 12 months from the date of listing.

 

9. Inability to Fully Convert.

 

(a) Holder’s Option if Company Cannot Fully Convert. If, upon the Company’s receipt of a Conversion Notice, the Company cannot issue shares of Common Stock registered for resale or such shares cannot be sold pursuant to Rule 144 for any reason, including, without limitation, because the Company (x) does not have a sufficient number of shares of Common Stock authorized and available, (y) is otherwise prohibited by applicable law or by the rules or regulations of any stock exchange, interdealer quotation system or other self-regulatory organization with jurisdiction over the Company or its securities from issuing all of the Common Stock which is to be issued to a holder of Series CC Preferred Stock pursuant to a Conversion Notice or (z) fails to have a sufficient number of shares of Common Stock registered for resale in such holder’s name, then the Company shall issue as many shares of Common Stock as it is able to issue in accordance with such holder’s Conversion Notice and pursuant to Section 5(b)(ii) above and, with respect to the unconverted Series CC Preferred Stock, the holder, solely at such holder’s option, can elect, in addition to other remedies available to such holder, within five (5) business days after receipt of notice from the Company thereof to:

 

(i) require the Company to redeem from such holder those shares of Series CC Preferred Stock for which the Company is unable to issue Common Stock in accordance with such holder’s Conversion Notice (“Mandatory Redemption”) at a price per share equal to 120% of the Liquidation Preference Amount as of such Conversion Date (the “Mandatory Redemption Price”);

 

(ii) if the Company’s inability to fully convert Series CC Preferred Stock pursuant to Section 9(a)(z) above, require the Company to issue restricted shares of Common Stock in accordance with such holder’s Conversion Notice and pursuant to Section 5(b)(ii) above;

 

(iii) void its Conversion Notice and retain or have returned, as the case may be, the shares of Series CC Preferred Stock that were to be converted pursuant to such holder’s Conversion Notice (provided that a holder’s voiding its Conversion Notice shall not affect the Company’s obligations to make any payments which have accrued prior to the date of such notice).

 

26

 

 

In the event a Holder shall elect to convert any shares of Series CC Preferred Stock as provided herein, the Company cannot refuse conversion based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law, violation of an agreement to which such Holder is a party or for any reason whatsoever, unless, an injunction from a court, on notice, restraining and or enjoining conversion of all or of said shares of Series CC Preferred Stock shall have issued and the Company posts a surety bond for the benefit of such Holder in an amount equal to 130% of the amount of shares of Series CC Preferred Stock the Holder has elected to convert, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds of which shall be payable to such Holder in the event it obtains judgment.

 

(b) Mechanics of Fulfilling Holder’s Election. The Company shall immediately send via facsimile to a holder of Series CC Preferred Stock, upon receipt of a facsimile copy of a Conversion Notice from such holder which cannot be fully satisfied as described in Section 9(a) above, a notice of the Company’s inability to fully satisfy such holder’s Conversion Notice (the “Inability to Fully Convert Notice”). Such Inability to Fully Convert Notice shall indicate (i) the reason why the Company is unable to fully satisfy such holder’s Conversion Notice, (ii) the number of Series CC Preferred Stock which cannot be converted and (iii) the applicable Mandatory Redemption Price. Such holder shall notify the Company of its election pursuant to Section 9(a) above by delivering written notice via facsimile to the Company (“Notice in Response to Inability to Convert”).

 

(c) Payment of Redemption Price. If such holder shall elect to have its shares redeemed pursuant to Section 9(a)(i) above, the Company shall pay the Mandatory Redemption Price to such holder within thirty (30) days of the Company’s receipt of the holder’s Notice in Response to Inability to Convert, provided that prior to the Company’s receipt of the holder’s Notice in Response to Inability to Convert the Company has not delivered a notice to such holder stating, to the satisfaction of the holder, that the event or condition resulting in the Mandatory Redemption has been cured and all shares of Common Stock issuable to such holder can and will be delivered to the holder in accordance with the terms of Section 2(c). If the Company shall fail to pay the applicable Mandatory Redemption Price to such holder on a timely basis as described in this Section 9(c) (other than pursuant to a dispute as to the determination of the arithmetic calculation of the Redemption Price), in addition to any remedy such holder of Series CC Preferred Stock may have, such unpaid amount shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Until the full Mandatory Redemption Price is paid in full to such holder, such holder may (i) void the Mandatory Redemption with respect to those Series CC Preferred Stock for which the full Mandatory Redemption Price has not been paid, (ii) receive back such Series CC Preferred Stock, and (iii) require that the Conversion Price of such returned Series CC Preferred Stock be adjusted to the lesser of (A) the Conversion Price and (B) the lowest VWAP of the Common Stock during the period beginning on the Conversion Date and ending on the date the holder voided the Mandatory Redemption.

 

27

 

 

(d) Pro-rata Conversion and Redemption. In the event the Company receives a Conversion Notice from more than one holder of Series CC Preferred Stock on the same day and the Company can convert and redeem some, but not all, of the Series CC Preferred Stock pursuant to this Section 9, the Company shall convert and redeem from each holder of Series CC Preferred Stock electing to have Series CC Preferred Stock converted and redeemed at such time an amount equal to such holder’s pro-rata amount (based on the number shares of Series CC Preferred Stock held by such holder relative to the number shares of Series CC Preferred Stock outstanding) of all shares of Series CC Preferred Stock being converted and redeemed at such time.

 

10. Vote to Change the Terms of or Issue Preferred Stock. The affirmative vote at a meeting duly called for such purpose or the written consent without a meeting, of the holders of not less than 75% of the then outstanding shares of Series CC Preferred Stock, shall be required (a) for any change to this Certificate of Designation or the Company’s Articles of Incorporation which would amend, alter, change or repeal any of the powers, designations, preferences and rights of the Series CC Preferred Stock or (b) for the issuance of shares of Series CC Preferred Stock.

 

11. Lost or Stolen Certificates. Upon receipt by the Company of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of any Preferred Stock Certificates representing the shares of Series CC Preferred Stock, and, in the case of loss, theft or destruction, of any indemnification undertaking by the holder to the Company and, in the case of mutilation, upon surrender and cancellation of the Preferred Stock Certificate(s), the Company shall execute and deliver new preferred stock certificate(s) of like tenor and date.

 

12. Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Certificate of Designation shall be cumulative and in addition to all other remedies available under this Certificate of Designation, at law or in equity (including a decree of specific performance and/or other injunctive relief), no remedy contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit a holder’s right to pursue actual damages for any failure by the Company to comply with the terms of this Certificate of Designation. Amounts set forth or provided for herein with respect to payments, conversion, and the like (and the computation thereof) shall be the amounts to be received by the holder thereof and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the holders of the Series CC Preferred Stock and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holders of the Series CC Preferred Stock shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.

 

13. Specific Shall Not Limit General; Construction. No specific provision contained in this Certificate of Designation shall limit or modify any more general provision contained herein. This Certificate of Designation shall be deemed to be jointly drafted by the Company and all initial purchasers of the Series CC Preferred Stock and shall not be construed against any person as the drafter hereof.

 

14. Failure or Indulgence Not Waiver. No failure or delay on the part of a holder of Series CC Preferred Stock in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power, or privilege.

 

28

 

 

IN WITNESS WHEREOF, the undersigned has executed and subscribed this Certificate and does affirm the foregoing as true this 28th day of February 2023.

 

By:    
     
Title:    
     
Dated:    

 

29

 

 

EXHIBIT I

 

PRESSURE BIOSCIENCES, INC.

CONVERSION NOTICE

 

Reference is made to the Certificate of Designation of the Relative Rights and Preferences of the Series CC Preferred Stock of Pressure BioSciences, Inc. (the “Certificate of Designation”). In accordance with and pursuant to the Certificate of Designation, the undersigned hereby elects to convert the number of shares of Series CC Preferred Stock, par value $0.01 per share (the “Preferred Shares”), of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”), indicated below into shares of Common Stock, par value $0.01 per share (the “Common Stock”), of the Company, by tendering the stock certificate(s) representing the share(s) of Preferred Shares specified below as of the date specified below.

 

Date of Conversion:

 

Number of Preferred Shares to be converted: _______

 

Stock certificate no(s). of Preferred Shares to be converted: ________

 

The Common Stock have been sold pursuant to the Registration Statement (as defined in the Registration Rights Agreement): YES ____ NO____

 

The holder wishes to exercise on a cashless basis: YES _____              NO_____

 

Please confirm the following information:

 

Conversion Price:  
   
Number of shares of Common Stock  
to be issued:  

 

Number of shares of Common Stock beneficially owned or deemed beneficially owned by the Holder on the Date of Conversion determined in accordance with Section 16 of the Securities Exchange Act of 1934, as amended: _________________________

 

Please issue the Common Stock into which the Preferred Shares are being converted and, if applicable, any check drawn on an account of the Company in the following name and to the following address:

 

Issue to:  
   
   
Facsimile Number:  
   
Authorization:  

 

30

 

 

 

 

 

 

 

 

GRAPHIC 3 ex21-1_001.jpg begin 644 ex21-1_001.jpg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end GRAPHIC 4 ex21-1_002.jpg begin 644 ex21-1_002.jpg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�?B-X$^'=[\4_'6H3? M#S]HSX<^)_C9\$#XKU73/V-OB?I/PK_: T>SU;QM\[?%']J+X^_L:_';_@H; MXG_9&\1?#3Q]KWQ"_P""B/[1WAS3_P!E&/PEHWCF\^)?Q7L?^"'OPO\ CQ\/ M/&>@3>"9O"/Q&OO%&H?M0_!/PW\%?$'@'0$GF\;>-/%NO_"NSU'4_C)JVD^) M'_J^HH _E=\'?M_?MS?%#Q9^S[\&M!_:^_9YL)/CY^T/\;?ACHOQC^&_A*V^ M-5M<>$?!O[+WPO\ C+I?@W0?%7Q0^#?[$_@3Q-\^$?#6J_M%_%SX-?"'0_$W M[2_[/_@']IS7_AK\*/BKXF\_&SXG_$_Q1X#^-7[./BRX_JGHH _C MLTC]H+X;_&W]KO\ 8O\ VH?^"DWQ'T3PCHOP2_X)=_$_]H'QUX,U7X9Z9##K MOB3X.?MJ>!%^'7[1G@WX;W7@SQ)^T'\-K+XQ6W@CX=?M6>#]*\!Q:#X]M/#G M@_PMH=_,W@J'XB>&-:_3#_@MK_P4/^+_ .QI\%/ACXS_ &:/'OAO0]7\<_#7 M]ICXM>'O%>J^!-/\_P 2?#'@X_$(W>OVFFW?C%=2_P"$F\,^ M$?"OP]\5^)?BCI'A77=1'CWX(_"SP3\4?BQH'[+?&3X.?#G]H#X:>*O@[\7? M#S^+OAIXYM;/3O&7A,ZUX@T*Q\4Z+::I8ZM/X;UZ?PUJNC:AJGA377T^/2_% M_A2\O)?#?C?PM=ZOX-\8:7KGA+7M;T34/1[>W@M((+6U@AMK6VACM[:VMXTA M@MX(46.&""&-5CBABC58XXXU5(T5550H H _'']BS]M#XI_&_P#;W_:F^!'C M#XK>%O%_A3X:6?Q:OO#'@SX?>!]'O=!\+Z5X/_:%U'X7>&$\<^)WO]"^+'P0 M^*&CZ1I-]X6UKX.O!GP+@MOB([_$?XR>.M6\(?'7]EKQM MH_AB>\L1_8!10!_-[X\^%OAG]F;]@K_@E/??LI?$;0_A3\._'?[>_P#P3<^( M'QT^)_[/?A/P?\-_A[\9O"7Q,TOPO\/-0UC6M,^'8M/AEX9\$?$Z\_X53IU_ M=K9ZIX=\53VVAZ?JS:[XA\53:_=_GM^S_P#\%"_VBOV5OV)/@1X/_9I\!?^"D7CW]@WP7^VSX@_9_^ M,/@3XD:5XS_X*H?\%*_VJ;WQAJ8^$4VE?'[X=?"KQW_P3;U77M(TCQ>-:T[P MYXAF\5_!;]H'QNNF^'_@WX6TW7/%&IVWAGXJVOQ%^#'PI^'GC.Q\5_W@T4 ? MQV>)_P#@H%^VA\%/%/[8/@#1_P!KWX6>#;OQ!_P4P_;K\(3_ !R_;'\>:7I7 MPJ_96\'^'_V>?"WC3]A?X/68T/X/?%Z'P1X:^.DFJ7WCGPH?&&B:1X2^*?A; MX >/_AG\/=<\(?M _&33_$EW^MO[9O[5_P"U7\)_V7?V*?VR?#P\3^!_!7C! M/AMX6_:_^#?A/X8:7XD^(_A6]_:V^&D'P]^$?BKX>:'\:O#G@CXA3^.O@W^U MKXW^$OARW^$^O^!/#VL>.[;Q3>:;\2- \ 6.@^(;G2OVFHH _E7\"?\ !1G_ M (**^(OAW\(+WQ[\1/A[\$O'?Q2_X*"?"G_@D_?6OC'X4?#CQZGAO]HOP-^R M)\=O#?[4GQPTC1_!WQ.\/6GBOPAJG[>-CH+?"_P;/XI\/7%]\./@S9W,4*Z/ M\719IX?:?&?XI>!/C??GX#_&+PI\+=%M_P#@M'_P5O\ @EXQT?\ 9_T72?#7 M@SX[_M)>,O\ @FAXP^)WPIN/BKX7\4>*O%TGQ+^,^F_M*QW.A>&/ 'B;XEV. M@>*OB'<^&-)C\#R:KX=^'R^ _P"PZSL;+3H7M]/L[6Q@DNKZ^DAL[>&VA>]U M2]N-2U*\>.!$1KK4=1N[K4+ZX93-=WMS<75P\D\TDC320PRM"\L4QN)_&6C:]\(/B!\+/C+\2?VW8/$?PX\5>&_ MB-IWTU_P25_X*J_M%?M5_M$_";X2_M ^/O@?XNTGX^_L0?%K]H_P5/\ #OPG MIO@TVGC+X!?MN_$K]E35]*\+WNA?%+XM>&_&-KXV\%^%K7XB>)8=+\<>*-/T MO6M,U23P!JVH^"K:_O5_I(M;.TL8%MK&UM[.V1I72WM8(K>!'GE>>=UBA5(U M::>62:5@H,DLCR.2[LQL4 ?R_P#Q"^-OC[]EW_@L?^VAJO@GQI\.O &J?''X MJ?\ !#_PO)\'/B)X.TJY\9?MA>!_C7XL^,7[+7Q"U'X*:\WB_P )>(U;X"^% M;CQ'\6=>U?0/#7Q%_LNY^!&H6?B2\TCP(OC"RM?$]"_;T^*/[57P/\,W?[4W MQ?\ V8/$/B/1_P!K[_@C#\>9?AC\+M$^)OAOQS^Q-\2];_X*@_"/PE\8OV;_ M -HN[\5>#=-\#?#WQA\-M$T=/#VE^ ?'?Q$U7X^:KK?@S]HCXCZEHB?"5?"] MG\/?Z[** /Y6-(_X*?\ _!0SX[P>/?!7[/>M?![5?VDO&OPP_P""F/Q%TW]F M30OAWX?\1?%;]C7QM_P3Q_:F\!?"GX5_!CXLV]Y\5[F759OVN_!;ZW\/=0UW MQKX:TB[TKXS>,K#XA_#4#X::.W@JQ]Y_9#_X*3?M$_%OXT_%?QW\2?'>D^%O MV#OA'H/Q_P#VYM:^,?Q(^$-A\/[SQ!_P3S^+_ACPJ_\ P3XO_#EE9:Q+K^FP M:GK'@/\ ;'\1:YXEUC1]0\=ZQX3^ GAP^./#/@GQ%\3=+\*Z3_1=7*_\(+X( M%I?V \'>%18:KX8TSP1JEE_PCVD?9-2\&:(FK1:-X1O[;['Y-YX8TF/7M=CT MS0+A)-*L$UK5DM;2)=1O!, ;>DZKIFNZ7INN:)J%EJVC:SI]GJND:KIUS#>: M?J>F:C;QWEAJ%A>6[R07=E>VLT5S:W,$CPSP2QRQNR.K&_110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:?%C7O$/AOPMI6H M^&+=[K4KCXE_!?0;F)-1TW2V7P]XJ^,7@3POXNN# /#$:65_J0M_CY^RU?O9:> M85D=+#]I?X379O;EI;2[<6&AM$OB"^%O]GF>VTF2,W<$+S$@'OE>'[6[O8K5V=97NI8UM4EA@ MB=Q+/"K>CUY=\6H;2?PY9)>M:+$-;MF4WEE8WT7F"PU( +#J'@+XB0K)M9\2 M+HMK*%#JNJ0([VE\ >HT444 %%%% !1110 4444 %%%% !1110 45^8'_!:# MQ)XB\$?\$O/VS?'G@_Q?XX\ >,/ GP@U3Q;X5\:_#KXD_$/X3>+O"VO:/?Z? M+8:YIGC;X8>+/!?BJQ_LYV:YN++^W!H.KP1R:9XGTS6O#]UJ.DWGSI\%?A%X ME^(W_!6W]I'3_&7Q8\?:A\./V#/A)^Q%:?LY>#H?B!\;7U[3M,^(?PM^/>E> M(K7XD>,M9^,^M1?&!O&>JIK'B'XL:Y\2/"OB+QA\6M7\,_!&X\5^*Y6^#T2^ M* #]RJ*_E*_:%_;_ /VF/C)\4=<^!_BK7/AW\.I?AA_P5%_X)X1_ 5O@IK_C MNSN_&7PMU7_@I]XL_9PN9?BWXG\'?$[QE\//CE\(_$VD_##4-!^)'AJ?5/@E M\3OAI^T5X;^)/P4^(_[-=K8?#_PE\8?%7IUO_P %J?VE-*_X4&OB+X:? O6S MI'BNT\'_ +8[>#-.^(5LN@V6H_\ !6+6_P#@EWHWQ3\$7?C+QGH7ASX8>"/% M.K> _'7Q#\)>%?$7B?XW?$+5=>5/!=]I.C>!_!OC+XTQ '],]%?S.>)/^"Q/ M[:L7PN^'/B+PK\$_V6+CX@_$#P?^W5\2]-T/Q/\ $^;P%X/GT#_@F[^TKK'P M'_:!\)7/C?XP>//A!X8T:Y\<>'M0\(_$_P )^/K;Q!XHOOA9X7T'XF:GX\^# MGB70]*TW67_0C]C/]NSXJ_M#?MD_M?\ [/'Q!T?X0^%?#_P1U#Q'+\-=!\.R M^);WXA:]X*\.?&[XE?"#2_B?;>.M,UOQM\&OB[\/?&;>!+C3/$I\-ZQ\,?BU M^S?^T+X3^,/[,WQF^"Z:CX$\/?$_QZ ?JW17X43?\%'OVJ=>\:7-_P"'/!/P M'L_@]\3/VMOV\/\ @GS\+M.T\?$'Q=\=?A+\??V4/A]\??%GP[^,_P 4]-@N MM.\)^./AG\5!^S)\3]?\5?"FUT[X3^*?A5X.\1?";7[?XC?$[2_$7B6]\+_. M7P^\:_M2_LK?\&]/B[]MOP+\3_'/Q6_:G^,'[&?PC_:JU?QMK_B'XC?$'3/A MMK/Q4^'?@3Q!\1OCAIO@KXW>._CCIME?_"OP?XI\2_&GXC^$/!%IX<^$/CG7 M? FI7?@WX+> ;+Q#-X60 _IDHK\)/VL_BMX,_P"";W@?3?VV?AG^U+X]^-VB MZ'^R)K.DV7[,WQ1_:/\ '_QDT/\ :3;QG\5_V5_ 7PU_:]TC6O%'Q0\2P>!/ M!GP5U;QOIU]\>?BA\,?AKXMT34/AE\8[W5X=)LM9M_#D'B'B_B[_ ,%//VTO MA5\5)_V7Q\-?V:?$?QKTCXJ_M@_"B[^*T1^)]A\(=<@^"_\ P3]\ ?MY_"+X MC/\ #JPU_P 1^,_ 3:MIGQ&TGX8_$[X6:O\ $'Q-=6VJV&-.O?V?/@=8^./B9XZ_P""6VM> ]'M/B?X M^F\*:1\'/^"I7AOXFZAX(\.^+O%LO@(:S>?$[X.7OPOO[[Q1XKTCP-:>%?&M MIKECHNE^#O##Z?/XDO.?\/\ _!=KXX>"_AN?B'^T-^RG\*-,TN]^ GQ@\1^& M=9^''Q]\31>#M4^./[-__!1KX??\$V?BM:>,O$?Q!^#N@CX:_!+6?B+\9/AU M\75\6BS\=>)OA)\'[#Q3?>(-%^(>ORZ=I4 !_2]17X)_$'_@J)^V!X9^(]Y^ MS7X?_9N_9NU']HOPE\5?VC?A/X_U36_C]\1])^!UK OBQX9\._$/P1#X3M_$'A?Q=I>KP:-J&N>"KC_ (6'I/Z1 M_#']J[P]\9O^"?\ X)_;:CO9/@]X:^(_[).C_M+7%]J7A[6/B5+\*-/\0_"2 M'XD7\U]X7\/VMAK?Q$;P"MQ,_P"R'M=#C634[2@#[)HK^+ZW M^./[/OV9/V#;'PWK?C_XO>)OVP_V'_VNM,^/ MO_!03]E#]G3Q+^WS^S[\7_B!K&OZW\"I_$4?QKL?#'Q(^"?B/]F3PS!X%\-? M$;3-2^"OA?Q+I^DP>.;S]6_'7_!6SXP^"-7^+/Q$LO@W\*/'7P4\#_M%_MZ_ MLD:3\+-)\>>*- _:7L/C!^Q!^RA\;?VHK/7_ !M-<^'-=\#Z?X9^.^G_ +.7 MCBT\)>%[31X]<\.?#;XJ?L]_& Z_XM'C'Q!X \.@'[S45_*O^T!_P4F^-W@/ MXE_LC?&'QOXH\%^.O%?PS^*'QN\(ZGX;_9>^(7C?2/V1/&?PI_:5_8G\ ?&S MX'?'?]K9[OQWXI3X6_"_]GS6?$=O/\4_'_B7P[\5-=\%?!KPMXV_:S\*>%O MW@_QWHWP\U/]T/VH/VFO%O[+G["/CW]IZ6R^&GQF^(?P\^#FA>*[72= \27W MPZ^&_P 7OB'JUMH>EZ7HWPZOYA\3M>BM_B-XMUBTTWX4^#[&3QUXM\7ZMK7A M?P+H=YKWB37;"[N0#[8HK\1?#?\ P5.^-GB?4_!6BZ-^S)X=O[BUC_X*2^(_ MC/+=_$37K#Q)X:\ ?\$ROVTOAE^S5\5;SX=^ /#?@7X@#Q[\1?B/X%\>2>)? MAS\/(O'-K8?\+36T\ :MXX3PC$_Q)O?H+_@G'^V]\=/VR/#?B/6OC7^SAX,_ M9\N+[X2_LX_M"?!^V\-_M(?"GXV-\0?@W^TMX,\2:]X7U_4-(\":I=^,?"&G M:/XG\$^,/"6D^-/%'A?1/#/Q6M](N=;\#0KJ6A>.?"?@\ _3BBOY1OV4_P#@ MN#^UAJ?[%'PQ\<^/_A+\)_CI\=_"_P#P3P_:,_X*=_M$>)]9^*UM\$/#FL? M3X0?M >./A[IW@+X.^'/!WPG\=3^)?B?=^&O"7B3S[X:-9?#CP?)H/P\L_%_ MC?4K[XQ:?K^E?JC_ ,%#/BQ\>-'UO_@ESXH_9GN&N=9^*_[:J^&+KX7>-/B% MXS^"_@;XBZ)XJ_86_;$\;Z-I_P 8_$?@7P[XP\4MX6\#:SX5TCQ_<^!9/"OB M71M>\5>&-"CU723>:5I>IZ: ?K117X3? #_@L'\3_P!H+XF_"+2M&_9+\-^% MOA'>0?LO:!^TE\1-8_:K^"OG?"+XE_M8:3\1;3P/H?@"T\0W_@BV^-OA'2OB M7X9^'?PVT#Q/X+EGUKXW:Q\4]0M_A;X.N/$?PNU?PKXG[G]J#]L#XC_L]_MJ M?M&:9\./AK\6_C%KGA?]B7]AKQE:^"W^(OB"_P#@GI=G\4/VU?VAOA!XG\6> M'/@OX4\ >(O&EW\9M#\)?VWXPU;2?AFOQ%^*W[3.B_#_ .'OP:^'?P^TOQ-X M8L=1\1 '[045^ =W_P %E/B!)I_[-_B32?A%\%)/AU^T)^R5I7QK\)_%^Y^* MOQ;G^%OCOXYZW\!OVE/BO)^S[\/O&-A^SY+X;T7Q5X1UWX$>&=+U+P?\:-=^ M%OQG\:>&OB5K6I^ _A5J/B/X.>.O"LG&Z#_P6M_:)\?^._#WP=^$O[%7@?XA M_ ?"7]C/XR?"CPK/^TMIO@*S\3:7^TO\ L3_M"?M8^*O ]]J?C7P!IT$? MBSPQXE_9QUKX9>&KS0Y-.$^+.O:7I%K\,/$O@WQ( ?T745^ ^F?MX M_&+]J?\ :P_8CN/A]HNE_#7]G/PW^WYXJ_9S^(K^%_VB+/Q7XK^)?Q)M?^"3 MW[27[2/B/P=XU\&_#3P_JGPZ\4?!WPSXCU[PK<>#M//V9OVZ?BA+X-\*>)_B;J5A^R1^PAHWAKX8>+ M?VB?$W@7X$:UXO\ VH_^"C6N_LMZ%JD7@?2OA#\0+3P)\0[*\\7)/XB^*\,? MBV]\7>&-.\)^#[OP[X9TWPK+KNJ '[#=*\;2>-?AMJ/Q"_8]O\ XL:)H&K:/XUU[PWX+O-0 M\'^+9O NC:M-<^(?"GAN\T]=0O[+4]*LS92+7YQ? #]OC]KCP/\ 'U?%?Q/N M?"OQT\-^-_@5_P &_G@/XN6?_"XO%7ASPEX,\;_MW^//V@/@SXI^,/[._@/2 M_A'>>"-9U;Q5\2O&/@#QO\0+/4+;X/6^L> _"%OH5GJM[>:)X0L=/ /Z+/"&@Z?I>O\ @#7/!A\%6UM?W^LVD>E>)M1U[4=$ MT:&WU+P'XD$OP9\/O^"V'QV\4>%[KQ%XB_9*^%6AR^./V=/B3\:/V?\ 2]*_ M:4UG5=1\7ZW\.?VV/ W[%0\+_$"SUGX(^%FT'5O''BSXI>#O$'PY\!_"B;XV M?$_Q^]E=^ /!/A7Q'\6?&'@?X?WX!_1717\WFL?\%V/BMI7P@O/B8/V0O"D] MY\*OV=_VJ/C_ /M%:%>?&WQ?X=O?#EE^QO\ MM:'^R3\4] ^&VF>(_@-I>K^ M(=1\9:5:?$#Q[\.[3QU;?#W4],U70;?P;\1;#PK*MOJVN>MZK_P5]^/^H:OJ M7P0^%/[#^F?%?]KS2OV@?VT_@^WPST3]HG2-'^#NMZ1^Q9X%^%7Q2\0W_A?X MU^)OAYHVJ:GXH^)FA_'+X6?#3PAH%[\,-*;P_P#%'4?&U_XR_LKP3\-]>U*X M /WHHKX9^+G[7VM:'X%_8YU3X,> O"WC;Q[^V]\0/"7@WX3:-X\^*6C>'_A[ MHUEJ/P$^)G[4'B?5_%_Q3^$>F?';1;^&R^$?P?\ &FG>$]0^&-G\2?#/C#XA MZCX-L].\1#P-J]]XZTW\DO ?[6_[5/[>O_!1[]E;X;Z79^+?VZOX[MOA)KOQSL/B!XVO]7\,_$O6?V0_B M!^V'X>TW5_"VE_!'4/A3I"ZAX,^&NNZ&G@O7OV@M)^,DMK>V'Q-?X9V7PSN? M#>O^,?F;_@I!XT_;GM?VTY?@Y^Q7\5/CU:^-_&G_ 3+_:G^-WPL^%?PQOOV M;'\/I^U'\*_BE\!_AS\&O&7C3_AJ?PJ?!=M\*[I_BS,=1O]0MU MMO$%AX,T/6[ >)== /Z J*_G[\1?\%I?B?X.T']JGQ!JG[).GZWX*_95\-_M MF>!;_P"+T/QC@\%>&OBG^UE^P[\%;/XO?$?X4>%_!'BSP;)JUEX+^(5IX,_: M-N/AYK_@OQ?\9?'^B>%O@H_BCXE?#;PGIOB)I]([WXV?\%;?BY^RS\7_ !'X M!_:7_9#L_ WA/P9\'/C+\9M6\9^$?BUXJ\;Z7X]T3X*?!#]K#]HCQ1H7P$\6 MWOP-\(_"KQ_X_LOAM\$_A"GB/X0?$CXB? [XV>'=3^)WC7Q?I/PU\9_ KX>: M7\9O&X!^X]%?A?K/_!6;X_\ A;Q7X,^#WB?]C;X?6_QX\6_$;]B'P[%X?T7] MJS^WOA/#X'_;P^'?[0M_\.?%4_Q4LO@2=>MM;^'GQB_9V\7?#_XC^&H/A;J< M5YX!?3?BU\/]8\7RZO#X!L_>M*_X*?:-I/\ P3 U;_@HQ\3?A9<:+/X7@\:> M'=>^%/A#Q=;ZWI]]\3_"/Q\US]F:RT;1?B)XGT3P98Z7X#\5_%/2K*YB^(OC MG0O"NF^"? FL-XN\>6>BV.A:V+8 _5:BOPMU/_@HO^TUXJ_;#_9H_9%M/AE\ M./A7\2?#O[8=_P# 3]M;1M$^)NM?$'P-<>$_'O\ P3X^-O[77P;UWX!?%/Q= M^SWX/UKQGI\F@>$+WQ+K\NM?"7X<:CIWQA^$)OCCXLU^X_:&U M?]M+2OBOX*O_ (A?&_Q-X2^!/Q*\5_"O7;.]_9B^,?Q2ETOPOX9_:&\4>/- MU?X>Z3!'8_%;QCJW@'PN ?TXT5^4_P"S3_P4&^//[17QR\-?"-_V++OX=Z?I MOPJ^!/Q)_:#U77?V@/ >K>*_V?+OXQ:/^USHNI>%];\%Z5H7E^+=4\&_&[]E MJW^%]UI^D>([+Q6=&^)6D>.O$?A'PA<:!XC\&Z?\'?# M^N6WA_P3\ /^"LG_ 3-_9I^'OAWP9XYA\$M\1]$^._@;]F'Q9J7P_\ B]X@ MF^"WC#Q'8_#_ ,:>+?VD8=<^(7B+P=K[:W9Z/X)\._#ZP\&:_P"&+KQT?B> M?T/T5^!OP[_X+F:1\0K[]B2XL/V=3)X7_:GU_P"'?PZ^(-YHGQ:N_$GC'X-_ M%/XA?M"_&C]E5+6P\%:9\)6M=1^$_ASXT?!#Q''-\7OCYXM_97L?B;X+ODF_ M9Q\.?'3XI^%/B1\(?!7MG[!O_!5C5OVPOC?IWP.\:_LZQ?!;7?%/P0^._P : MO!>IZ1\6+SXF6UY:?LQ_MC^+?V*_C/X:\7:?K/PG^$^I^$=5M?B'HGA_Q+X$ ME@M_$:^*?"/B&_;7[?P/K_AR71-2 /V&HK^<^?\ ;$_;5\;_ +37]EZ5>^%O M$B?"_P#X+>_'O]CKX=?!WP!\3+?PA\.OB/\ "O2O^".GQ2^.?P^\._'7XA+\ M.+SQ%IVE^$OB8--^+/Q4DM-#^)^J^#?%MSXMT/PQX!^)NK?"'X56.M]_\#?^ M"WVI?'WQ;\!H?!'[(6O7GPQ\<>!/V)-8^/GCV'XO6CZG\ /&_P"VW'X@M/#F MDVFBWGPUTWP5XY^''PV\1:=X?T'Q1\0/%7Q3^#_BWQY<>*H(?@;\(_BIK6AZ M]H-B ?OC17Y/_MQ?\%,]9_8Q\;_'GPP_P$M/B/I/P8_8(\0?MU66N)\59/"5 MQXKTGX<_&+2OAQ\4_AO/I2_#;Q4WA_5],\,^(M"\7>!?$'VO6--\7ZP^I>$] M>MO MC9+XOF^>_'O_!<71OA!>_$?Q=\6_P!F+Q+X7_9_\)>.O^"D/P=\'?%# M1?BIX9\4^,/B!\9?^"=-]KT^M>&#\+XO#NEVW@WPI\;O#?@;XFO\/O&OB/X@ M1W&A>,O =QX>\;>%M$\*^)?"/Q#UL _>2BOYOH/^"F'[5OP*^-_[7?P\\6? MJ\_:%_:+\6?M6^!_AW\$OV6/!OQ>\4:QX%^'6C>$O^"7'P._:U^+'A3PC\7= M#_9MN-7U6UN/%6MZAH'A"^UKX*>'+7Q%\1/B/H)?B)XU^.#^&-,TG5?$ M/PT_9,^,%[X@^(7A_P"&?P:^.7Q#\#> /A[\//V@OB/KWQ7\;:1X&\>Z'\/K M3X.6>JZ] M+?\ @DY\/_ASX!^)'[47PCM?VK>'K'X:>'_#W@76O"OBCQ)<\-_P#!=#6_ M$EE\'O%@_8YU?0?AW\0_@?\ L,?M"^+=3\1?%_4;7Q]X3^&_[=G[:7BC]C'X M?S^$?AIIOP4U:]^*&K:;K.D^'_BK81Z?KOA[0?&OPY\0FXT#Q$NJ+X8LO&0! M_0517X6^$O\ @LEXT\>^'M6\2>%/V.KW^Q_'7QZ\'_ W]E7Q)XJ^.-KX0\'_ M !AN]<_;*UG]CGQ9JOQ$U;4_A4^N?#B]^'FL:5IWQ,\1:?\ "/PK^TYX>C\) M^-? 7A6?QI8_%/Q!/X%TOZG_ ."27Q*^+WQ1_8H\/Z]\?M ME^+-%\!^#='UNT\-K/8^%_#P231=/ /TKHHHH **** "BBB@ HHHH **** " MOGC]IK1O$FL^ _!B^%I?%ZZCIG[0_P"RQK-[:^"]7L=#U"^\-Z?^TC\+9/%T M6K:A>6=U._A"S\+MJ^L>,M(TR;3[[Q-X9TS5/##7C:?K-_8WOT/7A7[15OI% MS\/_ _'K>J:UI%FOQV_9(+Z75[3]IKX1W7A_2Y[#QY:7FAP: M+K>O0Z;HOB/6[&%/&?AKP]?ZIXC^'%W8?$/2O"]];@'NM>._&[1]4UOPII]I MI-S):W,?B&TN'DCTCQ?K+- FFZM&R&U\%6EYJL8,DL;?:+B)=/0J(Y9!DT444 %%%% !1110 4444 %%%% !1110!X-^TU MXH_9V\$?!7Q9XQ_:M'P\_P"%%^&;WP=K7BE_BCX>L/%?A"'6K'QQX;E^'<[> M'M0TO6DU7Q+#\21X1D\"VMAI5]KK>.5\.-X<@;7UTTCY\_8\?]BKQGXO^,WB MO]G+]F_X:_!KQY\$_BC\2?V0/$GB32_@M\-?AGXPUZT^!=E\*? _B"P\(ZSX M2LQJVN?!W3K'P9\*/"&AJ+RWTR"Q^&_@OP]=:+I+>#-#TO3.9_X*W_LS^-?V MNOV ?C7\#_AW\//#OQ=\8ZGK?P1\>:5\)_%&N:/X7TSXJ6?P9^/WPN^,GB3X M7Q^*/$*_\(_X;U7XE>%/ 6N^ ]$UW7YK+0--U?Q%97&O:CINC)?7UO\ CSXU M_P""2G[8NH_%C]HBY^&NF^$/AGJ'QT^,7_!9LP?'+1/'D>B6FG_"']N']D#X M6^#_ -FZWU^7PYJUKX_FT?P_\=O#OAK4->\'6WP\UJX\(>+?A'<>,_#U_:Z? MI_A'6/B0 ?NW\0?V>OV O@3X1^*?Q]^('[.O[+/P^\+^$_%C_M>?%OXDW7P+ M^&EK-;_$GX3#Q3XZMOVAO$NI:?X0EU?5_BIX(GUSQCXCT+XA,+_Q[INJ:]KU MWHFHKJ>MWAN_G?X(>(?^"9'[0/Q0T/X0>'/V3O"W@KXO^!_"GQ$^-WP[\"_' MG]@#Q;\ /$T7P]\6?$WPU??$7XM?"H_&;X)>"[2YT[QG\2M=\#^*?B+_ ,(G M?CQC9>,-?\,W7Q8T+0/&DJ6EO\;^'_\ @F%\7OB5_P $R?VXOV5H_@_\%?V- M/%?[27QKC^,'PO\ @D/&<'QD^$6@>)O +_ K5Y=-^(4WPW\$_#?P%H?PD^/G MQ3^"&MWFH^%?@[\+_#_]D_!CXAVWB_Q-X)M/C-XB\>?#7P_[/^U=X(_;[_;7 M^"?C#0M#_9.\&?LUZ]IWPAA\/ZY;?$+X]>!KCXT_%+Q7#^T!^S+\2?BA\ _@ MO\5O@[:?$_PMX<_9&_:"^#OPL^*GPL\:>+?BW:>"?'7Q(\0:S\+#X\_9Z\ > M#_#GB)]1 /T\N_V5OV7[_P %^%_AO??LW_ 6\^'?@CXBM\8/!?@*[^#_ ,/; MCP7X0^+3ZWK7B9_BCX7\+3>'7T/0/B*WB3Q+XB\0-XVTFQM/$K:WK^M:L=3- M_JM]<3]-X)^!7P1^&GBSQGX]^''P<^%?P_\ '/Q&GFNOB%XS\$_#WPCX4\6> M/+FY\2^)O&EQ<>,_$6A:18:QXHGG\8^-?&7BR:;6[R^DE\2^+?$VNNS:IKVJ MW5W_ "M_'3_@E]^U3XNT3QA>?";]C35O /P\OO@O_P %7;_]E7]G'2OBI^S] MH6H?L:?$?XY^"?V'=:_9'\):?_9/QMM_AOX)U]_VQ?@#\8?VN?#Y^"OC#Q?\ M-_@+XB\8>'TT/Q/INJZ-I=I8=G\:/@?+\"?COX!\(>-?V./'>J_L\_'G_@KK MK?B[X'?L8:!\2OV:+'_A=?PP^(7_ 1Q^)^D_'WP['X$\3_M.^%/@E<^"M=_ M:T\#:CX\^(GPU^+OCO0_#'BZ;5+J#1M!\3W_ ,4KSPGXN /Z3M1_9:_9CUCQ MYXN^*>K_ +.?P(U3XG?$#PSK7@OQY\1M1^$/P^OO'GC;P=XDT?1O#WB+PGXN M\7W/AZ7Q!XD\,Z]H'AWP_H>M:#K.HWNEZIH^A:-IE]:SV6EV4$'>_#;X7_#/ MX->"M$^&WP@^'?@7X4_#KPU#/;^'/ /PV\(Z!X&\%:!;W5U->W,&B>%?"^GZ M7H6E0W%[^&7[*/[-?PZT# MXS:-?>'/C!H?@3X%_"_PCI'Q6\/:G;:G9:EH7Q*TWP_X6T^R\=:-J%GK6LVE M]I?BB#5+&[MM6U."X@DBO[I)?)_BM\!_V(/V6O@+XU^+,7[%?P:';>.=#DM?#7C#5#X;68V_R=\4/^">_CWQ+_P28^)'[/FFW6I?\-BZ M_8_$7]L+1?%G@C7-'\":C:_\%%_%GQ,\1?M=PZIX0\227<&G^$_"#?M-:W-X M.TU9M>@:Q^$$Y\+WOBY(S<>(:_./5/\ @E)^U\GPP_X*<7][X9OO$WC?XP?L MA?M0V/[+'PW\.>)/A/X=T&#]H7_@IO\ #WX0^)OVS_A=HFI:GXYABT;X7_"7 MXX?L_>#])^"6I>--?\,0:;\/OB)XRT*^NOB)<^'=(\<:J ?K/9>,O^"7?A7Q MSX?\"6?[/GPA\)>*?#G[3'[-W[&OA6.3]DO3_":>'OCGX3^!UE^V%^S)X+TF MZO/AUI9\,VGPI^'OB.S\8?#/47&EZ;\+O&.LVND^'9-"\4ZO907GUM!^Q/\ ML:VBSQVG[)?[-%G'=>&/B9X)O(K3X%?"^UBO?!?QIGU"Z^,7@Z^BM_"\<=[X M3^+%YJNI7OQ*\-W2S:+XZOKZZO?%%EJEU,\I_$>Y_9+_ &R-0^-^E>+E_93\ M:67@[4/^"K/_ 3;_:GGAN?B9^S/'I/@3X2?#G_@F_X"_9Q^-/BWP_X1T_XN M73V&H_"3XG?#RV\(^.;31M6NO$GC/PIJNF7'PC\*^.=&\-W5QX@Y[]OGX2_% MCXX_\%3OBUX._9;'CJP_:9T']E/_ ()4>./A]\7?"/QOT'PIX9_9NF\)_MY_ MM?W7Q/\ B5\4/A%XA^,/A2+XN^$U^!FJ>*- U'P1IOPH^+-SJ^C^-=0\!3V_ M@?3OC=J>N:\ ?O#8_L9?L?Z7Z9^RG^S=IUYX>UGXD>(] NK#X'?#*SN= M$\0?&31+'PU\7MW\,1R:?JWQ4\.:7I>@?$?4;1HKOQOHNF:=I?B674[* MPM((?6?"OPM^&7@3X>:;\(O!'PZ\"^#_ (4:-H$OA31_ACX7\):#H'P]TKPM M/#-;S>&=-\&:586GARP\/26UQ/;/HEKIL6F&VFEM_LODNR'^-SXW_!+X^_LW M^%_VP/C=^TOH'B+]CS2-2^'WB[XQ_LU^*O&OQV^!WCG0?B1_P4+_ &>_VY_V MOOVO/V8_AMX:33_C'\0?C9\5O&?Q\_9P\9V'P@U=_&EC=^,?BIX4O?B#\)K+ M1?!#Z#\'/ @_9KQ;^R3\?Q_P2,^)'PST;X:_\)]^U;^U)XGM?VB_VA/A>_BK M5K"QM?B3^TK^T-X6^,W[3'@#P'_;GQU^"FGWNA?!KP=XB\8^ _A%\.O%GQO\ M ^!?B'I7P[\)^#/BUXAO=#\7^.;C60#W/XR:%_P2J_93TWXE?!WX@?LK?L\^ M#O"&I_L=?%[]HWXJ^#O#G[(GA"^^'OB7]EG]CC6_!VM^,;/Q38>'_AU+X5\6 MV/P]\0?$S0=;\*_#>ZCU6]M=6U/;/X<2:_IGAF'Q) MI)TOX _L_+#<>'=5U2TTVP\+?"71/"JC9X=\.Z5'_/OJ/_!/S]O*+X%^-O@I MHO[/_P 1]4TT_L(_\' WP"^'%UXK^*W[,EL=,T_]N?XR_#GQ/^Q%\%[RR\*_ M%K3O#VAZA%X)^%5C!K^G>%/#>F? [X7'4_#FCZ-K.FZ=875AX:_4#X\?LM?$ M+XA77_!&WX]:?^S9/K M^.[U#QE>^!]=N_A+\;I_@CK=QHWPQ\:^+/MC^#7U/P,_B==.TK6+< ^^-*_8 MK_8XT'PQX,\$Z%^R=^S5HG@OXWTCP[8_%;PYJ^JZ%\2;/2;.TMO'.D:C>Z?XGBU2UN98F[N\_9^ M^!%_\%Y?V<+KX,?"Q_V?9O"8\!M\#T\ ^%H/A*G@E8EAB\)V_P /;?2XO"EK MX>MXU1;72+;2HK&U,<3VT,3Q1LO\BVN_\$FOVY_!WP#_ &&(_P!G[]FGQ=\, M_C3\'/V3_P!G6_UO5='^/?P>U#Q]X$_;Q\"_$_\ 8W^'?[1/C+QGXB^(/QM\ M<>"O#G@;QK^RG^S7I?AOX/:[^R\TOC#7O =AXO\ @7\3-4^&GPO\9ZI\-/&_ MLWC7_@F#^U/?>(_C1J\?[-7Q;DM/C=\1?^"O>C__AG\=?V=]$^(7Q!_9\ M_:/_ ."@'P"_: _9K\%^'K_XC_%+6O"R:%=>";#XR_%GP]\$_&6D6GP9\6^* M[OXG? 7]H;0/AWX6_:Y^+OQ*M0#]M/B2W_!,?]B[XM?"S4->^#OPG^&?QHU# M4?BU\5/AW=_!_P#9@\1>+O&_A2+XA7_P_P#AO\=?C!K$GP*^&'BC4/A=X(\7 M:OXI^'/A[XL_%CQL?"O@;5M7U'0Y?&'B674(A<0_7_P._9H_9U_9DT77?#?[ M./P(^$'P%\/>*-;?Q+XCT/X/?#CPC\-](UW7WMHK+^V-5T[PAI&D6E]J"6<$ M%G#UC]ISXM?&SX7:YXJ^#VF^(=)UC M7O!'BKXZ_#;]E?QQ\2O!7P^_9X\2V_PU\.ZPFI^]_!#]@[XW^)OV@OV8KGXR M?!+]L+0?V=;;QA^U3\4/$FG?'7]JCX'>,?&GPC^*;^(?^"=/QJ_9^COM+_93 M\3^$/"?A/P5!^T!^R-\5_&_A/PUX+E^-^CWVHWVE^//B9XP\/^(/CYXP^$O@ M0 _5]OV$O^")-?^/\ _P *OU/P[X7\1:YX'NOV MDOB=XS\;:UXLO- U%[[7-%\!_&+XB^!_&4,.@7L4/PZ\4P_#BX\%:=HMQX;^ M'-GH&@_2OQL_9]^"/[2'A?2O!?QX^%O@OXK>&=!\4Z5XX\/:9XST2TU=?#GC M+1(+^RTSQ5X^#_ -J#QK_P2*\6/\2/A9\4_ASX M5N?%7@C]G&\^)7A_]H73IO"'C_XC>#_!_P 2=1AT*T\ ^$M7^$GQ*U7P=X)U M[P1J6K>+-=7XBZ7I;?!SXP_//PN_9>_X*4>$T_X)I?$3XK_LG?'GQCK/[-GP M0_9[\&_MR>!_#7[4_P /=1\5?M(>(OA_\3OB!K_P^\46%M?_ +0&G> +CQY^ MRGK7P%^#7Q8\7^+X?'&K:]^U?X+^,^B?LYZ]9/X+\'O8:( ?T?V/[$?['NE_ M$'X/?%;2OV8O@7I/Q(_9]\#6?PR^"/C/2?ACX1TS7OA;\/=+M+NPT/P;X+OK M'2K=]#\/>&K+4M9M/"FF6FRV\)VWB'Q/#X;32X_%'B!=2N?$_P#8V_93^-7B M[6?'WQ;_ &?/A1\1_''B#PIX7\#:OXN\8^#=(UWQ'=^#_!'C:P^)7@WPV-8O M[>:_MM)\*_$/3++QQX?M+2>"/2/%<)UZP$&IRS7,G\X>G_L3?\%1[/X/?$OP MWX^'[='CGXT^([8Z;\1_'&F_M8_LU>(_@IXS\9^$_P!ISXF_&/P5XU^ OP?T M?XC?LQ_%[Q-\*?B1X(?5OAQ\5W^-7[3_ .S]\;O@M\,?B9\$_AK\$M \?1_! MG0-<^!OTI^V7;?$FY\;_ /!![X+/C_\-;OQ5)X<\:7.I6>C>,O$7QT75]7> M&+6-3\8ZA'J>KZE=@'[0Z+^Q3^R'X<\0>!/%.A?LT?!'2=>^&'ACPWX,^'6H M6/PW\+0/X)\,^#M.\;Z1X2TOPQ"FFBUT>/PQI'Q-^)6D^'[BR@AO-'TSXB>/ M-/T^XM[/QAXBAU+S6#_@F1_P3QA^'>H_"=_V*_V:;[X>ZO=>"[W5O#6L?"+P M;KEKJ=Q\-9/%1^&K:A=:SI5]J-['\.++QQXPT#X>V]S>26_@?PEXDUCP;X6B MTGPI?3:,WX4>%?V:_P#@H7X"^('[.WB[]K/Q%^T#X>^$_P +_AO^S7X&_;8^ M,^J_M9Z#8?"#5/V?_!W_ 2T^-WA3]JOXF^(_B9=?M'0>-_!5UHO[3GBZ8>+ M;;PQ\&_"NI:CXF\ ^'/VI[GXY>(O%NK^ ;OX*^6^%OV>OV_?C_\ L"Z'XT^" M7C_XL_M&^+?B'\2/B?\ LW^%_C%X$^.-U\.;G7/V/_V,OV8/VQ/V4OV3_CIX M:L?'/QF\'^'?%.O?M-?&W5[;]IS5_C3K'C?7KK3?B/\ %+X7?&[1_A_\4?#' MPB^'.GZ6 ?T&^!/AK_P3Q^(_[3?QH^*?@KX/_"[4/VG_ -E37_AM\-_BQXSE M^#VL^'_%?PZ\1>%_@]J&N_"Z+2=0UOPKI.EZU?Z5\$/C7=67ASQCX#.ML/ _ MBBR\)Q:\]AI6FZ/IG6Z)\*_V'/V[O!_@[]JZV^%GPT^-WA[X\_!3X<6?A7XI M>*OAY>V.O^,?@CI_CK2/CU\+])N;?QCHNB^+]-T+0OB39:-\4?#.BZWINF7W MAWQG:VOB"WL]/UF+SE_$OX:?LI_\%$M-_:JUS]H#5/A9\>O"7C_XO_'+_@F/ M\^'=6\&?\ #-.AZCI7QX6#X<_#3XR7 MW@'4_A7X<^-=L ?U">"/V?/@;\-M(^*F@> _A)\/O"NA?'+QYXW^*'QET;1_ M"ND6VE?%/XB?$NUM;+XA^,_'VGBU-IXJ\1>-[.QM+3Q5J>LQ7=QKMM;Q0ZD] MQ&H6OD+2/AE_P35^$7B;Q!\$%^'OPH^&NK? _P "_L-7VM-XT\)Z]X2\/:-X M2\#>./$W@3]@<6OQ=\$O&.K>#/BAX3\1Z)\'[/2O&_B+Q7X:^)<1D$% MCXPUJQGU'\_/^"C/[+W_ 4"7]I7Q]\:OV+=,\4>+O#.G>!_V<_VP/"W@>[^ M,GB?POX2\9?M<_L>_%37?"NJ_LX3Z'8?$7P^NG?#K]J_]GGXP3:KXKT6;3;' MX9W/Q(^ /A[Q#KZW/B3QCKNMV'C7[1_[!_[5^B^ OBG\#?"FA?M%?M.:%X5_ M9@_X(W>$--^*NO?$P/KOQC^-7[*G_!0O5OC?^U7XR\,MXX^,EMK_ (0\6WWP MI\3^&?&]K>Z=>>']+O[K2=8\)Z!XHO\ 7/!MG9* ?N%^QW\/_P!BO1?#?Q ^ M)'[&7PC^%_PWT;QU\3/B3X,^)>K> ?@\WP@U;Q!\1O@=\6OB7\-_'_A_Q1I. MI>%/"7B*7_A!/B[9_%;3[.UO=.70HM:U7Q7X@\,">T\5W>K:M"__ 3P_89E M\+0^!YOV4_@?/X-@\%>*_AO#X6N/ 6BW&@1> ?'7Q(MOC'XR\'II,UN]D/#W MBCXN6-A\4-&_A]X[^)/_!;+3/CY=S?$6XUOX37NE?%+_@H/)^TS^PUXQNOAU<_$ MO5O#.A6VM_#OQA\7+GPYXD\&^!M+\5:?KOC37=$\;PV7_"1W5S=?*_Q0_8X_ M;!UOP9<^-;[P9^WMC4_VQ_V\?"G[5GAW]G_]I;PGI7[2/Q;_ &<]<^)W[:6O M_P#!/WQU^SA%\7_C)/\ !FP^%?P9T[]J^#4KKP--KGP;\4Z9XOT[PU\09/#7 MB35/@/X!$@!^Y\W_ 3P_87N-%UOPU-^R=\")/#GB30?'7A/7/#Y^'?A_P#L M34O"/Q-^(>D?%OQ]X/GTD68L/^$/\5_%'0=%^(>K^%([=/#T_C+3+/Q$--35 M85NAK>+?V#?V,/'^B>+/#7CO]F+X+>-?#WCOXDW?QE\9:)XM\!Z'XCTOQ/\ M%W4_"L_@37/BCK=EK%K>6^H?$+Q-X'N9_!OBWQC<1OXA\7>%)7\.^)M0U71S M]CK^8_\ :_\ AQ^W3\"O@A^WC\6O$VF?M+_#W1M-_P"";/C!?%OQK\5_M)W> ML?$/P1\>OAS\"/V#=%^'UMX#_:"^$/Q'^'/_ O7P;XP\2_#+XFWM\-4_9I^ M$_C'P7\;-*_:/\:MXD_X5E^U[KOPW\0>^?&K]E3]N/Q;XA\4RZ'\./\ @I?% M^R;K'QS_ &R-,^&OPH^%'[9_POT']JCP?;?%SX%?L3:;\*OC++XG^/WQV\=> M'[?X>VW[2'@7]MWQ#X$_X2;Q\WQ+^!=I\9O"7BW2_!FC>"9M>^'L !_1O\7? M 7[.\?PGC'QIT#X7:#\&/@C%HOQ-M-3\9CP_X2\#?!>'X.P#7] ^(>EZ_>2: M3IGPP3X866DG5-,\7:=J&@_\(=IUC-<6^HZ?913$>07_ ,&OV'/V2YO#/QK/ MPX^$GP:U3X,_!'Q1\./ 6O\ AWP]'IOB3PW\!_A[X;UGXD>*_A=\.O#GAJWF MU_6/!VCZ+X>UKX@:A\-O!VBZHE[JFD3^+1H%YX@M(]13\'/VN/V+OVZ?C'X5 M_;_^'>L_!7]IKXG^,?B;;_M*WESXJF_;.TF\_9*^+/P \:_&[X,?%W]G#X6_ M 3X):WJUMXLTSX^?"3X>_#'_ (4I::/K.D?LX>#?"NL^(?VC?'@^*/Q!L_BY M\/\ 1)ONC]MG]FCQUX[^-W_!._X_^"/V7OBYX[T;X&_LT?MV_#_Q)X$F^)7A M"X\;^ [KXN_LMZ+8?#SX:^.UU[XK>)O!_BS5O&^N^$+OX8ZYXL63XQ^&V\9W M7A^Z\7:OJGANXA\0@ ^]/#W[-'[#G[1OB'X3?MN^'_@M\-/%OC3Q9?\ PV_: M9^&GQSB\'7OA;QSKFIW?PCD\'_#OQ]JES<6?A_Q1=7Q^$?B6RT%-(\:V+3P: M;I_A6VUG1XM3\#^%QH'O%Q\ O@U=_&73OVA[KX>>'KCXX:1X;O?!FD_%">": M7QAIG@W4U@_M/P?I^JO.9;+PGJ=S:V>IZCX:MA'HE_K=E9:]=V,VM65K?Q?R MN_#;]BK_ (* ^ /!/P\^&N@>!_VS_#7P3\)^!O\ @D%XT_:%\#>"_CKX6LOB M=\7?$?PI_94^/OP^_;'T+X?:KX\^)VN>#[W4] \>ZC^Q5#\4/AY_PD?@/PO\ M2/!/P,\2^#OA*VO7F@:5::WZ2_[$G[:WBWP-^UQJA_$SP=XK^&OPO7XZ:U^S!\ M0?AIX/\ $VJ:[X7TOX1V7[7+^-/C%X.\0^._$VFW_P =/$X!^[OQ!_8Y_P"" M?/C;XO:] -'@\!>$/BIJ- MU ]O!XI\9>&X-,USX9^!_B?JRQW]G<>'M=\%^"O&=W-HFLZ-I-UZA>_LB?LN MZGX[U#XFZK\ /A-J_CW5I-*N-5\3:OX(T+5=0U2_T+X>:K\(M$UC4?[0L[FW MOM>TCX4:]K_PPTSQ!=02ZW8_#SQ!X@\%6U_%X;US5=,N_P"9[Q7^PS_P4 ^T M:;X[^!/PP_:^\*ZSIG[&_P#P4Q^'?[)%W\?/VE?@CX@_:%_9N\4?&36?V8/& MW@/P5XE\2_"GQ1X7\!_"*S\>Z'HG[1GPJ_9;LD\>_M6W7P U.X^#WC3XB>+? M"^G^&=)^'WP;_2OX6_"[]K70O@;_ ,%1XOA9\/?VF/A_X!^(OP7M[G]@OX%? M%KX_:9-\?/#GQK?]EK4] ^(4/@/XJ:G\2?B3>? K1O$OQ>@\&:3X5L/$_C/6 M-/\ #/Q@T/XG_'G1?$.H^$/BGI/V$ _0_2/V$?V-M!B\-P:1^S3\'K"'P=XU M^$GQ%\*Q0^"]*V>'O&GP!T6/PU\"->T=7A86%Q\$_#D2>'_A%;VX2R^&VA@Z M1X,M=%T]GMVI^--!_8T_94^!FE?!WQEX'^'/@/\ 9Y^,OQ,T3X VGPJD^'MQ MXH^''CGX@?M:_$+_ (0N'P'K'@33M!\1:3=:=\8?B#X_NX/&4NO:4GA*[NO$ MVO:_XXO;;3[S7-4/\^GP>_8^_;SO/%7P)^%WQO\ "G[9]_\ !?P?^V9^U#\4 M]2UY/CQXA^&>LZ'^SOXB_P""4NC?#3P)HVD>)/A9^U[\6?BEX*.O_M>ZSX\B M\)>%-+^+GC#QE9:CK7B#Q5XUOM.N/$VN_P!H3>$?V:O^"C_BRT_95UW]I7X0 M_M,_%OQ_\+KG_@BOXE\ 7TGQH\"7_P */AKIW[//B#X-6?\ P4*MOCA\)]?^ M+?A>P\G_%75_#7QA;QII5O^SWXK^%?B/1/%'P.NM0\- '[ M@1? O_@G_K/QYT3X 6/@#PG;?'OX!^)/AC_P4#L?#VC6_CKP[K^D>)O$&A_$ M/]FCX K@]G#_P3N_8AAT.Q\.7?[-7PQUK0-(^%?PS^"6E:3XKTJ?Q?8:1\)?@O MKUGXL^$O@+2H/%5YK$>F>'?AMXLLH_%O@NTL1;_\(YXJN-3\2Z8]MKFL:M?W MOY]_MO?!_P#:S^(?[6'QLF^&U[^TWX2^#/B;]G']@WPUH'C;X47MWX@\(:7\ M6?AE^VK\2?B=\4)M9^&%A^T!\!/&VO?#^?X9:M\/-%_: B^"_CGP)\7/&WPA MU'Q/X7^'>O>)=?TC4?"TBZ[X$_;B_P"&+?\ @E)IGC_X9?M#ZCJ?PW\7?"'5 M_P#@H1\*O@Q^TMJ>I_M,ZQ:^&?@7X^TG0I!\:-7^,O@;6?B)X7TS]I6Y^%OQ M%^-.AV'Q+O >E^(?#.D>*/@YX(O?%FM_#JP;PUK,>F2P+H^J M^./&VK)=:OH-IXGFU?Q3XCOM:N;C4=6U"6;YL^$VJ?\ !)']N'XTP_$OX46? MPQ^+_P 9OC3X1_9]_;/@\267AWXB:)?>,-%_9%^,WC?X9? 7X_1IJVF>']$@ M\6_#SXG:1XD^'L7B406?COQ3X4\-^&/"7BUO$GPP\+^!M/TW\@OV*/V4/^"F M_P $-?\ V'O"?Q&\#_MB>#?A_P#"WX6?\$]M%^&FC_ 3XZ_!NP^"_P ,]/\ MA]XH^*]K^W=X _;3^'OBWXD30>(X?%_@[QPNNV)^'?PY^+WBCQ^= ^"%MX ^ M*7@;QS\/M1TW1>D_93_8@_X*#>)[+_A1WCK4?VH/V4OA'\2O^"9'[8GP^\.: MWI7Q5U?2-$^"7[:GQ&_X*+?%WXQ?";XBZEX5^$'QGB%A\5M!^%&I>$/%L7BV MQMYK/7?"!O?AG<_$;3AJVH>$_$ !^YVG?\$O_P!A#1;KP_=:!^SYHGAM?"WB M/1/%WA^P\,>+OB-X:T32_$?A7]J6]_;1\&ZK;>']"\8Z?H7G^ _VC]9\5^.? MAZDFG20?#_1_B#\4OAGX,BT/X5?%;XC^"/%%F\^"7["?['_B_P"#_P 4SX&\ M+_"/QGJWCO7/V?OA)XDT6+QM-JFI>*OVMOC)XD^*'B'X906VASZG]K\/?$CX MS^+-=^(.J:5K]I)X*T'7H++Q3#]%OM$_%;5O@5_P %-OBK\)/@=\;/ MBC;?ML?##6OVAG_:J^)GQJ_9O_8U^->@^%_B1^S%\1/%'PH_9]^"W[$G@[0+ MSXF?&KX1:3?^%/ 7P<^#GQ#U[QHWC#Q5KGAC3?VMOC2/B-\0OAA-HT5YKGP[ M]8\'?!+]OJW\:>,OB]XF;]M.P\3>)_\ @JM^RY=2?"W4OVEK[XC_ ^T#]C' M0M&^'OC+XI:OX6LK"7P!X>T_X9Z%\6O%/Q]TOQ/X2T_3%A\4>!M%\,:#8^%/ M'NBZ#\%O( /V4O/V(_V8;_Q]XK^*%S\,V/CWQG\8M*_:"UKQ'#XV^(EK=0?& MO0_A!H_P#TKXF>&[>U\6PV'@OQ;9?!W1+;P!'J?@VTT&1M#OO$2RA[OQ9XHN M=8\%^+/[,?\ P3&_9#^%WAS]HKXN?!3X(?#/X8_L8>'=.\0^%?'&M>#[K7+? MX5Z!X0\8Z_XR\ V.B:5:VFNZQKP^'OQ#\=:]K'P&\'V>D^(+WX=>./%"*;^;/6_!O_!5G]DC]EOXY>)_B'\4OVX/#%SXT_8%^-WPYE^)7CG] MH3Q)\;/$,_[<&N_\%(+WP;^R7X"\%Z3\0_BWJLGPVU7X^_LV>-?!OPT3XF_! MS3/!/B?PCI/BRS\0:'K&E?M":%:_V9]W>(/AW\>/CI_P2X_X*U_!+P7#^T)\ M2?VQ]3^,'C?PM'\"_B;\6OB=\4KKX7VOC_6/ OQU^ _P?^'_ (S^,WQ.\7^# M[_1='^!_Q8\(W^K^-M ?P7IYNKJXT;Q)H=O9>!M%" '[??M-?L _LA?MC:K8 MZW^T?\&=-^(^J6/PZ\=_"*2[;Q/X[\)MK7PP^) L)_%'@/Q;'X&\4^&8?&OA M<:WI&A^-?#.D>+X](_!VI>-OVM/"E_X'_:1UO5? .NZQJ'@? M5/\ A<7A/6-=T/QEIVH>'KG2;ZS\1>)O)L+>7Q)KLNH?AY^T-^SU_P % X?B M7\0OAY\*]6_X*0M^QAI?[3WQWU"R?X1?M(^*=3_:%?B+X]USQ'^V];^+M-_;7^#?AWQMX#T'X]3#7/$ M7[)+_L]?LT^-?BWXC^"J>'O'7P.\)%$_;U\(^+-9U\_";Q/\$=>UW]G1?BI\ M)OAOI_A;P5XI\'>#H@#]?'_X):?L*R^!=6^'D_P6U"ZT76O'/@SXEWVM7?Q? M^.5W\2%\=> OA-X<^!&@>)-/^+]S\2Y?BSH]]-/\ @EO^T1XF\=_#OX'_ !0\0?L[:;!\ M%-6^*_\ P5!_9=^-GA3X >/_ "D7B%)M9^&^L>,/&NL?M)_$3X9:UX\\<\/ M^V+^R+^WI9_LS?%CX):MI/[6W[1?AN7_ ()L_L0^-=:3P]XQ\?\ BN'7_P!I MWX5?\%&]0_:+_:W\*_#7PYIOQ6N_&FF_&5?A5XCT#3OA;#HFHZGXH\3>!_ _ MAKP-I/C3QA?> XM,< _1_P"(W[!/[)?[8>B:Y/\ L%>/_AK\)_%?[.O[2_PF M^%?QA2V\-?&[Q3\*;CQ9^P%\'/BM\(OA?^SU+X/\ ?';]GG4/AK=? >\^-^A MZ[IOCSX$>,_#6M:5XE^'_A?2-6OO$4WABWLM"^I_AQ_P2]^!%O\ "B[\$_M( M7?B7]J7QUXN\-Z%X6^)_Q&\?>./C,3XL\.>"_P!HKX@_M2?"CP1I>G>)_B_\ M0/%FG> O@'\5/B3KB_ >'QC\1OB-\2O!'A+3_#N@:U\5/&-SI)U>Z_.3]DK] MGO\ :H^"'[?^N_$.W^''[0/@KP3\;O\ @I]_P4:UCXJZ.?&'B/4_@!>?LL^. M_P!G#P-XS^$_QAU#P4OBGQ+\/=-\5>+OVB? _@FP\->*K"WTKXAR7/B3XB>' MKQ;;P9IA\/\ A[@_BQ\.O^"EVE_$#]K/6? VA?MH>,=%T'XO_!+XZ_""[LOC M%XMTC6;?2O"W_!5%_%_Q;^"7A[P9KW[0&M?!3XO^#-4_9-3QCK_P8/@3PQ\ MPW[.VK>$_@)^TC\.OB'\3])\%ZCX> /VKO/^"&;2X^.?B> MV\:^.=5TG6/&&B>(--\7V7BR/XB6/B?X5^)=&\1V'B#X#Z]8_%-9OC)8:K\# M=2^'5[9?&_4-9^-=K-#\5M1_L:? +]D77/BA+^V]^QYXLTN?X1Z]\ M,/BS^SCX3\*?#O09?#GPYN_$&F?MG_';XF_M"^-+K4=0L[77?'IO?V@M3\7V MGPX24?\ "OOA_93?$O7?@ZUUX8^-^JWMQ^7/A[X6?\%)=5^+.@:GK?A7]O>\ M^&3?&3]L6Z^%/AKPA^U/X9^$0\"^/[3_ (*O67QY^$/C3]HV_P#&VM^-T\8_ MLL>.?V/[#X??#'2M(NO#WQPU3P=\,?"/[1_@/X>_!"\UKXR^ =1U?T?_ (). M?LS_ +3?[/'QN^%&J^,/A-\:_A+\//B%^SC^VE%\:_\)O"7Q1_X M>!:GX_\ V1/#O@?X;1_$?QGX4^%8C_9\\:?%_7H]/\ 6+:3;Z?XIT_3_ (B> M*?$GQ3O]5UC5P#^C2BBB@ HHHH **** "BBB@ HHHH *^>?VGO#OA_Q1\-O# M6F^)4F?3K;]H;]D7Q%;"!+.1QX@\(?M8?!7Q9X3=EO;'4(1"GBK1-&>X=(([ MR*W6673[[3+]+;4K3Z&KY]_:9/A-?ASX;/C./29='_X:"_9+%FNLZMIFBV8\ M6-^U5\&5\!20WFK?%+X/VLVK0^.3X=FT'28O%FKZGKVN1Z=H6B_"WXY:SJ-A M\%/B ?05>*_'?Q!;>&_".G7UU?R:='+XDL[19X_$NB^%F=WTS6)A$=0UW1= M=M)@RP,_V..TCN9"@G2Y2*WFBF]JKYX_:7U"73? FDSQ0RSL_BVPB*1>-[CP M"P5M'UYRQUBV1WN5!C .FD!)B1=$YLU! /H>BBB@ HHHH **** "BBB@ HHH MH **** /(/CQ\=/AS^S;\+?$/Q@^*NIZCIOA#P_=^&M(\K1-"U?Q1XCU_P 4 M>-_%.B^!? G@WPIX8\/V=_K?B3Q=XX\<>)/#WA#PKH6F6$?%OC_XBV.N_L^_&)+_ /9R M\#>!?BIXL^!?BKQK^TI%IW@_48?@]X.TGXQ^!?&'@5_%WB&<^&;J'POXI^(M MCJUU\'_"7BKXB:)]/_M8_LQ^!?VP?@-XS^ GQ!UCQGX6TKQ-=>$_$&@^.OAO MX@F\*?$?X;?$+X<^,= ^(WPQ^)GP_P#$D,5Q_9'C'X>_$+PIX:\6Z%-=6E_I M5W>:2FFZ]I>KZ%>ZEI=Y\8^-?^"4?A7Q]X=U[1?$W[6G[76MZI\7O@QXN_9S M_:Q\8:[XP^&NN>(OVJ_@=XQ^*?Q-^+D_@/QQ::A\+)/"/PVA\*:K\:?C'\/? MAEJ'P$\+?"N3X8_!+XK^,?AGX*@TB/2OA=KOPU -Z^_X+#_L&:-KGQF\/>(O MB%\3/#>H_ >Y_:)M?',FL?LW_M%KI.HR?LF>,;'PA^T6GPT\06/PMOM!^,ES M\)(M6T?QOXSTOX3:EXTUC1?AI?77C^]TZ'PWX9\97OAS;^)'_!6[]@7X.77C MFW^*WQOE\"P> M?FT"^U/4OAY\3-6TO7&L_V9?AU^UUJNL>%;OPKX0\0?VYH M6A?!/XK> ]6UZ_A2,Z/XC\4^%O!=_!#XH\;>!=,\3\%\-O\ @D_\-_AU\(9+#P_: M:_?:/X @\.V.F^!KWQ#K/B;5[GP7-+X*\7W7B2PTWPK>>&_/O O_ 1:^%7P MF^ W[./PN^#/QY^+OP?^*G[-;_&/3] _:0\*Z%\*O&GQ ^(?@KX[P:'H?Q'\ M!_&+PO\ 'WP-\:OAW\3=#U7P1X"^#?@W3KKQ5X9U#6/">B_!#X6Z-X(U#POX M/\-0>$F /H+Q)_P5B_8?\,3>.$NOB!\1]8M/ 7C#PEX!O=8\&?LX_M'^//#_ M (K\7^-?"7AKXC:!X>^%.O\ @SX4Z[H_QEU>]^%7C#PS\8;72_A1>>,=1U/X M/:WI?Q3T6UU/P+J%EKMPW3_VXOA?;_$S]H;PI\<)O#<\OPD_:]\$_LW?!/PO M\,OA#^T!\7/BKK'B7Q+^RQ\.OVF;""_\*Z+\*=5UO7?&DWAR^\?_ !)DU+X2 M:%XA\"^$?@_X6M/%.N^,F72?$.JVGD'C_P#X)&>%/'7[/WQR_9N_X: ^(FF^ M /C9\?KKXV7,NH>&?!_CK7/#E@?V=O#W[/V@^$(-2^(EKXI?7-8\"77A'PG\ M=?A]\4]96;XA^%_V@O"GAKXDPZO=7NC6EJNMIG_!+)=#^)^J_'/1OVE?'UO\ M:M,_:(\"?M"_#3XB:EX2\.^*-5TJ]\(?L>^%?V'O$G@/XK-XKO-;O/BWX3^, M?P6\%>'-2^+EY9ZE\._%>I_$ZT_X3_P5XA\!ZA9^'[700#U9/^"K7["MUJOP M[T_1_C!JWB?3?B=I7[.>N^'?&GA#X3_&#Q;\.M+T;]K'X@^._A'\!M3\?_$' MP[X#U+PC\+;/QI\6OAYK_P +KF7XE:OX4'A/X@RZ5X4\9?V!JVHQ6Z^Q?M,? MME?L_P#[*^H^ ]"^,=WX_N_%'Q%T?XD^*?AUX/\ AK\#_C'\']+\1Z3>EM1BTXR6<][J$$K:;HVNWFF_G3?_P#! M#[X<6OPM^+OPC\&?M#?$S1/#GQ>\'?LR>'M?U+Q#X3\!>*/$5UXI_9I_:_\ MB3^W%9_%+6+VQTWPMI]YXY^(_P >?C-\5=2\:QZ!I7A/PC:Z!XK@TOPCX6\. M7GA_1=5MOT)^//[*U[\9_CO^SI\<]*^*6H?#[4O@'X7_ &B_!\FD6'A#0O$; M>+]&_:&\%>'/"M\5U/6YRGAR_P#"&J>$]!\5:3/'I>L6NJ7^GQZ;K%C<:3+= M6UR %?!FB?'33_$5]XSO?@/I6A>(O#'@OXE>)OAG_ &]^ MU#X/N?'W[._AC6_C#H/@W4?A/X5\7?&7PBFDZQ\/O"/BGQIHWB;Q$GC;X86E MEI3W_P 6/AG:>+/CGX&?\%D/A/\ &7P_\%/C[XFUOP'^SW^S5\0OV-_VB/VL M/&&B_&C2_B]IOQO\-^%O@[\6?AAX#TGQQINJV'@ _!6_^&D^E>/;.#64B\:7 MOBWQ%X\\5^$O"_PJLO'$6E^*KRW9\)_^"*_@/X7>&?A/X C_ &B?B;K'PT\+ M:W^P-X_^+?@(^$?AQ:Z9\7?BG_P3D^$GPF^$WP*\16.LWVA:WXL^'?A/Q7:? M [X4^(OC%X(LM?\ $U^''[37[17@/]H+P MYX@F^(VEV,L>H^,?@?JGPM^']IX0FU?PKJ/AS7=>TK6O$^N>'/L/BS7/"DX! M]P>(/^"KG[ WA 6*^,?CM-X,NKCQ+XU\*:QI?C+X3_&[PEKO@#4/AUXM^&W@ MCQIJ?Q@\/^(OAMINM_!+P=H7B+XQ?"V"?X@_%[3_ 1X#N=-\>>&?$-CXDNO M#NIP:J?9?@S^U)^R_P#'?XK_ !&\&?![Q GBCXE_#VSUE/'&K0?"_P ?Z!I[ MV/A_XK_$+X$Z['I'Q-\0^"M&\'^.K;2OBQ\#/B!X&OXO!_BKQ%';ZIX#N&E5 M;"'3;N?\]_B[_P $<=1^.&K_ X^(?Q._;8^,/CWXYZ-IOCCX>?%/XO^./@] M^S7K]]XR^!7Q*TSX8V_BGX=?";PC;?"W1_"G[-?BK0-<^$F@^,OA3\6_AO8S M^*_ ?BWQG\7=:U&W\87?CK3Y/"GT_P#LC?L)>)/V8_C;\<_C/JWQ^N?'"?&^ M/4[C7?ASX.^$O@OX)_#O5O&>H_&/XI_$3_A=GQ$\-^$+O4=.\?\ [1)^'WC3 MP!\"->^-4%MX3\4?$?P%\'_"VK?%A?'WC)[/7]# *7C[_@I?_P $\;;Q3X@\ M!^-_B;!XE\4?"_XC?V##H<'P(^-/Q"ENOC!X+^.?PY_9XNO#_P (WT#X5^(K M3XH_%'P'\>_B[\-OAWK6A_!Z;Q?XP\#^*_&&DKK%GI$3SW4/L?B7]N_]EWPM M\#/V??VD;[XA7]]\'/VIM<^$'ASX#>*-!\!?$/7K[X@:S\>=*.M?"?3;'PCI M?A6Y\::?J?C*RV0:5HVL^'M.UN?7KG3_ @FFMXQU72] O?S$^)G_!#_ %#X MB?&_XB?&W5OVE_!?CZZ^*'CW]HNY\;^#/VAOV3_!_P NO\ $GP1\1_%VC_L[>-?@AX$NOV9/%(\3?;_P 2/V!];\?_ #_ &$/@;/^T=X\U&X_8P^.W[)7QH\0_$_XB:/_ M ,+$^(/[0:_LM-#=/H_CK5I_$F@R6&O_ !*U:TL]9USQO+)XCN]/U*![J71] M;N)WFH S-,_X*^?\$^]1T3Q9XBG^-^IZ!I/@SX4Z1\9-5F\5_!_XV^%[K4O" M&I?$C2O@OJ%CX)TO7/AU9:K\2O'7@WXW:_X>^!?Q%^&OPYL?%7C[X>_'/7=- M^"_C#PYH_P 4))O"<&C=?\%9?V#[?3?$>HI\7]?F;PGX,_:R\;>(;"?X,_&_ M0[S0[/\ 8;N;RS_:E\/>(G\3_#K0]/\ "/C[X33VMO)J_P /?&-]X?\ &=_I MFN>%?$&B:+J7ASQ;X:U?5/C#7/\ @B1JOB+P1>^"KG]K[7_#XU+X&?MK?!_4 MM?\ WPAL_#>MZE6?CSX+WGQ<\.:CXHTO4?BA:ZMX(\XN?^"1/C;PU\2_@C^SAX:TK_A.OV1-+ M_;H^*/\ P4/^(GQY\9>(OAQX7UWPII7Q3\'?$+P]\8/^"?\ X7^!OP^\&>&K M'Q#\%_C_ .*?%<'_ G=C/;Z9\)M>^ 7C?XH_"CQEX6U";0/"MKXU /T)_;J M_;-U_P#9MT+]@_QEX>34-$\&_M*?MH_!3X'_ !$MM8^$?Q#\6?$VS\!_$GX: M?%7QO9:)X;^'7A[3;WQKHWC_ %?Q=X*\(>#]7L;WP+XCU/0M(UOQ-!/I/AW5 M;6/Q5X:\^\8_\%NO^">?P^\ ?#?XA>-_BAXL\(VGQ"'Q(FO_ CXI^%_CKPO M\3/A=8_!3XM6'P)^.5U\5_AMXBT;2O&/A6\^#/Q8U.V\-?$#PM:Z1K'C>ST6 MT\3?$W1_#&M?"+P'X_\ '_A;ZF_;._9.D_:O\)_!R'0_B3?_ E^)?[._P"T M3\,?VG_@YXWC\/+XR\/6?Q'^&2:_I<&C>/\ P0NN^$KWQG\//%GA/Q?XM\)^ M+/#ND>-/!6MW&GZV;K1_%>C:A9V]Q7Q)>?\ !'ZYT9;'Q/\ !_\ ;>_:4^"_ MQN^(EW\6M/\ VQOCQX/M?A]_PGG[4_@KXZ>/]3^)'C?3X4;PY:Z9\!OB%\/- M7U*7PG^R[\8/A-;Z=XR_9^^%Q'@>V;QJ]CX=US0 #]!?C[^V%^SY^S%XG^$O M@WXU>--4\+>)/CGK&J:!\*],T_P#\1?&;^+=:T74O"6G:OI5I<>"/"?B.TM= M3T]/&FE:]-_B EJ_@7X9_$CQ%X4\DT'_@I]^P?XIT#6O$? MAW]H?P]K-GI'BGP%X,L=.L/#/C^?Q7X\\1?%>_\ &FG_ EM/@YX'7PE_P ) MI\=+7XN-\./'VH_";6/@SH'CO1OB=X?\&>)O%'@34/$'AO1K_58.J^*O[)E_ M\0OVI?V-_P!I'1?BC=>%K+]E/PG^T5X%U?P'J'AR[\7W7Q4\,?M ^%?A[H,T M!?%ND6>B_#OQSX5.B?$' M2/'/B+XD 'UAIG_!5G_@G]K7@9/B3I/[1>B:CX,F^$7P\^/-GJ]GX+^)T\FI M_"/XH?&G5/V=_"OC71])C\$G6M:T^#XS:1<>!?&EII.G7FJ_#._N]$O_ (DV M'A/1?$GA[4]4I^%/^"D'P)TZXT[PY\9_B#\/_#/CSQS^U9\>/V:OA'X:^'[? M$3QP_C:]^$_[67@O]E2SCNWG^'^C-H_B_1_&7Q:^$NC_ !6T^,ZCX4\':SKN MNZGI_B[6?!GAK6_$&F?CM^S9_P $.OB;\1?V0_V=K#XT^-_&_P"RO\<_#G[+ M7Q/_ &3_ (O^!?$>F_#CXW7<_@VY_;O\/?MD_#GQ)HNI_#CXJ3?"?0/%4NO^ M ],M?&FI>'HM;3QAX.\97F@R6?@OQ!X3\*:EX=_3'X8?\$N;[X>?'[P!\8KK MX]P^(/#7@;X__P#!3'XS/X"A^%MYH&IZWH?_ 4@\4Z/X\UGP3-XZLOBE<7& MF:C\)_%]GJLNE^---\/0R>*O#NHV6D/X>\,ZMI+^)=2 /H30O^"E?[$GB[0M M=UGP?\?O"FO3Z1XM^'O@33="32?'%MXG\:>)_C)9:UJ?P0/PV\'_ /"(S^-_ MBKX2^.&C^'/$/B7X,_$#X5>%_'/@KXM>#/#WB+QK\-=:\6^&-"U/4[;X^U_] MO#PYXA_X);?LR_\ !4WXG? ?X+_\)=XGTG]D_P 1>3XSE76=!^!>A?M-_M#? M SP#XH\8:9XXO_"USXCL])^&*/B1[F?#OP%\'O" M_A[XVVG@SPS8:S_PD'P$^)G@_P"+7POUW4/ %S+JGA^_T/3_ !5X \*6/B+P MM<:H]UXE\+6NI:;-XGL]8U-O$5N >KWO_!2;]@CQ!+8>!==^,FCW$_CF?]I' MP;>>#?%?PV^)EE.FH?LQ^ 5^(7[1/@GXA>'?$?@*VD\&:SX3^%>H6?CR;PA\ M0[/0=4\;?#K7M#\6^#=,\4>%_$>C:CJ%GQA^W#\$?ASH?["OAWX5>'M9\36' M[=;-X9_96MM ^'WCKPSX$TSPWIO[.?B_X[^%M=\34?A5X%B\*^%-!T M:ZTG4_#%IXI\+:=KUQX@NO!\'A/X??$34O"?Y^?M7_\ !.+XD_%F71/@?K?P MYO\ ]I*T_:Z_;7T']KC]KC]J^Z^(/A[X _#[]G[P_P##30/@M\"]=^"_A+X+ M^%?%<_Q=\5>%/VA/V /"GQ1_8R6ST77/'%W$/ MT[_:>_99U7X]_$+]D7XL>$/B=_PJOQ_^R1\>M4^,6@ZE<^"X/'ND^,/#WBOX M-_%#X*>/OAOJ^B77B/PU'IUKXM\,?$N=AXJM+J?6M ?2_P#B2Q6]Y?#4;( ^ M7_V0?^"N7[-O[0O[+7P_^.'Q#\46'PT^)-_\,OV- MK;>)-)U?1[#U;XU?\%&/@WX._9T^ _Q[^ MYH/[3*_M<_ _L_?LFZ?X-\ M37=AX-^*_P 6/BKJ^L:=I%OK_C_2/"_C6?P!X&\%Z9X5\<^+OBQXKG\'^(=5 M\#^&/ 'B](_".N>*["S\*ZA^;6F?\&_.CVFA? :SOOVHQJ>O?LS_ +*_[/7P M"^$NL7W[/'@_7='3QW^S;\7?BM\4/!WQ0\>>"_''C7QEX>\=>&/$EA\7O$O@ MSQM\*KR&P:XLX[+Q'X2\?^#O$UM:ZA;?>NL_\$SO"NN?LC_ W]GBX^*VNV/Q M-_9S^.&D?M7?"/X\^'O!?A+PG;^$OVG=,^(WC/XIR>*=.^#7A2+1/ D/P?O] M<^(OCKP+/\$%G^R+\%_$=SX'3QE_PDT%K\0X@#T73_VS?$?P_P#BC\2OAO\ MM9?""V^!%EIFL_!K1O@#X_\ !'BGQ]\<_"?[3^L?&'2?B_J@^'WPRMK+X(^ M?%>I_&WX>V_P1\8ZU\1?A-X7\-^-=2\.>!K_ ,)>/+C5SH/B!7LXM8_X*B?L M%Z'??#2PO/VB/#UT_P 8?#WP7\6_#F]T/PO\0?$VB>(O"O[1.H>,M$^"GB7_ M (2'PWX1U70=(T'XB>)_ /B;P3H6KZ[J6F:>?B!!I/P^O;BT\:^)_#&@ZQPW MB_\ 8C_:'^)OBWX6_&CXE?MB:5J'Q\^ WQR\+_%SX(W'@_\ 9TTSPO\ L\^" M-#MOA;\3_@I\3? M]\&];^*GC7XE^*)?C3\-_C7\0K7QCXPU#]HZWU30O$FF M?"S6_ %EX3T[P7XD\._$/YF\!?\ !&2^^'$'AW3/#W[34$^BZ#I7[ ,36NJ? M!)?M-]K_ .PS^W#X_P#V]AJ,*:'\5]!\-^'/#7Q)^*_Q7\?>$-&^'?A+PMH/ M@[X,_"@^!O _@33Y++P/;RZH ?8UQ_P55_X)]6>A_#3Q%J'[37@S3=+^+?@+ MP3\4?!;ZCI7C*QNC\//'OQ"D^$FE>,?%>G7/AF/4/AYH&A?%&/\ X5Y\2-1^ M(-KX8M_A%XRFM/#WQ5?P;J=]96]QVWBS_@HC^Q/X$N/B?!XU_:+\ ^%$^#EA MKNK_ !!O_$$NK:3HVEZ)X2^)^D_!'QSX@TK7KW2X=%\7^'/AS\:=;L/A!\3_ M !%X-O\ 7]$^&7Q2%_\ #[Q]?^'/%VD:MI%C^.6L?\$?_C1JWQS\5_ EO&>H M6W[,_P 7/V/OVDOAE\/7M%\>Q:;X4^)/PQ\%^'CZ_ M\5O^"'>I?%+QS^TKX^O_ -J73/[>_:!^'O[4?PV_M;Q#\"=8\5^(;7PU\?/V MMO@Y^UG\/]&^(WB&Z^/FGWGQ/\)_ .]^&.K_ 7\(_#ZRC^'_@&^^"GB/3/# M&G^'/">IV'CK6_BB ??/C/\ ;7_X)S_%_P +WG@#XB_%+X,?$OP3XH@^/%UJ M?@WQUX7E\7>$M=MOV/Y[+Q3\&;_ $6^A^$D=OX<\-?@U>^&;OXN>#/VOO^"@>J M_M?^+OC[X2U'2?@9I_[&7PNN_AY\$O@9\??@=JMC_BA%XGU;X=7WQ&L[?_ (9Y^-WP_P#COX?T"S\-:3\1 M/A?):QZWXG^&OA[1M0U!/$+&T\-W&LVUA8QZE=6&J:6 =!X!_;8_91^*?Q>F M^ WPX^.O@3QM\5[>'XJM/X4\-W]QJOE7WP.\9Z1X ^,'AR37+6UD\-IXT^'' MB?Q#X>A\7>!&U@>,]'TCQ%X?\476A)X6US2M9NZ^N?MR?LB^&/&OQ$^'GB?] MH'X<>&?%?PHTWXAZMX_L_$6L_P!A:?X?M?A%\/?!?Q:^+,3>(M5AM/#FI:G\ M+OAA\1? WC_XC:+H^K:AK'@?PCXIT;7O$]AI>G7B7%?%_P +?^"6>L_#O]I? MX!?M!7G[0.F:WI_P(_:1_P""FG[0=MX&L_@]?Z5/XK?_ (*/^(4\87_AN^\5 M:G\8/$PT.[^#OB*]\0P:7K6@>'+/1O''AC4=-L-7\&:/XHTV_P#&NN^"?'?_ M ((8VO[3'Q5^.'B7XV?M1W_C3X5_&CQW^U;XE'@*Y^"?A^'QYX*\,_M8_LZ_ M"/X*ZSX5\._%(>-Y-&@N?@UXK_9V^ WQ)^".KV?PLTS2[<^$?$FF_&/PM\9_ M&OB?1_BEX, /T4U__@I1^PUX7\'R^.]?_:+\&:7X:L/%_B_P-XEGN++Q1_:G M@#7?AWXF\#>#_B3/\5/#<>@/XE^$WACX8^(OB?\ #.P^)WCGXEZ1X4\$_#A? MB-X!OO&_B'0=.\9>&[O4MW6?^"@W[%'AWQ'XQ\*Z[^TK\+-)U7P&OQL3Q-/? MZ^+;0+;4_P!FOPS!XR_:(\,Z;XLDA'A7Q%XV^!7A2=O$'Q?\!^'-9U;QG\.- M*L=7N_%VA:1%HFL&Q^+/&O\ P3&_:4\>ZA\/?B3K7_!06XM?V@K9?C%X)^-? MQ T[]D7X*ZC\./'_ ,"OCUH'[-&B?$/X=?#CX)>-]4\::/\ ##Q;!J'[)?PC M\?>#?B/XX\3_ !UM](^(%[\0Y/$O@?QI\//$7AOX;^".?^+?_!(OXA_$[PO\ M0_A1%^V++IOP0U3XS_MP_M'_ B\):M\!K#4/'?PQ^,?[(/ MB;X3^*G@!OB1\'_!GBS]J?\ :7^(NC?#\^$O!WB[Q$WCSPEX \7?%75_A]X& MO]!\: 'L/[1?_!7']FCX8_ =OB]\!_%'A#]ISQ%=>._A9X2T;P#X1\3ZQI,= MWI'CG]K+X8_LG>)?&.M^*-/\%^+X?!_AOPKXO^(-\-%UKQ#H]MH?Q \0>&;W MPGX5U6ZO&NKS3OHO5_\ @H?^Q)X=;XC?\)+^TI\,O"\'PFN;FV\?:AXIU:X\ M,Z1H@T_XV']F[6+V+6==L]/TG6](\/?'T#X0>*-<\/WFJZ-X6^($D'AKQ%?Z M9J5Q!!)\%?&#_@D'X\^('P_\/^ O!7[5?AKX>VNN?LD?L4?LM?'9[[]G2\\: MV7C"[_8,^*5[\7O@=\6O@W'/\>M \0_!3Q9:^*/%GQ%M-2L?$WBKXVVATC6? M!T]C=6?BOP*WBKQ+XW\1O^"%'CCQ_P"/?CG\2W_;%\,6WC/XLZ7\7-#TC7]6 M_9EUG7M7L=%\<_\ !1+X-_M^?#?3OB3JH_:7TK4/B/8_!&/X7ZK\ ?!.B^'+ MGX5>%].^'GB6PU+PKX>\%:II/B2W\>@'Z>:Q_P %-OV _#O@O1_B%XA_:N^$ M&@^$M;\7>-? ]OJ6M>(6TJXL/$'PUOM"T[XCKXDT>_MK?6_".B_#VZ\5^#E\ M=>*O%6G:-X6\(0^-_ MWXAUG3K3QMX4GUCVK1/VJOV"+;7K8ZGJ?B#X)/&'PRTOQ;X2U3XF>$- M O=2\3?#O3/%GA?4?&FE:'9^(M&GO?S$US_@DQ\7(/C!\=OCY\,?VN? ?PX^ M)'QS^,G[56L:UI5U^R+H/Q%^#S_LY?M:?"/]F3X8^-OA%XE^%7CCXR:C!XK^ M+.A:Y^R+\(/BYIGQP_X2/1? WB7X@7WQ+L_B%^SCXN^'_CJ7P3I??? G_@DS MX;^!?[9&J?M0Z;\1?AYKVE_\+>^.'QUT$7'[*?P6TC]J*?QG^T7I/C+_ (6A MX&^(O[8FE01>+?'?P"_X3OXE_$#XG>"_AIIG@#P3XG\,>(KWP?X:O/B=X@^& M/@+1_ _"/X=LEQIT<)UOXC>#].O==\(NLQT_6K.VE%G>R3@0GY*\?_ M /!7;]FSX>^&_B9\:GU;2?B%^R_X(^ W[(OQHT'XE?";Q)8^,_B'XS'[67[1 MGQ%_9TT*.T^#\-^#]4B\;:KK%JWB1/$'B:PT+0+RY\%WC7N M%^V]_P $KW_:F^+'Q#^.OP]^.>M_!7XA^*_@%\/O".A6^CZ1?_V5I?[4'[-_ MQ>E^+W[&G[5FKWVB^)='F\1:O^SMJ/BKXLZ#)\-]?TC6O"OQ'T;Q_IT?B*>U M'@30(GY3]H+_ ()"CXD0?$'P_P#!/XU>$?@/\/M5_9*_8)_95^$_@B^^"?B+ MXFV_PHTK_@G]^U%K7[1OPQU:XU8_'KP->^-?#^NZ=X@O_AOJ_A25/#FLVEG9 MZ)XD@\>7%S::EI6L@'UI^S%^WM\+_P!H'Q]\2_@OKNI>!_A]\>? ?QS_ &K? MA?IWP^&M*^(&F6DNJ:JUCJES:>/_M$_\%6/@_\ !3XN?$?X&:'X:UGQ3X]^!OQI M_P""=7PS^.FK>([E/ ?PX\ >'/\ @H/\99/AQH/BRW\97UMJ9UJ[^&OA:T?Q MUXELY]+T;PK>?V]X7\.V'CA]9C\:VW@OG?AQ_P $R?&G@3]I+X9?'.Z_: \% MZKX>^''[<'[=G[8I\%:?\"?$VD>(O$-I^V-\+]2^'/A_X<7OC[4?VAO$ME;W M_P *G\1>(M5UGQO'X$FTWXA62>$] T/X??"N'PW=W_B"+X_?\$RO&WQA_:G^ M)_Q]\,_'[0?!?ACXE>)?^":?Q.OO"/BKX477Q-UBQ^)?_!.G]HOQA\:=!L?# M^M1?$/P#;^%OAMX_\/:[#XRU?Q);>+M3UKQII_B73M,6_\&^*@#ZFM M?^"B_P"PS?>'/@YXPT[]J3X/ZIX4^/T$-S\*/$>E>*;?5-%\26L_C[2OA.+J M\U+3TN;3PK:P?%G7-)^$]]<^,9= @T[XIWT'PXOY+;QJ6T-?0_BU^V#^RW\! MO$=YX1^,_P ??A9\,/$^G^'O"GBR]T+QKXOTG0-3M?#?CO6O%OAGP3K4]K?W M$4D>G^+_ !5X&\4>$?#-PPVZ[XOTZ+PIIGVKQ#J>DZ;??C[<_P#!"JXN/B!\ M5O'=W\>?@9XL?]H76?VD](^..E_%S]A+X;?&Z*;X5_'?]K7QQ^USX2MO@R/B M?\2O$&D_"_XV_!;QC\6_BQI6A?$3Q5H/Q;^"_P 0?[3^'?B#XG_LP>)]0^$O MA6W;Z4_;/_X)4S_MA?'WXP?&.^^/EMX'T/XF_L5?#']F31/!LGP6\/?$"]\" M_%7X'_M43_M:_"?XZ1ZSXO\ %EQX4\7^$;;X@6WAC2_B7^SYXE^&\WACXM>' M/#5II?B;Q?#I[Q6%J ?0^N_MY_\ !.SXD>$;SP[XQ_: ^ 7BOX?^-OASX[\2 M^(M(\TW4M T;X+_&N\\4_#GQFE MCXLM=)^#WQ;NM0\,BR^&WC:30\+X:?MA_P#!,7X.>#=*\+_!;XM?LQ_#;P#> M?&;Q/\(K'PM\([3PQX8\+VOQ:T[7/ FB^+H;SP]X'TFTTW1+2#6OBC\)X]:^ M(&IV5CX-D_X6M\*+^Y\4/:?$KP+!M!^&_CWX]>.M2\&?M#:'XC\!:GJUQ\;;7XH>*_ASK7] MM6^@>+O@+XXTSP=X3O+, _0/XK_\%7?V*/AI+X7TVQ^,W@CQQKGBG]H&Z_9A MF@T'Q?X8L='^'OQ6'AK]H'5M,N?B]K6MZK8/X%^&NJ>)_P!F?XK?#6#XCP:9 MXAT=O'?AW5M-LX+^T\,^,;[PYTOPT_X*,_LWZQ\%?AS\2_C/\4/A/\&/%&N: M+\*-/^*7AMOB=HGCCP'\*OBO\1_V6+']L+4O #_&W0[>'X<^+/#_ (6^!3ZM M\39/BKI6I6_@&_\ AGI#^/Y-4T[0KA'3X;\$?\$>OC+\-K']GS2/#'[8GPUU MK1OV0?B7\-[G]FVW^(G[&]GXDUV']G;X4^ _VU_A7X#^!/Q_\?>'OV@_!7Q# M^..H^"OAG^V;JO@_P+XKL?%/PS^&WA.W\"G5[3X"76O?$KXCZEKOFMW_ ,&_ MOA/7?!>D_#OQ-\?)SH,?_!-/X>?L2Z_>^#_A\GAFRUSX_P#P7^&NJ_L^_"K] MM74? FK>*_%^D:K\0[']FGQ;XW^!VL^']3UV9)O 'B'4?#*Z_=6D_A^[\& ' M["Z=^V]^R'J?P?U3X_0_M&?"6S^#>@?$!?A1XF^(&M^,-,\.:'X1^*)\5Z?X M'?X<^,V\02Z9=^#?'-OXKU;2]&O?"GBBUTG7;&XU&RDO+&"VN89WX6V_X*3_ M +"%_P""T^(NE_M0_"S6? S_ -UW]I5?%.A:O[ MTBRO4CT?P-\1Y/\ A"?'MN^W5O OB2.XTOQ;I^C7-K_#'X4^#=4^'/[3O['^O M^*]9C^%_P^U_QE\8/B=X>\$>%/@?KGQ#\=>.OB5\4]6^)?C>T@O?"?AWQ%\. M] B^'?@SP?Q'BO\ X(=_$&Z;X_:SX*_:K\!:#XY_;0^'W_!2_P"&O[6OB'4_ MV;-3NO"5YI?_ 4+O?AE?VGB7X$_#K2/CSHUU\/O$7PEL_@K\/O#&HQ>-?'_ M ,2K;XHK?>,?'.KW6@^+=3C4@'ZF^*_^"C'["'@JX^(%EXB_:U^ ]OJ/PKOD MTGXAZ1I_Q#T#7M;\)ZRWCNW^&#Z'JNB:!=:GJR:];?$.Z@\&7VAQ6YCE1/'OA;_P %1?V>?'G[3/Q8_9[\1>.OA)X*LM/\#?V7/&T MGQ;TS6HOVO[7]HW]F_3OVB?#/C#X6V<>A:?X>O?"-[:3ZUX.\&Z[X7\9^.M+ M\;Z]X:O;>VOM+U;5?#V@ZIX;H_\ P2I^*'A#1-3U+P/^U%X!T7XM:'_P4:O/ M^"A/PF\8:G^S-JFN>!]$U*__ &;;S]E&[^%'Q7^'B?M$Z7KWQ0T^;X1:OK4) M\;>%?B?\(-5M_$LNAZIINCZ?I>@#0=1XSP?_ ,$ O$3Z3_P $Q1X/OXO!NF0?#;XJ>$/A=X=M?BKK MO@'PRO@V#PU\)M&\#_ 3P<^N>$M-^'GQ%NM0L_$NF@'W???\%-/V =/\$:C\ M2I?VM/@O<> M)\8VO@6^\6:7XK@UG1(]=OO _B3XG6-U%>:1'?1W?A2]^&G@ MSQC\1+3Q]:>?X$N? GA'Q3XO@\22>'O#NL:C9>V^#OVI/V=_B#\8_&O[/O@C MXQ^ _%'QH^'=EJ=_XR^'>C:Y;WOB#1;?0;OP[I_B'/BI\/\ 4?A]X[\7_M-?$/3/!EO^R_\ "_0OV@6\5?M8 M?$CPA\8?B)H'Q._; M]0O?'GQ(^$'A#XE:9XUUSX4_#+1_!WPZ?2[+Q9X9TW MXG>*?BW-\)?AYJ6E 'ZH4444 %%%% !1110 4444 %%%% !7@W[1^NV7AWX> M^';_ %"]TNP@N/CS^ROH4<^K_P#"2_9)+WQ1^T_\(/#6FV47_"*>$_&FJ?VI MJ6HZM:Z=HGVK1[/PU_;5U8?\)GXL\!>#_P"W?'/ASWFO*/C/9"_\(:/ WQ)T MGX5"/XK_ &O?^$GUJVT>ZL]4.F_'+X=:BOPVABUR^TZR75OC*UJ/A!H%S!< M2:Q9Z[XYTZ[\/6.J>((-,TR[ /5Z\)_: OKZT\)Z3'IFCOKE[-XA@?[$FB>( M]=V6L.FZFL]T;?PWIFIWKMEM%N=$U^"$A8R%U3["DML"UI'=Q)?RPW ![O M1110 4444 %%%% !1110 4444 %%%% 'R?\ MN_M%ZC^RG^S7XX^-6B:?X0U M?Q#H^M?#3PEX;TOQQJ?B_3] O-?^*/Q1\&?"_2R;/X?>#/B#X]\6:M8W/C%= M3T#X=^"O">H>*?B7KECI_@#1+S0;_P 1P^(M)_&Z3_@ME\?]0^'/PRO?#?[+ MW@#4OC3K_P ,/C/XSN_A1%\0O$_B&Y^,/Q*^!?\ P4 L_P!@_P 4? ?X.R> M?"OC#6/#WB"_O/[1^*MQXZUK1O'NC:9IXL_#O@/P]\:/#^C?$[XG?#7]^?B] M\'OA9\?OAKXO^#GQL^'_ (4^*7PL\?:4=%\8^ _&VC6>O^&M?T\7$%[!'?:; M?12PFXL-1M++5=)OX1%?Z/K%C8:OI=U9ZG8VEW#^7_[2/_!$7]C[]HOQ'KNM M1S^)?@SH_B7X1_%OX1:KX&^%?P\_9L_#KXU^/\ 5O$5WI^O_$OP!K?AO5;C1;#P]:B%;GPSX?O=- /'-9_X*G_M M5>)-4U3P=\$/V9?AAXT\=^.OVP/VQ?V-OV>M(UKXB^)-#AU[QW^Q!?\ [8FO M?$S7OB)JFK^'O#_@71-.\>^$?@E\"_#OPZ\.Z;\1V\8-JWC[XX?$N71=7\(? M F3POXMIZ7_P6-^-OB>'QOX^\*_LB_#6\^"O@6SUGP=<^+=5_; ^'>DR>)/C M?;?\$U?!_P#P41T;PUX$OI?#$G_"UO!.LGQ0OPH\.^,?@+X?^-&F>/\ P&ES M^U=X!OM<^%&DRZ)J/Z;ZW_P3]_8B\4_":;X&>+OV4_@+XQ^%-]\2+7XSZYX- M\6_##PCXCTSQ5\:((8+:\^,OC'^UM*NI_%WQ:\16T,EKXR^)'B.;4_&/C:SO M]8L?%NL:S9:WJ]O>W]?_ &#_ -BSQ/XUN?B1K7[*OP"NOB!>?";6_@1<^-8O MA;X/L?%$WP>\0>$H_ &I?#QM;T_2K74!X:_X0))/ VGV*W _L7P9>ZKX5T9[ M#0=8U6PO #\JO!O_ 6H^)NI>,/"%[XU_96\$:)\$+WXG?LY?"_QGXO\%?'S MQ'\1?BOI6I?M4_L6Z-^V-\-]3\._!^T^ VBVNM0^&-,U&?P1XYT.Z\?Z=XKO M)SIGB/P1H7B.WU2QTJYSO O_ 60_:A\;Z;\%M-E_8B^%'A#XA_M+^(/V*[_ M .!>E^(/VP]/UOP)J_PG_;A_9^_:C^*/@3QUXD\8?#/X,_$+Q-I,W@_X@?LK M>-/ VHPM\.H])\;:%>V_BKPKJL+VEYI47ZKZ9^P%^QMH\V@W6F_L^^!+2^\, M^/O@/\4M#U)(-3;5K#XA_LQ_#RP^$WP&\7+JTFI/J4^L_#7X::;:^"-$N+FZ MF$_AS[3INJIJ$%_?"YY_P9_P34_8&^&W]A#X:_LE?!#X:CPU\ EL?C3X+TOQ1H7@WQL%\)+HZW$GA'0O&OB[0_"VA70G\,>'M%\2:QI. MD:)9Z??SVS@'Y.?#?_@K;^U'\6=>^(OQ2\!?"'P;JO@?2OV$OV-OB7:?L]?\ M)3J7B3Q[H?QV^+_[;'[2?[/7QC\;_#O2?"7PL?XH?M ^!O!?PX^$/B;QZGP_ M\,II?Q-\<_\ "MOAY\/OAO\ #>+XE?'+4%\)_LA^RQ^T!H_[97[+_P //BA' M=:#X5U3XO_"JR\4ZCH_PQ^)4OBJ?PSI/B^?Q)X>TOQ%X7\6OX?\ !7BVSL]3 MNO#VN7/A;4?%/@3P'XTTC4=*O]&\5^#?"?C?PUXE\,Z-RF@_\$VOV$_#&D:5 MH>@_LP_"_3K+0/A[J/PJ\.RPZ7=OJWAGP%J/Q=TG]H!-!\,:_-?2Z[X;&B?' M70=&^,O@_4]#U*PUCP+\4M,L_'O@S4-!\40IJ@]I^%/[,?[/7P+UJ\\0_!OX M.?#[X8ZM??#WX??">:?P1X>";&PTV*#3]-\/>%9_&/ MB:?3M.TZUM83-J]Q++_!%_'/XG^. M-U^RKI'C[XO_ H^*OBNQ2S^,7AV3QOKUIHWAGXY_LQZ;XR\8_L3\+/^"G.M M>._VI/AI\'->^#OA;0/A3\>OVBOVZ/V4_@UXYT3XLR^*?B5!\7/V!M2\;6WQ M!N/BS\,F\!:-I?@;PY\3-.^&'Q1UGP+!IOCGQ+K.@:)X6\":KXDAN)?C+;Z3 M\.OM*U_8Q_9AL_A2OP0A^$.@-\+%^+&@?'7_ (1&YOO$%[:/\7_#?Q-T3XS: M=\09;Z\UB?5YO$=Q\5/#]AX[UZ\EU!QXJ\13:S?>*(]8;Q'XA75-G0_V3OV; M?#7QOUO]I'0_@QX#T[XY>(&U>;4?B1#HT;:\E_XCT?PUX=\5ZWI0F>2PT'Q) MXT\/>"_!>@>.O$VA66F^(/'&B>#/!^D^+=3UG3_"V@V^G@'\_P!^T#^V=^UC M\,O^"BO[07B'5M&U_P ;Z!\"_P!H_P#9-_9I_94^!/PX_; \2_#'P-\2O$7[ M3?P7U+Q#J'@_XX_#._\ V8]>\$>,-&\1^#=4\:_'J]\;M<^.OCA\/_BS\%OA M-\!/@/#J7A;XE^/_ !+J?UEX4_X+!?%_7OB%\./!^N_L,S>!=*L-%_9WE_:[ MU3Q-^T;HJ:O^S!XB_:!_:A_:+_90AM].CLOA3=?#CXH>%/ _CG]G76?$7B#6 M==^+'P>\:7GAGQ+IFBZ7\-)OBGI'B/X;:7^BWBG]@?\ 9"\=:A^TGJ7CKX(> M'/',O[7H\ M^T3:^-M4\4^+M'^(EW\*M.32_ACJ[:!XBU[4M#\*^(/A[:06+ M>"O$?@G3O#>O>&+W2-!U/1M1L]2T#1;NPXZP_P""8/\ P3WTKQ+^SMXOTG]D M+X':1XA_90TR#1_@'?:3X,LM+C\"V%EK^I^,M(CEL+ V^F^+IO#?C_7->^)_ MA*\\^+'ABXTGXCZWJGBB[ /EO]OS_@I-\>_P!A[XN^(/!6 MG?LR:'\=/#_C;]F[4OBI^RII_AGQ9\1-.^)?QT^/OPX^*?P[\+_$_P#9-TKP MCX.^$WQ;U+5_'^N_"WXA3_&'X>:[X;TBZ73/#G@'Q]JGC/PU#X!\)>-?B'X, M\E\,_MJ6W[7'[3W[#7Q*\,^$-*UOX'W?_!1;X\?!C]FGXP^'_'_Q*M/"WQ(^ M'>C?\$EOBI\2/'7Q0T30= URT^%GQCA@^/5A\8_@KH?C76[?6])\)V'@CQ#I MFB^&='^(3^(]8TG]HO%_P=^&7C[QS\)?B9XO\'Z7K?C[X$Z_XH\3?"7Q5<&Z MAU?P3K'C;P-K_P -O%LVFSVES;B>T\0>"_$^KZ/JFE:DE[I-R[:?JCV/]L:) MHFH:=XSHW[#G[+?AN#]GBT\,_"Y?"]A^RCX@\9>*OV?-+\,>,_B%X( M/B#<7DOC+5-/TC1/%EAIFKW&O6FJ^(- NU\2VNM1)X/\6^-_!-M'!X0\<>+M M$UH _G%_X)&>,?&'BVU_X(0Z[XI\4^)O$.MZIX-_X+LZ3KNL:WKVKZGJ?B2' M0?VL?#FFZ;=>++Z]O)KGQ;KRP:)83WGB;Q-)JWB75-32\UK5-6O-8U35KZ]^ M\/B3^V3\>/VB7?_ 1P^$WB[0/%'QP\7^%;WX.6 MW[6GQI^-7P&;QI\$OA?#\-O'7@WQ3K]QXW\?^#?$GQ%L;[Q3\*KCQ!X>\,6M MJVN:M?6>CKI?Z;_!G]@']D/]GL_!/_A3OP:TWP6G[..E_%71?@?#;>*/'>JV MWPWTOXXZE:ZU\7[+P]:Z_P"*=6MDA^(NN6-GKWBL7<5TVK:]:V^MW#'5(DNU M[OQM^R/^S)\2?BWX7^._C[X%_#3Q=\7/!LWAR\T#QOKWA?3M1U.'5O!&KKK_ M ,.O$6H03Q-IVO>*_A3K;ZGJGP>\6Z_9:GXF^$%[XF\:S_#/5?"C^.O&1UT M^+_^",OV;M$^!O@OQ[\ OAC^TQ\ O$VG?M$^ ?BQK?Q M$^&7Q)U_Q;I4UKXR^'>E:/X9\6?#7Q-X+ATWPG;ZU+;0^.?!EYXBUSQ#X8;Q M;H_B7P=?Z%=?G7\4?^"D/[47[2/PC_8I^)W@;X=^ ?@.OQ8_:9_X)#/%'PE_::\,Z+\"/"GC[X/Z9X?L_#N@6GQ' MM;3P9\9?A9XA\2^('\,^#O'/C3Q#\-/&.D6G[X_!K]E;]FC]G;7?B)XF^ OP M#^$7P:U_XM:K8ZS\2-5^&?P_\,>"KSQA?Z:MXU@=9D\/Z;8>=:6M]JNO:Y%I MJ"/35\3^*?&/BO[(?$OC+Q3JNK^3>$?^" M]!_:>U74M/\ "MM'?:C\=/"6N^+_ !1X*\>WEV[//<7'@'Q/X_\ &OB7X>:% M+(WA?P!XA\4:SKG@W1-#U2]ENB ?F#\*O^"[=Y\4?$'[$D<'[*VFZ+X*_:NO M?@)X3\:>(&_: F\0^(_@[\1/C]\1OCW\,?#>DIX5\,?!#5=*NO!T7B#X$7TW MA_QA\=?&G[,6K?%VS\2QVOP1\$_$?7O!?Q%T3PI@:I_P7?\ 'WAW]EO]G_\ M:=\8_L??#SX>:5^TQ\#?B_\ M"_"#PQX^_;!_LEO'7A/X&_#7X9^-/$WPO\ M"?B+1?V;_$FG:I^TS\4=8\<>)++]F?X)W]OHH^+?@[X>:[XH\3>,OA7XMDE^ M&.G?I;IG_!*K_@GSHE]\+=1T3]F+P3HMU\%9OA7>?#$Z-JGC+2H/"NJ?!+XS MZU^T'\+M>AL]/\36]GJ7B7PG\7/%'C'Q3;>)]:@U+Q!J%OX[^(/A?6-2U'PA MX^\9:#KGSA\=?^"/?@+Q9=_L?6G[-OQ"B_9L\#_L=^ OCC\,/AUX*@@^/FM3 M^&/"GQ[\6?"SQ5XMU7X7?$OX1_M2_LZ?&#P'XTM$^&*^$[ >)_'_ ,4/A/=> M O%.O^"]<^#VK:!,MF0#S/5_^"UFO>#O$O[0VI>._P!BGXE:;\#/V8O#_P 7 M=-^+?Q3\->-I->U[PA\:/@O^QIX!_;+\0_#77O!^N_#CP9X.MM&\3^'_ !7X M@^&7@?Q'I'Q*OACK'[+.K_#3X'1_&'6/'/PF^&^N>+OV-O _B37O!?A?XFW7 MPD\&Z]8>%/$?C^TN]3\0ZK'\,+AX-3U#6/$UCH=]-J+Z:WNGA;_@EY^QCI7C MO2_C%XZ^%L/QU^/8^ 6D_L[>.OCG\;KS_A,O&_QE\*:?\.Y_A)J/C?XP>'[. M#0_A1XR^-_BOX77VL?#/Q9\<3\-[#XGZO\+_ !!K_P *1XEM_ACJ]YX/D]C_ M &:?V+?V:/V0-)\0:+^SU\-F\#67BS1O /A_Q/)?^,_B!X^U/Q#I7PN\+#P1 MX M]:USXD>*_%VM:G+X9\'1VWA>QO;S4)KZ30=/TG2KNYN;+2-+AM #\EO@! M_P %C_'TW[-7[.OCCXN?"+P]XU\3:5^S-_P3"^)W[8?C7PQ\1;CP_/]!^$GP&U3X0> )/A-;:1XZU&\OGU7XE_''PQK'BGX4>'?A%8:CH_@[X: M>*?CI>#5+[1>5_X*Y?MU_M1?"#XM_M*?L[?"/Q3I?PY\%>#_ /@F)H'[6&A^ M/O"UQ/:_&./XOW/[9WA3X00>$]$NK[P_JOA^TT;QOX5#>!;74;C4O#TOA^]\ M8:GXGN-'/\ @EO^PCX43]GZ/1O@1$(OV8?!>B?#CX21:I\1 M_B[X@BB^'OA'QQ9?$[X>>!/B3%X@\?ZFGQV\'?"/XDZ=9?$+X(^&?CHOQ'T7 MX(>-[=/%?PDLO!FO%K]O3/V@?V%_V4/VIM:U7Q)\>/@WHGCSQ#K?P/\ '?[- M^K:\^L>*_#>LWWP6^(WBKP3XY\2^"Y]3\(:_H%Z5A\9?#SPGXH\)Z^LR^*?A M]KUEJ&I^ -;\,W?B'Q'+JP!^;'QA_P""P/QG^%GB+XG_ 2TS]B33_B5^UIX M"^+?QW\%>'/@;X!^//CGQ3HWQ2\#_ S]F#]F;]J6ZU_P3XP\*_LK>)/'$WQ) M\7^&/VM/A%X,T7X<7GP:@\&Z1XTN=>?Q5\9]#\(:2OBN[]A_:3_:5^(Q_:$_ MX)"^.O@)X^^(6H_"3]K+QC\6-/\ &GPI^'=]^SWXIT#XP_#>Y_8V^*/[27@B M[C\4>)CK7A@:EIOB'X=>%;NR\9_#CXR:-I.I>$+OQ19:#KWB"V\0:=>GZ!\: M_P#!,/\ 8B^).L?$S7OB%\(-8\<:K\7_ (Q^'_CYX^N?%GQD^.OB!=2^*?AK MPGJGP[L-!/&GP4M](^#'C'PUKO MPMT#0O"6G>S^.?V1_P!G_P"(GCO]G'XD>(O!.H6OBG]DB\UF^_9W/@[Q[\1_ MAQX<^&TVO^'[#PAJT=GX'^'GB[PMX(UZQNO!E@W@A=,\6>'=>TZU\#ZMXH\& M6EK!X8\8>*]*UD _'[]FC]M[]J'PYKGCWX8WD?Q!_:T_:2^*_P"U1^W5X;^$ M?PV_:%\:_!CX#>'?AE^SY^PMXC\*>&O$SZMXT_9J^!'C?0+_ ,;ZK=?$WX>: M/HVEZ#X)\57'C76?$VD3ZMJGA#3_ ]XT\2IROP'_P""K>L>+?CO\4_'W@U? MB)\6_ _[8NO?\$L?#O[%'P1^*'B#PO\ #?1/A7J_[5G[-'Q9^-/C:P\5^(?# M/AOQ@W@_3-#\%_"WQGXW\;36%E\8-&?"]_JNCZMX?ETG])/^'3_[ M"G_"'7_@D_"[Q^UAJ'Q!UWXL2>)'_:8_:E?XH6?Q+\8>']9\)_$/QUHOQE?X MTM\7/#WB?XL^%_$.M>'?C3J^@^-]-N_C5HFHW&E_%:3QC9%85[*]_P"":O[$ M5Y/\0)XO@/I.BGXC-^S*^HV_A3Q=\1/!EAX,F_8TL6TW]EZZ^".F^$O%^BZ= M^SI>_!6S9XO!M[\ ;7X:7=NTDLU[->SRR2L ?D1_P3R_X*G_ !MC^"/[&7PS M^(GPG\>?M ^+=?T7]G:Z_:M^.?B7XK6B^-/AE?\ [;G[6/[2_P"S_P#!?5H] M-3X=1> ?B1IOACQY\'8]%^(P3Q]\(CH_AGQ+X1/P5\%?$>YM=3\$>'?M;X9? M\%"/VC_CW_P3!^._[=>A_LT>$/@CXCTS]G3Q[\8/V?\ P[XA^.5M\3=(\7/X M5^%^J:]J.J>)[[1?AAH=UX;AT'QWHGB#2]'T*\T&]N/&&@:;H&KZM/X)O?$F MK:!X0]Y\/_\ !*'_ ()\>%K[X$:IH/[-?AK3]3_9HL?$>F?!?4D\4_$:?4/" MEAXB^(FJ_%V"UO[VZ\8SW/C6+P)\5]/)?$Y^ GC_4+CQA\$C\/_ M ! _]H#W70OV._V<_#'[+DG[%OA_X?2Z/^S++X'U[X:-\,+#QI\0(+&(8XO#H32U /Q8_8C_ M ."@7QE^&6DQ>#?'^A?$S]IGP'8?%_\ 8.\(_M#?'3X@_'OP-JOQ*^"WQL_X M*;^"/@5J?P\\'_"CX90_"KP5??$[]G71/B/\(O$?BKX?:U\*(?C M=X@^%OP.^'GQ!^&OP$L=)TC[4^ ?_!37QM\6/^"='Q/_ ."AGCS]EE_A/X=\ M(?"CQ7\5_!'P_N/C_P##W7!XVL?!/A2\/BOP]XG\>:YI'@/1_A)K?AOXJ>'/ M&G@/Q#-XSTO^Q-'\-:9H7CNZU8:EJGB3P'X(^DM-_P""='[&^E^,_A=X_A^$ M,MYXH^#W@;X3?#WP5,_BE\,];U6^UWP5XQT/6)WOCTND?L+?LJ:+^R%;?L M&V?PHMY_V4K+P1)\.[#X6:QXN\?>('TWPM_:/->\5:E\2],UKPYK MC0:YX-\6V'C*W\6^!];TW1-8\'ZYH>I:#HMU8 'Y9^,?^"WWC+P]\+;'XB:+ M^Q9JFMWNE_"S_@I9\5_B7X<\0?&;4_A==>!O#_\ P3!^*WPV\(?%Z>'2OB9\ M"_#/Q(U)/B-X"\?-XL^%^C>(OAEX(^(:>-E\-^ OB+\/O /A?5_%7Q8^'_UE MX*_X*73>*_VP;']BR\^!-[H7Q9O?C9XLTK^SW\=7>HW-_B;K/@7]F"ST#^UEL].^-.K>,_#LGCF\UGX=:GH.I^AZA_ MP2J_82U33?&.E:A\&M*=1UK8_9W_8RU;X8 M?M"?$S]I?XK?$/3/B?\ $6_\!6?[-OP*.C^&M;\.V_PC_9"\(_$#Q/X_\#?# MSQ-K/B;QKX]\7_%WXM:CJ7B&P/Q0^,/BSQ#$GBMO!OA.;P]X-\'ZE)X[U;QZ M >/_ !>_X*:7/PG^-W[0'AJ3]G?Q-XC_ &;OV17N-$_:@_:&T[QI9CQ#X!\8 M1?L;>.OVV_LWA;X,VWAC49O&'@J'X [N\^,?QR\&>"?" M_A3Q/;Z7XCUO3_GO5O\ @LQXO\.W_P #O!'B+]D2'3?B]^T'XA_8'U'P'X-A M_:&T;4?"]C\&O^"A&I_%KPI\-O'?BKQ]:_#$I9^._ACX]^#OB/P[\7_ACX:\ M-^+-,M],U#1O%'PR^)'Q.T^34H--_2_Q+^Q)^ROXP_:+TO\ :P\2_!W0-6^/ M.DZ)I.A1^,;C4?$B:;J47A[3/%^A^%]9\3> 8-;B^'/B_P 9^#_#_P 0/'7A MOP5X_P#%7A+6?'/@SPSXQ\3^'/"WB+2-#US4K"Y\F\,?\$N?V(/!VG>!]+T' MX4>*(K7X:_$+X&?$CP%)J/QY_:(U_4/"=]^S+JNNZ[^SYX#T75]?^*^IZK:? M 3X.:UXG\0ZM\/OV94O3^SIX:U'6=0O-.^%L-QOH_@'X5:Y MJO[*NIZ9\1OV@/V?/%7B;]GWX6:E\9-,LK_XP_MB_#G]J/P9^Q_\1_V,O"FM M3?#Y?M-UHOQ>^(_@74] ^,]OHUYHGB/X4:SJ/Q5NO!GA[PMX7\23:=)XS_X+ M9ZKX4TW]I[Q[9_L<>/\ 7_@A\"[?]HV#P#\6XO%'B[1- ^+'B;]E+]J'P7^R M]\5O"5YK6O\ P2T_X:>&-3\3ZWXJU'QK\$;[P7\4?B_H?COP[X1\3:'XUU/X M4^/?#_BCPGX=_2_X<_L*_LM?";P;^S_X!\ _#2XT;PM^RY\6/'_QO^!=E=^/ M?B5XCOO!/Q,^*.F?&'2/'NOGQ!XH\8:UXB\26WB*Q^/?Q5CN/#WBS5M=\-6L MGB2";3]'M)?#OAA]&\9\:_\ !)3_ ()_?$%OV@9/$WP(NI9?VG=1U?6/BY)I M7Q=^./AW[3JOBCX@>#_BMXZU#P!#X?\ B5IEO\&+CXH_$?X?>!_&7QD_X4U# MX!B^-&N>%-#N?BQ'XR6PAC4 _/G]L/\ X*C?&73_ (9?MQ_LZ>,/V;/B-^S) M\9OA]_P3K_:)^-)\;^'?CQI&B^*-!\5^%_V3O#GQ8NO$W[/WBS6_ _@^S^+G M@#PSXQ\6^*_A'9?'SX!7_P 2O%'PL^-/PRA7XP_!SX6Z?XU^'&H^)/LZ[_X* M7R6?QC'AG3?@L_BK]GO1?VL/AA^PCXQ^/FD?$RRN?%6B?M,_%?X:^ ?'OABX M3X10^!;?3-3^!<.M_$[P-\*O$/Q13XFZ3XOM/B9KA_L7X,:S\.K9O'Y]?^(7 M_!,/]AKXJ^+_ (R^.O'OP,M]=\2_'SPI\0O!WQ*O$\??%'1[>[TWXO>#M%^' M7Q@U3PEINA>-M,TWX9>-/B]\.?#/A;X>?%7XA?#.T\(>._B)X#\+>&_!WB_Q M%K'AW1-/TV#H+?\ X)Y_LG6OQ/\ #/QAC\#>-V\>>$X_"MQIUW//#/B3XX6NAZ5 MH42?$'SM T2>P /'OV!/^"BM_P#MIW]GHWBOX%3_ 'UWQ5^R/\ LI?MM?#C M2I_BCH/Q*G\3_ O]JRR^(%CX;O-7_LKP_P"&F\-^*/#_ (R^%7C&QOM$MXO$ M-G)X-U/X=^)M3UCP_P"*O%.O_#?P3^F]?GYX2_X)>_L8>!=,\$:-X5^'OC+3 M])^'?@C]F[X:>%=,OOC?\+-6N(E^+G@AI]#N]+\&13:Q:^%O$\(D\->.?$UXB^$_!?@K5O$'C'QY M+!X&T'Q%/& >C5\T?M3V.J7W@'14TK4[K39D\7V32/;>,_AWX&\V(Z+KP*OJ M_P 2?#/BG1[C:^TKIME9V^IS9:Z2Y%K9W44GTO7@G[1/AW2?$W@K2[#6)-/C MM8?%-E=QMJ0T/2=;A4(-;\>_#NU\WR[B4KY>M75QL$FS2YX_-N[$ ][H MHHH **** "BBB@ HHHH **** "BBB@ HKYC_ &T?CKXE_9=_9,_:)_:7\*^$ MM#\>ZC^SS\(O&WQPU#P3X@\17_A*R\5^$OA3HMUX[\>:!9>)--\/^*9]'\1Z MIX'T'Q#:>$;R?0-2TQ/%D-?3Q?#W@3_@KA\.=*U[XLZ/^U#HGPX^ M$.B_!_\ 9X^#?[2WC/XF_!3XQ:W^U-\+?!O@WXS?$C6/A+HWA+XD:SH/P;^' M/B[P7\2M+\9Z+=7&H:-;>!?$OA6#P4MUXRO?&VG6&D:W;Z: ?K[17SG/^UK^ MSS9>"?VDOB/J7Q'M-&\"_LB>)/&/A+]HCQ1K^@^*] TGX>:[X!\ >%_B?XMM MWN-:T&Q_X2FSTGP3XR\.:K_;'@I?$FC7]U?R:#IFH7OB'3M3TJR^:O"7_!2W MX"^//C%I7AWPSXZ^'=M\%K?]EC]I7]H[XC^/_&^M^+_AC\1O@Y+^S!\;/ OP M:^)>C?&SX.?$SP)X-UWX'Z'X5U76_&UOK>J?%74/#/B5/$7P[\<:*?!UE;>! M_$6J@ _2&BOSX\:?\%5_^">_P]\ 1?$[Q?\ M/>"=*\''Q9\0O 5[=QZ7XSU M/5] \=?"GX<77Q>^(G@KQ;X3TCPS?^+O!OB[PG\-+.3QCJGAKQ7H>C:TND36 M$D%E--JFFPW?2_$7_@I)^Q'\,9_&]CX@_:"\%:EJO@'X)?$+]H/6=,\'R7_C M22^^&GPN^%GAWXX>-+CPUJ7AFSU/0?$_BO2_@YXR\%?%5?A_H>KWOCJ[^&_C M7P=X^MO#TG@_Q-HVMW@!]Q45\#_"O_@IE^QW\5O"G@CQ!:_$R3P9KGC)/V4[ M2Z^&_CW0-8T;XA^!O$_[:^GO>_LV>#O'>D:?:ZQIFC:S\3;F"[T?P[JEGK6J M>#-7U*U!T;Q5J6G7^D:AJ.5HG_!5[_@GKXD\+GQKH/[37A'5O"BWWBJT;7K' M0/'L^G)9^ ?!MS\0/B-XH>9/"9\OX?\ PO\ "-JVJ_%3XE.%^'_PP>XT[3?' MWB7P[JVJZ98W8!^AM%?G?^V9_P %%_A?^PY\4_V9_#?QGTVTTKX/?'K0OVD= M9\3_ !OE\1RF'X8/\ /A99?%73].M/AYH_AO7_%7Q0U'XDZ6NNZ/H&D>#)&\ M1C7=-TO3-'T'Q/J'B*RLH/8[K]MC]F>]U&S\+> ?C'\.?BA\0/$O@;0/'/PW M\%>!/&>A:]<_%"V\<_#CQQ\6OA?I/@G7].N;OPSJ^L?%/X=?#GQGXZ\ Z?:Z MK/?>)/ OA[5O'&DVEYX5L9]54 ^K:*^ ?@!_P45_9]^*GP5_8]\>_$7Q_P## MOX1_%#]K7X*?LP_%+3O@[>^-[76M4\'ZW^U1X'_X2/X9>$]9U466FG2[7QOX MJL/$7PV^%?B/Q=IOA&S^*_C_ $9?!'@V"_\ '&HV7A>7M[G_ (*$_L2V?@G4 M_B))H)+BS^$_PJ\<7'PP^)7C271XD?7#IO@/X MFVLGPV\5P)IK:CH?Q!DM/!.H64'B>^LM+N #['HKQC]HSX\>!/V7/@)\8OVC MOB>-=;X>? _X<>+OBAXS3POH\VO^(I?#O@S1;O7-3@T72(I(%O-1GM[-X;47 M=W8:;#*ZW&JZGIFF0W>H6WQ%\'O^"JOP#^)'[17B;X%>,-6\#_!RS\0:!^RE MXC_99\0^/OB?I6G>)_VI=/\ VIOA=K?Q$T:;PEX!OM$TN+2(-'U;0K_XOC54T'7+21HXH=?\ "&N:AX=\6^'M&\;^ M'9=6\':IXN\"_$+P;8Z[/XK^'OC71M!^>+C_ (*C?\$^[7X;:=\8IOVJ_A;_ M ,*LU?X'>(OVD-+\?QW^IS^%M0^#GA'XD^'O@YXH\4V>KP:7):W%]X?^+/BS MPU\-=7\&QNWCFP\Y\-1ZS<)9T ??%%?FG\'/$:+JFD^)O##ZY[)I?[>_[*<<=EI?C MGXX_"SX>^.+7X37'Q=\=^#]?\;Z9%_PK;0=%^%'ACXW>+[/QAX@NTT[2-%U/ MPO\ "GQ9IOQ+N=)UN31_$-[\,4O_ (D6NA?\(=I6KZKIP!]D45\C:/\ MW_L MB>*KRRT+P9^T1\'_ !'XNUR+XA_\(IX5/CW1-'U+Q-<_#'7/C?X8\6+I_P#: MTUM_Q++#Q!^S9\?+0:^8WT:\L/@_\1O$&F7>H:#X1UG4;7&^&'[=7P%\1^ / MV8-2^+OQ3^!'P5^,/[37PM^ 'CK0?@S,/$/ASQ]X8^$7BSP="=+^.3?#SQ?J_P ,[76+30M9BTP ^TJ* M^=?@]^U[^RI^T+X@OO"GP'_:/^"'QE\2Z;X:C\9WVA?##XG^#?'.JVWA&3Q! MJ/A,>)I++PWK&HS_ -A+XHTG4O#DVJ*C64&N64^ESS1WJ>2?!OVB/^"H_P"P MS^S1\)/VB_B_XT^/O@CQ5IO[+.AQ:Q\7?!GPKUS1_B)\2='N;WXG3_ _2=!@ M\'Z%J4EV-6U+XX6UU\');C4Y]+\/^&OB-8:SX>\;:[X8D\.>))M( /T#HKX3 MTK_@I3^Q?/-^T"?%OQQ\&?"/2?V:_P!I&_\ V4OB'XE^-&OZ#\+?#=Q\7M)^ M%VC?%W5=/\-:IXMU;3TU/1=.\(W_ (AN;G6KJ/38/(^'7Q%\00QS>"_#1\4W M>3^T7_P5#_8A_9G\)_$OQ'XT^.W@?Q1K/PFU'P+I/C/X;?#CQ5X2\5_$O3]0 M^(GC?P3\/O#D4OAG_A(=/2QM4\2?$3P?%KVKZSJ&EZ+X7L](/A5\,/CQ\)_'OQ,\*V&MZKXC^'_A7QWX=UGQ MEHVG>%_%+>!?%MY?^&[._EU>&#P;X[5_ GC1S:8\'^.$?P=XF_LKQ*CZ6/@+ MPW_P6A_8\\0_$GP+I][\1?AG\/?@'XST[]LW1&_:$^+7Q>\&_#K1-.^,?[&_ M[2WP$_9TU?X:1:+K!?1M0L?BG%\=]&^*GP\\4MX[L-1N? -OIM[?>#('U;4V M\,@'Z\45\/?'7_@HY^QM^S]X3_::U_Q7\-/"=OKV MJ:+:ZW:7C5/VE/V[_AW^S1K7[(NL^+1X3A^ ?[3?CGXA^%?$O[0GB;XCZ5X( M\&_!W1/!W[,?QC_:5T+QGJ5KJVDW*^)=$\6Z7\'=4T$W,FK>%],T"WU"/Q!? M:Q:=J6@>&+;6)=6U>WU#P)I6J>.+#[!;7#WO@S3-0\5VJ M2Z!97.HQ>">#/^"@'P\U3]L?X^?L=?$:Q\/?"KQ5\-_B'\%_AS\%]8UGXB:+ MJ>H?M':S\6OV>==_:$OXO#?@N'3K'6O"-UX+T7PAXRTB[BU>XU*PUR308[K3 M-66^U2UT, 'W]17Q^_\ P4&_857X*-3\%#X@V?QE\!7W MA%_%>C>!?^%I:KH46NV6N3Z?+J&G_"PI\4;J**=Q#\,YK?X@LP\'W$&LR=U\ M=?VM?V8OV8+GPG:?M%?'OX4?!&?QUI_CC5O"*_$[QMH7@U->TGX:Z/9Z]X^U M6PFUN\LX'TSPGINIZ1)K=_))':6=UK>@Z:\W]I:[I%I>@'T-17SY)^UI^RW% MX_\ #GPJD_:,^""?$OQ?X87QIX6\"'XI>"O^$J\0^$Y/">K>/K?Q#H^B?VU] MOO\ 2;OP'X?\1>.;&\MH9(K_ ,&>'/$?BJS:?0?#^L:A9?,OC[_@IA\%-"_8 M#\#_ /!1?X?VO_"?_ ?QSJ'[/-S!?ZAXG\/>"8_#'@;XY?&_X<_"#7/&WCG6 MKR?6-'\)0_"*R\=W_B[Q_I>KSP/H0\)ZQH?B:^\+-;:MJNB@'Z.T5\OR_MN_ ML8PZ)\,O$TO[6W[-"^&_C5J.NZ1\'_$7_"]/A@=!^*6I^%O&.F_#KQ-8?#[6 M%\4'3O&%UX=^(FLZ+\/MB^#;\0>)-7T[3+F.\_;C_8LT[6/ MB/X?U+]KO]F33=<^#UQ;VGQ9TC4?CO\ "ZPU#X9W5UX_M?A/;V_CVUN_%,,W MA.:7XJWUE\,5CUU;%_\ A8EW;>""!XGFCTM@#ZDHKPSP;^T]^S=\1/@YKO[1 M/@#X^_!KQO\ 'POIWC'6/$GQM\)_$OP=XA^$VA:/\/8[^;QUK&K?$+2=8N_ M"=AI/A&VTO4+SQ#J=SJT=CI5C9SWUW<16B>=7F7B7_@H/^PAX.\.^"_%_BK] MLK]F#0/"7Q%N?B39^!?%.J_'/X;6GASQ5=?!N)I/BW!HVN2^(UTN\?X92".R M\>B.ZQX3U6[T_1M<-CJNI6%E<@'V!17E_P 8/C!X%^!WP:^)GQY\>ZO#8_#C MX3_#CQ;\5/%FLP2V\L<7A'P9XJ:^(?%G_!4'X(^!_V!_AC^W5XIT]]"LOBO!\+_ KH'P?UOQ?X.\.^+M'^ M/?Q*\:Z-\*M1^ WC+7/$FJ:-H'A+Q7\'OBQJ&M^#/CSU^$_A']G'2=:N_"WQ+_9,^!WQW\9 MZ?\ MA_LHP> _A5\7OVH;7POXDL]/\*ZWXE^('AFY^/7@RW\"Z_J>H?#.]^$ M6FZ_\6?BWXY\(^)/ADWP2\":]9-=5]%_"W_@I5X*^(_C#P'X*?'.D>+! MH&J>()=2^"&G_%;0/AEH$VAZE\3=>\/6>JRW&G@'Z745\=K^W]^QU?\ CSX M?#CPM^T-\)O'_B7]IOQQ\5?AW\(?^%>_$'P;XSTGQ#XJ^"7A1_%OQ2TH:UH> MO76F_P!H>#H)]!T;5]&M+B\\06VO^+/#=D^D""[N[RQ]G^#W[0/P&_:'T76O M$GP ^-OPB^.7AWPWKT_A7Q%KWP>^)/@WXF:+H/BBVL[/4;GPWK6J>"M:UNQT MO7K?3]1T^^GT>^G@U"*SO[.ZDMU@NH'< ]=HK\YOVH_^"J?[%?[+W[./Q$_: M3O\ XX_"OXJ>&OA]X^\%?""7P[\+?C#\'M5UO5_C'\0[G1QX4^&4>HZUX]T/ MPMHOB1M"U@?$+Q##XAU[2SX7^%.B^*?B5JT#_V M0-4U7]C;XVZYX[_:]\7>._AOX;^'?@/XB_LSZX_AKQ_X ^'GQ,^+4T)\;^)O MC7X'\$^+/ ?Q!^%_P;^(WQ"^$GQ$\/:M+IGB;PM8>'6\66'@#Q!XNTGP\0#] M(**^)?@1_P %$_V//V@/A1\+_BUX;^.'@+P99_%;X?VGQ&T;P/\ %7Q?X1^' M_P 3-$T232/BOK6IP^)O!VKZ_P#:;270K'X!_'JZO=5TNYUCPIJ>D?!'XJ^* M_"WB3Q#X,\$ZSXDM_3-*_;%_9&UW2OACKVB?M3_LXZQH?QLO6TSX-:SI7QO^ M&6H:5\6]23QWI/PM?3_ACJ-IXGFL_'MZGQ.U_0OARUIX5FU6=?'>M:3X0,8\ M0:C9Z?, ?1U%?/OA/]K3]E7QYJ^B:!X&_:9_9]\9Z[XF\7>+/ 'AO1?"?QF^ M'/B+5_$'CSP%X,L_B/XY\$Z)INC^)+R\U7Q=X,^'FHZ?X\\6>&["&XUGP[X, MO[/Q1K%E9Z'=07ST--_;*_9!UG1].\0Z1^U7^S=JN@:OX/USXA:3KFF_'+X8 M7VCZIX \,:-KOB/Q+XXT[4[7Q1+97O@_P]X>\+^)=>USQ-;3RZ+I.C>'==U2 M_O;>QTC4)[< ^D:*^2OC?^V1\+/A/^R1\8_VS/!#)^TC\*/@EX+^(/C_ ,4' MX!>+_AMXJNM2\-?""[U6+XO-XT\-^+I_$'AZ3Q7:ZP= M2\*ZMX6LK6Y\5BVT:?Y3O?\ @K%X$TCX>?'_ %;Q=\!/BG\*?C-\"OV5O"/[ M8L/P%^,7Q"_9F\(ZK\0_@9X_N?$NB^%?'GA_XG^'_CIXV^$7A_PO:>,/"FM> M$/'=_P"-_&'AS5_!&IV2W=QX=U/2=:\(7WB< _6&BO"=9_:?_9TT'QOXB^%N MH?''X3_\+<\*>"]5^(>O?!VS^(7A+4?B_8>"]%T.T\2:EXC?X86&KW'C>32; M?0]0TW4_ML.AR6TMGJ>FSQ2O%J%F\WR3^RU_P5!^#_[2WA5O'VN_##XO?LS? M#:\_9W^&'[5?A?XK?M%7?P3T7X2>+?@E\6]9\3Z/X;UFQ^)GPW^,WQ,\(>'/ M%GA^7PY;_P#"Q_AWX_U/P?XR\#3^(_#T-]I-U!?K=J ?I917R%HW[9WPDUOX MGZWX$?B'X[^(7@R&5=#M/& M#^*M.\&PP>#-+UO0?C!<:?+\+/&;:_?^']"\3MX@\)ZO8OU\G[8O[(L5UX!L M9?VI_P!G&.^^*W_"O?\ A5UG)\*]/\-_VE=^'=8ALP#Z.HKP"7]K']EB#5_B M)X?G_:6_9_AU[X03Z1;?%G1)?C)\.H]7^%]SX@\3GP3H-O\ $337\1B]\$SZ MWXS!\(Z1%XEATR34O$X.@6:S:J/LE;FA?M$_L_>*?%'@WP/X8^.GP<\1^-?B M+X&T[XG_ ^\(:%\3O!.K^*/'?PTUBP?5=)^(?@WP_I^MW&K>)_ VJ:7%+J6 MG>+=$M+[0+VPC>\MM0EMT:0 'L=%%% !1110 4444 %%%% !1110 5P_Q'L] M8U#P9K-IH'C&U\ :M,=-^R>+KVVAN[;21'JUA+<"2WN+RPAD_M"U2;2TWW<6 MR2]1UWNJQOW%>-_'#7(M,\,^&-'6?P(^I>-_BK\)_!NGZ%X_LVU73_%6GW_C M_0=2\>:+H>A0B2ZUCQ7:_"W2?'?B701#;W-IH-QX??Q=K\+%.IPJ-.U&QUW4((6-K>D7J0^'O"'C2]66, P+++I=O: MJERZ/J$4KP6UUW->%?M >$+'QCX1TJQO-)FU;[+XCMKN..V\.77B6>'_ (EF MK0NXM+/3=3G@A;S$62Y,*1!_)B>4/)$C@'NM%%% !1110 4444 %%%% !111 M0 4444 ?.W[77P0UK]IG]EO]H3]G+0/&.B_#Z^^/?P>^('P;G\:>(/!NI_$# M3/#FB?$OPUJ'@WQ+J+>$='\=?#34-8OH_#FLZJFD+#XWT-++5WL=1N6O[6SF MTN^_+_Q'_P $_O$O[/7A#4?C9J/P[TS_ (*#_$#P/^PEX:_X)G^%/V6OAA\/ MOA5^S+HGQG_9K\:_%SP)I7B__A;'B3XD^.?&6F>*O$_AWX;:3HLN-3\=?#WX M2Z)H^D?%T^%? 'AF7XLO;>&OT3_;S_:,\0_LB?L9_M+_ +3GA/P=:>/O$?P. M^$'C'XB:/X5U*YO[+1]1O?#^FR7,=QXAO-+M;S4+3PQI #:UXGNK2));?P_I MVI3"ZL@AO;?\G?%G_!3_ /:C_9_UKXJ^+_C??? 'XN?LS?LB_'G]GGPI^TI\ M??V;/@G\1)[3X@_ G]L#X'>'_%?PU\8?"7X;V?[1OQH\0^#_ (F?!'XO>+OA M=#\3?#4_BGXP6WQ#_9X^,OAKXM>#-'T+5ETCPUJX!]N? O\ 8(\9_#/_ (): MZ1^PMJ_Q1\/WGQF\2?!/Q=H_QB^-7COPE'^U)X5\;?M"?&B]UWQ[\?\ XD^- M_!GQZ+?\+S\+_$+XN>-?'&M^(- ^(ITJ?Q=X>URXTZY7PP\]O'I7YQ_&?_@C MU\>?AU^S;\7;7X:?$#2/VK/&]I_P3>_;T_8=^%_P8U3P7%X2OKV+]L;XW6/Q M=\ Z=X5^)/QS_:$\:)HGPX_9,M7;PAH.HB3XJ:;.G MAS2=.H)_P5!_X*.>%K?Q;H/Q2T']C/X=_%?X!_"'P-:?'3X1^./"OC+2?%OB MOXX?%+_@GIXZ_:[\*ZW\(Y-%_:;UO7]2\*>'OC-I[?L_7_PYTKX8^-](^(&B M_LZ_M0?%73OVD_AQ)I:?#WX??1'[0W[7W[8LG_!'Z;]L2#Q+\%?A+\3/BYKW M[)WCCX3ZQX,T3QMJ>E>%/@5^U%\8O@!I?A[0?&UIK_B_2;FT^*/A/PU\5M5\ M)>,/$^@^(KSPMXE?0/\ A,] T3P@WBE/"'@P \)_9W_X)W?M??%^>W\>?%35 M_#'P,U'X=?%S]IKQWH'C7XB_#+XJ:_\ &3]J#Q1^T7_P3Z\/_LEV7Q.^*OA' MQ/\ M_?M,:K\,;'X.:NT6@V.D#XX:A>_%#P3\.M"\*^&/A]^SIX>\.>'_''Q M-ZWX*_\ !"CQG\*_$/P@&M_M;>'_ !OX ^%_@K3/A]=^';KX!ZYIGBG7?#FK M?\$Q_@/_ ,$X?B9'I'BVT^/9TGP7)KNF? 'PU\2/!W]D^"KJXT&?5=2T/Q_? M?%F\TSPCXB\,_-?_ \:^)W_ 3Y\4?M_P!UIOA^'X_>!F_;7_X*+2)::[J7 MB/4/'%K\7OAW^P[^SE^VQHNLP^-;OQAJ&B^&OV'/V?-<_: M!_86TW]II/!^H_"K5;OQA\'OC"OPY_9R\,?M)_!3QGXC^'WA/XG^/]=^&#^+ MO"?Q%\%V?COX2V?QZ^(.I:.MK>ZWIGQ1&F^(M-&C 'G_ (-_X)#_ !L\*R?" M&*]_;1\/^)M-\-_#C_@E'X'^-*ZW^SKKEUXE^*>H_P#!*/\ :>U3]H/X;:SX M/\2S_M$SZ9\*M-^)VEZQ-X6\>Z"_@[QS>/XKL+/XB:?XBMDU+Q-X/US'\_"_B;PUX+UGPS\7=6^(7CRRUK68/'B?$CP/ MX\T#XBZAHVE_.?QF_P""S?[7WPZC^/WPG\/^ OV8=9_:%\"V^F_&3X9ZI=VG MCBP^&NJ? C5OV&/B1^VOK'@GQ5I7B;XK^!].B^(OP;/@/PW\,OC-\7-8^-?P MY\#Z3X,^-'PL^/&B_"^_\0ZWIW[-NM\1^VA_P5T_:8\0_#S]NG2O@IXN^ WP MK^'5W_P3S^(/QV_94^(-M;>,M5^-E[J]A^S[^R?\4O&=WH?B?PG\3Y+'0?C+ M\.[3]I76(->^$7Q9^&G[/7C[X)^'M2_9Z_:?TN7X_?#7Q/\ $3PK\/P#]JOV MA?V+_'_Q#\3?L8_$WX.?&_2/!GQ<_8M;XD6O@_Q5\:/AG>?&71?'-C\4?@9K M'P2UO4?'7A_P5\0_@5=W7B&R:]TGQV9]$U_1-+UG4](O= ;3M&M=<@UCP_\ M%?PQ_P""*%E\!OB+\+-?^#OQL\ GP-\,O 7[,>FPQ?%S]E?X9?%7]H?_ (6# M^RQ\#E^ _AR^^'/[3>IZOIVH_!/X4_%GPEX6^&*_&SX<>#?AK?>([R;2OB9? M_"#XE_!O7_C#XJUR/[$_:E^.?[4'PRUK]@GX9_ W4OV>]<\3_M4_%'QO\%O& M?Q.^(7@WXI:OX*T?6="_8V_:!^/_ (>\>^"_!GA#X@0W%QH-SXH^"K:E=>$_ M$7Q@N-7UOPM(?!VE>+(;O5]1^+/@7\+=4_X*K?&[PI;:]^WKX:^&'PZO/BW\ M2/\ @D/_ ,$:_C/X@\ ^(O%WQ7L?A3J&J_M!_M^_%;X4>+?#&CZ98:[>6WAB MUM]$^)OCBX\&>,[CPY\0?$_A;5K_ $:6_;Q?I.G>)?"?C ^T(_^"'?C1?@C MI?[-+_M.>#_^%-?$+X'?\$^_@1^U$UO\%O%UC\3O&5C_ ,$Z]9T^/X>?$GX" M>/K/X\0_\**\8?$[P%X1\#>%O$VAZKHOQ0T'X=^*],N/BC\/;F/Q)<:]:>+? M;_$/_!&[P/XE_:)E^,>K_$?7[_P1/^V[K?[2H^#LWB+XG+X$L_@YXU\$^#/B M=\4_V?[;PH_Q!N/!DFD_%_\ X*,?#'X9_ML_%"X?PW#HGC35/!]EX&UG0;G0 M;C4+>]^)_%/_ 6H_;"\/7&O>#M(^$?[-.O^+OV?_'/[>]I\9_'GQ"\2/^SA M\'/C]X#_ &$/C5X/^&?C/4?@SJ/Q'^-.LZO\#+J[TC7/$Z>)-3U*7]J^]\%_ M$?0? ^AW7@34?A5\3M8^-GPHM>%?^"H?[67P2\#?M3_&_P >P^&?C[\(/!/_ M 51_P""B7[*7B/5?#_@CXG:QXN^$<7PV\ CP[^PY\./!O@#PA!?7FH:5\2/ MV@?"FA? 3Q1DZ7<^+/"W[-OQ+\0?$GP%\#/$?CKP MUX.UZV\,W'B?PSX+UNU;1(O#/C=[[QA\/=(\">)_&.M^&?B?XF\:Z'X;^']2 M_P""1/[0&O\ C.W\=^(/VD/A/=Z_+\6O^"/GQ"NY+;X5?$M+#3-"_P""8L&L M^(_%'@W0-,U7XV:S!9Z%\4OBGKFL>+/"&GP2V$OA"R\2>*8?$VJ>-->U.SU_ M3/I3]J2?]H?QU\-O^":7[.GQD\:6?PL\?_M#_AM^V5>_LVZ]XV\&6=Q MI?@']C[]I#]JKXL?"OX.^/+?Q+9_$WP9X.\>^/OV?]*^&5UXXTCQ3IOCT_"[ M6O$(TW4='UG6([C3_P <_P!HWXU_\%#/V6_B9^U_XSTSQA^T-I?[0/@WX&?\ M%@?VE/'=MXA^-?@7XV_LTZ?^R1X6TC4/^';?QD^%G[.O_"8^.] ^ _B/P9XN MTSP)X"\,>&-?^#'PZ\0_&T^"OVO_ !Q\4O$OQ.L_A_>:9, ?L'_P3Q_X)=/^ MPAXSN]3'Q1^&WCGP?X(^%VN_ /X%6?@W]E_X:?!CXI-\'=9^+FK?%JQ?]J7X MR^'K_7/$7[1_Q3\)RW.D^%= \9Z5I_P@\-ZC)_PL;XG^-_ ?B[XK?&#Q!XHT M7X(S\;K-OBKX\^&__"K]=\+VE_X2TWX-Z;XPEN_!U]J, M.C)I/BR/QG\Y?%7Q_P#%7]E#X6_\%0?&_P $OBA\6/''A/\ X)1?$+]D']HC M]EKXT?%?XS^-/CEXA^+%E\:?V?OA+\0_VS/V;/BAXRU^[\4>)O&_P]^-OAG6 MH_B;?Q>(Y[[PQX*^(_QX\&?%/P#8>#K7X0?#A?"?WW_P6:_:C^*^A>&?BU^Q MS\*;[0_A9/XP_P"":'[?G[6GBWXW^/3\3/#%K>Z-^SUX,\.Z'H_PK^ OCGX= M_$'X;7-E\7E\2^/M/^(?Q#UJYUCQ)I_PZ^%7AN&37OAWXPT[XC0OHH [XZ_\ M$A/C)\6/$?[5?C?P=^U%\.?AIXR_:B7]M'X3Z]/M<_90T?7_C M/H/QX^(/[ $'_!._QEK_ ($^*/B3XF^)?$G@G]FS7OAL/^%E0_ #P]^(/A_J?GGA#_@IK^V-KOQ3U3]FK]FWPS\ ?B/=ZY^S5 M\:)_V//^%B^$/&'A#5O&_P ;?V5OV>OV*OBGJ/P^\>^+'^/$/ASQGKGQ-E_: M4UWPMXGLM!TGX7> _P!GSQ-X6NM,;XV_'S4?"GCRRTC(^('_ 6B_:BF^!K_ M +6GPI\ ? 33OV:M1U+6/%?AC4OBKX.^,47Q9O?A%\$?V:? WB#]I#Q+J?P6 MT'QA9_&:Z\#^%_VR_'[_ +-GCCX[?#;X5_$[3_V6M&^'VO?%#XE?!OXF_"GQ M%'\4?"(!]P>+?^"$_BA\ M9^)?Q$TCXU^#_%7Q0\%>.?C[\" M;N/XK>#/A!X[T&P^+=IK/P\_+BS_ &-_VI/V?/VF/V=/A#H/[+'B3X]^$?@+ M\!_^"1'PET'Q+;Z=<^!_V=?VB_BK^PX/BU!=?M/?$?XD^%_'[WWPEOO@1X8\ M?2WF@>#OBSX<\=_VWXK^%O@#4] \ _%GQ+9?!'0=*_JN\,>-?!OC:/7)O!GB MWPQXNB\,>)]<\%>))?#&O:5K\?A[QEX9NOL/B3PEKCZ5=W:Z3XG\/7O^AZYH M-^;?5=)NO]'O[2WE^2NFH _&_P#8>_X)K_%+]E/XJ?L[^/?%7Q2\ ^-]/^"? M[-'[6?[/.H6F@^'_ !)H=YKO_#2/[77AK]I[1_%5@FIZCJ\%BWA+3?!^C^!= M:TR>>?\ X22_N[SQ7:7VA6UG:>%IOC[Q_P#\$)?BU\3(/VU++Q-^U5X1@B_: ME^#/[9WPET+5M*^&GC5M7\+']I3]KSPC^UEX2U+4-*UKXKZOX!T;0-"NK+Q3 MX!\=>"?A-X*^&^F>*+J^N/C UY/\5O'7C_7-2_I1HH _ #X@_P#!&/QSXN\1 M>.O&NG_%GX :OK7B?]M;XF?M*OBG\"OVH/V M2OV@?AE\9/BU\*O"GQ/\&?#3PQX_NO#O[+2?#7XX_P##,>C_ (\-?M#P>)_ M!/B7QKH.F:G\ ?A9'9_T.T4 ?EU^R]^P=\2?@A^V!\7/VF/%/Q'^'#^'?B%H MOQIL_P#A6/PE\%^,? _@W7/&/QA^..D_%"X^+NJ>!_$/CWQAX*^'WQ,B\'^% M?"O@7XEZ[\*=-T&]_:+\36MW\7?C;J'B?QK;>'FT3Y?\8_\ !(OXH>(_AO\ M%3X;)\7OA1=:7XJ^#_\ P6O^!OP\O+GX!_"?_ 5R^._PZ^-VE>)- M1FM_$&IV&J>+_@9>Z'XZT'41X=TGP=H_C[PQKND>';*V\&O%J^OWW[RT4 ?S MR>)O^"+7QH\5^,?VKO$&J?M2>!9](_:9^$7_ 4J^#5OI]]\)?%U]K?@#PU_ MP40^'7P1T]&TV^L_BSHO@:2W^!GCSX(:+#IFF:!\,O",WQ3\-:[XL\9^/]:D M^+/B?4_$=?HK\??V8_CU\=F_8G\1:S\0?A5I_CW]FWQ!\0_B=\3-2T#POXR\ M/>'/&_Q3\:?L??'#]F>WB^'VCWGBCQ=JW@SP!!XB^//B'QO<:?XB\0>,?$:: M)X)_C5=_$?]E?]CGPK^Q5I6D_"/XN>-O$>K0_"7X2^// M_@C0O'6J6UIX.UOXI^$-#_ C\1K70?B=KNJVWKGQB_P"";WQ:^+G[ M0_QN^,-Y\1/A#8:%\3_VIO\ @F/\;O"EA<^"?$>L>)_ /@S_ ()\?$&7XCZO MIT=_>ZO_ &5J'Q"^*FK&[T6Q\1:?8Z#I7A7P?XDU;0;W3_$=S9?VSK7[(44 M?RN^%_\ @WU^.?A'X./@_P", MO%G[,FK>!=.^$>CZ1#JWZY_MJ_L6?%+]I?XU?LM?$KP=X]\"^'M$^ W@']L/ MPAXIL/%FBZI>^(/%&H_M,_L^:A\'?#VM>']0TJ+[!X='@S6GM]( MM*OKS2]-U3P_!:W5IXC_ $OHH _!7X,_\$C/BS\-/#_P0^%>N_&3X9>)/A'X M-^/G["G[4/CV\L_!&O67Q5L/B[^Q+^RC\-?V;S9?";Q5JFJZW;^'/ OQ:O?V M];FM88M \6^!/ =[\?/A)<^*OB-X3^)6FKX<]EN_^"<7QD\7_P#!(7P; M_P $V/B#\:/AP?&_@;X6? #X1Z-\2_!7P^\6Z1X-OO!7[.7BCX8W_A70_%/A MG6/'VM:GXDN/&?A'X8VWA;XC:D;O3/"^O-XDUIW^&S^&C/X0U+]A:* /Y_/% M_P#P1Z^+/BSQ!X@^(\GC[]D+4_'/Q9\3?MAWOQ7\%_&/]E27X[?!'P_I?[3? MQF^"7Q/\(ZQ\.O!UQX]^&U_JGB[X8V/P-TB/Q?9^*[^V\#?'?QYXIUKXA>.? M#-EJEC';ZIQGC+_@C'^T)/X!^,_PV\-_&K]FSQ#H&MZS\6YOA%XN\7_ _P 4 MZ?\ M#3^'/C-_P % ?AM^WSJ6@?'/]HZ]\;_ !(\3>*;?P3XD\'>+O!,%IX$ M\+>"]&^*^H>.M*^*?Q,TN;QA\.],M]>_HVHH _(&\_X)\_'B;]EO_@K'\![+ MXO\ PTT_Q5^W[\7OVEOB3\*O%K>"9M:\/> /#OQZ^$W@KX;0?#_XC^$_$UIK M=IXDCM(/"=]9>)/$5L=3BU/3O$UU=Z5X8TG^R=/T1_C[0?\ @CQ^U!X8FT^\ M@^*?[.?B631_CI_P4*^/FFZ;XMT[XV^+;&7Q!^VA^Q#I/P!\/:#XBUCXL>*? MC#XQ\:6GASXQ:W\3=>^(VO\ C3Q'X@U3QS\/]2TD6-KHEWJ&I^$+'^C^B@#\ M>M:_X)[_ !=\3_L'_P#!/+]@3Q-XF\$7WPJ^ ^B_LL>"_P!L.Y\/>/OB#X#U MSXM> OV6O WARS\/:#\)?%'A?P?!XV\(W.O?%_P9\/\ XK7NMZ;XH^'WB.TT MGP')\-+?7C8>/-7\3:%Y5%_P30_:0^'_ ( _:?\ @A\'O%OPL/P+^(7[9W[/ MO[']"O=6^(%Y<+X"_9B^!S_L^ M^*_!&KBS\&Z=#I_CKQSX6\*^$/%>C>([2YUK1=$\0>+/$&B:KINN:3X TN_^ M(ODGC+_@DO\ M0^.]"T'2[GQ/^S!X9U1/BY_P6?^(>IZY'/BQ#\-_B'\6;;1?B1X9\?1:=X:\=?#_P %Z9>& M.Z%['X!TC^BJB@#^<#X7?\$=?VF?"?C?PWXJ\3?&'X;?8M?^-'QQ\4_%"+P? MXZ^-/_">>&_AG^U%_P $\_@-^R)\04^%_P 5O'VF^-?$VN?%OX-^-_@-I.M? M#?QAX\M5T_XDZ'KUUXJUVQ^%>L:58^!9/J+]@;_@F+\1/V9OA?\ 'OP#\3_B M7\/+*_\ BS^SS\&?V5[/Q-^SKX:\2>&?%]YX6_9_^&OC/X0>#?CUXD^(/Q#U M7Q1XQTSXH:YX*\2:)'X:^#_A:[@^"'[.MKX1L/#_ ,-K?Q++JOB#Q3JO[.T4 M ?S(^/O^"/O[8_CK]GKPSX%/B3]F3PW\6_AU^SG^P)^QAX6\1^"OB'\5? GA MWQ9\)/V&?VD/"/[3%M\<_$^H^$_@CINO^"OB3XRUOX=>&_ OP[^"'@"PB\._ ML_VOBWXG>.])^/?Q#N=7\.>"/#GZE_MQ_LS?&C]I7XK_ +$-YX9\$_ ?Q1\( M/V>?VB#\=/BM9_%+XH>.O#/B'Q)9ZC\&?C1\!=1\)>%O"GAWX(^/-$UC^S-! M^-M]\1+#4]>\8^'8=7U[P5I_@.\TO2],\57?C?PU^D=% 'X1_M)?\$>I/VB/ M%O[8'@G2KGX1? 7]G3XO_L3_ +,_[,G[.EK\,=$,FN?!7QA^SOXG^/NN66M3 M?"2'P9X5\!67P^UWPS^T%XN^#^N>'_"WCFV\0:U\%]3\>?#VUUOPQI'Q*U2/ M1O*O O\ P2:_:>C^.OP?^.GBR/\ 8]\"^*;#XX_\+V^)FH_"_6OC9XPGTVZD M^-OP]^('C'X9>(K+XM^&=6C_ &T_#/Q2T3X4>"OB'H?CWX_:A\//B5^RC^UC M8>'?CK^SAJVDV7@#3/!NO?T8T4 ?SM? 7_@EM^V5\$E^$WC?PWXD_9'\+^*_ M@S^TQ^S_ /%/P+\$;>[^,GC[X/>$?A[X4_90_:&_9C^.?A?X??&#Q+X?T3X_ M^&O >HW/[5'Q&^(G[,O[-7C>]^+?@']FY_"MKX#\,_$JZ\'?$W4K/X<<#HO_ M 0[^-FK?"#XY_"GXD?%;X.WVK^+OV0/@O\ _X6_$S3(?'^MG2/B7\*/VQ_ MVJ/VM[B[\1?#C6[.QATGX:Z_%^T%HOP:GET#X@ZG\0++X?Z#XJ3PWK'A=_%L MEG;?TQT4 ?CI>_L(_M"Q?\$TOVW/V5='N?@+#\8OVR=,_:0M+#PU9^*/B7I7 MP8^"TO[5GAC_ (0_XA2R_%_Q#X-^(_QO^.WB+1M3U_QW\.?BUK/[/WQ(\9_#'QRGB]OVHOC5XJU[X1Z+X\?QQX5TO6 M?%W@KX::##X0\=>,GT/6/$EQ\2?CAXVO?&6D'X8?TR44 ?A+J'_!,S]I.;XS M^(]3T7XD?#_PQ\/M3_;G^*__ 4-\)_&+2?&.LG]IOX=_%3XJ?L6>+_V=;CX M/:?;R?!%?!/C'X?^&OB3XLM=7\/>._&FO:E'_@3XB^%/B73(K#5- M$\'\-?\ !'W]JS3]/U?Q]I'BW]E[X'_$*VM_V'_B[+^S5\'Y?',G[$_QJ_;F M_9.^,_AOXQ>/OVM_&'@_2OAI\*IO@3XD^/\ 8^#_ Y\+M6T/X1>!/$$&A:7 M9)\1O&-Q\6_&>G>'+30?Z4J* /YMM0_X)!_M8^7K]QX=\5?L7^"M0NO@!^SL M?#FC?"KP+\0_@9\-O#/[0/[.O_!4[QM_P4D\)_#+0_ OPDL_#DVB? !M.\:- M\&=4^--KXCNOC]J^NZ/)\<+;PYX>\8^,_'VE^(^+^(W_ 1:_:7UWX9_&/P? MX*MOV,-!U3XJ?L>^&O@EH$$6L?&/2O#GPM^(NL_\%%OB9^W#XZBT=[_P'XXU M[Q)H'@+3?B/8Z=\//BU->^'/B!X_^,'@2#XI^,?!/@V/Q3IV@_#K^GVB@#^= M3XO_ /!(3]IGXCZ/\6K6Q^(_[)-AKW@G]H_Q]^T=^R3X[@^$GCWPG\7?&\WC MK]N>\_;]B^#_ .U-\:O _B?1_'WA+X5>%OB+XG\<>"M*LO@!<6FI2^([OP9^ MTU!-I/Q*\#Z?X-N>\_9%_P""5/QJ_9N_:=^ WC^.^_9F\(?!OX*V/C6_OM.^ M"VE>+]#E\?IXK^'GC_PCX)^&FM_!+QCX8\1^"]*U_P#9SN/B?KOA3X-_MI^' M/BEI7[1^N_L_Z=K?P*^+6B^-M(^+?B_7]'_>^B@ HHHH **** /+M&\0:!X9 M\?W?PTU[XM/XE^('CRW\8_%?P9X#\2S>";#Q'H_PV\+7?@+PMXFM_!^E>&/# MOAK4M8\!>"O$OB_PK#?:]XC7Q-XBL-7^(&EZ?K?BJ[@OM!M+?U&BB@ HHHH M**** "N3\%-8EM=:\3^'IH8K><:OX-\/VWBKQ-:1P7EM+,-*\/7?A[Q M7%JLMS"DEI-;KX>U.Y%K//+9Q17D<%Q#UE>$_M)>']6\5_"34_#FC^#G\?3: MSXP^%%CJ/A9+/3[PW_AF7XL^"/\ A,+HMJ?CWX<6FF)HWA0:UKDGB(>(-3N_ M"\>FMXDT_P"'_P 5]0TJU^%OC$ ]VKA/B%HRZYHMK:-H4_B$1ZI!=Y1GMY&U%3.L<*&VENV7NZX7X@^(]0\,:-:W^G M7&G6T\VJ0V;OJ<6C36YBDM+V9D1=<\=?#^T$Q>WC96CUFYN BR!-,FB,UU9 M'=4444 %%%% !1110 4444 %%%% !4%O-)-&SR6L]HRSW4(BN&MFD>.WN98( MKI3:7%U$(+V*-+RU5Y%N4MIXEO+>TO%GM89Z* &2Q13Q20S1QS0S1O%+%*BR M12Q2*4DCDC<%'C="5=&!5E)5@02*\DTO]GWX":'\-=8^#&B_!#X0Z1\'O$3Z MM)X@^%&E_#7P9I_PUUV37KLW^NOK'@6TT6'POJ;ZU?$WNK->Z5.VHW9-S>&: M8[Z]>HH \O\ $?P0^"WC#QF/B/XM^$/PO\4_$-? ^K_#%?'GB/P!X4UOQF/A MMX@>[DU[X>CQ1J>DW6N#P/K;ZA?OJ_A,7W]@ZD][=M>V$QN9B]J;X._".Y^% M/_"A[CX6?#BX^!W_ A$7PS_ .%-3>"/#,OPI_X5O!HZ>'H/A]_PKN32V\(? M\(1#H$<>AQ>%/['_ +!CT>--,2P%DJP#T:B@#Q"Q_9D_9MTSQ5X:\=:;^SY\ M#]/\;>#/$GC[QEX/\8V/PG\!VGBKPIXO^*V@6GA3XH^*O#7B�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

+_"=U_PH>;QCHW[1 M/P^_;*B@#^5KXE?\$F?VLO%<'QDTOPG\+/@]INN_&KQS_P %W]&\3?$7Q%\2 MCIYU7X._MWVOBWQI^RQX*\5S^"=+L_&>K_#75?BEXETO6_&G@Z.XFO?AIXJ\ M.OXUTVVU>YD4:EZM^S5_P2E_: \%?M$>&_%?QD\!?"1OAC:?&'_@HQX_\'S> M&/B#X7^(]]^SIKG[4R?L _&SX)?%[X<^$_''[/WA;X>R^.?AW^T1^S5\6==3 M0_#GPW\)^'? WQ1U[PO\4O"NGZCI7VW3S_2?10!_('HO_!%']JGP?^S1J?PN MT[]GK]FRY^)#:1^SG\/]#UJ+]J#XC?$_PC=_$;]G#]EC]I/]G?2/VF?'?A/X MY?""^^'VI_L_?%7PA\8M$^ _Q,_9.A^&6N?$?PQ\"]8\?Z[X5^,7C#XD^'/@ MU-X&_>O]L#]G[XO?M)?%W]C[X;Z8U]X0_9H^%GQ+7]H_XQ>/O#6J^#H?%=[\ M5?@M!:ZM^RYX&T/PSXNL_%=CJ?A+2?B@W_"VO&5UJGA.\:Q\2?#GX2V>CW5[ M9ZAXP;2?T1HH _F>O_\ @FU^UW9_LQ_L._LQZK\,? GQ;T'_ ()__P#!5?P# M\4?@MXO\8?%/PAKWB[5_^"&O"MY;>.9+3^W_ U8>?:)_P $;?VG= \>? ;Q&O@_ MX&^*M"\$>/\ ]K:RE\,:G\:/B-\+?#OP;N/'7_!4B7_@H!\%/VG?"D7PD\'0 M>*OB3KD7AOP;\*/"FK_!_3?%OP2U>77_ ("?VL?A+\;?&_PX_X1;Q' MXG'PU^*_Q9_:>O\ X%1:KKFAZ?H^A>*M4^#/PH^/<7A_PO93Q2V>@V%A:^"[ M6_F\.:)I45M%\>O@7_P4J_;-_9,^(_[*/Q(^'G[,/P"UO4/V(_V-M7T2/P[!X6L_ 7 MB*Q_:&_:%UCPSK_Q#L/!<6B6-W\/?@S\,?'GC*PU/X@:]J'A/X;^@?![_@CA M\4-(\5?L@>*?$7BWPQX!-M^QA^Q2G[:7]E6D'C'Q5XY_;Y_X)T_#P^$/V3?B M-+XBDO--3QQH^A>(/BYXU\;^,]:U59Y]?U;]E_X :;;_ &"PUC7;H?T<44 ? MRM_LT_\ !&GXK^#HOV1_ WQ[_93_ &9-4^'7PC^//P$U[XTV>A?'_P"(/Q[T M7XJZ?\ _V+/VK/V;KKXOZAX0^-?@/P;X6\/Z/XX\6_%'X"7V@_"#3O"/BOQG M;>"_AEJ>E_%+XM^/(=!^$VB>!F_##_@EU^V+X8M1JVN?L_? W3;K_AXA^P!^ MT]#[[QEX#34OB?=)^S7I MGQE\4^/OVG8;WQ[\4?"OQ?\ CCK?@32?AN-,_JFHH _D[^+7_!(C]L#5?V?? M$7PW\"?"[X$'XP^!_@3XX^$NH_&RQ\<77A'7/VV_BCXA_P""DO[.'[6/PI_: M1^*U\#J?C+3_ !M\-O!7P5^(?Q8\?7'C3QC=3V?[1W[1GQ9\._ _1=(^']U+ MX@\0?HE^QE^Q=\8/@9\>=2U'QM^S)\";CX=^&/VU?^"A7Q$_9T^(4?Q&M[37 M_P!E+]FG]H#0_A-J/AKPM\#?AAH'@2\T2.X_:"^)>G^-]?\ B/X=.N^ +7X> M:?!JUSYGBO4O$XMKK]LJ* /S<_X*(_L^?$']H[4/V+?#/A7X6Z%\4?A_X'_: MVL?'W[1&C^+]2\%P^$[W]GK7?@-\=?@!\4_"NH:!XM>[_P"$VNO%WAWX\7-K M+X0CT672]:\):?XRM=1UW1]4?P[I_B'\YK/_ (),?M->!?&OQX\:>#O'7AGQ M_>_##]L/]A7]I+]B?2_B1X\UK1=/^(OPG_9.^%&J?"]?V?/VB_&">$/B3XNC MUGP_X!\;^-/A_P"#?C+JFE?$7Q/JGBKPE\'_ (X>,HM>\5V/BS3;O^CRB@#\ M$/VC/V-OVJ?VA/BOXL_:^U?X,^&?#GCZ<_\ !._X5_#WX$:)\7O!>J^([?X. M_LI?\% /#?[;WQG\=_$WQEJ/@K1?!UWX_P#%MSX3TSP1\'/AUI'C'Q7X8\'6 M5M?^*+CQUHNM?%3Q=HW@7R?XA_\ !)SXU_#72/\ @I1\/?@38Z7\1O@U^T1_ MP3F\7?LC?L.^#M5\4:'X-U;]EI_C)XG^-^L?$/X$Z[/J7VBW\7? [PEXU^*> ME?$7X8^+%U2#7OAI\,M.?X ^'/!?B33_ AX4UG4OZ1Z* /S*_8C^#OQI^%W MQJ_:-\0:O\$KCX*?"+XPR>"OB3KO_"R_VB_$O[3_ ,:_'_QZL/!'@SX-RZA: M^,]4\3:Z/"WPU\(_![X.> K!M-\3:IXP\4>*O%/B&6?3=2\(^'O"$>CZ[^FM M%% !1110 4444 %%%% !1110 4444 %%%% !116!HK>*3>>)U\1PZ!'I\>OA M?!LVBW.HS7EWX6;0M#E:;Q/;7UI!!I^OQ>)I/$MB+;2KK4].N-"L]#U4W=MJ M&HW^CZ6 ;]%%% !1110 4444 %%%% !1110 4444 %%%% !7S/\ MB:5;:S^ MS;\3K.]T2V\164=EH&IWFCWDWA6""ZM-%\7>']9N7+^-KRP\,F2T@L'O8(M0 MNXI+B>WC@TX2ZI)90R?3%?/G[5&J^(=$^ OCW4?"UY-8:W''X;M[6Y@U;P1H M<@@O_%^@6&HPG4_B-JNB>#((KK3+F\M9X]:U.V6[@FDL[ 7&J7%E;3 'T'7C M/QRGU:#PGISZ-K\_ARZ/B*T62^M]1OM,>6 Z;JY:U,^GJTSJ\BQ3&%AY3&!7 M8[XTS[-7S;^U#K?AG0_ >C3^*H?$DUA-XNLH8%\,^!O$WCV\%W_8VNNAGTOP MOX7\5WEI;>2LX-_<6-O;++Y=N;M9;B.&8 ^DJ*** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKYZ_:P^,GC']GS]F[XS?&;X M=?!SQS^T'\0_ '@75]8^'_P3^'&D:KK7B[XF^.9$33_"'A.RM=#TW6=5L]-U M/Q%>Z:GB77K/1]6?POX976/$KZ9?Q:3):R@'J_A+Q_X%\?#Q,? WC+POXR7P M9XNUKP!XN?POKVF:]'X9\=>&FMT\1^#=>DTNZNDTKQ1X?ENK>#7-!O6AU/2; MF46VH6MO.&C&)X7^,/PS\::W\7/#OAGQCI.J:O\ ?Q=9^!/B[;J;BUB\"^+ M+[X>>#/BO;Z1J]]?06U@\G_"OOB#X/\ $D]U8W5W8V=OK"VEW=0:E9:C96?\ MT'@/X&_M_?L(^#?VNOV=/A!:^.?C=\6OVSOV$?$W[3UA^T#\.?AQ\8O!6@:/ M_P %+?#G@K5/!7Q2U75/&OBSPEXJ\&>%OC-^UWX,T?P]X[\&ZGXH\1?#WPYX M"^+WP@TS1O%7PPTF7XO>&+G7.Y^%/@3XX^'_ ![\0/$?A[X:?M]?#_\ 8I^+ M/[+OAM\1_#NF^+_ -XKMK'5-/L?$WA;68%N]&\0:9!K-CIU_)I M&LV+PZCI%^]I';ZIIES::G8/<6%W;7$OH-?QH?L_?LW?\%,_"W[%?CGX8_"G M0?VP?@A\5/@U_P $U/V0K']FCX4VWBOQ5\)O!,_Q"_X2K]MWX2_M/Z:L>GZC M;_":X_:=C^!/Q!^'WQ%\-:9JVKZ:LG[0=A\&/B?KD$4_@C2+_0/HC5=,_;BO MM<_91UOPGK/_ 5(\6_#ZS_;%]<^&)T M?]E'XB:" ?U3UXE\./VDO@'\8/''Q)^&GPN^+_@#QYX^^$&IOI'Q(\)^&/$F MG:KK7A6]@U?6/#5X;VSMIF>XL=.\8>&O%W@'5M5T_P"V:7I'Q'\$>/?ASJ=Y M:>.? GB_P_HOY>_\$O--^/MKX5_:RTW]HW4/VT?%/A/5[/X<^*/#WQ,^.US\ M;_!?C'QS-XY^'NO:]\3&\ _!#Q,NL?%W]G3XK^#I[W2?!OQ+\$?L\_%+Q)^S M/=^/=$TKQ?\ L?>"_@E#K/B/X=Z9^0/P#^!O[7_P<_8@TW2?!7@S_@H3\*=: MMOAC_P %)?'WP7M? Q_:COOBK'^W5>(O$O[$^G?&KP9XSU>_\4ZQ\&M? M^"6L6'BO2? _Q4-E^QOK7B;QI^T!XH_:4M9/C;XOTGQ% ?V4S316\4L\SK% M#!&\TTKG:D<4:EY'6VUJ/[,)]$N MD&K16_!/4_"?P(;PUXP^$NA^)]!M-(\7V*>+OAYX\G\->)O#FJ:@-(7QGX MWM8+'3M&\5Z):I\$> _"'Q,_:+_9Q\$? /P7^S=\?/"WQ3L?^"O?Q)_;+F^) M/QO^"GC[X Z9^S=\%-6_X*J?&/\ :SM/BCX<\6?%OP[X1N?%_CKXH_LQZOJ? MPGM? ?P/N_%'CK39OCEJ'A3XK0^!?!D_C:_M@#^@WXC?$_X?_"/0+#Q1\2?% M6E>#] U3QCX ^'VFZEJTDB0W_C7XI>-M ^''P^\-VB0QS3SZGXI\;^*-!\/: M;#'$P-YJ,4D[0VL<]Q%D?"SXW_"/XW1_$&7X2?$'PS\04^%'Q3\:?!#XDGPU MJ,>H'P5\7/AUMX M)_X*CW7@WXA7/QM\-_MH^-O$OA_XU?L_^)OC-X)U?P-K7QL^ 5E\5_A=_P % MGO@/^U#X&\>?LLZ6GQ5OOB?\6?!OA_\ 9=U?XC+>P_!KP#\!_@W'\'_A=\/? MA[XF@\#?&/PTFA6?UGXM\!_M^VFD?M/?&/X,V_[47B7XE?"[_@JK^T+HOPR^ M$7Q,^)?[3?PQ^'_QA_99_::^"&@?LUZ+JRVWAZ"9?$7P9_9[^._CG3OVD?"' MC'0/"_B/5_ GP[^!OBB;X4ZMH9\1Z9K5T ?TQ45_)Y\:_A!_P4H^%7CO]I'X M9^%OB#_P4/\ B7=_"K]E3QYX,^ 'Q4T#6?B'XA\"?$OX3V__ 2]N/ &B?$/ M5O'/AWXHZW-J_P"U)KG_ 4B\'Z-XGOO!6D_#4_MCV'B;Q#I'Q%\*_$;4OV7 M-1\:Z;IWT/!IOQWN?VN/V1/V9OA7^U1^T$MI^TE\&/A7^U%^U!X9^*WQC\8^ M*?CG^S#;?L;?M,>"?VHOB#X+\1Z!;>(]#NO!\'[;EG^V/X8_9/\ &GA?3-!^ M$&G>"/A9\)?!^F6=I\0_ >CO\)2 ?T<2RQ6\4L\\L<,$,;RS32NL<444:EY) M99'*I''&BEW=R%5068@ FO!?A-^U=^R[\>];N_#7P,_:/^!'QE\0V/AVV\87 M>A_"OXM^ OB!J\/@^\OO[+M/%QT[PIK^K7;^%;G5@^D0>(XXGT:76(;G24O3 MJ-M<6T7P=\9/@5\3?C9_P2^_;!^!WP(?VV=%TCP7^U'XW;PY MX\\>V'B3]I_XOS^(OAU8^-($2'P1\%_C#X-?5_!G[.FKQ_9H_"_[/_C'X8ZA MJ6IB[M=0UR3P;]HOQ?JWQL\):7\1_P!F[]B7]M3X1^.?A)\-?@'\./B3XSL? M OBW]G+XG^$OV9O%G[8G[+_B+]K']D+X,^%-!\8>&==^*'Q)T3]GOX9?$36= M'^*7[.:^,?"O@5=*;0?V4OCQJGCCXHW,$X!^]%%?R6?&M?\ @J)::'?7?@"? M]O:VO/AC^SY^U;\5_P!F;^QK/XR7^K:G::?^WY\"K7]@#PW\=M-:^\9:9\8/ MCK;_ ++&J?';3?B7\+_C_'XH\:^)_A"? WB;]I_P*?C?HWB/4_#^1\7_ !?^ MVEI>O7W[/WA#Q5^WUI/CP^"_^"Y&F_LBZ)IWB+]IJ]\=_$?QC\._VB_V(/B5 M_P $_P#QEX[\6>,H([OQ7\,_!6O_ !;G^'VG_%/XQW47PAM/A#/J?P8^*WCK MQ9X$U'QVWC@ _K>U'4=/T?3[_5M6O[/2]*TNSNM1U/4]1NH+'3].T^Q@>YO; M^_O;EXK:SL[2VBEN+JZN)8X+>"-Y972-&87*_D6_:R\"?\%+/B%\*_VE?@=< M>!?VN/%^J:MX7_X+E?#_ ,=:-HFJ_$SQ7\'_ !KX>_:(^&-C\7?V*K;P1K&N MZO8:-X]\ WMOH^J_#GX1Z!X;'B/7_@+KFJWG[.6K6.AZ=XFU+3?&,?QETO\ MX*8>"M3_ &H_'/P2US_@H9+=Z)^SS\5;+]G+X6>$/AW\<-<^'2_":\_9Q^"4 MG[%NL+K'QG^+/B^:\_:0\!?'KP]%8?%KP):? Z?]IOQ'XBUW]I6P_:5\6>(/ M@3-\-O$U ']6/Q)^)W@'X/\ A5O&_P 3/%.F>#O"B^(O!'A$ZYJ[RI9GQ+\2 M?&_A[X;^!-%4P132O?>*/'7BSPWX7TJ)8V\_5=8LH2460NO>5_)E^UI\(OVL M;CXR_M':9X1U#_@I-\8OA9JUU\"+KP9J6LZ-\<-4\(?!?2_AQ^T]_P $K?&^ MH:KX/^#NMQ?$+X;?M%>*M'T?_A=/QI^!/Q,\,^$?#_Q4\,:]X3_:5^"/[77P M=_:3^&5IX;N/#?+?%[0/^"I^FIIO@WX;7W[?<5G\!/C%^WU<_!K7;K5?C_XP M_P"$P\%?#'_@H1^RGK_[/7AWQUK^G^(]&\2?&R6[_8_L/C1<_#KQM^U9XH^- MGP_^+7@F7Q)\/[+P9\6/B;J_V. _KVKQ?XL_M(?L[_ 2338?CI\>?@Q\%Y= M9TO4]/XL?%#P1\.GU71=%UGPOX(?''@O0M1OK;S M;6RUGQ=X9TRYECO==TN"Z_F^^-/P]_X*9:KX9MO$OAOXA?MW^#-(UC]JG_@J M+X*U*3X=:)\3?BG\2!::3^TC\:=9_P"";'B;0OA?JOQ_^ EOX0^'&I^"_&?B MKPSH_P 1-:UO4OV9396?[,VF_M-_"C6O@1X?MQ_LW_M!_%OP3 M9>)/AWX1O?$6K^"?!FG^ _%OBW4O[,L=.\.:]J7ARSO++3&UJ\T'3Y0#]6? MGQ"\ _%'PW;^,OAEXX\(?$7PA=:EX@T:U\5^!/$NB^+O#=SJ_A+Q#JGA+Q5I M5OKGA^]U#2YM2\,^*]#UKPSX@L8[IKK1?$.CZIHNI16VI:?=VT/7U_.W^V5\ M'OVB8/%?_!1R7]C/2?VF?A@EI^SS^RI^TY\(_#OP+T?QK\'?"/Q9_:7U+QY^ MV/+^V!!X>DTK0_"^A>./C#X[^%/BCX*>)?%GA\ZU!XP\;?%VP\ 76MWMUKGA MS4[?3OERRO\ _@H'XF_:*A\>2:7_ ,%,)_ >A?\ !2/]HCQA\)OA<^E?'7X> M>&/''[,_Q'^)W_!/N'P%J=_XUU'QE:^'_ NE_#K1=;^.'C/P)\$/VN/@YXL^ M GB#X*:S^T5\+9]0_9J^,W@?P]JW@8 _JELO&'A+4M"U#Q1IWBCP[J'AK2;C MQ)::KXBLM;TRZT+3+OP;JNIZ'XOMM0U>"ZDT^SN/"NMZ+K.C^)(;FXCDT/5= M)U/3]36UN["ZAB\N^%G[4'[-'QSUBY\/?!/]HCX&?&'7[+PIH/CR\T/X6?%O MP#\0=8M/ WBH9\,>,[G3/"7B#5[V#PIXC'.@^(I8$TC6!SI]Y<5^#?@+]COX MU^,/^"#-A^R>/@=\2O$OQB\)?%#P'?\ Q=^ /Q>\1:]H.I?&*T^#'[:G@CXM M?&[X8^ /$/QH\03^%+/P-\6/ G@OQ1X0^'=^EW!\ O%MKK277AUIOAQXG@\2 MW7KW[4GCOQ?\4M>\$?M&?L:?LL_M/?#SQ3\-/$?[)_P>_:@^,?B']G?XW_!K MXG^)/V&-4_:=\+^(?VA?V;_@7\(=6L/"WQ>^(_C/X?>$[/4O'S_$GX??"GQ# MIG@OP5XD\9^'_P!F7XG:I\3/''C#3_#H!^_-%?Q__&+Q'_P5'TG1=5U#P9J' M_!0[Q$_PT^ /QF\>?!'5-"^%WQS_ .$PUC1O"G_!5_X5^&?V);?XF>#KWPH_"*P\(>./VG/ OA7QG;:GK M/?VU/ 4_P[^!&I?&#_@I'XO'O[97@3QY\6M/\%? M'O\ :/LXK']OW0?V>OV7-*_: ;XD?#:P^,OA'_@H;^QS\._A=_PGL]EI_A#X M<>*?B%\/?V0_V]/BCJ?Q?T8> [>QT?X4?#;PE\5O /A2#2E\/?!F7X: ']-? MCSQ_X$^%G@[Q%\1/B=XU\)?#GX?^$-,GUKQ9XY\>>)-'\(>#O"^CVVW[3JWB M+Q-X@O=.T71-,M]R^??ZE?6UK%N7S)5R,\3=_M%?L^Z?=?!JQO\ XZ_!NROO MVC+8WG[/=G=_$[P3;77QWM!H^F>(3=?!JWFUQ)OB?;#0-:T?7#/X(37(AH^K M:9J>[[%?VL\OR+X-^/&G6O[/_P"V#\!?AIKOQX^('QN_X)Y_#N'X(>*_%_Q( M\'R?$7XM?%GXB:?^RAX%^+W@KXHZ/HFAV'BS4?B_K/Q%L_&>DSO9IX.CUOQG M\0K/Q+INF^ [[1+_ ,-W/B+\??V*_P!G;]J7X#:)_P $1?!A^'?QC\5?LKZ9 MK-A^T/XUM?'FF_%W2_B[^PO\=O#O_!+S]K/X6?%CX%^+O#OC_1],\3Z5^SI\ M2?BE\0;>_P#@ZOBM?#MM\,_B&WBOX4^=XA\ ?%CX(>&_!0!_3MK7CGP3X;\0 M>#?"?B+QAX6T#Q3\1=1U;2/A]X:UKQ!I.E>(/'6K:!H&H^*]=TOP;HU]=P:C MXGU'1?"VCZMXEU:RT2VOKG3= TO4=8O(H=.LKFYBZFOY<_VL/B+^T-^U=XXG M_;[^%'[.O[5'A?2_^">/PG_8X^.G[)'PO\6_"3]H+PK\7OBG\2?VBKWP=\8? MVJ_"_A+X:?#;X?>-?#/QOU7Q[^S'?Z1^PEK]B/%^LVO[.?Q UW]H76O%0\-> M&+K2_'>I_P!"7PB_:!T3XR^*/'GAW0_AK\>?!]EX)T'X3>);3Q?\7/@IX_\ MA#X7\>Z9\7_!8\;Z5#X$;XAZ/X?U_4-?\%6I_P"$=^+7@_6] \/^,/A9XU#> M$O&F@Z5K(-O0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %>$_M,7&IVWP/\ 'L8Y$NM*M;^RDCDCN61O=J\4_:)U5M#^#OB_ M54OKO3FLSX=<75A'\7)+OY_%6APFWB/P*=/BI!]M$ALI+SPNER+"*X>]UVPU M'PW;ZQ87(![77B_QT&G'PEIPU-]-2#_A([38=5&M&W,W]F:OM"#0M \1WGG; M/,*^98Q6VP2;[I)?)AG]HKQGXY0:_<>$M.3PYI=SJU\/$5H\MM:Z=)JF^- M?'>F>!8=6MO!.G>,O%-G8PZYXGL?!UOKVN0>%;36[^^M_#T.M:M%I$=FFHWB MS=G10 4444 %<)??"WX9:I\1=!^+^I?#KP+J/Q9\+>'-7\'>&/B??>$M N_B M'X<\(^(+JWOM>\+:#XTN-/D\2:1X:5KNA> /BEK/@SPYJGQ$\"Z+XI@-KXGTCP;XUOM-G\2>%],\26K&V\0 M6.AZE8VVM6X6#4HKF)50>B44 %>4^(_@5\&/&'Q8^&_QW\5_"WP'XD^,WP=T MGQGH?PI^)^N>&-(U3QM\.=,^(=G9Z9XVM_!?B"\M9M0\.2>)=*LET;5+O2YK M:\GT6\UC1A<+I>O:W::AZM10!RGA7P)X'\"#Q$O@CP;X4\&KXO\ %>M>._%J M^%?#ND>'AXH\<>)'AE\1>,O$0TBSLQK?BO7I+>WDUKQ%J?VG5]4>"%[Z\G:) M"O5T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %?*G[;EW?6/[+_P 4+G3-.TC5;]4\'QVUGKNE^*M:TQI)_'_A M6W^T3Z7X)M[OQ+=R6*RM?6:6-M/ E[;6\NJ1/I$=^I^JZ\&_:+5M=\#>&;":67Q7H5O;03:Y\2;BU\$V#SW,L,5N^NW$,4M MR\-O9N-2FLP0#WFOGS]I.2.+P-I32>&O$?BE3XLL0-/\,#0C?PG^Q]=(O)AX M@U_P[9_8XP#!)Y5[+=>=<6^RU>+SIH/H.OF']K&\M[+X=:++<^(]2\,(WC73 MHQ?Z7KMYX?N)G.A>(V%F][8Z%X@EEAD5&F:U:RBC=[>.4W2-"D4P!]/4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110!^=L__ 4"\-I_P4>L/V#(O"&H/H;?"B]O-4^-I@U]O"MK M^T_>,?AA?Z7INK^%],^%_P 9=5U[QA=:K\>)OV75 M_P"%(Z5IGP\N[S]HVVTC]HR'_A27BR^_9^A^)MCX)^)<]EX1\8W.A:Q?V-M< M>*ZW_P $K]&UCP[XM\10?%+1-&_:M\1_MG:+^V9:_MA:=\)FG^+UAK_A/Q?? M:OX'^&E_>:Q\1M5U'7?AMX)^%^L:[^RMX=\+7/B&V\-VO[*6K7OPJD\/RZIJ M6O\ C37.7NO^"0&E)%=Z3X=_:S^.WA;P?\.?B?XJ^.W['G@C2-)^'$/AO]EG MXV>//VE1^U1XM\91V*>&(D^,.G-XODUOX.>%-&\>*FI^#OV4OB1\:?@1IOB> M4?%SQ5XRE /I?PM_P5#_ &%/'$?P\N_!WQWM?$^C?$WPG\$?&N@^*]$^'_Q5 MU#P/H&A_M(^(O&?@OX&1_%3QY;^!G\&?!#Q!\2_'OP_\5_#CP[X0^,^N^ ?% MC?$VPL_AM>Z)9^.M=\/^']4QM+_X*Q?L ZQ+X-@L/CT\EQX^^'7P=^+/AFVG M^%/QLLKF;X?_ !\_:);]DSX6Z_J]O??#>WG\+'6_VB0/A?J^D^*8]%USP1K, MD%_X[TWPUH-S;ZM+X[_PZ3\*W'B^XU_7?VC/B[XWTGXDW/[*7B#]J&P\=:-\ M/=:UO]H/QY^QE^T9KO[3OP8\6OJVF^&]"\.?#&TN?&6LVOPV\<>!O!7@B/P) M<_L\^%O!GPB^'.@?#"/PIHGB2R\I\+_\$/\ X?\ @KQ3X.\4^&_C[XSBNOAS MI?PL\#^!4U3P3X9U";3/A/\ _\ X*,^$?\ @I'\)?!6LWL%[IT_B35_"7Q' M\,W?PVE\8W@AN==^'FMW-UK&DW/C=+CQ5?@'UK\)?^"E?P9^.W[57PU_9I^% M/AGXEZ[8?$;]FOXY?M")\3O$?PR^*_PTT_PUJ'P&_:/TG]F+QC\)/%/A#XE_ M#KPIXD\,_$+2/B)%X[T_Q=HGBQ?#FN^!;_P=INE>(- 2?Q]X0FO?BZY_X*[^ M.;+X;?&KPW>>%?@Q:_M7_!;]K3P+\!M/\'3ZC\4K#X3_ !W^$?C?]M[P%^P? MJ?Q_^$?B#Q!X6T#Q#>:)\'?CEX]U#X=?'#0]'M?'<_@#XF?#74/#>I7D?ACX MM?!SQWXB^R?V??\ @GEIOP*^-?@_X[#XL7_B+Q9X"=)T#1/$^ MG_\ !0']J/P3^UOXTTNX^TZMXCUO3[?X<_$[PWUJ627PO??8-7^TZB MFHZKK'G4O_!*+P'XN^&5GX&^+GQ+U'QGXE\)_ML?$+]M/X5_$7PIX5'PYU[X M;ZC\9?VCS^TQ\:_@;#%9>*->;QM\"?BOXKU7Q=X:\9> _B!?^)=,UKPKKVC2 MZO!J?BSX=_#[Q1X= /4O$7_!5[]@GPE=?$.U\2?&[4]'_P"%87U[I_B>]O/@ MQ\>H]'OKC2OVG]+_ &,->D\!:ZOPO?1?BK8^&/VG];T;X0^+]3^%U_XQTWPA MKVK:;?\ B:[TKP]>VVLRK:?\%6OV$[K2?&>LR_%SQ7I%KX!\*:OXN\26WB;] MG[]I#PGK26WA_P"-4/[-^O\ AC0_#OB?X1Z1X@\7?%#0?C[=Z;\'=;^#?A+3 M-<^+6D_$;6= \)ZAX*M]8U_1;6_^/O&G_!#GP#XV^(OQ/^)FH_M#^.8_$7Q4 MUOQI?^)-13X>_#[_ (2'5-.\0_MY_ ']NWPO;>*?&D%I:^,?&VK_ [U#X'6 M_P"SYX2U3Q-K=]IFA? "3P+X.\,>'?#4WPZ6^\4:6N?\$2_ ?BO4/%FH>)OC M]XPN7\7:O^U1XWDM]/\ AU\/A8^&_BC^TK^W?\%O^"A%EXS\.Z9XFM?%FE:E MIOPT^-/[/OPQTVS\$_$NP^(_AWQOX+T[5O#WC*.^L-3AM]/ /T/^#'[<'[,O M[0GB;P)X0^$7C[6?%.N?$KX3^._C3X/CG^%_Q;\,:9>^"?A9\3M)^#/Q0L]3 M\0>+O N@^'_#/Q'^&GQ0US2?!GQ"^#'BC5-&^,?@G5KZ+_A)_ >EVH>Y31_; M#_:;TO\ 9(^!>L?%NX\*77Q$\3WOB_X8_"GX5_#'3_$GA[PCJ'Q.^,WQO^(_ MA?X1_";P-#XE\47,&D^'M-U?QUXRT23Q9XGF@U5O!W@FT\2^,1H6N1Z!)I5W MQ'[-/[+'Q,_9XUG1DG_::\1_$#X=#PE\3Y_&/PMO/A5\+O"/A[Q)\?%[0K[PKI%GJGP_T3PGH=[J?PR\)?"+PQ-%X0?0+U_%WC2Y\9_$Z;4_& MVJ>M_M,_LY> _P!JOX/ZW\'?B#?>)]"T^^USP1XS\->,_ NHV.C^/OAQ\2/A M?XUT#XD_##XE^!-6U72M>TBS\6^ ?'WA7P]XHT=-=T#Q!X9U.;33HOBSPYXC M\+:EK.@ZB ?G_P#'W]NO]K_]F[Q9\&_!OQ3_ &8_A+IUA\4_C]^P7\&[7XO^ M#/B_XS\;_#O4+_\ :F^/5]\*/BYX1TS2_$GPJ^%&J:=XV^$NBV%KK7ABZNM9 MU6S\:67BOP_KUQH.DW=O?^!F]V\/?\%3?V&/%:^&9?#GQAUW6+;QI\5_@O\ M!OPC?6?P1^/[Z;XE\3?M%^(?%/A'X%>*M#U)OA:MAJ?P/^*OB[P/XQ\)>"OV ME+.XF_9VUGQ3X9UOPY;_ !2.M:?<6*<+\2/^"?\ \6OCC;_#N]^.'[8OBGQU MXD^&7[0O[)_QX\,Q:7\*_#_@OX=VD_[*'Q \1_$[3+*'P!H_B>6XA\6?%CQ) MXB@TGXJ^-?\ A+)+._\ _A#P1X:\+>#O"UUIVOZYXG_ #O^)_\ P2)^)'P% M^$7Q&^'W[.VJ_$O]I[XE?M=>#/A-^R_XK^,_CC7?A/\ #'Q-^S4_PO\ C!\6 M_C3\%O\ @H3XO\;:*_@GX@_%/XV_LU>)OB+_ ,)@+[PU>ZG\2/B'\1?!GPQ/ MA%/AYH.C65AX< /T%\.?\%>_V2/%'BKQ1'I-[\3+WX4:-\&/V9?BYX8^+NG? M O\ :!U>V^)]Q^U=\>?BK^SU\*?!?PS^'^E_".[^('C76?$/C3X9+-X:N?#F MAZI#XWT?7KC6_!L.L^'_ /X_P!:\-]A=?\ !6O_ ()\68\'/-^T$C1>-_!W M@WX@6%Q;?"WXTWMIX;\&^.?C5KG[..E:_P#%"[LOAQ<6OP9L]&^/7AO7/A%\ M05^+LO@BX^%7C[3Y?#?Q/A\(:B\,,OEWQ _X)1>#]>^,OAOXH?#CXE1?"K0/ MA=X,_8!TCX#_ \TSP-?:CI'P?\ %'_!/GX@_'G5?A\^C7&G_$+PS87OPH\? M?![]HSXF_ WQU\)(_#^E&/1=>O/%GASQMH_B)K0V'C_B+_@BAHNL^#?C!H4' M[2WBD^*/C;\%?#_P_P#&GB[7?AMX>U&*Z^)=I^WO\7_^"AOB_P"*T?AO0?$' MA*QMM/\ &GQB^./CS0W^'>G76GV7A[P:VAV&B^(X[O3+B[U( ^T?^"A_[>W@ MO]@#X.:9\2M>T"Z\=^)-8\1VSZ9\/-*B\2R:S?\ PP\"O!X\_::^)BS>&O"G MBY].T7X!?LXZ)\2?C-J]SK%EI^E:U/X0TKP%9:HOB_QKX4TS5/O>&:&XABN+ M>6.>">-)H)X766&:&50\?[0O[ &@?M,?M"6 M7QN^+FN_#GXF>&O"?[(?QV_9L^&/P/\ BQ\#=#\>_#CP'X[_ &AKKPW:_$WX MXP7D?BOP[XTU"^\:^!/#-E\)_&'A&#Q-I%S<_#5]2\/^"_&O@&3Q;\1[WQUW M'[+7[-/Q[_9\TOX/>#_''[8_C3X]_#OX1? !_@M_PCGC+X9>!M,\1^/_ !+I M?B3P_<>"?C3X_P#B7!+JOCG6/B!X9\ :-=_#S4H+?5;+P]XW&KW/CCQ7IE_X MWC_MF8 ^%KC_ (+$:OH7B#]JR\US]G"P\1?#G]CMOV[[[]H)/AG\:M,UOX]? M ?P]^R'9^)M:^#VN_&3X"^-/!'P_U'1?#G[<'@OP%XN\>_ 'QSX<\5^(O!$> MEWOA/2]2UJ^CN]:\0Z/]E^%O^"D_[*>NR^'M$U;QAXH\->-M2UKX,>#O$?A2 M\^$GQKNHO ?C[X_#]G>U^%'A7QAXH@^&J>&O#\?C_7?VI?@_X>\">)M=U#2/ M#/C75M0\96OAW4[V?X3_ !;A\"_.'Q5_X)(:7\?- M*[W0/@-X"U#2-!\(:7>Z/X+\4>,M'\7:YX&\*SZ78A_X)4WL7@WXW6/_ TC MJ[_$OXK:_P#\$[/B+H'Q%_X5K8PZ=X*^*O\ P3FL?@]?_#K5+_P#:>-+;1_& MOP[\;_$+X.Z?XV\4?#V_U#2M5LXO%GB?0=.\?$VG@K6/" ![-#_P5B_8*E\) M:YXT/QF\06VC^'? -Q\2=4LM0^!/[1&F>+E\-6?[2/B#]D'4+6P\ :C\)[7Q MWK/C72_VE/#.I?"+5_AGHWAN_P#B1I'B:XT!]2\)VNE>*_"VHZS[E\'?VUOV M7OC]\2_%OP?^$?Q:TGQ?\1?!FE^)=>U3P]'HWBO1AJOAWP7\5/%OP/\ &7B? MP/K'B+0=(T'XE>%O"/Q>\#^)OAUXI\3_ ZU3Q3H/A[Q78V^DZOJ-G<:MHRZ MA\@Z+_P2?^']AKO[)FNZW\5/%'BV;]E[]J/]KG]HNZ@U;1+;3;3XJ:-^U1\> MO%O[5\/PM\3Z;X7U?0-"CTGX6_M2VG[/?QY\,ZQJ&C^(HY?'/[.7A.\L?#_A MXZE;/X;T_P!B_P#X)7_#K]BKXW>,?BOX"^(5]>>'=0M_CGI_@CX=Z9\.?AWX M'_LW3?V@OBSX5^+?BG_A;GQ \,Z1%XY_:$UOP!=^!O#'@;X'>(OB#JB:E\.? MAS)XH\/WQ\6WNNV6L:$ ?JA1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R=^W'876J?LM?%*P ML;NY3P;'!:W&B:#XCCWCX@^$V^T+HOB?6_#V@7LUD%-[;#5-5AMX+FWB MN?LVI20IIMY]8UX!^U'J_AO0O@5XXU7Q=%IT_AZU;PO_ &A%JUG:ZAI[&?QE MX>MK3[1:7M_IEM+MOIK5HO,OH/+G$;(B0R 'O]?-?[4GA72_%O@+1K'5O M$USX5@M_%]C=QZA;^)/&/ADSRKHVO0BS>[\%Q3ZC/YB3/.+>YB^Q'[.96D2> M.!9/I2O'OC;=?9/"NGR?\)3XH\);O$%HG]I>$M \0^(]2GSINK-]AGL?#4\% M]%92;?/DNY7-HD]M;0R*9IX" #V&BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FS4OVK_@[I?[ M7?A']B*XU:];X\>,?V>_&W[35CI,<-DND6/PR\$_$'P7\-'DU&]N-1@OO[<\ M2^(O%]Y+X7TS3=+U**[TKP+X[O\ 5+W2!I.G1:Q['=?$/P!9/XQCO/'/@ZT? MX=Q64WQ 2Z\3:+;OX%AU/38]9TZ7QBLMZA\,1:AH\L6JV4FMBQ6[TV6.^@,E MJZRG\,-8_P""?O[:6N>,!^VO]K^&47[>-O\ M^>&OV@-,\%W_P 4=.@^!.E? MLO> /!WC7]GOP_\ +3_ (IG]F?Q;\8K:TU?]DCQ]\1M#O-)M-+LO!UI^U/\ M6_'/QWMM L;.[DTV7RS6O^".OQGATWX@6MC\.?V-O'FM:!^T!<_''1/BAX\\ M1>.8OC-^W/X6O_\ @H;HG[=UK\ ?VQ-=@^#6J^&?AQX \+VMQXU\#WEQI.E? MM*1?$KXE6WP;^*:Z/\)_!GPLUCX._$@ _HCO/B%X!T_7?!GA:_\ ''@^Q\3? M$>WUB\^'GAR\\2Z+;:[X\M/#VFP:SX@NO!FD37J:AXHM]#TBZMM5UB?0[>^B MTS3;B"^O6@M9HY6P_#WQH^#OB[3M.UCPG\6/AIXGTG6- ^'GBO2=4\/>._"V MM:=JGA;XNZUJ/ASX3^)=.O=-U6YMK[0/B?XATC5M!^'FL6TLNG>-=:TO4=+\ M-W.IWUEYT[P[^R)X%\/ZYX1_X)TKINJ^ -<^),6I?L M,^(/V&_VS_BS^TE)X3_8Z\)>-_A;XV@\5Z+K?PW^)&E_#U?'7B#QY\$]+\7_ M !.T+Q5\5O$WP)TKP7\2+WX(>'/&/!W_ 1*_:D\/:Y\,UUI/V2/%?A_X*^" M?@3\%]$^W>)O'VGI\5/AC\ ?^"NWPY_;_P!&U_Q5HES\%/%,7@C6O&/P:T/Q M_P##K4_AG%J7Q&\.^%?&/B*..S^(/BCPUXJ\0SZ ?T/Z)^U1\ /%'Q>^'WP M-\)?$_PKXP^(7Q2^!WBW]I#P+8^$-5L_$^DZ]\%_!OB[P#X&U+QW:^(=#FOM M%_L?4/$OQ(\/6/AF=KT+XI6V\27&@&_@\+:^^G_)UO\ \%4?@//\(/C!\1G\ M ?&2V^(O[/G[0/P;_9A^.G[+DMK\)9?VA_A=\8?C[\3_ (&_&&L_%;P?J^B_$'P=\7?$W@'5="?Q ND^)-0\0^#_%GA_1?$OV/_ M /@G1\2OV:?VE_A7\39M"^ VG_#GX>Z9_P %9_">G:3X U/6+6_\)> _VU?V M]_A?^UG^SGX?\(Z'+\,/#VF65CX \$^'O&7@GQ5X0LM0TKP[X-U76+N?P9J? MB73M:OD;YR\9_P#!'SXL^-/"'QJ\72:C\-_!OQK^(7[*/VU/4-:TKX8>(=$\(_$K4])L[+49[G4=/^'GBSQ+X<\,>.;RSCFMO"7B'Q M!HFBZ_)I^I:K86T_CG[1W[7OP6_9E^!?QG^/?B_7HO%N@? [X7?$_P"+OBCP MA\/-7\(:U\0M7\+?!Z\N-(\?Q^%]!U?Q/X?L+_4_#_B2W;PCJ,6H:SI5CIOB MV2'P[JVH:?J ],^'/BQ+FS\>W&B>*_'\V MJMX.\.^.-"M4U*2U\,:?W'Q@_P"",W[07B_Q7^U++\'[;]DKX!>"?C]X2_X* MB?"O3-(^'6K>-O#5M:?#G]LC]E;]D7X0?!T>)?"GAKX+Z)I-Y+_PM?\ 9W\4 M>/\ XQ^#H=9O/#^@:IXHTWXA>$=4\=^)UN/#MB ?T4R?$CX?V^DZ3KEYXW\( M6.DZ[XIA\":1J%YXHT"*PU+QW/K]QX3C\$:??C46L-0\7MXKL[SPNOAVPN;G M5)/$5G=:-%;2:A!) J3?$OX*M"B\27EW MJR>/)-*MK70WOUU2XN-33X6?$Y]/AAM7DO4^'/CQK99!X0\0'3_YQ_B?_P $ M9_C/\4O%OQ,^)NN?"K]D?5=)^.?B3]H:PU+]COQ#\8/C7H'[.?P5L/V@OV<_ MV,/@[>_'[3_&WP;^%'PV^(WQ2^+EAKG[)WBO7?'WPJM+'X6Z+\18OCSJ<>@_ M'KX:^+O"FK_$_P"(/W%^S7^P5\3_ ((>*+OQ;XL^$O[(OC_QEXG_ ."E/QS_ M &B-7^)E]J/C#6/B/X2_9J\=Z+^TEXJ^&5]X'\8:I\-=+\0Z7\;? 'Q1^/GB MK14\"ZSJ/C'P'%X$^*GQTN]/^(47B/XG:M>V8!^QE%%9.OZ+:>)-"UKP]?R7 ML-CKVDZEHM[-IM]:?>I#.[6M]:2Q7-I.(YX)$E MC1@ ?G'!_P %9?V3T\%^%OC%KZ?%SP=^SA\1]*^*&O\ PB_:8\4?"S7K3X1_ M%KPY\%O@W\3?CS\3O$'A."P;4OB?HVE:+\-?@[\2/$?A67XC?#;P+/\ &32/ M#%UXD^!5O\3_ ?<6/B.YUYO^"GOP!CTF'3HO!WQPN_CQ-\4;CX/C]D.V\ 6 M/_#4">--/^#'AW]I76HF\#3^)H/#3Z-H'[-OBWPU\9]8\00^-Y=(M;'7=&^% M274W[0^KZ7\&KSXLA_81_;L\4_\ !/:R_P""7'BT?LN>%_A5\-?@-<_ ?PQ^ MTUH7C3XD:_XM^*/ASX5^!)-'_9=U"Z^ [_#GP[IGPO\ $,GC/0/AGXA_:/U" M[^+?Q.TR]T'PGXV\)_#C1;[4/B]IOCKX(5Y?V%OVUE_:GD_X*7P^%O@1-^TP M/BI(\7[*,WQJ\46WPGD^#:_LG-^SM;V\O[14?P-N_$=MX^;XFD_%R:]3X-7F M@0?#:67X?1:/<^-%_P"$JF /MW2O^"J'[(6O:SX4ET/Q1XJU/X2^*_#?@'6( M_P!I+_A$+_2_@)H'B3XL? FZ_:?^%_PO\4>)]>ETGQ+HWQ+\;_L]VUM\4K+0 MI?!\NG^'M/\ %'PS\)^-]9\*_$?XS?!OP7X^S[3_ (*K?LP7GP"_:0_:'BTK MXW)X9_9A^$>B_M!^.?!MS\'_ !-:?$[7/@#XY\,^*_&WPA^-'A#P?*+[PIJ?@N'0_$.D?&W2OA1XF\)>,=#\/?FA;_ /!%OX\: M5\,?#_[#B?%+P'K'[+?B&Y^!/Q/\>_M(V%I=>&OC5X=\>_ '_@G5\,/^"?6H M_#O0?@7J>F^,O!&L:!\53\)_ ?Q@T3Q;=?$:-/!^BZC\5?AOK7AR^U/2/A]X MV\6^H>&?^"?&SQ9XVN/A_=>(DL?B%XZ_:(\4>*O"'@F?X=^- M/&'@WX=>$?"UCK7CS_A*OB%XT\.^!@#]>/'?[4_PM^'7[1?[.O[+OB(^(5^* M/[4'ASXR^*OA>MMIEL?#TVC_ (T7PMKOQ ;5]9N]0L_(O[6T\9^'EL-*TNU MU?4[K[9+>2VEMI5C?ZC;?+_@#_@JO^SE\68?%-I\+/"/QS^(7C2ST/PQXY^% M7PT\-?#NTD\;_M)_![QQ\8=;^!/@K]H#X$Q:CXET[PWJOP \0?$;P_>P77Q? M^('B3X=^"O _@Z_\)_%+XF:IX)^%OC_P!XR\3ZGQ>_9J^-OQ7_;6_P"";W[2 MBZ7\,- \'_LM>&/VEU^,.G2_$?Q#J7BJ#7_CW\'-'\&6>A_#O2D^#5MI_C;2 M-#\4:#8"]\4ZYXU^&,DNC2W-_P#\(+J6H"QM--_/']F'_@G%^VK^SEK_ ,.- M0/A3]F'XD:-^RC^P_=_\$W/@KX4U/XX?%SX3V?QW^%/B[XC:/\0?B#^T/\0_ M'/AKX._%+6?A'XEU7PU\.?@YX3L/A'HG@;Q]]B^(;?%OQ!9_$:S\*6OP^N-3 M /TP\._\%)/V;OB)H?[/5W\%_P#A97QP\8?M2_#OQ!\7/@Q\+/AY\/-9M?'V MJ?#'P3XI\)>#OB%X[\<'X@'P+X*^#7AKP)XA\::/I&JZG\:/&?P^AU[7!<>% M? 1\8>,/LGAZ[]O^%W[4GPK^+_QU_:;_ &=?!TOB5_B1^R1J_P *=$^+\6K> M&[_2] M[_P",WP\MOBAX)3PSKUQ_H7B19?"=Y;7.K&R(?2;F:&WN4 N+>6;\ M"?$G_!$#]I#4?AM\-/!>E?$CX")X\\-_LY_LE_!#X>?':_N/',WQ"_8"_P"& M6_VX_B-^TIX./[*.H7?@G5O%_P 6%\#? [XIZ/\ L]>$_$_B_P"(7P%UWQ_# M^SC\/O$7QBL_$=C\4?$WAWP!^IO[*7[)GQC^#O\ P4)_X*C_ +4?CQOA_P#\ M*W_;-U3]CS4OA%;>%O%&MZWXLTZV_9]^"NN?"#Q7;?$#2=4\&^'-/T&_U"ZM M=&\1Z-'H.M^+;&6PUR:QN+^VO=)F-X ?II1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S!^V5 MX6M?&W[.GCGPG>Z=XDU.SU[5/AW87,/A3X?^)_BCK-K#)\3O!KR:N/ G@KQ/ MX/\ %FN:7H83^V?$!T#7$U+2] L-3UF'3-?&G-H.I?3]?,_[8=MH5W^SG\0[ M?Q+X>UWQ5HLC>#_MN@^&K[PSIVM7VSQYX7DMC97OC'3-9\.0BUNUM[VY_M'3 M;GS+.VN(K/R;][6>( ^F*\N^+=K=W?ARRCL[1;R5=;MG:)H?B#,%C%AJ2F39 M\-HIM=!#,J[KM1I(WXG87AL ?4:\F^,>C/K?ABQM$TZ'4S'KUK<>1/8^(K]$ M":?JD?G"'PSX>\2WZLOFA!+-816BB1DDNXYGMX9P#UFBBB@ HHKE] /C0ZMX MX_X2E?"XT,>*+0?#8Z ^K-JS^"_^$+\(&_;QP-11;./Q0/B(?'RVB:"TFDGP M6OA"29QKCZU'& =11110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 445QEGK'C.;XA^(O#]YX+M++X>:;X,\&:QX>^(@\56US?>)/&>M:YX]LO&/ M@M_!$>F)>:+:>"-#T#P+KD?BJ[UF>V\3S?$"72-/TRTE\(ZG=WH!V=%%% !1 M110 4444 %%%% !1110 4444 %>&_M):;J&K_!;QGIVE^$O$GCF_N#X;\CPM MX0U#2-*\1:IY/BW09Y?[/O\ 7=-U?2H/L,,4FHW?VK3KCS;&SNH8/)N9(9XO M&?&6A)XE\-ZE_:?C[PMHZ?V MCHLFHZ2EZ;)]074+/.H6_P!FO[2UNQYIMQ!* ?3M>1_&A>)?V@OC1\,/@OH?BGQ%9>#_ I?_$SQMX>\&Q^+ M/%VHI++8>%/"L6NW]E<>)?$MY!!<7-OH.AQ7^JRVMM=726AM[:>6/P0?\%+_ M -@$G'_#77P,YXY\#_BCI?@O5]2\ M76_POG\*_!SQ;XF_:IU"/P)X9_9P^'>F_'T_M(Q?"J3QQK_C3Q]X9^(UIIWB M2Z_9<^(4$_B[0OACX@\!>'8-3\):WXI\6:)X:U#5=;T3U33O^"G/[%6J6)U" MU^*'BR.&V\,W?BS78;_X"_M#Z3J/@K3+;XL>,?@?!9?$G2-5^%-EJOPP\4ZY M\4/AU\1?#?A+P1\0[+PSXT\:1?#SQ[X@\(Z!K?ACP7XFUG2P#[XHK\J/$W_! M83]EKPUXO;PY/X>^+SZ%<:%\"/$NA>/]:T/P'\.-"\6Z#\?_ (^? ']G3P_K MOA3P=\7OB/\ #SXT:QX8\$>//VA_"_\ PM;QJGPJB\#> 3X6\=^$M6\3'XH: M3I/P_P!>[;P__P %<_\ @GGXF.E/I_[0B6=EJ^D:IXBCUGQ)\*_C9X.\.:9X M7TCX0:=\?;GQ=XG\3^+OAOH?A[P=X.N?@WK6A?$'1_%_BS4]%\->(= \0^'9 M=!U34KCQ!HUO? 'Z0T5^=OP[_P""I/[(/QG^)/[-?PV^"'C#Q-\7Y_VHO#^O M>*/!/B[P=X!\8P>!?"^CZ'X2^*7BLP_$KQ/XHT;P[8>"/%ET?@WX]\/3_#/5 M67XI^'/$&FVL/B_P3X>TW4+;4VXOP!_P62_8 \=?"3X>_%F?XN:QX-;XB> - M'\?:?\,?$OPX^(-_\8=.35/A]\)_BA<>$W\ >!_#GC'4?%'C#3/!/QP^%OB7 M^SOAU+XUL?$?AGQGH7C/P/JGBKP1JFG^);H _4:BJ]G=17UI:WL*W"0WEO!= M1)>6=WI]VD5Q$LL:W5A?P6U]8W"HX$]G>VUO=VTH:&Y@BF1XUL4 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%> M=^ =#^)>C7WQ&G^(OQ \/>.;+7OB)J.N?#.P\/\ P_D\"'X=_#27P]X9T[2? MA_KEU-XQ\82?$#Q#9:_IOB;Q'J/Q *>$X]47Q/;Z-;>#M'M- @FO@#T2BBB@ M KY,_;EO-/T_]ESXEWFJZCX3TK3H)_ +WE]XX\.2^+/#$RU1X;=+)KVV^LZ^>/VJ_%OA;P+\"?&'BOQK;Q MW/AC2-2\!R:L))7B:VCNOB)X3L;?4;=H_"7CF1KW2KRZM]3L(4\,WCW%]:6\ M"W>BF0:YIH!]#UX#^T6UD/!FDK?VFN75N?$]H1_8*:1+=1S+I6LB/S4UC4M, M@^SNC2Y>*:259%C'E['9E]^KYB_:G.MCP7H'_"/7B:?J9\41;KJ+4M'TV_\ ML TG5/M%O"VLZOH4$MI+<&RDO%BU$S+-!8G[%<(7GLP#Z=HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\F_P!A?P[X8^.7[5'[?W[8 M_C*P/B7XD>%/VHO&'[&?P9O/%%EIVHW7P0^!_P"SCX0\$^%O$WA#X9SS+?7' MA*U^+OQJO_B=\5?B%?:)?V5QX]M]7^'^G>*[9E^'OAVPTG]9*_+;_@ELL:Z= M_P % 1$MFB?\/2?VT6(L9KJ>#S&\4>'6G9I+QY)A>/.9'U*%6%K;:DUW;6"1 M6$-M$EK]N[XK_$#Q%\$]-L/$VDP:EX@^#_P ) MM'^*_P 5=!T^V\9:!X*UC3P#Z<\>_L7_ +*OQ+^*>K_&_P")7P7\&^-OB!K7 M@J#P#XDU3Q<-1UKP[XA\'6'A[XA^%;+3?$_@;4]0G\ >(#I?A/XM?%/PSIVJ MZWX:OM5TOPW\1O'&B65_;Z7XHUNUO?/(/^":7["L%C#8C]F[P/\6^(-:U M/Q?X+O\ QUXXN?!>N^'Y/&/B5M4^,/VOO!7[%O[+?_!/[]L7]A#X*-Q^''_ 6F M_P"">U@?V5_A=\3_ -H?X>?"CXD?'/\ 92^$/[0GV?QKXMT[3O /P\L?BA\/ M/"GC7X=^ /B)\6]>'A[PAX=^)7Q)\.:KK/B'X;>$M=ETCQ%XR\-^$M5UX:1I M<6M>#+?Q. ?2VF_\$Q_V"-(O/!5_IW[,/PYM;CX=67PQM/!06/6WMM N_@WK M7PVUSX<>)K:REUA[*;QYX>?X.?"G0W^(MY;W/CW6O!'PZ\'?#SQ!XCU7P%H& MG>&[?RS]G3_@CO\ L%_LY?"/3?@Y:?":3XT:%I_B"[\0SZY^T9JS_%_Q)K#M MX-?X7Z/HFL-KEM!X>N?"?AGX/+9_!_1?"L/AVVT*;X>V3:=KUCK>J:UXGUC7 M?RX\??\ !>/XD2?M3:?-X.^!?C;X:_LK? _]G3]M#XD?M%6OQG\,367C?Q]X MN^#WP<^%7[0WA?X7>$?#&F:5_P )S\'?VI/A7X)T7X@VWQ2^$GQIO/ GAKP[ MX%^(%UX]DD^)&H6?P=TSQ?\ I)^S#_P6-_9(^/>I?#/X;^.?%>B_ ?X_^/?A M3X,\?S_#3Q=XM\/Z[X2N/$_BCXX>(OV;Y/AU\-/C)HEP/!'Q5UN^^+.AZ/)\ M-$T=M+UKXQ?"[XH?!_XJ^ ?#>H^'?&T\>A 'U)X0_82_9$^&GQ&\"_&SPW\( M](TCXD_"GP]>Z-X3\?:EXI\:ZQJ^EV$^C^+-#OM9UJ]\1^*-2A\2^*7\-^-O M%N@3^/?%R:UXR7PWK%UH;>(!H\=O9P?._P .O^"8W_!._P 0:9\%OB7\%O!N MC_\ "I=+^%_Q?N?A#'\*/&DR>#=9T7]K#X,?#+X/:O\ %WP;\6/#EU)\6;?4 MY?V:O GAKX2?"O6/ ?Q(? G M[!_[2\O@O6'\/_$/X@> %^ GPLUZ%=8>XT7XO?M+>(-%_9X^$6JVD.@>&_%^ ML7-[I_Q+^*'A6[LK.R\.:D]Y=Q0VLB6\,TEW;_-/_!";X[VOQQ_X)C_LPVVC M>%_%=KX3^!OPZ\/?LS>$/BAJ^@0^&O!OQ\\/_L\6$7P@TWXO?"S2]0UV^\;# MP9XGL_!UO-)/XX\-^"]37Q&-+.UBL;2ULH6N'AL[>"UB M>\O+O4+MXK>)8HVNK^_GN;Z^N&1 9[R]N;B[N92TUS/+,[R-2T37M#\2Z='K M'AS6=)U_29KB_M(M4T34;/5=.ENM*O[K2M3MH[VPFGMGN--U2RO=-OX5E,EG M?VEU9W"QW%O+&GXW?\%(_P!FKP=^T7^T?^S/\+_&'[9_C3P'K7QH\/\ CS0O MA=^Q3XW\)>+OB)^R)\>-3^#"6WQ2^(WBKXT_#'X6>-O@5K_Q.TNP\%W4/AKQ M-X&^*_QKNOAEKNF:EHD&E^"_[:BO[F_^"OC3_P %"OVP?V,/CI\.?V#/V=OA MU^PMX@\!_#GQK\ O"OBGXN? WX>7OP[_ &;?V>=&^+$NH?"U/@[^T3^SS\,/ MC'\<_B/^RSJGBWXR?$?X3Z]^SO=3WUG=_&>ZT_Q1\._#OA:33;?Q5\3?#8!_ M4W17Y-:#_P %I?V(Y_A_\'_B=\1M2^+7P!\'?M >)?!VE_!?6?CQ\)O$O@/2 M_B'X*^(>H>!=,\"_&W2-=1=6\-Z?\%/$5Y\3? :2>-_$6M:+_P (O!XDM;SQ MQIGA>RMM1N+/YT^*'_!>3X<_":RUS5]9_9U^(WC33] ^*/[4'PC&F_"#7[/X MF>+/&7B'XG07;V<^DZB(+'^V?#M M_=Z+>:SX7U2\TRQU27P]KS^'M5US1H]9T^WU"U%VFFZQJ>GRB6*ZT[4+_3KB MTO;C9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH *^9_VP;K2;/\ 9Y\<7.O6-OJ6B1ZE\/O[7L[KQ9J/@B.737^) M7@^.]:/Q)I7@SQ_?VEU!;/)<65G#X8F76[R*#0[C5_"UMJ4WBG1OIBOG#]K3 M5Y]#^!'B:]M[WX;V#R^)/A9I+W'Q9T.Q\2>!WM]?^+/@?0KJTO-#U/4-+L=0 MUS4+74IK#P7') MH)%-[#H=W8QR?V5JJ@/:>(+^SLVNW5G^S7,4&_$&NZ5X7UWQOJFC:+J MFJ:=X-\,7'AJT\2>++[3[*>ZM/#?A^Z\9^(O"/A"VUK6YXH]-TN?Q3XK\->' M8KVY@DUK7](TY;F_M]RL;Q%UT;4[GPYH>LZU/X;T? M6=>@LIY=(TK5?$5KHOB2ZT#3=1U!;>SOM:MO#NO3Z5:S2WT.BZI) MC. ?G/ M^S?_ ,%4_@%^T5H'P)\83^ /CM\"/ O[47A7Q#XP_9R\?_'GP?X2\/\ @?XM M:7X.\"ZU\2O&-M9>)_ OC_XB:7X USP[X'\*^,O%2Z!\8I_AOJ_BOPOX*\6> M+O -GXM\(:)=:\/OZR^(_P /-3N+6TT[QYX,U"[OM 3Q796MEXHT.[N+SPM+ MJ:Z+%XEM88+Z22XT"367324UB)7TY]39;!;DW3"(_P W'P&_X)9?&?\ 9<^$ MW[$'B?XWR?!#PZ^&L.F:#INO6?C[6 M)]&] _8>_8LN]?\ V4/BKX^N_@#\-?VF_"7C37/A[^SM^Q!\+OVPM O;#1O^ M'3OPA_:;N_BE\ ]+\=>#OB;X%U_Q/X:\8>&_#7C[QEXK\!V'B_39-=^('A/X M.?LAW7Q+T_P5XZT+4X?#(!]X?\$M8X8M._X* K H2,_\%2OVTI"!J=AJX,TW MBKP]-#?B_\/?"7Q+\*)K.FL[:=JR^'?&>D:UI"ZG8-)(UE M?BS%U:L[F"6,LV?Q*^$7[6WBGX#_ +77QJUOX>?LL_MU_%_]F#]MO5O#GQ]N M-"T_]A[]J7X9?$G]D_\ :3TSX7>%/A[\2-!\967QP^%7PW^'GBGX2_&70_AO MX1\36FL^!?B?JOB/P-\;O^$V@OO!&N>"OB+9^._#7W7#_P %-?A>\5E-_6]TJ2TNTAN9)K!M M4M8KCPUJ6@Z[JX!]8_!7]FG]G/\ 9MTS5-%_9X^ GP8^!&CZY<_;-:TOX.?# M#P5\,]/U>Z6XO;N.?4[/P9HFBP7TD-QJ-_+;FZCE^S&\N%MQ&LKJ>*\ _L3? MLA_##1[C0O!'[-?P7T?3[[P-X&^&.J-+\/O#FL:EK7PY^%]PES\,_ >OZWKM MAJ>M:_X0^',D%HG@+P[K.H7VE>#K73M*LO#MKIMGI.FP6OY$_M!_\%S;7X3> M.OVA;'P]\&?BK+H/P0_91L/VA-(\%_$+]F#]I#P)\2_%GB:_^''[3OC%_!GC MBS\2:%X?\7?!OPY8ZI\!M)M7^*L_P<^(?PB;2M9UW4-6^(_ARVT'5K[1?FGQ M1_P<<:_X=\)>/;J;]GG4K3Q[X3^'OPYGTWPYK'AX:/X5U/QKJGBK]GWPQ\6_ M%>I?$+7_ (IZ!X:\*?#/X%/@%\=/&%_+X5^ _[87Q- M-A8ZIXD /T>_9:_9!\)_M(^&?C+\:?VG_!'B.[\3_$+_ (*4_MC?'33_ )\ M0/"0T%%\&>#_ 7\3O\ @ESX#\'^-O"'B?3;RS\9?#;XE_L5>#K6;4-(U+3/ M[$\1Z9\0X]7LI+UHK'7[W]'])_9D_9OT+3?!6CZ-^S_\%=+TKX;>)_"'C;X> M:?8_"WP1;VG@7QK\/OASIOP>\!^,O"$,>AJGASQ9X*^$NC:1\+_"GB72!::U MX?\ AYI>G^"])OK3PY9V^FQ_SB^/_P#@XE\;:-#\3YO"GP)T[;HVL>-X/ 7_ M G'@[XI>#!;6O@K1?V]]8CL?BBWC.3P2?AI+XA7]ESX*PS:G\:4^!&M:,?B MG\;Y?"/P]^+"?LL_$;S/3K7_ (+V^*-?\">/=;\ _L_^//B)\8)_C-XE^#7P M,_9TT']F7]K0:E\3=8\,?&'XKVNHG2_BE9> M@>,=+O/!NM166C^$?&OBC1P#]N/VL/V;;G]I_PI\(_"D7Q&U+X=6G MPQ_:D_9B_:2U/[#H%CXBMO'=M^S9\:/"/QGL_ASK%O=7NF76FZ;XFUKP=I1C MU_2M1AOM"U:PTO4Y[+Q#I%OJGA?6]_\ 9K_9N\%_LL^"_%_PX^'&HZS+X$\0 M_&3XQ?&30/#6JP>'H;/P!>?'+X@:Y\5_&O@WPLV@:'HDC^#H/B+XM\8:[X;M MM<.KZOHEAKZ>&XM8FT/1=%M++\8O&/\ P7Q\#)XQT:X^'7PY\6:W\&_%GQ@_ M8TT;X7>.==_9V_;DTO5OC?\ !7]J31=%N-2\5^ +74/V7M#\.0?$G2+C6=7\ M6_#;X =0G^"]G\1_'OC"P\#^&?,?@+_P %_?$'Q?\ '/[/ M_A;Q)\'9?!>F_$BZU2Z\6ZUX*^"W[3OQT@U"&/PG^R+X_/@SX<)X+\#:7>ZS MXF\'/^TKXO\ @AXJUWP]IOQ&MM2^*_PBL/$=CX4T?PE\6/"^F:: ?T"_'G]F MS]GO]J3P;9_#S]I/X(?"GX]>!M-U^R\5Z9X3^+W@'PQ\0M TKQ1IUGJ.FV/B M32M-\4:9J=MIFO6NF:QK&E1:O81V^H+I6L:OIGV@V&IWUO<K_LEZ7\-=#^$?P0OY/#E_HOA;X!V-C\%!X"\1^"_&.@_$3P1XQ^'+_#V MST.#P7XL\%^/_"WAOQGX:UG1K6&73_$.B:??%)O*:-_P\\$?\'#&O>+/'7@_ M0Y/V+OC?##XH^'_[4&OQ?#.S^#_[2.L_'QO'OPB^._[5GPL^&7PQ?P'X0^"G MC&>V\4^(-'_9LT\_$O\ LVT\3>&/ACXH\1_%;3O'OC#P-?\ [/MSX=^*'Z4_ MLY_\%5?@/\8?@#^SY\4/$^B_&W2O'GQA^$WP>\:ZWX(\ _LC_ME?$:QTGQ?\ M3?AMH/Q!N?#7A?4_#?P!U*;Q5I%IIVJWFNZ+KUC#+:ZQ\/M/E^(44A\)176L M0@'V!/\ LD_LM75E\(M-O/V*M"T);'3?$/AF"/1-7MKS3E%O3[ MW]DW]ES4]5\2:WJ?[./P,U+5?&/P?TO]GSQ7=ZC\*? U^_B/X#Z++--I?P9U MF.[T.:'4/A=9R3?)X#N8Y/##)!8Q2Z8\6G6"6W"77[;OP9M$A>7P7^UXXG02 M(+7_ ()]_MZWKJI&X":.R_9LN'MWQUBN%BD!^4H&XK7M/VPOA->G$/A+]J5# MYMW#_I?[#?[:^GC?9(7F.;_]GZV'E.JD6DV?)OWQ'8R7$C*I /1_@;^S_P# M_P#9E^'NG?"?]GGX3?#[X+?#72KN^U"Q\$?#3PKH_A#PY%J6J2B?4]4?3=&M M;2"YU34IE62_U.Z6:_O&2,W-Q+Y:;?7J^85_:Z^%+6.G:A_PBO[3BP:I#//; M1R?L3?MFQ7L:6^PR+J&FR? 1-1TF8AP8;;5;2RN+A5D:WBE6&4I:NOVKOA=9 MJ&F\,?M(LI>Z3-M^QK^U]>X:RGFMY]WV/X&SE5,D$C6[MA+R#R[JT:>VFAFD M /I2BOFD_M8_"T0/<_\ "+?M*^7'#'.R#]C#]L,W.R2*\F4)9CX%&[DEV6,Z MO!' TT(_VU?@MX4NEL]9\._M/"=UU%U.E_L._MK^(8"N ME:9;:Q>G[7X?_9]U2T&RQNX6AS,/MET)]/LOM&H6MS:P@'UG17QZW[<_P-6S M:^/AO]JK[,J7#EA^P9^W.9=MJQ6;%N/V;*([>/?<3P12@'U' M17S:G[5GPODB@F7PQ^T@$N(Y9(P_[&_[7D4@6&.]D=989/@<&.@#Z(HKY\'[37PX:>2W'AO]H/S(H;>= MF/[)/[5:P%+F2ZCC6.Z;X,"VFF5K24W%O#+)<6L;VLMU%#%>V3W%>X_:D^&5 MM/\ 9I?#?[1!E^P7>I 0_LA?M9W,;6MC);17"K-;_!.6%KS?=P>1IRR'4;M# M+):6L\=OP6,ME:7=Q!PEQ_P %"?V>+6XGM9O#_P"U MJ)K:>:WF"?\ !/C]OR9!+!(T4@2:']F>2&5 Z,%EAD>*1/3-:^ M.'PF^'>C:[?&6*1I=+T._P!1U.WMT-W<6D5KB8_0% !1110 4444 %%%% !1 M110 4444 %%%% !7R)^W9H*>)_V7_'FAO9ZOJ O?$/PB*V&@^!++XDZO>2VO MQG^'U[#;67A#4/"GC6UO9)I;=(WU-_#=Y)X9B:3Q1;W6CW.C0ZUI_P!=U\Z? MM8Z5X6UKX">-=-\9Z)X1\1:!/?>!GFT?QSI/B#7/#=UJ5M\0O"EWX?>YTOPK M8:IXAN-0M/$$&EWN@-I5C-%G%N=/U1G8ZAINN>'YYE$BQ V;WDL,A99VMG>WCEA]8KRC MXQ:NFC>&;&Z>7281)KMK;[M9M]7N+4EM/U.3;&FC:MHUT)SY1*O)=26XC$H: M!Y&BDB /5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_X M@_%GX5_"6#PM<_%3XE_#_P"&=MXY\8:9\/?!5Q\0?&7ASP9!XP\?:U8ZIJ>C M^!_"TOB/4M-C\0>,-6TW0]:U#3/#6DM=ZU?V.CZI=VME+;Z?=R0^@5^ -1T;X<_#WQ-\4_'=_X?\=^(M$\) M>+8?"O@7P=H/B3Q-K>JGPCK&NE%T?29;FR@$]^;G3X;62_M@#[AU/XG?#;1/ M'/AOX8:S\0O ^D?$KQE9:AJ?@_X>:GXLT&P\<^*]-TFVO;W5=0\-^$KK4(M? MUVRTRSTS4;O4+O2]/NH+*VT^]GN9(XK2=X^XK^63]H7P]^WE^S!\3/',?A?3 M/'OQM\!_L]?\$O?^"G?BG_@G]^T[\*HH?B5\=6T;XC_%7]@GQ5X%_9^^(=E\ M8!XXLO$7QP^ GAOX?:WH_A#XM:SK'B[Q)^T7\$4TS7[;P+X^^.O@SXEZ3XP[ M/X8?&']N'XD>/?AQX(^+GCW]L7PY\)_$W_!5#XV?"/6M<\#_ #^,/P_@T_] MBWXC_P#!/#2O&/PFTC7/B1KOP!T#XH^%?!^C?M9?$;PQ\,/!_P >O&EU\./B M-+KFHZEKEGKGAC4/"NFW_P -P#^FBBOY$O!GQG_X*OZ?\+O"^K.G_!0+Q'XM M^('[!_PF^)7QTTC7?V9O'KZ[H7B;X:_M\?#;X4?%]OA?I'B'X;_"^R\'?M+> M*?V!M'^,OBQ/@7X#\9>!/B5\2O$HT#XD^!/!UC\2O$G@OQ3JGZI_L=ZK\4YO M&G[.%A\5OBI_P4*\1VEEXN_;(T_X,7WQ"_9XUOX-_#3XK_!5-(^$FJ>"7_:M MT'QNOQ ^-/A+5?A2-0UGP#^SCXC_ &F=>^#O[0OQAU;PK\0/&_C+PYXPM=7L M?$7B@ _3+XO_ +2'[._[/C^$T^/GQ[^"_P $'\>ZC>:1X%3XO_%+P/\ #5_& MFK:?':RW^E^$U\9Z[HI\1ZC8Q7UE)>66CB\N;:.\M7FB1;B(O=\%?''X'_$; MQ'9Z!\.OBI\-_'?B36OA;X-^,FGVG@KQ;X?\3W6K?!OQOJ&MV'P_^)-E<:'> MWT>H> /%VHZ5XBA\'^)H)IM$UZ;3M9;1;NZ%I>M'^7NGQ2?LP?\ !17]NSXU M?M%?"+]H#XE>#?VF_ W[.\_[//Q?^&/P8^.?[6WACP9\)/@7\-[?0?&_[,L_ MP^^"WPU^)OB_X*:[8_&W5?'_ ,>K6U;1+;P3\:&^+L-YH%]?^/\ P+XITRW_ M #(\9Q_$O]G?QS\3/$7[./[+W[='P:^&'AK_ ()S?\$H_P!G'P;H6H?"GXN: MKX]\ _#/1_V_OBC;_%SX6GXG?"3PQ\>-1U/7? ?[,?Q?T2+Q9_PSCKGQ;_:- M^&'@[Q'-JG@BVTCXL_#;Q#>^ @#^LJ"QLK:66:VL[6WFGCMXIY8+>**6:*T1 MH[6.62-%>2.VC=TMTJM=:H+^,17$^H-/>^:]R9):_EQ\3?$C_@IS!^SS M^SDWA/XH?%RT_: ^.7Q=_;?_ ."6=_X/^,WAKXD?"O4O!6M^,?BW\=M=_8T_ M;P\':-JW@K2_%/Q*F_9V_9?^%]WXA\7>+Y%\91_$;X?ZA>?$_P 7^(O$'Q'^ M#OBB[ONH\9ZA\?\ ]GS]L']MC7?!L_[8EM#K/[C>+3IO[5I^(W@WXD:%\$H=3\7_ 7\ M$?$+X]?%_1_A]X7N='USQAX( /ZA%MK=)%E2"%94%PJ2+$BR(MW*D]TJN%#* M+F>*.:X ($TL:22;G16&):^$O"EC=6U[9>&?#UG>V;6[V=W:Z+IMO=6KVFD- MX?M'MKB*V26!K707?1+=HG0PZ0[:;&5LV,)_E6^(WQG_ ."G^K_#[Q;ING_% M?]L[0M4\+?L\?\%D=9^!&N>'?V?=-T/XA_&O4_@G\:O $'_!+FX^,.@:C^S0 MUMH_Q<^.FB>'/C#I/@SP;X=T?X?>*/C]X#\%^']?T[P_!=^/_$&F^*/U^_:? M_:-^+?BW]BSX*Z'^SXFO:?\ M+_MV>%/!/PU^%7C.;PMX\\"Z)\%M:^)?@2/ M7O'?Q@^(UQJ/@3Q-XB^#+?##PT==E\*Z9XY\"WFKCXV3_#OX:>(/#=O.? WB70/&?@KQGH&C>*_!_C#PIK.G>(O"WBOPMXB MTZVUCP_XE\->(-'N;S2==T#7=)O+35-&UG2[NZT[4].NK:]LKF>VGBE:/Q7X MQ\(^ ]&D\1^./%7ASP9X>BO]'TJ77O%>N:9X=T:/4_$6KV/A_P /Z;)JFKW5 MG8I?Z[K^IZ;H>CV;3BXU/5]0L=-LHY[V[MX)/PR_8'^+5_\ \$^_#O[87[%/ MQ=^&?Q;A^&?[&=_=?%[]EV+X9^%?CI^TCIVI?LR?$;1_!/CO5?V=?A;\2[_X M>:;XF^-7B[]ECXE?$Y_AUI^B7-C!XTTSX.>*_@I:WVG746BZ[K:>S?\ !6"Q MN]1\2_L13Z?>?'3X=:QX(^-'Q1^)OA3]I/X6?"?4OVDOAK^S_P"+M&_9]^(W M@6SU#]IO]F:T\$>,H_B3\$?B5X=^)7BKX::EXIL;_P"&7BWX;>(/$&B7GA7X MP?#V37]2U*8 _7'0?$?A[Q3IL.L^&-=T;Q'I%Q/J-K!JN@ZI8ZOIL]UH^HW. MCZO;0WVGSW%K)/I>KV5YI>HPI*TECJ-I/_AW\1/&?P8L_P!JW4[;XA_M _!S]GW]HM-'EMM2\.?#7]G7PMI? MB34- \-Z#\0Z_P"T!^UC_P %%OAQ^S+H/Q$T7XQ_M/:CXO\ CC_P2%\:_'WP M#+H?[.GA?Q++X9_X*#6WC[P+\7-<^$]EI7A;]GC4[OPE?_#SX=WOCSP,OPY^ M*\7VFR^%OA#7I=8DN?&O@[QCXXM #^LNBOP%^+^I_P#!4O1OVLOBO\ ?@1KG MB3QAX&&FWG_!1'X(_$/Q\-'\/>%K[3-/^$?Q)\"3?\$T/$^OSZ,ES)IGB?\ M;+7X/?$]KJ[U#2]4\)_LM^+?'W@R/XEZ)XB\+^!I[SUK_@C_ /%W]JCXNZ#\ M1=8_:)^+/[1?Q8L$^%_[-]W"?VA?V&[_ /8KU7X;?'6ZMOBSIG[0_P *M.AU M[3O#.K_%37O"EQH'PWN/B)KOAOPG_P *=T#Q=J]U9?"GQ?K-GJ.O>$/AX ?M M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M>8?&07Q^'NJMID&H75_#JGA&YMK72M272=0N7M/&.@7)M[6_?XG?!V**698F MC\NX^(6CVMRK-:W5AXHMYI?">N>GUY/\;+Z_T[X?S7FF>#XO'5Y%XN^&03P[ M-IEIK"-#+\3/"$-WK8TR\U+2ENY?"=I)/XK@2TNI-66;1(Y-$T[5]82QTF] M/6*^=_VF"@\":3YDEO$O_"6V&&N9K:!"?[&U[@/=.D9B^'OM>GPZB;K5+GRHM6TKQ'?\ AV,06G[R2ZN- \+^*%M=:S-& MNCPWD%JUU8MKSVTKBTN$ !]"4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110!Y"WP!^"[_'?_ (:>D^&GA.;]H,?" MRU^",/Q33O#TOBO6M0UR^M+!; M(? VH)'XS\77?@;08M6TKQSXSU*UT[5?BE MX,TO5M1^VQZAIDMCIVE:5>WFI:U?PW3366C6FH74-GJ4L*:==@'LU>&_&J/P MO'#X=U#Q-VCS2V M-[-8Z?-/&+C3[1A[E7@W[1$=Y)X*TM;*_P#"FG2CQ39%I_&&G^)=2TQH_P"R M=;!B@@\+>./ &H)?,Q1XI9M8N;-;=+I)-,FGDM[JS />:*** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/U;4[/1-*U/6=0- MPMAI&GWFIWS6EE>ZG=K9V%M)=W)MM-TRWO-2U"X$,3F&RT^TNKV[DVP6EO// M)'$UR*19HHYD$@26-)%$L4L$H5U#*)()TCFAD (#Q31I+&V4D17!4 $E%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D/QO\ CG\- M/V>O K>/_BCXCMM!TJZU[P[X,\,V BO-0\0>.?B%XTU6W\/^!/AQX&\.:5:Z MAK_C#QYXW\17EGH7A;PIX%K6&*6WU MCP%\ OAQ^U!K5SJ.K:A<6HTWXU>%WLM#:\D@UG3@#[6_9+_:9\&_M=_ 7P3\ M(?"KZ\NKZ!XZ^&_C32M2T#X@?!WXM>"-9O_!WQ:^#'Q%T#6+#2]2TC MQU\*OB%HOB'P3XCAEL(K*^O=&.LZ%/J7AW4](U2^Z[P-^T#\%/B1XOUSX=># MOB9X3U/XE^&+"_UGQ+\+;G4DT7XJ>'?#^G^+M;\"GQ3KOPQUY=,\>:1X1U+Q M3X=U?3?#GB[4/#UMX:\5):IJ/AG5=6TJ\LKZY_GA^"'[2GCB_P!3_:9^%'[& MOC?X=^ OB#_P4G_X*$?M+?M"? WXZV#^"_B1X ^ G[%'PDTG]G[]F#XO?MMW MGA15E\*>)9?CC\>OA?XVTO\ 93T[58+WP5\&/BWK7[/W[-6F?&O]@O]GW1++PI-XT_:K_X M**?\%#OB[\:]*\8?\%#_ (L0:UXMUC0?%GQQ\76/B[]E+X<>!-=^+OQ N_#/ M@_\ X2CX:?M0>/=7\3:#\#?A[H?C:@#^E:BOQ]^(/[3O[9'P_P#B;^QMXN^. MWPE^#/@WX??'+]I+X=_ _P -_ CX7_%3XL>./BOH?B/XL> _C++%\3?%'QDT M&7X??"3XI6'P\\%Z)J&K_$3]F.7X'>-_!6@0PZA\=?"_[1FN7GP?\,SW5SX8 M?\%5X_CA^U=\(/@9\'_V?->\8?!/XG_$7]HCX7+^T\WC66UT#6-7_9E\&>(M M7^+GQ#^#_@K3O FN2_$[]GKX:_%*U\!_LS_$/X]>(?%WPM\$']H;XI>$_!OP MV&ER^)O&NMV M>BV%UK6KS_9=%\/:2MS(+G7/$VO7A6QT#PUHT%_KVNW[QV&D:=>WDB0-^1_[ M>'_!2SXK>%? O[9MW^Q[X2^&^M^#_P!A?P'X[N/VFOCO\;I?B5IOP]U+XT6' M@A]5\)?L9_L_67PTUSP3XQ\;?'[Q1J>N^#K#QA\0M)\::-X7^"6H>+/!?AW3 M[3XC?$?Q/?\ A[P!=N/AZOPR^!>O?\%1_P#@H'X[\(_"+]H?P5X#T_XF>#HO MC+IEU\9_AG_P3G^'6KR^&[R^_9T^$?A2/Q3X2N?&OQM\7:+'9?"7XR?&KPKK M&D?&#]I7XJZK!H7A>2U\!P_#+X0:( ?K!\'_ ([?"'X^:/XIUOX0>/="\/O#.IV]CXC\$>.= 6^TZZU/PI MXJTK2-=MM.U72-4>Q_LW5M-NKKUJOS^_X)R_"'XC^"?@YXS^-OQWTF_\-?M' M_MK?%/5?VMOCGX$U"?3+L_!W6O'/A#P5X-^&W[/=K>Z;X>\-C41^SU\"?A_\ M*O@[K^N7-BUQXP\>>#_&7CUV@;Q:UE:\E^TK\6OB3\6OVB]&_8T_9,\8WW@K MXR>&/ =A\0OVD?CU;SWFK^'/V5O@I\3=5NM'\*#3O 6HQ7WPT^)7[4'QEE\# M>+;?X#^'OB-HGB/PW\*?#_AKQG\9/&^BW^CMX0^'WQC /NN3XN_">'Q-X7\% M2_$_X>1>,O&^H>*])\%^$I/&OAM/$WB_5? ;:TGCG3/"^@MJ8U77]0\&/X;\ M1+XKLM)M+NY\.MH&M+K$=F=*OA!Z'7\[W[47[&'P:NI/@]_P3V^ ?PL\#>'_ M (Y_M!_'#X._M!_M'_&32M?U?QY^T/X2_9I_9:_:1\/?%>^_:H^-G[4'B[0- M2^*OB'XV_&E_A_X;^$'PHA^(EKXEO-2^+GCGQ[8^'?%/BOX=?![XA^,M&_HA MH **** "BBB@ HHHH **** "BBB@ HHHH **** .:\3>*K#PK%HLM_8>)=0_ MM[Q+H?A6SC\,^$_$GBR6VO\ 7KP6EM?ZTGAO2]3_ .$>\-6/SW.N>+->.F^& M]#M(S/JFJ6OF0++TM%% !1110 4444 %%%% !1110 5XC^T+I/\ ;WPU&BKX MS\.^ I]3^(GP7MK3Q!XGU.STFQ>[_P"%R> IK;P]I]Q?V]Y9W'BGQA+$OA+P M7I5Q8W\6M>+M;T32'T^^6^-I-[=7D7QOOK'3O UK*-#\0Z;6]@0 '?T444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->#/"MEX'\)^'? M!^FZEXFUBP\-:18Z+9ZKXS\4Z_XW\6:A;Z? EO%=^(O%_BK4-6\2>)=7G5!) M?:SKFIW^IW\Y>XO+J:9V\!^*]<^&?@G3/B1X]TG1KN_\ "W@+ M5_&$?@"P\7:I;*)8M"?QE-H/B:U\/W&H(LD%C?WVC7&G+?-;1:C/IUC)<:E: M=/I,^I7.E:9V1ZBEKG;C MPAX3O/%FC^/;OPOX=NO'/A[P[XD\(:!XTN-%TV?Q9H?A/QCJ7A76?%WA?1_$ M^)G_ 49\%?! MC5]9^'7PB_:"_P""@'[0NF?M6?MH:/:W.C^(+#X+_L[Q?#G]CWX>?LK?LIWT MUIIMIK'Q1^*'PQ^!NM^)/%'[2GA&;Q1X2^ OP^^(6GZKX0\5:C^TQX@;0/@5 M^UO_ 41^*7Q0^#'[#O[47Q"^!_AGQ5XO^-NF_!_Q7HOP7T'P7H.N^)-?G^+ MWC6U'@?X8WL>F^'+>?4HM*T7QQXCT+6_$FM22:;I'AKPWIVK>(_$6N^'?#^E M:IKVF_CQ\&/^"5__ 4P_9NT[X 0? +]J7]G'X>)IWPO_9Z^!GQD\*Q>%O%$ MG@CX;?"3]DI-8O/@;X?^#:>&_!?@_P 8?&:?Q=\2_BE\)O$VB?";0?%WP0^&G]O37P!P/[/NOZA^TG^U5_P %'OV9?V7=.\;? M"2SU#XP^$OV$O$'Q=^&4/ASPSX;_ &#/^">G[#7PH\(_#^'X)_A%H&M:Y^T[XET^3PU\-/A1\._B?]*?L6 M?#/X)V/C7]H;]KS6/"&A:#\"_P!FO7?BG_P3>_8,^'_C275++X)_LV_LH?L= MV6K^ _VG_B%<^+M1T35O!WA9OCK\7?A5\79O'?QM\>WFI1ZU\._AI\'/ACK? MQ'MM9U/6/#MU\H^,?^"(G[='Q \#Q_ ;2?VO_ NB?LVZQ^T+X]_;C@\1?&KX M8K&OAMXN^-/Q+_:/\3_ +86L^-OVB]:TYH]4\>:?X3^ M-?CG4K?P;^S'HWB+7_V>?#^F>'[)_B)KO[3%ZWA;7O!8!^<'[5_Q]\:_M^_' MOX/6WP<^'WQJTC0OC9X?F^#O_!.K1-7T_5?@MX1\?_L:>,M;\-:5_P %+O\ M@IMHWQ0OOAGXGMOA%J)_9QDN/V?\%'OVCO 7[-G[*?[-/C+PQX: MU.S_ &;O@+I7[2/Q!L?@9^P]^RS^S'JOC+PO%I&G_LD?LY^)=3TOXB>/=$-O M)\1?B_<^'?%'QU^+7A2RU_XC>"?"^C?#O@S^R;^TW\(OVH=7^/I^(=CX*\;_%ZSU67XO_!;Q3\&?A3X8L[3 MXO>)?!^N_"W]G7XK>(_%_C?X[^*=1^'/B;Q3\4;+PCI'P!T?P%J7B2^^*_P1 M /B.VN?@);?&+]A+_@EUX(\576O?LC?L2ZE\>OVFOVS?VC_B-=03> /CO\>O MV*8/ /CCQUX9\2>/;S7=7LM8\4^$OVJOVC?#7[4?[87C/Q5#8?#3P=\7?#5K M\(YO&E[\4(/B'X%\$??/PGT?QC_P4A^-7PW_ &L/B-X:;PI^PQ\!/&%_X]_8 MA^&/B?3"?$O[4/C\:79Z7X2_;@^*_AC5'O++PS\/?" ?Q#X@_8H\'7EC;^,[ MB+Q)I/[2?C*#PEXMM?A?X=\)?EY;?\$%/VF/'GQ9\$^&_'7Q[^'WP4_9#^#O MQ _;@U/X.?#KX*Z8/BCJUK\.?&GQ,_91\2_L?^ /B+X)_:+\(>-/@EXH\ :* M?V:?AY\4_BA\)KOX<:[!??'3X5ZU\9O%WQ4^*WQ4_:0\3^)/A7]M'X!?\%TO M@[X.^#GA;P3^W+^SU^TKXC;Q'/I?C&7XF?L[3_"?2/#_ (8T7]GGXK>!M'U3 M7OB]9>*OC5XR\1Z1/\2O^%/_ !?U;P[<_"O6/B1XZ^+MGXDT>3XW> /@MK$O M@O3P#]FOC!\3=!^"GPE^*/QD\56VJ7GA?X2_#KQM\3?$EIHD%O=:U=:#X#\- M:GXJUBVTBVN[JQM;C5)]/TJXBL(+F]L[>:[:*.:ZMXV:9/Q0_8?^/UM\!OV? M?AGX:7PY)^T9_P %3?V]4_X;'^-WPC\+Z]>PRZ-XV^/WAO1_&VF>,?C;X^U& MX\;P? _]C7]G/P-JGPW_ &=/#7Q(L[;QGIMKX5^&^A?#7X&^"?C'\8?LGP[\ M0]/^S?\ L _\%0O$G[/.H?!7_@HG_P %/;3XB:-XW^".N?"CQ_X;_9N^ 'PU MTCQ9=W^OZU\0H=;UC4OVB_C1X7\9S^-K+Q-\/_'T?@O7X--_9V^%&L6\/@'X M9ZGX6UGPYK6F_$S5_C WP-_P1:U'X6_!GPE\(OAW^VC\1]'C^%?CO]G[XO\ MPZUJY^"OP,L9_'_Q?_9O\2>'?%?P_P#%O[9.L_#WPS\.OBC^U1I=M-X5T'P) M-X?7XJ_">XNOA+HVC>'-5U[5?'6E6GQ/0 ^^_P!BG]FO5O@EX)U7XC_%_4[K MQY^U]\?K/PCXK_:I^+VM66B66L>)_%^A:3<6GA_X>^'--\.:AJ_A[P=\&?@U M9ZKJOA3X1?#SPSJ=[HVC:?=:[XOUG4?%'Q/\?_$GQ]XR^U*_/+PW:?\ !5_4 MX;_3?%^O_P#!/+P5<6YO(8?$E_P##+4_&WPA? MP=+I=G'I^H2>";?XM>.DU^YO;S1U\?\ AN+3(-=U;2\.?"W]N'Q3)\0/#GQ1 M_;"_X175K5?#K>&?''[/'[)_PP^%G@]HM3M+V/5!X:T?X[_%;]M#7-7O-+@C MB:\;Q7)I$.G^+OL^HVUGXA\(SOX9 !]]T5S?@[1-4\->$/"OAS7/%NN>/M:\ M/^&]#T36/'?B>U\.V/B7QKJFE:9:V&H>+?$-EX/T/PQX2L]<\1W<$VL:M:^% MO#7A[P[;W]Y<1:)H>DZ8EK86_24 %%%% !1110 4444 %%%8.N3^)X)-"'AO M2M!U.*?7K6#Q,^N:_J&A2:5X8:UO7O=5T**P\-^(EU_7H;V/3K>UT"_F\-Z? M=6MU>WDWB2TEL(+'4@#>HHHH **** "JUXMV]I=)I\]M;7[VTZV5S>6LM]:6 M]VT3"VGNK*"\TZ:\MHIBDD]K#J%C+<1*T,=Y;.XG2S10!Y-\)_"7Q'T#2?[8 M^+'Q!7QG\0?$^@>!)?&VE^&M,CT'X0^&O&^B>#M+T3QE+\&?#>I?VQXY\.>" MO%/B*TOO$<.B>._B!\0=9L9;M8UUT SK+ZS110 4444 %%%% !1110 5XI\? MM T#Q+X#TC2_$PA;2Q\7_P!GO4HTG\8)X$!UK1?CW\-=8\+R0>(#>Z=.VHVO MB>QT>\TCP[8WL.I>--7M[#P9IZ7EUK\5A=>UUX3^T19F^\$^%(7\1_#WPO9I M\=OV:KR]U+XE7MG8:+=#3_V@_AG?Z=XT?XA>+]!/'SBPD!:2YO)=,LT@N(;&%;]6NS;S^PUX5\9=?FTF\\+65I>6 MD5Y?VWB*Z2SEL=.U&[N+;3Y?#\-QV:7+ MRO+;", ]UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH *S(]'L(M9O-?2.?^U+_3--T>YE:]O9+8V& MDW6JWME'#ITEPVG6LZW&M:@US>VMI#>W\;6D%_<7,&FZ;%:/PUX2G\9:W;6/AR+Q-XAD30]!DU)=5U9UL+2X8=K$[211R/%) [QH[02F( MRPLRAFBD,$DT)DC)*.89I8BP)CD=,,0"2BBB@ HHHH *\I^,-[>V?ASPV+&[ M\96$MW\5O@U92W7@:'2)M6%E-\5/")O[34QK6J:5:Q^#=5LHY](\?36\E[J\ M?@F_U]M#TO4=8^PVS^K5\=?MH:_'HOA?X"6=QI%CJ-KXF_;%_94T">_U+Q+X M?\.VGAV1?C#X=UW3=7$6MZIIUYXDOKK6=#TWPYH_AKPQ#J_B"\UK7].O3I9T M+3MIZU\* M[G08K1]#UC2KAK*YL=)\2/J"S+<0^?:Z:+-9\,Z]I7ACQQ!HNF>(YO!O MB'4=*N[/1?%E\.ZE-;:O'HNK(VF:H]F+&_5K6>4'H+=)H[>".X MF%Q.D,23W B$(GF5%6680JSK$)7#.(E=A&&V!F R0":BBB@ KG_%FJZOH/A7 MQ+KF@>%]2\;Z]HWA_6=5T3P7H]_H>E:OXOU?3M.N;S3?"^E:IXGU/1/#6FZE MK]Y##I-C?^(=9TC0[.ZNXKC5M3L+".XNHN@K \67^OZ5X6\2ZIX4\/1>+?%& MFZ!K-_X;\*3ZS;^'(?$VOV>G7-QH_AZ;Q#=6M[:Z%%K6HQVVFR:S?C%I_[-NNS>'/C!\*O"G[7$/CB'X ^-/BMX M+TS2O"'C'Q-\-?#WBSQ;XV\":UK_ (3\3^,K+X:>,M'\,> ?'FMV6F?%1_!- MIXJL_!GB%?!NH>(KFTBMY_L"7X^_ F"R;4Y_C5\)8=.3P&?BF^H2_$?P='9) M\,1J0T8_$9KM]9$"^ QJY&E'Q>9!X?&I$6/]H_:B(J_!CX(_\$N?CC^SWX7_ M &'_ !)XWNOA7X!NOV!/&GQE^+'Q#^+OPD^*_P =?CSXH^-OPA^)_A'XDZA\ M;?V?=*_9F\7?!GPGX$TJT^(FI:_X2LD\8:7J_BGQMIEE\/4E\ >&M'UGQUJ& MF:=C?L8?\$_8+[]E']JCXB?#WX$>"_BWI_Q,\'Z_^S;_ ,$ZO@W^W?X.GT#P M5HO[ 6F?%7Q#\:_ACX7^+7A"Z\,ZE\4?#/ASQ%\7_B;X[\1Z?%XB+_$/7/@+ M\+?V3YO$OA3P=\4?"^N0D _I:HKXEO/V\/ASI][>Z?>?!']MM;S3[R[L+M;/ M]AK]JG6;,75E<26MQ]BUG0OA7JFAZQ9F:)S::MHFIZEH^I6YCO=,O[RQG@N9 M:W_#??PP_P"B)_MQ_P#B!'[7W_SG: /N.BOB*V_;T^&EW58HS<7M]\([:RLH [J9KN]N+>TMH@T]S/#!')(LL/[=W MPXGBBFC^"G[;(2;^T=@F_89_:LM91_95C#J-WYMO=?"B&X@WVTZ)IQGBB&MW MPFTK1#J.JV]Q91 'VQ17PY_PWW\,/^B)_MQ_^($?M??_ #G:/^&^_AA_T1/] MN/\ \0(_:^_^<[0!]QT5\.?\-]_##_HB?[+4[:\L9$6:V<51NOVP?AK:C66/P^_:JN%T;3K/4&-K^Q=^UI.=3^VV&J M:@ECHR+\&?,U'48%TMK2\MHT7['J%]I=G<.DU]$ ?55%?$,W[>WPQA=4_X4 MO^V]+N@M9]T/[!G[7LB#[5:PW7E,P^#@Q/;^=]GNH^L-U%-"23&25MOV]?AC MQ6\'G2K%YUQ*?@X1%;Q;O,FE((CB5W( M.W% 'V[17PV/V_/A@0#_ ,*2_;D&0#@_L$?M? C/8C_A3O!'>M)?V[/A>.X2Y,R6T%U' M9WTML ?:5%?+4O[8'PM1VC3P3^U+.RZC!9Y(XOV$ MOVW9V8-&\@B@>']GN2&ZG C9&AMI9G60I&P#2QAP#ZNHKY<3]K[X5R7$,"^# M?VH\3SQVT<[_ +$G[945NLLFJR:,?.>7X#HUM!'>)'+)>7*160TJXCUY+A]" MCNM1M\U/VU?@\Z1O_P (9^UJGFV:WP1_V!?VZ@Z1,J/Y4BC]G,F.\ D4-8-B M]#!U\@M'(% /K6BOC+_ANCX4&1UC^%W[9LD*I;LMU_PP1^VC#'+)=>*+7PM% M"D%S\"H+\.LUW%K=Q)+9QVUGX7CNM?O)X+&SNWAAN?VZ_AC;>=_Q:#]M.X\G M/_'M^PE^UY-YN-0N]/\ W./@V/,R;3[:,8SI]S:7728*H!]IT5\-M^WY\,%5 MF_X4E^W(VT$X7]@C]KXL<#.%'_"G>2>@'YN;9KCS9/^"?G[=) M+.#3]=TZWU2RMM8\/Z_!;72EXHM9\*Z]IOB?P[J*J&7_ $C2/$&D:9JUFQR( M[RRMY"K;,'8KP?X0_M'?#KXWZQXFT'P7HOQNT?4O"5AI&IZNGQ;_ &9/VD_@ M!:RV>N:AKVF:<^@ZE\>/A/\ #?3?%+SYVM>*M+TB.TNOB79^!=3EUFQ\#V.H>*/$BII?C6]_X1 MW1888?"MOXX/A7Q'\5+[3OA!H'C^^M_N*OC']N2\2Q^''P,64 MP!]G5XK\7](FU5O#AAGL8/LZZP&^VW,]N6\XZ5M\KR-(U3?CRCOW>1MRFWS= MQ\OVJO*_B680VB><\J?+J>WR]/O[[/.G9R;&TN?*QQ@2[/,R=F[RWV@'JE%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\]?M8?&KQ/^SM M^SE\7_C/X'^$/CWX^^._ G@S4=2\!_!?X9^'?%'B?Q?\2_'5T8M+\&^$;2Q\ M&^'/%WB#3M*U;Q+?Z7!XG\56GAK6H/!7AM^%O'7@GQ MS_PD?_"$^,/"WC >#_%6L>!?%I\+Z_I6OCPQXV\/?9QK_@_Q"=*N[L:-XIT, MW=JNL:!J)MM5TQKB%;VT@:1 >JK^3A? _P"V9_P2W^$/_!2#X9ZQXI\>^--6 M_:$_X)T_'G]LO1OVJ?AQX3^+NH?#KX=_\%$OA3\'O'>C_&OX@^-?B5X@\#7_ M ((^$WB/]J;3]%\!?'#PWI>L^/O#/P[^&_B_X9^+O"6C:#H,/BWP%/XOM_%G MX]?M>^$/^$,\=>$_CY^WK>_LE?$/XU?\$CEO_&/Q0^%$_ASXWWGQ6_:&^,OB MC2_VL/AO\)=%T_\ 9I^$_CWQS\+=<^!GC'X2>(/$&A^!?A-<>%/"OQ9DN?!W MP%@\(ZOH7CCX4^'P#^KRBOY9_#MS_P %2?B#\2-(^&,GC3]L71HH_P!GG]NS MX@?LE_$#QOX"\??#GP3XR^-OP;_;JD\%/AAH&F^&=/^+/[+ M7@Z;P=\8OAM\7K'X?:MXS^&&O:OHOC+POHOQG\1>"=3?U;P)-_P42^,OAKX@ MW?P(UG]LWX8ZKH/_ 3I^#_BUF_:\T37/"-]9?\ !3OX6^,KSQ4/AC:6WC'P M!X1MOB?X"^-V@P>(O G[5'B/X,>&](_9VLO#VH^"KW]GR;3O%-];/\,P#^D* MN/\ %'Q"\ ^"-1\%Z/XS\;^$?".K?$?Q0/!'P\TOQ-XDT?0=0\=^,VT76/$B M^$O!UEJEY:W/B;Q,WA[P]K^NKH6BQWNJ'1]$U?4Q:_8M.O)H?YQ_BK7Q/^V-X!\"_M9^%OVL_C19>#/@O\)?$?Q1^,?[)_QH\>ZI\!]7_8 M!^ _C7X3ZKXP^$L?PZD\.? 3P/XFT3XK6?QS\1>+OV1_"G[8?CWXYV7Q[U;0 M/@UKOPK\3> [?B%OVK?'O[6W[+-U\Z;\&/B++ M^SEX%_8A\3?LI_M#?";X)^,M"\;?#7PSJ7P6U./Q'<^)?"-W\6-8G\8>(?'/ MP_\ B#\0?B/H'Q'U#P_\,+'P-:V8!_1%\1_BE\,O@YX5N_'7Q=^(O@3X5^"- M/N+*SO\ QE\1_%WA_P #^%;*[U*X2TTZUN_$/B?4-+TBVN+^[DCM;*":\26Z MN)$@@625E4\IX;_:-_9Z\9?"OQ#\=?"'QW^#7BOX(^$M-\3:SXJ^,?AKXG^" M-=^%?AG1_!5K=7WC+5?$'Q"TO7+KPEHVF^$K*QO;SQ-?:CJ]M;:#:V=U<:I+ M:Q6\KI^/W[:VE>,?BO\ \$&OVI/"/@7PC^VK\5?'WQ(^#?QH\"^!?!GQ^^$/ MBG6/VO\ Q3XC\0_%;Q-X<\,:7XF^&7@CP@WB.*RCFELSX4U.Y\-68TOX2VOA M[Q?XSO+"VMM;UF'Q/QAX?^,?@7QS_P %8?B5>_#GXR:M\>OVROV(=0TK]AOX MG_#G]E'QSJ'PL\3?#WX/_LX?%/6?AO\ !GXR_"2Y^'WB6YMOVP_ OQ)\2>*] M*UVY_:PFDG_:&\'7_P ./"7P1\.>#M+M?%GP-\+ ']'D?B#09=!3Q5%K>D2^ M&)=(7Q!'XCCU*R?09-!>S&HIK::PLQT]](?3R+]=26X-DUF1="8P'?5/P?XQ M\(_$/PIX:\>> /%/ASQSX&\9Z%I7BCP?XS\'ZYIGB;PIXK\-:[90ZEHGB+PU MXBT6ZO='UW0M8TZYM[_2M7TN\NM/U"RGANK2XF@E21OY_?@S\>?VN['XQ>#- M:^*^H?MOZ/X:T[6/V:O%_P ,_AKX*_9"U'5/V;?$_P"Q]J_["7@_4_CQJ'Q3 M\>:1\%-$NOAK\8/"W[15C\7?%VN?"_QOXCL_V@M$\5_#_P"&?P2^#?PJO=$^ M+B+XB^,OA/X__;K_ &6_V0?V:OAWX9M/VW[?PAH/_!)7]C74_BAH^H_LZ^/M M+U+X%_&/X5_M5? #X+?%WP+X8U/1?V4_%'B#P;-HWP"\7?%^W^*NA^&_AW\6 M_CI)\%/A9I?QS^%GA_7_ !YI7_"Q/'H!_7E7$/\ $WX;Q_$FW^#_$VU^%C>*=#7XBW/PWT[7K#PK?_ ! @\%&^'B27P59>)]4TWP[=>*4T MTZ'!KM_9Z3)?+?W$5NWX*?L_?$/]N'Q]\9/V6OAI\3?''[8GA73=*U7_ (*> MZ!XF\;7/[,OQ0^&_@;XGZG\"?V^/@)\1/V(_#_Q UOQO\*?$>D^!/!7QC_8W M\#>.?"VG>/O'OBF7Q/XT\ :Y\0/!NG_$.[^-FO\ _"3:KA?L O\ '?Q3^W7^ MR+\5OCYI_P"V=XI^+S_\$P_V@OA5^U7XN^./[._Q5^'_ ,(_AE^U[K?Q^_99 M^)_C7X:?#+Q/#\$OAS\$T\(W;:'X]\&^"?$'@+7O%OPX\9^ ?@1\/+WPKXP\ M3>-M7\:>.?BN ?L7XJ_;Z_84\":WKOAGQO\ MJ?LE^#?$GA?Q!JWA+Q+X?\ M%7[1WP>\/:WX=\5:!,EOKOAG7=*U?QE9W^D^(-%N)(X-6T;4+>WU+39G2*\M MH795/UIUZ5^*WB/X,?#;PW_P5+_9]^%VC_ O7/\ AGC6?V!OV_?A/XRMK?X! M_$_6O@=>?$3]I'X^?LV_';Q1X;^('Q+N/".L_".ZO_C9I'A#XV^*]93Q!KNF MW/B7Q+8^+=-\1:WK/B;Q5I'AR]^C_B9X[^'6O_L'?MP> OA_^S9\_C7?ZSI?P:^.WP M:^+>I^';O5M/\0:=\,OB?X(\>W^A7^@SZ9;:[9:S9^%=WO?B#X"T[QOH7PRU#QOX1L/B1XI\/Z_P"+/#/P M^O/$FC6OC?Q%X5\*7FC:?XH\3:%X4GO4U[5_#_AO4/$?AZQU_6=/L+C3='O- M>T6UU&YMI]4L4G_E$^'GAG]J7X2:9XEU3]F;P)^T+\5="^ _['W[*GP8\#_M M5?\ #(/C7]GG]M;X6_L;:/\ M?\ @K4?B;^Q3K?P.^+/@[0OAA^U7^TM\'_V M6;/XD>+/A9X\^!WPJ\,^)/#^O:1XF\,^-/ADGQ/^*_P9G\<=?\+ M]!^)_P (KW]N_4/&OP,_8H_X+5']G#XU?$_]DR'0_BYXQN(;?]C#XD_LL>$] M?\$7/PCU*[M(==\ /A_I_QW^&W@/XT?M!Z;\(-3U74O!^M:9\3]"U MCQP ?U=45_,:?VH?^"C%_P#&K3K3S_VD?#G@3QC^W9_P2-\"]T7PUH'Q2?XCW?B'P-J.H:)\:_@+X MOTS2?$6NVN@>!])NX9?'M ^.7_!3CQ/^ROI_CR+XU_MYGX[ZQ_P2D_;)_:4\ M2>'[O]DOP[X9N/"_[9W[/?Q[\%:3^R#\-=$\+ZA^R)HELNJ?%L:[\3O#?BWX M+3V.J^*OBE\,?AUX/\4ZS!)X?U:Z\:>.0#^M.N'\6_$[X;> =7\#^'_'7Q"\ M#^"]?^)WB0^#OAMH?BSQ9H/AW6/B%XN73;S66\+>!],U>_L[WQ9XC72-.U#5 M7T308+_4UTRPO;]K86MK/+'_ #/WO[5G_!675OCHGC?X:?#']H:VU3Q7I7[1 M_@G0_@E\5O@EXQ7X'0_$;4_V(HOC'^RQ8:QK-O\ "OP3X%^&WPSC_:6'ASX< MV_Q3UO\ : UCQAXL37_$VC_''5_@#JU@OPR\.)KNM_''XS:Y^P1+?:__ ,%% M_'_A*U_;V_9*^(]]XU_:/_8]O/A'\1O@3XQ\C_ !OM3XO_ &>?AK\"]:^*O[-'AO\ 9XE7QQ^TY;^' M?@%J7@7XB_$OXH?!_7?!7C/PCXFDT_\ <7_@GUX@^-OQ%C_:"^('QD\>_&J> M\T']I[]KGX*Z%\+OB;\-O^%?>&-+^'G@/]KSXZ^)?@#\1O AUSX;>#?%/B6V M\5?LZ^/OA?X='C#3/$GB_P"'_B7PEX1\#P:<=/\ &_A[QY<:J ?H]7/Z/)XJ M?4_%B>(+/P_;:-#KEHG@:XT?4M1O=3U#PTWACP]+?7/BRSO=)T^UT?7(O&4G MBNRM+'1[[7;"?PQ:>'M4FU&WU74-2T?3.@HH **** "BBN$^*5O\1KOX9?$6 MU^#U_P"%=*^+ESX$\76_PLU3QU!J%UX)TWXC3>']0C\$7_C&VTF*?5;CPK9^ M)FTRX\0P:9#-J$VD1WD=E%)(7TU]?&F6 UQ]'2YCT MA]8%K$-3?2H[UY+Q--:]\\V*7;O9!(T;JDJJQ1@-IK: M1IYTG2=+TIK_ %'56TS3K+3SJFKW"76K:D;*VBMC?ZI=1Q01W.HWAC^T7MPD M$*37,DLBQ1JP10#1KY8_:UUC6M)\'_"6+P_9W.H:GK/[4_[+&CM:6EAI&HS' M19OCIX)N_%EX8M:L-0MH+;1_"-EKVMW]_:QVVKZ=8:;=7NBW]AJL%G=1_4]? M'_[9^F?VGX+^"H_X2V7PD;#]L#]D74P_D65S8^(OL?Q]\#EO"6IPW[1PB+7D M=K?3)X[B"]LO$::)>Z@Z;K&GMI'C199 M]9U'2--TVSO/MO@HVD1EUB5H9+Z[@%\]K'%932?9[2^8W5JJF*]^C*\<^)"/ M;^)?"6JV>GZ%>:I;Z%XQT^&77]8&AV\%AJ%_X+N;Z.&^6U:9II[C2]-;[(NH M6T-.EH **** "BBOS2_:__;C^*'[-?[27P&^!'ACX M3_ GQ)X>^._P<_:+^)]I\5/C1^U!JG[/WASP%J'[-&G^$-8\7:5XS"? 3XIV M,7AC7[#XB>#(],\76&LW&H:*Z^*]2U?PA)H^@17>H@'WM\2?AMX$^,/@3Q1\ M,/B?X8TSQK\/?&^E3:#XQ\'ZY')<:#XI\/W;)_:/A[Q!8+)'%JWA_6($:PUW M0[X3Z5KNDSWFCZQ9WVE7UY9S\%XI_9@_9Q\;^'/A+X/\8? GX2>)_"?P#U7P MIKOP.\,ZY\/_ QJ6@_![7? EC;Z9X'UOX9:1=:9)8>!M9\&:=:V]CX3U7PU M!IM_X\6>&)O$'C_ $/X+_$Z+X=: M!H7B+6=5^)6M>&%\.> ;3Q'XCUSP[I.J]?>_\%5?V#['PQ:>+YOC7J4VD-J' MQUTOQ#;Z?\&_COJOB/X9WG[,?C+P/X _:"3XX>#=,^&-YXO^ 4/PA\5?$SX> M6/CF\^->A> ;/1+3QKX9URXG_L'6;'4Y@#]"Z*_(WQ!_P5-\#?#WX&_'3QGX MWU;P'K/QF\,_&'_@HC\+_@#\*/ 6@?';6YOBU<_L.7/Q0U34+74+'2OA9XD\ M!]*TCXZ_$OPOX/\1_"GP=\0-47PUX<\1:[J>N>#=(U_H?V*/B_\.OB%XPT3X;^%=4^$[>-O!WA?2?'%MI_Q*\3>'O ?Q6N/ M#M_JC? 7Q)JD6D?&JW\#:LJZ=)^E]GXGN_%/P^MO&7@/2KF>_P#$7@^+Q+X- MT/XBZ5XR^%=W->:KHPU/P]I7CK1/$OA'_A8'PZGEGGM+3Q+INO> SXO\).U[ M;:GX2;6;";1R =E17\_GPJ_X+<^+_'WPR\%^+]7_ &7/AY;^-OC!^R)^TI^U MW\*/ /PV_:A\1_%.'0/"G[*\]G%\0M)_:>UX?LO>#]6_9]M/%"8OAU:?'WX;^'?B[X:\&KXH_X3"[T?P+X^M1XE^'AUO6 ME\/^&8%\4:CX$U'P[JOBW1+'3[O3/"WB>^U?POI7B/QAINCVOBW6_I2@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "OC+]MZ]@T_P/\#KB]DABTQ_VS?V-K*])T:XUN^:?4_VB/ .F M>'X],BB\7>#H+":7Q;=^'TU+6;Z[UJWTGPZVMWL/A'Q7J,5CHEW]FU\6_MMZ M^GACPU^SMJYN-7BD;]M+]E'0(;>S\*6/B_0K]_&OQ:T7P1+;^,;'4;FQMM)T MBWMO$EQJ?A_Q6M]!?>$_B/I_@;Q#I-MK>KZ?8^'=8 /M*O)_'^G0R^(_"VK- MJUGI,]EHGBW3HY=5UJRTO2I8M4O_ ?F+)ZQ7E?Q'OH+*ZT$WFI26%K)!K.1;VBW-U-<))H_DE6EU*PBC@BC:X M$RE9I)))+"(?AI\/?!'P\MO$WC3QG;^!O"F M@^$[?Q=\2/$M[XS^('B:#P_IEMI<6N>-O%^I#^T?%'BK5([5;S7O$&H9OM8U M*:YO[MGN+B1CVM%% !1110 4444 %%%% !1110 4444 %%%% !7P)^T?^Q+> M_M!_M:?LA?M+7GCCX=V_A_\ 95TOXRZ)+\*/'?P,M/BC:^/]/^.UOX)L/&EU M#XGU+X@:%%X&\1:18?#WPW_P@WB#2O"VIW>AWLWB(:U'XHT+7IO#UO\ 9?Q M\4:IX*\%^)/%>B> O&'Q1U?0M+GU#3OAY\/Y/!\7C3QA>1;1!H7AN;X@>+? M7@B'5+UV"03^*O&GAC0X?FEU#6;*W1YE\4_8Z_:?\.?MD?L\>"?V@_#'A'Q3 MX!L_%6K?$?PMJW@?QI+H%SXF\(>-/A%\4/&GP<^(?AK4[[PKK&O^&=4.B^/? M /B33[36= UK4M'UFPM[75=.NY+6\B- 'QE^T/\ \$O;S]HOXA?MK^+/$'Q\ M7PYH/[7'PY_8^\.Z'HVE_"6P\2:W\(?B'^PS\5]<^-_P&\=+>_$3QQXS^'WQ M!\+2?$CQ)JM]\2OA-JWPHT3PSXYT.+3])6^T*]N?%VM>+O)O'W_!'/6/B1I? MATZS^TGX2\+>+;?Q9\3_ (A7WC#X3?LE?"GX5:W\)/B1X_UKX)66C?$3]BOQ M/X3UZV^)_P"S'XM\#_"?X/3_ N$_B?XE?'S2/B9'XL/B;XT:-\1;KPQH>F) M^X-% 'XZ7O\ P2L\8R>(_&?C+2_VK[K3?$WB[XQ?MUZG=&;X#>!]3\/ZG^R[ M_P %!M3^&.O?&+]G7QGHUUXA%WXG\6^"_$?PC\!:_P#"#X\:?K7A?4-$N/"' MAG0O'WP]^)7@A/%?A/QCRWP#_P"",VA_L\>*_A5KG@SX_">P\*>"?V.-$^)4 MVK_L\_!G7/B/XY\5_L3?#KX+?"OP!JG@;XO>)M.\0^-/A%X!^)W@WX#?#^P^ M-GPTM)O&"ZC>Z=<^(OA#XK^"_BK7/%6O>(OVTHH _GZ@_P""%LTWP3^&OP2U MC]J?S]'^%?[!'Q5_8N\.:UI?P8U*WU:\\1?$']I/X5?M)Z3\9-?E\2?&_P 7 M2ZE:Z+K_ ,#OAKH7B#X=1W-G-XJLF\=W>G>/O!Y\2^';/P-^GO[/%I^V;)XC M_:RN/CYKG@JW\,:G\5K.W_9,A?PWH-/C5H7C?XJ_#GPAK_ (^U?XM:)X'\9KX5\>>/+74+72])\*_9%% 'Y3? M+_@F1%^SW_P3I\>?L*^$?BEX,'C'QK\,/C'\*'_:1M?@/IND^(SH/Q:U7QQJ M":EXF\'V_P 09V\8Z[X.@\?ZW!H-+32I[F#3[R]TAXUU&RU+B/A=_P $ MK_&G@CQK^SO\2/$7[1/@/4_'7[(O['?BK]CSX&ZY\//V:C\*H/&GA+Q?\./ MG@BZN_VNM%@^-OBS2/VB_"7AG7OA]IGQ'^'_ ,(_#]I\%OA_X2\8ZSXDU&.P MO[R?0;[PY^R%% 'RO^Q!^SAJ7['_ .R/^S[^RWJGCG3OB5)\ ?AIH'PJT_QU MIG@^Z\!1>)/#O@V)]'\*W][X6N_&'CQ]/UT>&;;2+?Q+<6_B6XT[5_$,&J:U MI6F>'-,U&S\-Z3]4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 5\>_MI6*:CX'^#%O+*MM"G[87 M['M])=S6":C:V[Z5^T1\/]4M(KB!M/U>2)M4O[.TT33K^#397TS6-3TW49-0 M\-6MK<>*]"^PJ^-?VMM*UR_\6_L4:A8?;)?#WAW]LOPIJOCFQAC>73K[0[[X M)?'GPOX<_MM;K6=&\."STGXH>(OA]XBTR3Q-_:J0^*=&\/3>"]&O_BHGP_$0 M!]E5Y7XVTU]4\6^%+=+1-3*>'?&V@NKBS,@MX M+N7Q#8RV,>H7,,&C:TFH7%]H'JE>>>(=.35?'/A:SN)YEM!X4\<73VGDV-U: M37,.K_#^*WN)K74;*^MFN;6*XNHK6X$:3PQ7=Y'&_EW$RL >AT444 %946NZ M)/K=]X9AUC2IO$FF:5I6NZEX?BU"TDUO3]$UV[UC3]$UB^TI)C?VFE:Q?^'? M$%EI6H7%O'::A=Z%K%M:333:9>I!JUA)X7\,Q^)KCQK'X=T)/&5WH5GX7NO% MJ:1IZ^)KGPSIVH7VK:?X=N->6W&JS:%8ZKJFI:G9Z1)=MI]MJ&HWUY!;I:1X&\5:I\+O M"GAKQS\0]/T2^N_!W@[QAXSO_AUX8\3:]!"TEAHNM>.M,\&?$.^\*6.H2J+> M36[?P1XG:Q9UF;2;F,.!\5?\$T_V=_CE^R?^SC%\!?C7:?"VYNO#OQ*^._CW M0O%WPV^)?CKQ]-XI7X[?M%_&7XZ:@OBBT\=?"[X?WFB:OH,/Q$TC2KF^M-6\ M4P>*-636]32V\+V<5AIMS^@]% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 5\,_MO66FZI=?L:Z7J&HZ%:2W7[F\2VT.NZEX9T?Q_ MXQ73M-G\.>+O!\:Z[967AV]\1Z-#XCN->\-7]_H46FW_ (1\2W-Y8Z9+]S5\ MF_M4:2^M:A^RU9"7PTD,7[67PVU:YB\2^%K;Q2ERF@>%_B#K]O%H8O- U^W\ M.^)8M0TRSO-&\4XT>YT>:U=M.U_3-2GLWD /K*O-]4BD;XO^!IQ?-'%'\-_B MK$^FB],:7L$T"7IB,?'FO\ [+UY MX5\.:)XET_X>_M-^&/B#XZMM<71UBTOP=IOPU^*VAMXCTZ[U.XBOK+6_#_BC MQ%X8U726\.6]_K%_=VR:+63_A9O@ZU@OY+::7 MP)\1[@6C/?26ES';>(/A9&]S+9130Z?-<6;74<5M=71-Y:Q7MW#8#R+W437H M5O+GXA>%_%:7UY'8:+X,\=^'KG34,7 MV"[O/$VM_#G4K&^N5:99S>:?#X2U""Q,=M+$L.IZ@)IK=V@CN0#LJ*** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H =HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D! end GRAPHIC 5 ex21-1_003.jpg begin 644 ex21-1_003.jpg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�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�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end EX-31.1 6 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Richard T. Schumacher, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Pressure BioSciences, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: November 20, 2023

 

/s/ Richard T. Schumacher  
Richard T. Schumacher  
President and Chief Executive Officer  

Principal Executive Officer

 

 

 

 

EX-31.2 7 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Richard T. Schumacher, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Pressure BioSciences, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: November 20, 2023

 

/s/ Richard T. Schumacher  
Richard T. Schumacher  
Principal Financial Officer  

 

 

 

 

EX-32.1 8 ex32-1.htm

 

EXHIBIT 32.1

 

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

 

In connection with the Quarterly Report on Form 10-Q of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”) for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard T. Schumacher, President and Chief Executive Officer of the Company, do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:

 

  (1) The Report of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 20, 2023 By: /s/ Richard T. Schumacher
    Richard T. Schumacher
    President & Chief Executive Officer
    (Principal Executive Officer)

 

A signed original of this written statement required by Section 906 has been provided to Pressure BioSciences, Inc. and will be retained by Pressure BioSciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

EX-32.2 9 ex32-2.htm

 

EXHIBIT 32.2

 

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

 

In connection with the Quarterly Report on Form 10-Q of Pressure BioSciences, Inc., a Massachusetts corporation (the “Company”) for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard T. Schumacher, Principal Financial Officer of the Company, do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:

 

  (1) The Report of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 20, 2023 By: /s/ Richard T. Schumacher
    Richard T. Schumacher
    President & Chief Executive Officer
    (Principal Financial Officer)

 

A signed original of this written statement required by Section 906 has been provided to Pressure BioSciences, Inc. and will be retained by Pressure BioSciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EX-101.SCH 10 pbio-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Business Overview, Liquidity and Management Plans link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders’ Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Schedule of Contract Balances (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Schedule of Future Related to Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Schedule of Customer Concentration Risk Percentage (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Computation of Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Assumptions for Grants of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Right of Use Asset and the Corresponding Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Lease Cost for Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Convertible Debts and Outstanding Balances (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Other Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Other Debt (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Related Party Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Related Party Debt (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Preferred Stock Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stockholders’ Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 pbio-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 pbio-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 13 pbio-20230930_lab.xml XBRL LABEL FILE Short-Term Debt, Type [Axis] Convertible Debt [Member] Related Party [Member] Class of Stock [Axis] Series D Convertible Preferred Stock [Member] Series G Convertible Preferred Stock [Member] Series H Convertible Preferred Stock [Member] Series H2 Convertible Preferred Stock [Member] Series J Convertible Preferred Stock [Member] Series K Convertible Preferred Stock [Member] Series AA Convertible Preferred Stock [Member] Series BB Convertible Preferred Stock [Member] Series CC Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Warrant [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Legal Entity [Axis] Nexity Global SA [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Geographical [Axis] North America [Member] Europe [Member] Asia [Member] Product and Service [Axis] Hardware [Member] Consumables [Member] Contract Research Services [Member] Sample Preparation Accessories [Member] Technical Support/Extended Service Contracts [Member] Agrochem Products [Member] Shipping and Handling [Member] Other [Member] Transferred at a Point In Time [Member] Transferred Over At Time [Member] Award Date [Axis] 2023 [Member] 2024 [Member] Customer [Axis] Top Five Customers [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Federal Agencies [Member] Accounts Receivable [Member] Antidilutive Securities [Axis] Stock Options [Member] Convertible Debt Securities [Member] Common Stock Warrants [Member] Series H2 Convertible Preferred Stock [Member] Plan Name [Axis] CEO, other Officers and Employees [Member] Income Statement Location [Axis] Cost of Sales [Member] Research and Development Expense [Member] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Collateral Held [Axis] Equity Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Real Estate, Type of Property [Axis] Corporate Office [Member] Geographic Distribution [Axis] Medford lease [Member] Sparks lease [Member] Related Party, Type [Axis] Battelle Memorial Institute [Member] Target Discovery Inc [Member] Debt Instrument [Axis] Convertible Common Stock [Member] PBI Agrochem Inc [Member] Title of Individual [Axis] Three Lenders [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Forbearance Agreements [Member] Four Lenders [Member] New Loan [Member] Ten Loans [Member] Short-term Non-Convertible Loan [Member] Investor [Member] Others [Member] Award Type [Axis] 5 Day Average VWAP [Member] Series AA Preferred Stock [Member] Convertible Debt One [Member] Convertible Debt Two [Member] Convertible Debt Three [Member] Convertible Debt Four [Member] Chief Executive Officer [Member] Non Convertible [Member] Merchant Debt [Member] SBA [Member] Payroll Protection Program [Member] Paycheck Protection Programme [Member] Merchant Agreement [Member] Officers & Directors [Member] Other Related Parties [Member] Series BB Preferred Stock [Member] Series CC Preferred Stock [Member] Series BB Restricted Preferred Stock [Member] Series CC Restricted Preferred Stock [Member] 2021 Equity Incentive Plan [Member] Vesting [Axis] Unvested Stock-Based Awards [Member] Stock Options [Member] Exercisable Options [Member] Accredited Investor and Consultants [Member] Long-Term Debt, Type [Axis] Payment in Kind (PIK) Note [Member] Common Stock and Warrant [Member] Scenario [Axis] Issued For Services Rendered [Member] Conversion of Debt Extension [Member] Debt Settlement [Member] Class of Warrant or Right [Axis] Lender [Member] Dividends Paid In Kind [Member] Debt Extension [Member] New Common Stock Issuances [Member] Conversion of Preferred to Common Stock [Member] Restricted Stock [Member] New Conversion Debt [Member] Series A Junior Participating Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Board of Directors Chairman [Member] Two Thousand Twenty One Equity Plan [Member] Mr Schumacher [Member] Drs Ting [Member] Lazarev [Member] Executive Officer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Accounts receivable Inventories, net of $905,759 and $982,973 reserve, respectively Prepaid expenses and other current assets Total current assets Investment in equity securities Property and equipment, net Right of use asset operating leases Intangible assets, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES Accounts payable Accrued employee compensation Accrued professional fees and other Accrued interest and dividends payable Deferred revenue Convertible debt, net of unamortized debt discounts of $744,393 and $455,517, respectively Other debt, net of unamortized discounts of $0 and $0, respectively Related party, net of unamortized debt discount of $514 and $7,915, respectively Right of use operating lease liability Total current liabilities LONG TERM LIABILITIES Long term debt Right of use operating lease liability long term Deferred revenue TOTAL LONG TERM LIABILITIES TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES (Note 4) STOCKHOLDERS’ DEFICIT Preferred stock, value Common stock, $.01 par value; 100,000,000 shares authorized; 23,399,945 and 13,682,910 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively Warrants to acquire common stock Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS’ DEFICIT TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Statement [Table] Statement [Line Items] Inventory valuation reserves Debt instrument, unamortized discount Other debt, unamortized discounts net. Preferred stock, par value Common stock, par value Common stock, shares authorized Common stock, share,issued Common stock, shares, outstanding Income Statement [Abstract] Revenue: Products, services, other Total revenue Costs and expenses: Cost of products and services Research and development Selling and marketing General and administrative Total operating costs Operating loss Other (expense) income: Interest expense, net Unrealized gain (loss) on investment in equity securities Gain (loss) on extinguishment of liabilities Other income (expense) Total other expense Net loss Deemed dividends on extension of warrants Preferred stock dividends Net loss attributable to common shareholders Basic net loss per share attributable to common shareholders Diluted net loss per share attributable to common shareholders Weighted average number of shares of common stock outstanding, basic Weighted average number of shares of common stock outstanding, diluted Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: (Gain) on extinguishment of debt Non-cash lease expense Common stock and warrants issued for interest Depreciation and amortization Accretion of interest and amortization of debt discount Loss on extinguishment of accrued liabilities and debt Common stock and warrants issued for debt extension Preferred stock issued for debt extension Stock-based compensation expense (Gain)/Loss on investment in equity securities Common stock and warrants issued for services Preferred stock issued for services Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued employee compensation Operating lease liability Deferred revenue and other accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property plant and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Sale of common stock for cash Proceeds from stock option exercises Net proceeds from convertible debt Net proceeds from non-convertible debt - third party Net proceeds from debt - related party Payments on convertible debt Payments on debt - related party Payments on non-convertible debt Net cash provided by financing activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR CASH AND CASH EQUIVALENTS AT END OF PERIOD CASH FLOWS SUPPLEMENTAL INFORMATION Interest paid in cash NON CASH TRANSACTIONS: Early adoption of ASU 2020-06 Common stock issued with debt Discount from warrants issued with debt Common stock issued in lieu of cash for dividend Preferred stock issued with debt Preferred stock dividends Conversion of preferred stock for common stock Conversion of debt, interest, preferred stock dividend for preferred stock Conversion of debt and interest into common stock Conversion of common stock for preferred stock Extension of warrants for Series AA preferred stock Beginning balance, value Balance, shares Stock option exercise Stock option exercise, shares Stock-based compensation Series AA Preferred Stock dividend Issuance of common stock for services Issuance of common stock for services, shares Stock warrants issued Conversion of debt and interest for common stock Conversion of debt and interest for common stock, shares Issuance of common stock for dividends paid-in-kind Issuance of common stock for dividends paid-in-kind, shares Issuance of common stock for interest paid-in-kind Issuance of common stock for interest paid-in-kind, shares Common stock issued for debt extension Common stock issued for debt extension, shares Stock issued with debt Stock issued with debt, shares Conversion of preferred stock for common stock Conversion of preferred stock for common stock, shares Sale of Common Stock Stock issued with debt, shares Extension of warrants for Series AA Preferred stock Conversion of common stock to preferred stock Conversion of common stock to preferred stock, shares Issuance of preferred stock for services Issuance of preferred stock for services, shares Issuance of Preferred stock for debt extension Preferred stock for debt extension Preferred stock issued with debt Preferred stock issued for debt, share Early adoption of ASU 2020-06 Warrants issued for debt extension Warrants issued with debt Warrants issued for services Balance Balance, shares Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Overview, Liquidity and Management Plans Going Concern Accounting Policies [Abstract] Summary of Significant Accounting Policies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Debt Disclosure [Abstract] Debt Equity [Abstract] Stockholders’ Deficit Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Recent Accounting Pronouncements Principles of Consolidation Revenue Recognition Concentrations Product Supply Investment in Equity Securities Computation of Loss per Share Accounting for Stock-Based Compensation Expense Fair Value Measurements Schedule of Disaggregation of Revenue Schedule of Contract Balances Schedule of Future Related to Performance Obligations Schedule of Customer Concentration Risk Percentage Schedule of Computation of Loss Per Share Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share Summary of Assumptions for Grants of Stock Options Schedule of Stock Based Compensation Expense Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Future Minimum Rental Payments Required Under Operating Leases Schedule of Right of Use Asset and the Corresponding Lease Liability Schedule of Lease Cost for Operating Leases Schedule of Convertible Debts and Outstanding Balances Schedule of Other Debt Schedule of Related Party Debt Schedule of Preferred Stock Outstanding Schedule of Concerning Options and Warrants Outstanding and Exercisable Schedule of Product Information [Table] Product Information [Line Items] Revenue Receivables, which are included in ‘Accounts Receivable’ Contract liabilities (deferred revenue) Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Extended warranty service Concentration credit risk percentage Net loss attributable to common shareholders Weighted average common stock shares outstanding basic Weighted average common stock shares outstanding diluted Loss per common share - basic Loss per common share - diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potentially dilutive shares Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Expected life Expected volatility Risk-free interest rate Forfeiture rate Expected dividend yield Total stock-based compensation expense Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Line Items] Total Financial Assets Cumulative effect of adoption, adjustment in additional paid in capital Cumulative effect of adoption, adjustment in accumulated deficit Sale of stock number of shares received Investment owned, at fair value Unrealized gain Forfeiture rate October 1 – December 31, 2023 2024 2025 2026 Total future undiscounted lease payments Less imputed interest Present value of lease liabilities Right of use asset Right of use liability, current Right of use liability, long term Total lease liability Operating lease cost Short-term lease cost Total lease cost SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] Lease monthly payments Lease expiration date Annual cost of living payment Lessee operating lease description Operating lease liability Estimated borrowing rate Operating lease Weighted-average remaining lease term Weighted-average discount rate Mimimum royalty fee Payments for fees Professional and contract services expense Expenses Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Interest Rate Conversion price Totals Debt unamortized discount Principal amount Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Debt instrument, convertible price per shares Debt default amount Debt instrument lowest trading price Debt instrument, convertible, conversion price Debt default convertible conversion ratio Debt instrument, convertible, conversion price, Increase Debt instrument, convertible, conversion price, decrease Percentage of price Convertible lesser per share Convertible lesser Percent Original debt, interest rate of debt Principal balance Trading day Interest Rate Totals, Principal Long Term, discount Long Term, Principal Short Term, Principal Debt interest rate Debt instrument, maturity date Non- convertible debt amount Note payable Accrued interest rate percent Debt Instrument periodic payment Deferred interest Principal amount paid Borrowed amount Debt interest rate Debt instrument, maturity date description Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Totals, Principle Discount, Principal Net, Principal Debt instrument, interest rate, stated percentage Proceeds from Convertible Debt Debt instrument term Fixed rate Convertible Debt, Fair Value Disclosures Deferred Costs Repayments of Senior Debt Debt instrument maturity date description Debt instrument, face amount. Amortization of Debt Discount (Premium) Debt Instrument, Unamortized Discount Payments on convertible debt Interest payable Losses on extinguishment of debt Proceeds from loans Increase in principal amount Number of shares issued Preferred stock extensions Proceeds from Short-Term Debt Original issue discount Proceeds from (Repayments of) Related Party Debt Schedule of Stock by Class [Table] Class of Stock [Line Items] Total Convertible Preferred Shares Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding Preferred stock, shares outstanding Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Shares, Beginning balance Weighted average price per share, Beginning balance Exercisable, Beginning balance Shares, Granted Weighted average price per share, Granted Shares, Exercised Weighted average price per share, Exercised Shares, Expired Weighted average price per share, Expired Shares, Forfeited Weighted average price per share, Forfeited Shares, Ending balance Weighted average price per share, Ending balance Exercisable, Ending balance Convertible preferred stock, authorized Convertible preferred stock, par value Preferred Stock, Shares Issued Preferred stock voting rights Number of shares converted Preferred stock remain outstanding percentage Preferred stock, dividend rate, percentage Outstanding shares, precentage Preferred stock liquidation Preference value Preferred stock, convertible, conversion price Debt instrument, convertible, threshold percentage of stock price trigger Debt instrument, convertible, threshold trading days Debt instrument convertible benefically percentage Shares of restricted common stock Number of common stock for services rendered, shares Number of common stock for services rendered Convertible debt issuances shares Convertible debt issuances value Stock issued during period, value, other Stock issued during period, value, conversion of units Stock issued during period, shares, other Stock Issued During Period, Value, Other Common stock, capital shares reserved for future issuance Options outstanding, shares Unvested stock based awards Unrecognized compensation, period Closing stock price Options outstanding and exercisable intrinsic value Weighted average exercise price Weighted average remaining term Number of options, exercisable Class of warrant or right, outstanding Extension of warrants for series AA preferred stock Interest expense Stock Issued During Period, Shares, New Issues Fair value of dividends paid in kind Shares isused for options exercised, shares Shares issued, price per share Issuance warrants, shares Strike price, per share Fair value of warrants Subsequent Event [Table] Subsequent Event [Line Items] Convertible Debt Share Price Stock Issued During Period, Shares, Issued for Services Stock Issued During Period, Shares, Other Stock Issued During Period, Shares, Conversion of Units common stock, par value Shares of common stock Stock option number of shares granted Numberof stock option exercise price Number of option vested percentage Number of option issuance percentage Number of years option vested Other debt, unamortized discounts net. Recent Accounting Pronouncement [Policy Text Block] Warrants to acquire common stock. Hardware [Member] Consumables [Member] Contract Research Services [Member] Sample Preparation Accessories [Member] Technical Support/Extended Service Contracts [Member] Agrochem Products [Member] Other [Member] Transferred At A Point In Time [Member] Transferred Over At Time [Member] Loss On Extinguishment Of Liabilities. Deemed dividends on extension of warrants. Extended warranty service. Two Thousand And Twenty Three [Member] Two Thousand And Twenty Four [Member] Top Five Customers [Member] Federal Agencies [Member] Product Supply [Policy Text Block] Nexity Global SA [Member] Noncash Lease Expense. Common stock and warrants issued for interest. Loss on extinguishment of accrued liabilities and debt. Common stock and warrants issued for debt extension. Preferred stock issued for debt extension. Preferred stock issued for services. Early Asu 202006 Adoption. Discount from warrants issued with debt. Common stock issued in lieu of cash for dividend Noncash preferred stock dividends. Preferred stock issued with debt. Conversion of preferred stock for common stock. Conversion of debt accrued interest and accrued dividend for preferred stock. Conversion of common stock for preferred stock. Extension of warrants for series AA preferred stock. Issuance of common stock for dividends paid in kind. Issuance of common stock shares for dividends paid in kind. Issuance of common stock for interest paid in kind. Issuance of common stock shares for interest paid in kind. Stock issued with debt. Stock issued with debt shares. Conversion of preferred stock for common stock. Stock issued during period shares conversion of convertible securities conversion of preferred stock for common stock. Sale of common stock for cash. Stock Options [Member] Common Stock Warrants [Member] Series H2 Convertible Preferred Stock [Member] Stock issued during period value conversion of common stock to preferred stock. Stock issued during period shares conversion of common stock to preferred stock. Sale of common stock for cash shares. Stock issued during period value issued preferred stock for services. Stock issued during period value shares preferred stock for services. Stock issued during period value issuance of preferred stock for debt extension. Stock issued during period shares issuance of preferred stock for debt extension. Preferred stock issued for debt settlement. Preferred stock issued for debt shares. CEO, other Officers and Employees [Member] Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate. Forfeiture rate. Cumulative effect, period of adoption, adjustment. Warrants issued for debt extension. Corporate Office [Member] Medford lease [Member] Annual cost of living payment. Estimated borrowing rate. Sparks lease [Member] Operating Leases of Lessee [Table Text Block] Minimum royalty fee. Battelle Memorial Institute [Member] Target Discovery Inc [Member] Others [Member] Debt instrument discount percentage of stock price. Convertible Debt One [Member] Debt default convertible conversion ratio. Convertible Debt Two [Member] Convertible Debt Three [Member] Convertible Debt Four [Member] Percentage of price rate. Convertible lesser per share. Convertible lesser discount percent. Series D Convertible Preferred Stock [Member] Series G Convertible Preferred Stock [Member] Series H Convertible Preferred Stock [Member] Series H2 Convertible Preferred Stock [Member] Series J Convertible Preferred Stock [Member] Series K Convertible Preferred Stock [Member] Series AA Convertible Preferred Stock [Member] Series BB Convertible Preferred Stock [Member] Series CC Convertible Preferred Stock [Member] Stock issued during period value warrants issued for services. PBI Agrochem Inc [Member] Three Lenders [Member] Forbearance Agreements [Member] Four Lenders [Member] New Loan [Member] Ten Loans [Member] Schedule of Other Debt [Table Text Block] Non Convertible [Member] Merchant Debt [Member] SBA [Member] Non convertible debt instrument amount. Accrued interest rate percent. Deferred Interest. Payroll Protection Program [Member] Paycheck Protection Programme [Member] Merchant Agreement [Member] Officers & Directors [Member] Other Related Parties [Member] Debt instrument periodic payment principal gross. Short-term Non-Convertible Loan [Member] Debt original issue discount. Series BB Preferred Stock [Member] Series A Junior Participating Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Series CC Preferred Stock [Member] Preferred stock outstanding percentage. Debt instrument convertible benefically percentage. Series BB Restricted Preferred Stock [Member] Series CC Restricted Preferred Stock [Member] 2021 Equity Incentive Plan [Member] Unvested Stock-Based Awards [Member] Aggregate intrinsic value of options outstanding and exerciasable. Stock Options [Member] Exercisable Options [Member] Accredited Investor and Consultants [Member] Common Stock and Warrant [Member] Issued For Services Rendered [Member] Conversion of Debt Extension [Member] Debt Settlement [Member] Dividends Paid In Kind [Member] Debt Extension [Member] New Common Stock Issuances [Member] Conversion of Preferred to Common Stock [Member] Lender [Member] New Conversion Debt [Member] Series AA Preferred Stock [Member] Percentage of outstanding shares. Conversion of debt into common stock. Two Thousand Twenty One Equity Plan [Member] Mr Schumacher [Member] Drs Ting [Member] Lazarev [Member] 5 Day Average VWAP [Member] Product and Service, Other [Member] Series H2 Convertible Preferred Stock [Member] [Default Label] Stock Options [Member] [Default Label] Assets, Current Assets Liabilities, Current Deferred Revenue, Noncurrent Liabilities, Noncurrent Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Income (Loss) Nonoperating Income (Expense) DeemedDividendsOnExtensionOfWarrants Preferred Stock Dividends and Other Adjustments Accretion (Amortization) of Discounts and Premiums, Investments CommonStockAndWarrantsIssuedForDebtExtension Debt and Equity Securities, Realized Gain (Loss) Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Repayments of Other Long-Term Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Shares, Outstanding Stock Issued During Period, Value, Stock Dividend StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock SaleOfCommonStockForCashShares PreferredStockIssuedForDebtSettlement CumulativeEffectPeriodOfAdoptionAdjustment ForfeitureRate Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lease, Cost Debt Instrument, Interest Rate, Effective Percentage Preferred Stock, Liquidation Preference, Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period EX-101.PRE 14 pbio-20230930_pre.xml XBRL PRESENTATION FILE XML 15 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
9 Months Ended
Sep. 30, 2023
Nov. 10, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-38185  
Entity Registrant Name PRESSURE BIOSCIENCES, INC.  
Entity Central Index Key 0000830656  
Entity Tax Identification Number 04-2652826  
Entity Incorporation, State or Country Code MA  
Entity Address, Address Line One 14 Norfolk Avenue  
Entity Address, City or Town South Easton  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02375  
City Area Code (508)  
Local Phone Number 230-1828  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   21,726,433
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 5,263 $ 3,865
Accounts receivable 329,263 295,374
Inventories, net of $905,759 and $982,973 reserve, respectively 467,155 686,383
Prepaid expenses and other current assets 219,283 257,527
Total current assets 1,020,964 1,243,149
Investment in equity securities 77,918 63,638
Property and equipment, net 91,409 103,351
Right of use asset operating leases 159,424 282,095
Intangible assets, net 252,404 317,308
TOTAL ASSETS 1,602,119 2,009,541
CURRENT LIABILITIES    
Accounts payable 1,062,565 637,238
Accrued employee compensation 376,760 167,247
Accrued professional fees and other 2,722,666 2,497,762
Accrued interest and dividends payable 4,576,350 10,803,983
Deferred revenue 253,152 58,242
Convertible debt, net of unamortized debt discounts of $744,393 and $455,517, respectively 18,222,120 17,823,669
Other debt, net of unamortized discounts of $0 and $0, respectively 2,030,510 1,638,969
Related party, net of unamortized debt discount of $514 and $7,915, respectively 647,986 634,885
Right of use operating lease liability 66,259 142,171
Total current liabilities 29,958,368 34,404,166
LONG TERM LIABILITIES    
Long term debt 162,522 150,000
Right of use operating lease liability long term 71,287 139,924
Deferred revenue 10,645 1,822
TOTAL LONG TERM LIABILITIES 244,454 291,746
TOTAL LIABILITIES 30,202,822 34,695,912
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS’ DEFICIT    
Preferred stock, value 100 1,098
Common stock, $.01 par value; 100,000,000 shares authorized; 23,399,945 and 13,682,910 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively 234,000 136,829
Warrants to acquire common stock 35,684,321 31,995,762
Additional paid-in capital 93,973,646 69,006,145
Accumulated deficit (158,492,770) (133,826,205)
TOTAL STOCKHOLDERS’ DEFICIT (28,600,703) (32,686,371)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,602,119 $ 2,009,541
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Inventory valuation reserves $ 905,759 $ 982,973
Debt instrument, unamortized discount 744,393 455,517
Other debt, unamortized discounts net. $ 0 $ 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 100,000,000 100,000,000
Common stock, share,issued 23,399,945 13,682,910
Common stock, shares, outstanding 23,399,945 13,682,910
Series D Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Series G Convertible Preferred Stock [Member]    
Preferred stock, par value 0.01 0.01
Series H Convertible Preferred Stock [Member]    
Preferred stock, par value 0.01 0.01
Series H2 Convertible Preferred Stock [Member]    
Preferred stock, par value 0.01 0.01
Series J Convertible Preferred Stock [Member]    
Preferred stock, par value 0.01 0.01
Series K Convertible Preferred Stock [Member]    
Preferred stock, par value 0.01 0.01
Series AA Convertible Preferred Stock [Member]    
Preferred stock, par value 0.01 0.01
Series BB Convertible Preferred Stock [Member]    
Preferred stock, par value 0.01 0.01
Series CC Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Convertible Debt [Member]    
Debt instrument, unamortized discount $ 744,393 $ 455,517
Related Party [Member]    
Debt instrument, unamortized discount $ 514 $ 7,915
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Products, services, other $ 413,009 $ 144,032 $ 1,665,412 $ 1,122,169
Total revenue 413,009 144,032 1,665,412 1,122,169
Costs and expenses:        
Cost of products and services 229,457 126,203 844,684 742,707
Research and development 288,345 262,370 1,004,437 716,685
Selling and marketing 157,773 226,526 537,802 422,422
General and administrative 1,030,243 892,293 5,290,564 2,591,644
Total operating costs 1,705,818 1,507,392 7,677,487 4,473,458
Operating loss (1,292,809) (1,363,360) (6,012,075) (3,351,289)
Other (expense) income:        
Interest expense, net (4,338,759) (2,034,021) (14,112,098) (6,448,771)
Unrealized gain (loss) on investment in equity securities (5,965) (8,675) 14,280 (8,047)
Gain (loss) on extinguishment of liabilities (1,054,122) 687,591 (1,809,249)
Other income (expense) 7,588 (2,059) 11,820 (904)
Total other expense (4,337,136) (3,098,877) (13,398,407) (8,266,971)
Net loss (5,629,945) (4,462,237) (19,410,482) (11,618,260)
Deemed dividends on extension of warrants (3,626,950)
Preferred stock dividends (632,054) (431,709) (1,629,133) (1,295,566)
Net loss attributable to common shareholders $ (6,261,999) $ (4,893,946) $ (24,666,565) $ (12,913,826)
Basic net loss per share attributable to common shareholders $ (0.29) $ (0.44) $ (1.21) $ (1.24)
Diluted net loss per share attributable to common shareholders $ (0.29) $ (0.44) $ (1.21) $ (1.24)
Weighted average number of shares of common stock outstanding, basic 21,716,950 11,131,742 20,337,229 10,429,817
Weighted average number of shares of common stock outstanding, diluted 21,716,950 11,131,742 20,337,229 10,429,817
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Operations (Unaudited) (Parenthetical)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Product and Service, Other [Member] Product and Service, Other [Member] Product and Service, Other [Member] Product and Service, Other [Member]
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (19,410,482) $ (11,618,260)
Adjustments to reconcile net loss to net cash used in operating activities:    
(Gain) on extinguishment of debt (687,591) (10,000)
Non-cash lease expense 122,671 82,001
Common stock and warrants issued for interest 3,715,204 2,196,278
Depreciation and amortization 84,341 67,985
Accretion of interest and amortization of debt discount 3,213,622 1,777,863
Loss on extinguishment of accrued liabilities and debt 1,809,249
Common stock and warrants issued for debt extension 1,671,573
Preferred stock issued for debt extension 2,683,600
Stock-based compensation expense 1,706,420 128,984
(Gain)/Loss on investment in equity securities (14,280) 8,047
Common stock and warrants issued for services 1,978,645 367,370
Preferred stock issued for services 617,200
Changes in operating assets and liabilities:    
Accounts receivable (33,889) (11,568)
Inventories 219,228 (238,973)
Prepaid expenses and other assets 38,244 204,141
Accounts payable 425,327 80,130
Accrued employee compensation 209,513 104,258
Operating lease liability (144,549) (82,001)
Deferred revenue and other accrued expenses 1,551,380 2,083,239
Net cash used in operating activities (2,053,823) (3,051,257)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property plant and equipment (7,495) (20,754)
Net cash used in investing activities (7,495) (20,754)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Sale of common stock for cash 150,000
Proceeds from stock option exercises 81,111 17,443
Net proceeds from convertible debt 4,336,665 3,428,249
Net proceeds from non-convertible debt - third party 2,043,681 1,815,000
Net proceeds from debt - related party 159,186 762,500
Payments on convertible debt (2,462,269) (1,086,946)
Payments on debt - related party (159,000) (259,600)
Payments on non-convertible debt (2,086,658) (1,506,066)
Net cash provided by financing activities 2,062,716 3,170,580
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 1,398 98,569
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 3,865 132,311
CASH AND CASH EQUIVALENTS AT END OF PERIOD 5,263 230,880
CASH FLOWS SUPPLEMENTAL INFORMATION    
Interest paid in cash 1,219,038 938,451
NON CASH TRANSACTIONS:    
Early adoption of ASU 2020-06 473,027
Common stock issued with debt 1,293,270 512,593
Discount from warrants issued with debt 93,576
Common stock issued in lieu of cash for dividend 162,528 306,333
Preferred stock issued with debt 539,487
Preferred stock dividends 1,629,133 1,295,566
Conversion of preferred stock for common stock 14,869 44
Conversion of debt, interest, preferred stock dividend for preferred stock 10,017,212
Conversion of debt and interest into common stock 509,033 350,500
Conversion of common stock for preferred stock 6,240
Extension of warrants for Series AA preferred stock $ 3,626,950
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Warrant [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 1,099 $ 91,206 $ 31,715,154 $ 64,261,048 $ (118,277,468) $ (22,208,961)
Balance, shares at Dec. 31, 2021 109,878 9,120,526        
Stock-based compensation 64,483 64,483
Series AA Preferred Stock dividend (432,149) (432,149)
Issuance of common stock for services $ 370 77,330 77,700
Issuance of common stock for services, shares   37,000        
Stock warrants issued 39,761 39,761
Conversion of debt and interest for common stock $ 1,402 349,098 350,500
Conversion of debt and interest for common stock, shares   140,200        
Issuance of common stock for dividends paid-in-kind $ 318 63,938 64,256
Issuance of common stock for dividends paid-in-kind, shares   31,810        
Issuance of common stock for interest paid-in-kind $ 5,581 1,167,877 1,173,458
Issuance of common stock for interest paid-in-kind, shares   558,100        
Common stock issued for debt extension $ 2,145 470,755 472,900
Common stock issued for debt extension, shares   214,500        
Stock issued with debt $ 920 141,560 142,480
Stock issued with debt, shares   92,000        
Net loss (4,239,685) (4,239,685)
Early adoption of ASU 2020-06 (2,728,243) 2,255,216 (473,027)
Warrants issued for debt extension 132,537 132,537
Warrants issued with debt 87,436 87,436
Balance at Mar. 31, 2022 $ 1,099 $ 101,942 31,974,888 63,867,846 (120,694,086) (24,748,311)
Balance, shares at Mar. 31, 2022 109,878 10,194,136        
Beginning balance, value at Dec. 31, 2021 $ 1,099 $ 91,206 31,715,154 64,261,048 (118,277,468) (22,208,961)
Balance, shares at Dec. 31, 2021 109,878 9,120,526        
Net loss           (11,618,260)
Extension of warrants for Series AA Preferred stock          
Balance at Sep. 30, 2022 $ 1,098 $ 122,207 31,995,762 67,041,489 (128,936,078) (29,775,522)
Balance, shares at Sep. 30, 2022 109,874 12,220,611        
Beginning balance, value at Mar. 31, 2022 $ 1,099 $ 101,942 31,974,888 63,867,846 (120,694,086) (24,748,311)
Balance, shares at Mar. 31, 2022 109,878 10,194,136        
Stock option exercise $ 253 17,190 17,443
Stock option exercise, shares   25,279        
Stock-based compensation 32,074 32,074
Series AA Preferred Stock dividend (431,708) (431,708)
Issuance of common stock for services $ 400 67,400 67,800
Issuance of common stock for services, shares   40,000        
Issuance of common stock for dividends paid-in-kind $ 865 150,156 151,021
Issuance of common stock for dividends paid-in-kind, shares   86,464        
Issuance of common stock for interest paid-in-kind $ 2,245 386,270 388,515
Issuance of common stock for interest paid-in-kind, shares   224,500        
Common stock issued for debt extension $ 1,064 190,239 191,303
Common stock issued for debt extension, shares   106,400        
Stock issued with debt $ 220 35,628 35,848
Stock issued with debt, shares   22,000        
Conversion of preferred stock for common stock $ (1) $ 44 (43)
Conversion of preferred stock for common stock, shares (4) 4,400        
Net loss (2,916,338) (2,916,338)
Balance at Jun. 30, 2022 $ 1,098 $ 107,033 31,974,888 64,746,760 (124,042,132) (27,212,353)
Balance, shares at Jun. 30, 2022 109,874 10,703,179        
Stock-based compensation 32,427 32,427
Series AA Preferred Stock dividend (431,709) (431,709)
Issuance of common stock for services $ 1,135 166,240   167,375
Issuance of common stock for services, shares   113,500        
Stock warrants issued 6,140 6,140
Issuance of common stock for dividends paid-in-kind $ 520 90,536 91,056
Issuance of common stock for dividends paid-in-kind, shares   52,032        
Issuance of common stock for interest paid-in-kind $ 3,895 630,410 634,305
Issuance of common stock for interest paid-in-kind, shares   389,500        
Common stock issued for debt extension $ 7,079 1,043,396 1,050,475
Common stock issued for debt extension, shares   707,900        
Stock issued with debt $ 2,545 331,720 334,265
Stock issued with debt, shares   254,500        
Net loss (4,462,237) (4,462,237)
Warrants issued for services 14,734 14,734
Balance at Sep. 30, 2022 $ 1,098 $ 122,207 31,995,762 67,041,489 (128,936,078) (29,775,522)
Balance, shares at Sep. 30, 2022 109,874 12,220,611        
Beginning balance, value at Dec. 31, 2022 $ 1,098 $ 136,829 31,995,762 69,006,145 (133,826,205) (32,686,371)
Balance, shares at Dec. 31, 2022 109,874 13,682,910        
Stock option exercise $ 1,176 79,935 81,111
Stock option exercise, shares   117,552        
Stock-based compensation 1,430,244 1,430,244
Series AA Preferred Stock dividend (431,807) (431,807)
Issuance of common stock for services $ 9,905 1,409,430 1,419,335
Issuance of common stock for services, shares   990,500        
Stock warrants issued 61,609 61,609
Conversion of debt and interest for common stock $ 2,036 506,997 509,033
Conversion of debt and interest for common stock, shares   203,613        
Issuance of common stock for dividends paid-in-kind $ 737 101,698 102,435
Issuance of common stock for dividends paid-in-kind, shares   73,694        
Issuance of common stock for interest paid-in-kind $ 11,111 1,694,123 1,705,234
Issuance of common stock for interest paid-in-kind, shares   1,111,081        
Common stock issued for debt extension $ 5,682 1,024,257 1,029,939
Common stock issued for debt extension, shares   568,200        
Stock issued with debt $ 7,832 1,079,919 1,087,751
Stock issued with debt, shares   783,150        
Conversion of preferred stock for common stock $ (1,012) $ 4,935 (3,923)
Conversion of preferred stock for common stock, shares (101,154) 493,540        
Sale of Common Stock $ 400 99,600 100,000
Stock issued with debt, shares   40,000        
Net loss (6,857,834) (6,857,834)
Balance at Mar. 31, 2023 $ 86 $ 180,643 32,057,371 76,428,425 (141,115,846) (32,449,321)
Balance, shares at Mar. 31, 2023 8,720 18,064,240        
Beginning balance, value at Dec. 31, 2022 $ 1,098 $ 136,829 $ 31,995,762 69,006,145 (133,826,205) $ (32,686,371)
Balance, shares at Dec. 31, 2022 109,874 13,682,910        
Stock option exercise, shares         117,552
Net loss           $ (19,410,482)
Extension of warrants for Series AA Preferred stock           3,626,950
Balance at Sep. 30, 2023 $ 100 $ 234,000 $ 35,684,321 93,973,646 (158,492,770) (28,600,703)
Balance, shares at Sep. 30, 2023 9,935 23,399,945        
Beginning balance, value at Mar. 31, 2023 $ 86 $ 180,643 32,057,371 76,428,425 (141,115,846) (32,449,321)
Balance, shares at Mar. 31, 2023 8,720 18,064,240        
Stock-based compensation 135,554 135,554
Series AA Preferred Stock dividend (565,272) (565,272)
Issuance of common stock for services $ 1,475 170,925 172,400
Issuance of common stock for services, shares   147,500        
Conversion of debt and interest for common stock $ 4 10,017,208 10,017,212
Conversion of debt and interest for common stock, shares 401          
Issuance of common stock for dividends paid-in-kind $ 690 59,403 60,093
Issuance of common stock for dividends paid-in-kind, shares   69,073        
Issuance of common stock for interest paid-in-kind $ 10,340 1,286,106 1,296,446
Issuance of common stock for interest paid-in-kind, shares   1,034,000        
Common stock issued for debt extension $ 5,286 486,348 491,634
Common stock issued for debt extension, shares   528,600        
Stock issued with debt $ 3,021 153,653 156,674
Stock issued with debt, shares   302,092        
Conversion of preferred stock for common stock $ 444 (444)
Conversion of preferred stock for common stock, shares (44) 44,400        
Sale of Common Stock $ 200 49,800 50,000
Stock issued with debt, shares   20,000        
Net loss (6,922,703) (6,922,703)
Extension of warrants for Series AA Preferred stock 3,626,950 (3,626,950)
Conversion of common stock to preferred stock $ 1 $ (6,240) 6,239
Conversion of common stock to preferred stock, shares 62 (624,000)        
Issuance of preferred stock for services $ 1 505,699 505,700
Issuance of preferred stock for services, shares 57          
Issuance of Preferred stock for debt extension $ 2 1,396,998 1,397,000
Preferred stock for debt extension 185          
Preferred stock issued with debt $ 1 539,486 539,487
Preferred stock issued for debt, share 58          
Balance at Jun. 30, 2023 $ 95 $ 195,859 35,684,321 91,235,400 (152,230,771) (25,115,096)
Balance, shares at Jun. 30, 2023 9,439 19,585,905        
Stock-based compensation 140,622 140,622
Series AA Preferred Stock dividend (632,054) (632,054)
Issuance of common stock for services $ 4,926 320,375 325,301
Issuance of common stock for services, shares   492,500        
Issuance of common stock for interest paid-in-kind $ 19,490 694,034 713,524
Issuance of common stock for interest paid-in-kind, shares   1,949,040        
Common stock issued for debt extension $ 2,500 147,500 150,000
Common stock issued for debt extension, shares   250,000        
Stock issued with debt $ 1,735 47,110 48,845
Stock issued with debt, shares   173,500        
Conversion of preferred stock for common stock $ (1) $ 9,490 (9,489)
Conversion of preferred stock for common stock, shares (95) 949,000        
Net loss (5,629,945) (5,629,945)
Issuance of preferred stock for services 111,500 111,500
Issuance of preferred stock for services, shares 35          
Issuance of Preferred stock for debt extension $ 6 1,286,594 1,286,600
Preferred stock for debt extension 556          
Balance at Sep. 30, 2023 $ 100 $ 234,000 $ 35,684,321 $ 93,973,646 $ (158,492,770) $ (28,600,703)
Balance, shares at Sep. 30, 2023 9,935 23,399,945        
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Business Overview, Liquidity and Management Plans
9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Overview, Liquidity and Management Plans

1) Business Overview, Liquidity and Management Plans

 

Pressure BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”), (ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)

 

The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion-dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.

 

The UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high-pressure discharge (greater than 20,000 psi) through a dynamically controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company first introduced the UST Platform in May 2022 through participation in several cannabis/health & wellness meetings combined with a free-sample program. Executed agreements were subsequently announced with six CBD companies and one cosmeceutical/skincare company for full commercialization in Q3 202 3. The Company began shipping Nano CBD topical spray on October 2, 2023.

 

The BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.

 

The PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus for PCT is on making, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. We currently have over 350 PCT Systems placed in approximately 250 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific research & clinical laboratories.

 

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Going Concern
9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

2) Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows from operationing business since our inception. As of September 30, 2023, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past as described in Notes 5 and 6. In addition, we raised debt and equity capital after September 30, 2023, as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.

 

 

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

3) Summary of Significant Accounting Policies

 

Basis of Presentation

 

The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023.

 

Use of Estimates

 

The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.

 

Recent Accounting Pronouncements

 

In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $2,728,243 decrease in additional paid in capital and a $2,255,216 decrease in accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption of ASU 2020-06.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

 

 

Revenue Recognition

 

We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, and ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period. We measure and allocate revenue according to ASC 606-10.

 

We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.

 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

 

Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.

 

Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.

 

Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components.

 

Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.

 

We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:

 

  a) The fair value of the asset or service involved is not determinable.
     
  b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange.
     
  c) The transaction lacks commercial substance.

 

We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.

 

 

We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases.

 

Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.

 

Disaggregation of revenue

 

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

 

In thousands of US dollars ($)  Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Primary geographical markets  2023   2022   2023   2022 
North America  $251   $138   $1,067   $709 
Europe   76    13    130    61 
Asia   86    (7)   468    352 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Major products/services lines  2023   2022   2023   2022 
Hardware  $273   $1   $994   $532 
Consumables   50    49    173    165 
Contract research services   -1    -    35    125 
Sample preparation accessories   31    41    113    93 
Technical support/extended service contracts   34    41    123    94 
                     
Agrochem Products   15    10    181    93 
Shipping and handling   11    2    38    20 
Other   -    -    8    - 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Timing of revenue recognition  2023   2022   2023   2022 
Products transferred at a point in time  $379   $103   $1,506   $903 
Services transferred over time   34    41    159    219 
   $413   $144   $1,665   $1,122 

 

Contract balances

 

In thousands of US dollars ($) 

September 30,

2023

  

December 31,

2022

 
Receivables, which are included in ‘Accounts Receivable’  $329   $295 
Contract liabilities (deferred revenue)   59    60 

 

 

Transaction price allocated to the remaining performance obligations

 

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

 

In thousands of US dollars ($)  2023   2024   Total 
Extended warranty service  $48   $11   $59 

 

All consideration from contracts with customers is included in the amounts presented above.

 

Contract Costs

 

The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.

 

Concentrations

 

Credit Risk

 

Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.

 

The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.

 

   Three Months Ended
September 30,
   Nine months Ended
September 30,
 
   2023   2022   2023   2022 
Top five customers   80%   42%   49%   31%
Federal agencies   18%   4%   5%   1%

 

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.

 

   September 30,
2023
   December 31,
2022
 
Top five customers   80%   93%
Federal agencies   22%   0%

 

Product Supply

 

In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were:

 

  CNC Machining
  Contract Assembly & Kitting
  Component and Subassembly Design
  Inventory Management
  ISO certification

 

 

Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location.

 

We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.

 

Investment in Equity Securities

 

As of September 30, 2023, we held 100,250 shares of common stock of Nexity Global SA, (a Polish publicly traded company).

 

We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.

 

As of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $77,918. We recorded $14,280 as an unrealized gain during the nine months ended September 30, 2023 for changes in market value.

 

Computation of Loss per Share

 

Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.

 

The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:

 

   2023   2022   2023   2022 
   For the Three Months Ended September 30,   For the Nine months Ended September 30, 
   2023   2022   2023   2022 
Numerator:                    
Net loss attributable to common shareholders  $(6,261,999)  $(4,893,946)  $(24,666,565)  $(12,913,826)
Denominator for basic and diluted loss per share:                    
Weighted average common stock shares outstanding   21,716,950    11,131,742    20,337,229    10,429,817 
Loss per common share - basic and diluted  $(0.29)  $(0.44)  $(1.21)  $(1.24)

 

 

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms.

 

   As of September 30, 
   2023   2022 
Stock options   3,420,754    1,307,822 
Convertible debt   7,417,906    6,471,034 
Common stock warrants   15,732,940    16,293,768 
Convertible preferred stock:          
Series D Convertible Preferred Stock   6,250    25,000 
Series G Convertible Preferred Stock   -    26,857 
Series H Convertible Preferred Stock   -    33,334 
Series H2 Convertible Preferred Stock   -    70,000 
Series J Convertible Preferred Stock   -    115,267 
Series K Convertible Preferred Stock   -    229,334 
Series AA Convertible Preferred Stock   8,601,000    8,645,000 
Series BB Convertible Preferred Stock   8,580,000    - 
Series CC Convertible Preferred Stock   4,010,000    - 
    47,768,850    33,217,416 

 

Accounting for Stock-Based Compensation Expense

 

We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.

 

Determining Fair Value of Stock Option Grants

 

The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023:

 

Assumptions  CEO, other Officers and Employees 
Expected life   6.0 (yrs) 
Expected volatility   130.5%
Risk-free interest rate   3.90%
Forfeiture rate   0 to 5.00%
Expected dividend yield   0.0%

 

Valuation and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.

 

Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

 

Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.

 

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

 

Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 0% to 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense.

 

All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance.

 

The Company recognized stock-based compensation expense of $140,622 and $32,427 for the three months ended September 30, 2023 and 2022, respectively. The company recognized stock-based compensation expense of $1,706,420 and $128,984 for the nine months ended September 30, 2023 and 2022, respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations:

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Cost of sales  $11,183   $2,184   $75,724   $8,694 
Research and development   35,676    9,499    241,585    37,803 
Selling and marketing   17,150    4,583    102,675    18,166 
General and administrative   76,613    16,161    1,286,436    64,321 
Total stock-based compensation expense  $140,622   $32,427   $1,706,420   $128,984 

 

Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.

 

Fair Value Measurements

 

The Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”) as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.

 

The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement.

 

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

 

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023:

 

      

Fair value measurements at

September 30, 2023 using:

 
   September 30, 2023  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities  $77,918   $77,918           -            - 
Total Financial Assets  $77,918   $77,918   $-   $- 

 

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:

 

      

Fair value measurements at

December 31, 2022 using:

 
  

December 31,

2022

  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities   63,638    63,638           -             - 
Total Financial Assets  $63,638   $63,638   $-   $- 

 

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

4) Commitments and Contingencies

 

Operating Leases

 

The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $7,650 per month, on a lease extension, signed on December 5, 2022, that expires December 31, 2023, for our corporate office. We expanded our space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected in the current payments.

 

We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease required monthly payments of $7,282 subject to annual cost of living increases. The lease shall be automatically extended for additional three years unless either party terminates at least nine months prior to the expiration of the current lease term.

 

The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $221,432 based on the net present value of lease payments discounted using an estimated borrowing rate of 12%.

 

On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term.

 

The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $239,327 based on the net present value of lease payments discounted using an estimated borrowing rate of 12%.

 

Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2023:

 

Year  Total 
October 1 – December 31, 2023  $15,887 
2024   64,393 
2025   66,969 
2026   51,778 
Total future undiscounted lease payments   199,027 
Less imputed interest   (61,481)
Present value of lease liabilities  $137,546 

 

 

The operating cash flows from the operating leases were $122,671 for the nine months ended September 30, 2023 and $82,001 for the nine months ended September 30, 2022. The weighted-average remaining lease term (years) of the above leases is 2.59 year as of September 30, 2023.

 

Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:

 

Operating Leases  September 30, 2023   December 31, 2022 
Right of use asset  $159,424   $282,095 
Right of use liability, current  $66,259   $142,171 
Right of use liability, long term  $71,287   $139,924 
Total lease liability  $137,546   $282,095 

 

The weighted-average discount rate is 12%.

 

The Company had no financing leases during the nine months ended September 30, 2023 and 2022.

 

The components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:

 

   September 30, 2023   September 30, 2022 
Operating lease cost  $153,290   $152,193 
Short-term lease cost   110,205    123,514 
Total lease cost  $263,495   $275,707 

 

Battelle Memorial Institute

 

In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“Battelle”). The licensed technology is the subject of a patent application filed by Battelle in 2008 and relates to a method and a system for improving the analysis of protein samples, including through an automated system utilizing pressure and a pre-selected agent to obtain a digested sample in a significantly shorter period of time than current methods, while maintaining the integrity of the sample throughout the preparatory process. In addition to royalty payments on net sales on “licensed products,” we are obligated to make minimum royalty payments for each year that we retain the rights outlined in the patent license agreement and we are required to have our first commercial sale of the licensed products within one year following the issuance of the patent covered by the licensed technology. After re-negotiating the terms of the contract in 2013, the minimum annual royalty was $1,200 in 2014 and $2,000 in 2015; the minimum royalties were $3,000 in 2016, $4,000 in 2017 and $5,000 in 2018 and each calendar year thereafter during the term of the agreement.

 

Target Discovery Inc.

 

In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“TDI”), a related party. Under the terms of the agreement, we have been licensed by TDI to manufacture and sell an innovative line of chemicals used in the preparation of tissues for scientific analysis (“TDI reagents”). The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement in 2023 or 2022.

 

In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $1,400 for the use of a lab bench, shared space, and other utilities, and $2,000 per day for technical support services as needed. The agreement requires TDI to pay the Company a minimum royalty fee of $60,000 in 2022 and $60,000 in 2023. For the nine months ended September 30, 2023 and September 30, 2022, the Company reported $55,400 and $65,100, respectively in TDI fees.

 

 

Severance and Change of Control Agreements

 

Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by the Company without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination.

 

Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the occurrence of a change in control, as a disincentive to the control change.

 

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Debt
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Debt

5) Debt

 

Convertible Debt

 

On various dates during the nine months ended September 30, 2023, the Company issued convertible notes for net proceeds of approximate total of $4.3 million which contained varied terms and conditions as follows: a) 1-12 month maturity date; b) interest rates of 0-120%; c) convertible to the Company’s common stock at issuance at a fixed rate of $2.50 or at variable conversion rates upon the Company’s up-listing to NASDAQ or NYSE or an event of default. These notes were issued with shares of common stock that were fair valued at issuance date. The aggregate relative fair value of the shares of common stock and preferred stock issued with the notes of $1,832,757  was recorded as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not qualify for derivative accounting treatment on September 30, 2023.

 

For the nine months ended September 30, 2023, deferred financing costs and OID issued with the debt are $648,470  and the Company repaid $2,462,269.

 

The summary of specific terms of the convertible notes and outstanding balances as of September 30, 2023, and December 31, 2022, are listed in the tables below. The convertible notes are from numerous parties and with original issue dates from July 2019 to September 2023 and maturity dates from July 2020 to September 2024. There are approximately $12.3 million of notes that are past due as of September 30, 2023.

 

   September 30, 2023   December 31, 2022 
Holders  Interest
Rate
   Conversion
Price
   Principal   Interest
Rate
   Conversion
Price
   Principal 
Main Investor   10%  $2.50 (1)   $8,586,750    10%  $2.50 (1)  $9,393,150 
Others   0 to 24%  $2.50 (2) or $7.50    10,379,763    0 to 24%  $2.50 (2) or $7.50
   8,886,036 
Totals             -               18,279,186 
Discount             744,393              455,517 
Net            $18,222,120             $17,823,669 

 

Notes:

 

(1)Conversion price of these note is $2.50 except for a note for $189,750, which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25% discount to the 5-day average VWAP of the stock prior to default and $729,100 lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company.
   
(2)Conversion price of these notes is $2.50 but also varies with one or more of these notes having the following conversion adjustment:

 

a.Notes are convertible before maturity at $2.50 per share or mandatorily convertible when the Company up-lists to the NASDAQ at the lower of $2.50 or the up-list price.

 

 

b.Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.
c.Notes are convertible at $2.50 per share except that following an Event of Default the conversion price will be adjusted to 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.
d.Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted at lower of 1) $2.50/share; 2) 30% discount to 5-day VWAP prior to date of default.
e.Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted at lower of 1) $2.50/share; 2) 25% discount to 5-day VWAP prior to date of default.
f.Conversion price is lower of (i) $2.50 or (ii) the price per share that the Company last sold Common Stock after the execution of an anti-dilution protection agreement.
g.Note can be converted at a Voluntary Conversion Price which is the lower of 1) $2.50/share; or 2) purchase price of stock sold by the Company at a price lower than $2.50 except that following an Event of Default, the Holder shall have the right, with no further consent from the Borrower, to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) 70% of the 5-day VWAP prior to conversion.
h.Conversion price is $2.50. If note is in default, it is $1.
i.Notes can be voluntarily converted before maturity at $2.50 per share. Lender retains the option upon an Up-list to convert at the lower of $2.50 or 10% off Up-list price.
j.Notes can be converted at the lesser of $2.5 per share or 25% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of (i) original conversion price or (ii) a 35% discount to the VWAP prior to each conversion date.
k.Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $950,000 as of September 30, 2023 is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion.
l.Some notes can be converted at the lesser of $2.50 per share or 25% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of original conversion price or the product of the VWAP of the common stock for the 5 trading dates immediately prior to the maturity date multiplied by 0.75.

 

For the nine months ended September 30, 2023, the Company recognized amortization expense related to the debt discounts indicated above of $2,621,523. The unamortized debt discounts as of September 30, 2023 related to the convertible notes amounted to $744,393.

 

As of September 30, 2023, the principal balance that is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $352,188.

 

Standstill and Forbearance Agreements

 

In recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. During the nine months ended September 30, 2023, the Company settled one note with total principal of $302,484, leaving one final lender (three notes) with total principal of $272,500 outstanding and incurred interest, penalties and fees of approximately $253,425  in connection with the Standstill and Forbearance Agreements.

 

Convertible Loan Modifications and Extinguishments

 

We refinanced certain convertible loans during the nine months ended September 30, 2023 at substantially the same terms for extensions ranging over a period of two to nine months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications.

 

 

The cash flows of new debt exceeded 10% of the remaining cash flows of the original debt on several loans. During the nine months ended September 30, 2023 we recorded gains on extinguishment of liabilities of approximately $0.7 million  by calculating the difference of the fair value of the new debt and the carrying value of the old debt. During the nine months ended September 30, 2023, the Company extended 17 loans totaling $3,917,898 and increased the principal to $4,067,898.  The Company issued 1,346,800 shares of common stock and 741 shares of preferred stock  for these extensions and increased principal.

 

Other Debt

 

No notes in Other Debt are past due as of September 30, 2023.

 

   September 30, 2023   December 31, 2022 
Holders  Interest Rate   Principal   Interest Rate   Principal 
Non-Convertible   (1)  $1,016,500    (1)  $878,809 
Merchant debt (3)        1,014,010         760,160 
SBA (2)   3.75%   162,522    3.75%   150,000 
Totals        2,193,032        $1,788,969 
Discount        -         - 
Long Term        162,522         150,000 
Short Term       $2,030,510        $1,638,969 

 

Notes:

 

(1)Interest varies from 1% to 10%. The maturity is between being past due and May 2, 2023. As of September 30, 2023, $861,500 of the non-convertible debt is past due.
(2)The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $150,000, accrues interest at 3.75% and requires monthly payments of $731 for principal and interest beginning in December 2022. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the nine months ended September 30, 2023, $14,719 interest was deferred and added to principal on EIDL loan and the Company repaid $2,197 principal on this loan. During the year ended December 31, 2020, the Company borrowed $367,039 (two-year term and 1% interest rate per annum) under the Payroll Protection program (or “2020 PPP”). During the year ended December 31, 2021, the Company borrowed $367,039 through a second Payroll Protection program (or “2021 PPP”) and extended the monthly payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven by the United States and SBA.
(3)During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1% - 100.9% per month. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. The Company’s Chief Executive Officer guarantees the Company’s performance of all representations, warranties, and covenants made by the Company in the Agreement. For loans outstanding on September 30, 2023, the maturity dates ranged from June 26, 2023 to October 15, 2023. For loan outstanding on December 31, 2022, the maturity dates ranged from April 4 to June 6, 2023.

 

Related Party Notes

 

   September 30, 2023   December 31, 2022 
Holders  Interest Rate   Principal   Interest Rate   Principal   Security 
Officers & Directors   -(1)  $522,450    -(1)  $521,950    Unsecured 
Other Related Parties   12%   126,050    12%   120,850    Unsecured 
Totals        648,500         642,800      
Discount        514         7,915      
Net       $647,986        $634,885      

 

Notes:

 

(1)Interest varies from 12% to 120%.

 

 

During the nine months ended September 30, 2023, we received short-term convertible loans of $164,700 with $5,514 OID from related parties and repaid $159,000 of related party loans. These notes bear interest of 12% to 120% and are due upon demand. All related party notes are convertible at $2.50/share.

 

We amortized $592,099  of debt discounts during the nine months ended September 30, 2023 for all non-convertible and related party notes. The total unamortized discount for all non-convertible and related party convertible notes as of September 30, 2023, and December 31, 2022 was $514 and $7,915, respectively.

 

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders’ Deficit
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders’ Deficit

6) Stockholders’ Deficit

 

Preferred Stock

 

We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock, the following is outstanding:

 

   September 30, 2023   December 31, 2022 
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 75 shares issued and outstanding on September 30, 2023, and 300 shares issued and outstanding on December 31, 2022 (Liquidation value of $300,000)  $-   $3 
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 80,570 shares issued and outstanding on December 31, 2022   -    806 
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 10,000 shares issued and outstanding on December 31, 2022   -    100 
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; no shares issued and outstanding on September 30, 2023 and 3,458 shares issued and outstanding on December 31, 2022   -    35 
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 6,880 shares issued and outstanding on December 31, 2022   -    68 
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 8,601 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively   86    86 
Series BB Convertible Preferred Stock, $.01 par value; 1,000 shares authorized; 858 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022   10    - 
Series CC Convertible Preferred Stock, $.01 par value; 2,000 shares authorized; 401 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022   4    - 
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; no shares issued and outstanding on September 30, 2023 and 21 shares issued and outstanding on December 31, 2022   -    - 
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding   -    - 
Series A Convertible Preferred Stock, $.01 par value, 313,960 shares authorized, no shares outstanding   -    - 
Series B Convertible Preferred Stock, $.01 par value, 279,256 shares authorized, no shares outstanding   -    - 
Series C Convertible Preferred Stock, $.01 par value, 88,098 shares authorized, no shares outstanding   -    - 
Series E Convertible Preferred Stock, $.01 par value, 500 shares authorized, no shares outstanding   -    - 
Total Convertible Preferred Shares  $100   $1,098 

 

 

On May 1, 2023, Pressure Biosciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization (the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate 1,000 shares of its Preferred Stock as Series BB Convertible Preferred Stock, par value $0.01 per share (the “Series BB Preferred Stock”) and 2,000 shares of Preferred Stock as Series CC Convertible Preferred Stock, par value $0.01 per share (the “Series CC Preferred Stock”). Each of the Certificate of Designation of Series BB Convertible Preferred Stock (the “Series BB COD”) and Certificate of Designation of Series CC Convertible Preferred Stock (the “Series CC COD”) filed with the Amendment set forth the terms and provisions of the Series BB Preferred Stock and Series CC Preferred Stock, respectively.

 

Series BB Preferred Stock

 

Rank. The Series BB Preferred Stock ranks prior to the Company’s common stock, par value $0.01 per share (the “Common Stock”), and subordinate to the Series AA and Series CC Preferred Stock, and to all other classes of classes and series of equity securities of the Company, which by its terms does not rank on a parity with or senior to the Series BB Preferred, and all indebtedness of the Company.

 

Dividends. The holders of shares of the Series BB Preferred Stock are not entitled to receive dividends.

 

Voting Rights. The Series BB Preferred Stock has all of the same voting rights as the Common Stock. Each share of Series BB Preferred Stock. The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held.

 

Voluntary Conversion. The holders of Series BB Preferred Stock have the right to convert its Series BB Preferred Stock into Common Stock at a ratio of 10,000 shares of Common Stock for each share of Series BB Preferred Stock held, subject to adjustment as set forth in Section 4(e) of the Series BB COD.

 

Company Forced Conversion. The Company has the right to cause the conversion of all shares of Series BB Preferred Stock into Common Stock (“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares held by holders of the Series BB Preferred Stock, the Company may effectuate a Forced Conversion if either of the following conditions are satisfied: (i) the VWAP of the Common Stock shall equal or exceed 300% of $2.50 (with such dollar figure to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction that affects the share price of the Common Stock) for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series BB Preferred Stock that are issued pursuant to any exchange of previously issued securities.

 

Series CC Preferred Stock

 

Rank. The Series CC Preferred Stock ranks prior to the Common Stock, pari passu to the Series AA Preferred Stock, and prior to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred Stock (the “Junior Stock”). The Series CC Preferred Stock is subordinate to and ranks junior to all indebtedness of the Company.

 

Quarterly Dividends. The holders of shares of the Series CC Preferred Stock are entitled to receive, out of funds legally available therefor, dividends at an annual rate equal to 8% of the Liquidation Preference Amount (as defined below), calculated on the basis of a 360-day year, consisting of twelve 30-day months, and shall accrue on a daily basis from April 24, 2023. Accrued and unpaid dividends shall compound on a quarterly basis, and shall be, except as set forth in Section 2(b) of the Series CC COD, payable in cash. The first such dividend payment shall be due and payable on April 30, 2023, with subsequent dividend payments due and payable on June 30, September 30, and December 31, 2023. Each year thereafter, dividend payments shall be due and payable on March 31, June 30, September 30, and December 31.

 

 

Junior Stock Dividends. The Company shall not declare or pay any cash dividends on or make any other distributions with respect to or redeem, purchase, or otherwise acquire for consideration, any shares of Junior Stock unless and until all accrued and unpaid dividends on the Series CC Preferred Stock have been paid in full, subject to restrictions as set forth in Section 3(a) of the Series CC COD.

 

Class Voting Rights. So long as more than ten percent (10%) of the Series CC Preferred Stock remain outstanding, the Company shall not, and shall not permit any subsidiary to, without the affirmative vote or consent of the holders of at least 75% of the shares of the Series CC Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting, in which the holders of the Series CC Preferred Stock vote separately as a class: (i) authorize, create, issue or increase the authorized or issued amount of any class or series of stock, including but not limited to the issuance of any more shares of previously authorized Preferred Stock, ranking prior to the Series CC Preferred Stock, with respect to the distribution of assets on liquidation, dissolution or winding up; (ii) amend, alter or repeal the provisions of the Series CC Preferred Stock, whether by merger, consolidation or otherwise, so as to adversely affect any right, preference, privilege or voting power of the Series CC Preferred Stock; (iii) repurchase, redeem or pay dividends on (whether in cash, in kind, or otherwise), shares of Junior Stock; (iv) amend the Articles of Incorporation or By-Laws of the Company so as to affect materially and adversely any right, preference, privilege or voting power of the Series CC Preferred Stock; (v) effect any distribution with respect to Junior Stock or parity stock; (vi) reclassify the Company’s outstanding securities; or (vii) effect a transaction with one or more persons or entities whereby such other persons or entities will own more than the 50% of the outstanding shares of Common Stock following such transaction.

 

General Voting Rights. Except with respect to transactions upon which the Series CC Preferred Stock shall be entitled to vote separately as a class as set forth in “Class Voting Rights” above and except as otherwise required by Massachusetts law, the Series CC Preferred Stock shall have no voting rights. The Common Stock into which the Series CC Preferred Stock is convertible shall, upon issuance, have all of the same voting rights as the Common Stock.

 

Liquidation Preference. In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, the holders of shares of the Series CC Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company whether such assets are capital or surplus of any nature, an amount equal to $25,000.00 per share (the “Liquidation Preference Amount”) of the Series CC Preferred Stock, on a pro rata and pari passu basis with any parity stock (the “Pari Passu Preferred Stock”), together with all accrued but unpaid dividends, before any payment shall be made or any assets distributed to the holders of the Common Stock or any other Junior Stock. If the assets of the Company are not sufficient to pay in full the Liquidation Preference Amount payable to the holders of outstanding shares of the Series CC Preferred Stock and any series of preferred stock or any other class of stock on a parity as to rights on liquidation, dissolution or winding up, with the Series CC Preferred Stock, then all of said assets will be distributed among the holders of the Series CC Preferred Stock, the Pari Passu Preferred Stock and the other classes of stock on a parity with the Series CC Preferred Stock, if any, ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

 

Voluntary Conversion. The holders of Series CC Preferred Stock have the right to convert its Series CC Preferred Stock into a number of fully paid and nonassessable shares of Common Stock (the “Conversion Shares”) equal to the quotient of (i) the Liquidation Preference Amount of the shares of Series CC Preferred Stock being converted thereon divided by (ii) the Conversion Price then in effect as of the date of the delivery by such holder of its notice of election to convert. The “Conversion Price” shall mean $2.50 per share, subject to adjustment under Section 5(e) of the Series CC COD.

 

Company Forced Conversion. The Company has the right to cause the conversion of all shares of Series CC Preferred Stock into Common Stock (“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares held by holders of the Series CC Preferred Stock the Company may effectuate a Forced Conversion if either of the following conditions are satisfied as of the Forced Conversion Effective Date: (i) the VWAP of the Common Stock shall equal or exceed 300% of the Conversion Price for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series CC Preferred Stock that are issued pursuant to any exchange of previously issued securities.

 

 

Conversion Restriction. At no time may a holder of shares of Series CC Preferred Stock convert shares of the Series CC Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of 4.99% of all of the Common Stock outstanding at such time (the “Conversion Restriction”); provided, however, that a holder may waive the Conversion Restriction by providing the Company with sixty-one (61) days’ notice that such holder is waiving the Conversion Restriction.

 

During the nine months ended September 30, 2023 the Company issued a total of 953 shares of Series BB restricted preferred stock and 401 shares of Series CC restricted preferred stock to accredited investors and consultants, with the following detail:

 

92 shares of Series BB preferred stock with a fair value of $617,200, for services rendered;
741 shares of Series BB preferred stock with a fair value of $2,683,600 for convertible debt extensions;
58 shares of Series BB preferred stock with a fair value of $539,487 and issued with convertible debt;
62 shares of Series BB preferred stock from the conversion of common stock to preferred stock;
95 shares of Series BB preferred stock was converted into common stock;
401 shares of Series CC preferred stock with a fair value of $10,017,212 for the conversion of debt/accrued interest and dividends.

 

Stock Options and Warrants

 

At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Consistent with the Company’s existing 2013 Equity Incentive plan (the “2013 plan”), under the 2021 plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2023, options to acquire 3,420,754 shares were outstanding under these Plans.

 

As of September 30, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $963,322 , which is expected to be recognized over weighted average period of 2.2 years. The aggregate intrinsic value associated with the options outstanding and exercisable as of September 30, 2023, based on the September 30, 2023, closing stock price of $0.20, was $0.00.

 

The following table summarizes information concerning options and warrants outstanding and exercisable:

 

   Stock Options   Warrants         
   Weighted Average   Weighted Average   Total 
   Shares   price per share   Shares   price per share   Shares   Exercisable 
Balance outstanding, December 31, 2022   1,307,822   $0.72    16,278,769   $3.50    17,586,591    17,570,591 
Granted   2,230,484    1.50    100,000    3.50    2,330,484      
Exercised   (117,552)   0.69    -    -    (117,552)     
Expired   -    -    (645,829)   3.50    (645,829)     
Forfeited   -    -    -    -    -      
Balance outstanding, September 30, 2023   3,420,754   $1.23    15,732,940   $3.50    19,153,694    18,289,721 

 

As of September 30, 2023, the 3,420,754 options outstanding have a $1.23 weighted average exercise price and 8.14 years of weighted average remaining life for outstanding options and 7.75 years of weighted average remaining life for exercisable options. Of these options, 2,556,781 are currently exercisable.

 

On April 13, 2023, the Board authorized a 3-year extension of common stock warrants held by Series AA preferred shares holders. Therefore, 8,897,603 warrants were extended with new expiration dates between May 2, 2026 to September 14, 2029. Based on a fair value computation, this extension resulted in net incremental expense of $3,626,950, which was booked as an increase in the value of warrants and an increase of the retained deficit.

 

 

As of September 30, 2023, the warrants outstanding have a $3.50 weighted average exercise price and a 2.42 year weighted average remaining life.

 

Common Stock and Warrant Issuances

 

During the nine months ended September 30, 2023, the Company accrued approximately $3,715,204  in interest expense for these obligations to issue common stock. During the nine months ended September 30, 2022, the Company accrued $634,305 in interest expense for these obligations to issue common stock.

 

During the nine months ended September 30, 2023 the Company issued a total of 9,717,035 shares of restricted common stock and to accredited investors and consultants, with the following detail:

 

  4,094,121 shares of common stock with a fair value of $3,715,204 to lenders for interest paid-in-kind;
  1,630,500 shares with a fair value of $1,917,036 for services rendered;
  203,613 shares with a fair value of $509,033 for conversions of debt principal and interest;
  117,552 shares for stock option exercises (at an exercise price of $0.69 per share);
  142,767 shares with a fair value of $162,528 for dividends paid-in-kind;
  1,258,742 shares with a fair value of $1,293,270 for common stock issued with convertible debt;
  1,346,800 shares with a fair value of $1,671,573 for convertible debt extensions;
  60,000 shares with a fair value of $150,000 for sale of common, and
  1,486,940 shares for the conversion of preferred stock to common stock.

 

During the nine months ended September 30, 2023, the Company issued 100,000 warrants (four-year term at a $3.50 exercise price) to acquire common stock at a fair value of $61,609 to a consultant for professional services.

 

During the nine months ended September 30, 2022, we issued 3,100,085 shares of restricted common stock to accredited investors and consultants, 140,200 shares with a fair value of $350,500 for conversions of debt principal and interest for common stock, 1,172,100 of the shares with a fair value of $2,196,278 were issued for interest paid-in-kind, 190,500 of the shares with a fair value of $312,875 were issued for services rendered,170,306 shares with a fair value of $306,333 for dividends paid-in-kind, 368,500 shares with a fair value $512,593 for new convertible debt issuances, 25,279 shares with a fair value of $17,433 from a stock option exercise, 1,028,800 shares with a fair value of $1,714,678 for debt extension and shareholders converted shares of series AA convertible preferred stock into 4,400 shares of common stock

 

During the nine months ended September 30, 2022, we issued 277,500 warrants (three-year to five-year terms at a $3.50 exercise price) to acquire common stock at a total fair value of $280,608 to a lender in conjunction with the signing of new convertible loans, a vendor for services rendered and for debt extension.

 

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events

7) Subsequent Events

 

From October 1, 2023, through November 10, 2023, the Company issued seven (7) convertible loan with a principal balance of $439,000. The terms of the convertible notes were 15 days to 12 months with interest rates of 10-120% and convertible into the Company’s common stock at a fixed rate of $2.50 per share. In this time the Company also issued 278,500 shares of common stock for new convertible debt loans in the third quarter, 455,350 shares of common stock for accrued interest paid-in-kind, 310,000 shares of common stock for debt extensions, 505,000 shares of common stock from the conversion of Series BB preferred stock, 145,809 shares of common stock for Series AA preferred dividends and 40 Series BB preferred stock for professional services.

 

On October 18, 2023, the Board of Directors (the “Board”) of Pressure BioSciences, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Pressure BioSciences, Inc. 2021 Equity Incentive Plan (the “Plan”). The Plan originally provided that no one person could be granted awards pursuant to the Plan during any one fiscal year to purchase more than 300,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). Pursuant to the amendment, the yearly limit for any one person was raised to 500,000 shares of Common Stock.

 

On the same date, the Board granted a total of 1,500,000 stock options to a number of employees, consultants and the four members of the Board with each option having an exercise price of $0.25 per share. Each award of options expires on October 18, 2033. The options for the members of the Board vest in equal amounts over twelve (12) months. The options for Mr. Schumacher and Drs. Ting and Lazarev were each vested 25% on the date of issuance and 25% of the options vest each year for the next three (3) years.

 

In addition, on the same date, the Board approved the repricing of all outstanding options (including those held by the Board members and the named executive officers) to $0.25. The previous exercise prices of the outstanding stock options held by the Board members and the named executive officers ranged from $0.69 to $1.50.

 

 

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. Such statements include, without limitation, statements regarding:

 

  our need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all;
  our need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient additional financing;
  our belief that we will have sufficient liquidity to finance normal operations for the foreseeable future;
  the options we may pursue in light of our financial condition;
  the potential applications for Ultra Shear Technology (UST);
  the potential applications of the BaroFold high-pressure protein refolding and disaggregation technology
  the amount of cash necessary to operate our business;
  the anticipated uses of grant revenue and the potential for increased grant revenue in future periods;
  our plans and expectations with respect to our continued operations;
  the expected number of Pressure Cycling Technology (“PCT”) and Constant Pressure (“CP”) based units that we believe will be installed and the expected revenues from the sale of consumable products, extended service contracts, and biopharma contract services;
  our belief that PCT has achieved initial market acceptance in the mass spectrometry and other markets;
  the expected development and success of new instrument and consumables product offerings;
  the potential applications for our instrument and consumables product offerings;
  the expected expenses of, and benefits and results from, our research and development efforts;
  the expected benefits and results from our collaboration programs, strategic alliances and joint ventures;
  our expectations of the results of our development activities funded by government research grants;
  the potential size of the market for biological sample preparation, biopharma contract services and Ultra Shear Technology;
  general economic conditions;
  the anticipated future financial performance and business operations of our company;
  our reasons for resources expended in the market for genomic, proteomic, lipidomic and small molecule sample preparation;
  the importance of mass spectrometry as a laboratory tool;
  the advantages of PCT over other current technologies as a method of biological sample preparation and protein characterization in biomarker discovery, forensics, and histology, as well as for other applications;
  the capabilities and benefits of our PCT Sample Preparation System, consumables and other products;
  our belief that laboratory scientists will achieve results comparable with those reported to date by certain research scientists who have published or presented publicly on PCT and our other products and services;
  our ability to retain our core group of scientific, administrative and sales personnel; and
  our ability to expand our customer base in sample preparation and for other applications of PCT, as well as for our other products and services in both the BaroFold and Ultra Shear Technology areas.

 

These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 and in this Report. We qualify all of our forward-looking statements by these cautionary statements.

 

 

Pressure BioSciences, Inc. (OTCQB: PBIO) (the “Company”) is a leader in the development & sale of innovative, enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”), (ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)

 

The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.

 

The UST Platform (8 issued patents) is based on the use of intense shear forces from ultra-high pressure discharge (greater than 20,000 psi) through a dynamically-controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company began early commercial introduction of the UST Platform in May 2022, and executed agreements were subsequently announced with three CBD companies and one cosmeceutical/skincare company for commercialization in Q4 2022.

 

The BaroFold Platform (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high-pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.

 

The PCT Platform (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus for PCT is on making our, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. We currently have over 350 PCT Systems placed in approximately 225 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific research & clinical laboratories.

 

2023 Key Accomplishments

 

From January 1, 2023 to September 30, 2023, we announced the following key accomplishments:

 

September 22: PBIO’s partner Veterans Service Team increases existing purchase order by 10X for bottles of UltraShear Nano-CBD topical spray, effective immediately.
September 21: PBIO’s fulfillment of UltraShear Nano-CBD orders is underway; customer shipments begin first week of October
September 8: PBIO’s Barofold technology achieves pivotal equipment sale and begins scale-up in service to leading global contract development and manufacturing organization.
August 30: PBIO provides second progress report on UltraShear Nano-CBD Launch: “Drive to 420”.
August 22: PBIO reports Q22023 financial results, provides business update, and offers guidance.
August 9: PBIO reports strongly accelerating UltraShear Nano-CBD orders.
July 26: PBIO and master distributor Canopy CBD Farms announce major increase in sales pipeline.
July 25: PBIO to evaluate Company’s patented UltraShear process to extend shelf-life of fresh produce.
July 17: Company’s UltraShear Nano-CBD commercial roll-out program enters rapid expansion phase 2.
July 10: Company announces Nano-CBD topical spray distribution agreement with Crème de Canna.
July 6: Key academic publication further validates PBIO’s UltraShear platforms’ impact in clean-label foods.

 

 

July 5: PBIO partners with Somalab Int’l for development & distribution of UltraShear-enabled health products.
June 13: PBIO partners with Veterans Service Team to offer exclusive access for VST members to Nano-CBD.
June 1: PBIO expands on six key goals for June 2023 with expected multi-million-dollar growth potential.
May 22: Commercial availability of Best-in-Class Nano-CBD topical spray with lightning-fast action announced.
May 16: PBIO announces Q1 2023 financial results: all-time quarterly record revenue.
May 9: Extended consumer testing strongly validates market transforming speed and dosing efficiency of PBIO’s UltraShear processed nano-THC oral spray.
April 26: PBIO updates rapid progress on potential sales of exclusive THC licenses.
April 21, 2023: PBIO unveils powerful THC market leapfrog opportunity with exclusive licensing of UltraShear nanoemulsion processing platform.
April 18: PBIO announces expansion into strategic manufacturing facilities with premier process tech company.
April 14: PBIO reports Q4 and FY 2022 financial results – offers guidance for a strong 2023.
April 6, 2023: PBIO and NutraLife Biosciences renew partnership for development and distribution of next generation nutraceuticals.
March 28: Company reports fresh sales momentum for PBI Agrochem.
March 22: PBIO receives $1.5 million contract for UltraShear nanoemulsified CBD.
March 1: Company announces the exchange of over $10 million of debt into equity.
February 1: Company receives record order (nearly $600,000) for 16 PCT instruments.
January 27: PBIO and One World Products partner to develop CBD-Nano sports performance/recovery drink.
January 19: Dramatic consumer testing results confirm UltraShear nanoemulsion oral spray delivers first effects and maximization in lightning speed – simple, reliable dosing delivers profoundly improved results.

 

Results of Operations

 

The following disclosure compares the results of operations for the quarter ended September 30, 2023 (“Q2 2023”) with September 30, 2022 (“Q2 2022”) and compares the nine months ended September 30, 2023 with September 30, 2022.

 

Products and Services Revenue

 

We recognized total revenue of $413,009 for Q3 2023 compared to $144,032 for Q3 2022, a 187% increase. For the year-to-date periods ending September 30, 2023 and September 30, 2022, we recognized revenue of $1,665,412 and $1,122,169 respectively, a 48% increase.

 

This increase in revenue was primarily attributable to a $506,828 increase in PCT instrumentation and consumable sales, a $30,295 increase in technical support services and an $87,378 increase in Agrochem products, offset by a decrease of $89,350 in scientific services.

 

Cost of Products and Services

 

The cost of products and services was $229,457 for Q3 2023 compared to $126,203 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022 our cost of products and services were $844,684 and $742,707, respectively. Gross profit margin on products and services increased to 49% in the year-to-date period ended September 30, 2023 from 34% in the same period ended September 30, 2022. The increase in gross profit margin was attributable to $180,670 of Agrochem products sold in 2023 at no cost due to 2022 inventory write-off and a $79,901 instrument non-monetary exchange sale in 2022 was recorded at no profit.

 

Research and Development

 

Research and development expenses were $288,345 for Q3 2023 compared to $262,370 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $1,004,437 and $716,685, respectively, a 40% increase. The reported increase was due to a $71,777 reclass of salaries to COGS for a non-monetary instrument exchange in 2022 and $241,585 of stock-based compensation expense for employee stock options issued in 2023.

 

 

Selling and Marketing

 

Selling and marketing expenses were $157,773 for Q3 2023 compared to $226,526 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $537,802 and $422,422, respectively a 27% increase The reported increase was primarily attributable to the hiring of a Marketing FTE in Q2 2023 and $102,675 of stock-based compensation expense for employee stock options issued in 2023.

 

General and Administrative

 

General and administrative expenses were $1,030,244 for Q3 2023 compared to $892,293 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $5,290,564 and $2,591,644, respectively, a 104% increase. The increase was primarily due to approximately $2.0  million common stock and warrants issued for services, approximately $1.3 million of stock-based compensation expense for employee, BOD and financial consultant stock options issued in 2023, and approximately $132,000 of financial consulting expenses in 2023, offset by an approximately $423,000 decrease in IR expenses.

 

Operating Loss

 

Operating loss was $1,292,809 for Q3 2023 compared to $1,363,360 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, the operating loss was $6,012,075 and $3,551,289 respectively, a 79% increase. This increase was primarily due to $2.0 millions in common stock and warrants issued for services and $1.7 million of stock-based compensation expense for employee, BOD financial consultant stock options issued in 2023, offset by an approximate $423,000 decrease in IR expenses.

 

Interest Expense, net

 

Interest expense was $4,338,759 for Q3 2023 compared to $2,034,021 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $14,112,098 and $6,448,771, respectively, a 119% increase. This increase was attributable to an increase in convertible debt and merchant cash loans, in addition to stock issuances for interest paid in kind and stock issued for debt extensions.

 

Unrealized gain on investment in equity securities

 

Unrealized loss on investments in equity securities was $5,965 for Q3 2023 compared to an unrealized loss of $8,675 for Q3 2022. For the nine months ended September 30, 2023, the unrealized gain on investment in equity securities was $14,280 as compared to an unrealized loss of $8,047 for the nine months ended September 30, 2022. The reported change was attributable to movement in the market price of the Company’s investment in Nexity.

 

Loss on extinguishment of liabilities

 

In connection with debt extensions and forgiveness, we recognized a net gain of $0 for Q3 2023 compared to $1,054,122 of losses for Q3 2022. For the nine months ended September 30, 2023 the recognized net gain of $687,591 as compared to a net loss of $1,809,249 for the nine months ended September 30, 2022. The increase/decline in gains/losses was attributable to decreased extension and forgiveness activity.

 

Net loss attributable to common stockholders

 

Net loss attributable to common stockholders was $6,261,999 ($0.29 per share) for Q3 2023 compared to $4,893,946 ($0.44 per share) for Q3 2022. For the nine months ended September 30, 2023, the net loss attributable to common stock was $24,666,565 ($1.21 per share) as compared to $12,913,826 ($1.24 per share).

 

Liquidity and Financial Condition

 

We have experienced negative cash flows from operations since our inception. As of September 30, 2023, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have substantial doubt regarding our ability to continue as a going concern. As described in Notes 5 and 6 of the accompanying consolidated financial statements, we have been successful in raising debt and equity capital. We received approximately $6.5 million  in net proceeds from loans in the nine months ended September 30, 2023. We have efforts in place to continue to raise cash through debt and equity offerings. (See Note 7 to the financial statements)

 

 

We will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects.

 

Net cash used in operations for the nine months ended September 30, 2023 was $2,053,823  as compared to $3,051,257 for the nine months ended September 30, 2022.

 

Net cash used in investing activities for the nine months ended September 30, 2023 was $7,495 compared to $20,754 in the nine months ended September 30, 2022.

 

Net cash provided by financing activities for the nine months ended September 30, 2023 was $2,062,716 as compared to $3,170,580 for the nine months ended September 30, 2022.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

This Item 3 is not applicable to us as a smaller reporting company and has been omitted.

 

ITEM 4. CONTROLS AND PROCEDURES

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 filings are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

As of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective.

 

Our conclusion that our disclosure controls and procedures were not effective as of September 30, 2023 is due to the continued presence of the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended December 31, 2022. These material weaknesses are the following:

 

  We identified a lack of sufficient segregation of duties. Specifically, this material weakness is such that the design over these areas relies primarily on detective controls and could be strengthened by adding preventative controls to properly safeguard Company assets.
     
  Management has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training, and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles, particularly as it relates to valuation of warrants and other complex debt /equity transactions. Specifically, this material weakness resulted in audit adjustments to the annual consolidated financial statements and revisions to related disclosures, valuation of warrants and other equity transactions.
     
  Limited policies and procedures that cover recording and reporting of financial transactions.
     
  Lack of multiple levels of review over the financial reporting process

 

 

We continue to plan to remediate those material weaknesses as follows:

 

  Improve the effectiveness of the accounting group by augmenting our existing resources with additional consultants or employees to assist in the analysis and recording of complex accounting transactions, and to simultaneously achieve desired organizational structuring for improved segregation of duties. We plan to mitigate this identified deficiency by hiring an independent consultant once we generate significantly more revenue or raise significant additional working capital.
     
  Improve expert review and achieve desired segregation procedures by strengthening cross approval of various functions including quarterly internal audit procedures where appropriate once we generate significantly more revenue or raise significantly more working capital.

 

During the period covered by this Report, we implemented and performed additional substantive procedures, such as supervisory review of work papers and consistent use of financial models used in equity valuations, to ensure our consolidated financial statements as of and for the six-month period ended September 30, 2023, are fairly stated in all material respects in accordance with GAAP. We have not, however, been able to fully remediate the material weaknesses due to our limited financial resources. Our remediation efforts are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Except as described above, there have been no changes in our internal controls over financial reporting that occurred during the period ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors

 

Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2022 and, in this Item, 1A. The risks described in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks occur, our business, results of operations, cash flows or financial condition could suffer.

 

There have been no material changes to the risk factors set forth in Item 1A of our 10-K for the year ended December 31, 2022.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Except where noted, all the securities discussed in this Part II, Item 2 were issued in reliance on the exemption under Section 4(a)(2) of the Securities Act.

 

On various dates in the nine months ended September 30, 2023 the Company issued a total of 9,917,035  of its common shares, 953 shares of Series BB preferred stock and 401 shares of Series CC preferred stock as follows:

 

117,552 shares from option exercises;
1,630,500 shares for professional services;
1,346,800 shares for debt extensions;
203,613 shares for conversion of debt and interest;

 

 

142,767 shares for dividends paid-in-kind;
4,094,121 shares for interest paid-in-kind;
1,258,742 shares for shares issued with debt;
60,000 shares from sale of common shares;
95 shares of Series BB preferred stock was converted to common stock;
92 shares of Series BB preferred stock for professional services;
741 shares of Series BB preferred stock for debt extensions;
58 shares of Series BB preferred stock issued with debt;
401 shares of Series CC preferred stock for conversion of debt/accrued interest and dividends, and
62 shares of Series BB preferred stock for the conversion of common stock.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibits    
     
21.1*  

Securities Issuance and Exchange Agreement

 

31.1*   Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
     
31.2*   Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))
     
32.1**   Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
     
32.2**   Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
     
101.INS*   Inline XBRL Instance Document
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

** In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are furnished and not filed.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  PRESSURE BIOSCIENCES, INC.
     
Date: November 20, 2023 By:  /s/ Richard T. Schumacher
    Richard T. Schumacher
    President & Chief Executive Officer
    (Principal Executive Officer and Principal Financial Officer)

 

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023.

 

Use of Estimates

Use of Estimates

 

The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $2,728,243 decrease in additional paid in capital and a $2,255,216 decrease in accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption of ASU 2020-06.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down.

 

Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

 

 

Revenue Recognition

Revenue Recognition

 

We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, and ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period. We measure and allocate revenue according to ASC 606-10.

 

We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.

 

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.

 

Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.

 

Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.

 

Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components.

 

Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.

 

We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:

 

  a) The fair value of the asset or service involved is not determinable.
     
  b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange.
     
  c) The transaction lacks commercial substance.

 

We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.

 

 

We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases.

 

Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.

 

Disaggregation of revenue

 

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

 

In thousands of US dollars ($)  Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Primary geographical markets  2023   2022   2023   2022 
North America  $251   $138   $1,067   $709 
Europe   76    13    130    61 
Asia   86    (7)   468    352 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Major products/services lines  2023   2022   2023   2022 
Hardware  $273   $1   $994   $532 
Consumables   50    49    173    165 
Contract research services   -1    -    35    125 
Sample preparation accessories   31    41    113    93 
Technical support/extended service contracts   34    41    123    94 
                     
Agrochem Products   15    10    181    93 
Shipping and handling   11    2    38    20 
Other   -    -    8    - 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Timing of revenue recognition  2023   2022   2023   2022 
Products transferred at a point in time  $379   $103   $1,506   $903 
Services transferred over time   34    41    159    219 
   $413   $144   $1,665   $1,122 

 

Contract balances

 

In thousands of US dollars ($) 

September 30,

2023

  

December 31,

2022

 
Receivables, which are included in ‘Accounts Receivable’  $329   $295 
Contract liabilities (deferred revenue)   59    60 

 

 

Transaction price allocated to the remaining performance obligations

 

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

 

In thousands of US dollars ($)  2023   2024   Total 
Extended warranty service  $48   $11   $59 

 

All consideration from contracts with customers is included in the amounts presented above.

 

Contract Costs

 

The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.

 

Concentrations

Concentrations

 

Credit Risk

 

Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.

 

The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.

 

   Three Months Ended
September 30,
   Nine months Ended
September 30,
 
   2023   2022   2023   2022 
Top five customers   80%   42%   49%   31%
Federal agencies   18%   4%   5%   1%

 

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.

 

   September 30,
2023
   December 31,
2022
 
Top five customers   80%   93%
Federal agencies   22%   0%

 

Product Supply

Product Supply

 

In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were:

 

  CNC Machining
  Contract Assembly & Kitting
  Component and Subassembly Design
  Inventory Management
  ISO certification

 

 

Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location.

 

We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.

 

Investment in Equity Securities

Investment in Equity Securities

 

As of September 30, 2023, we held 100,250 shares of common stock of Nexity Global SA, (a Polish publicly traded company).

 

We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.

 

As of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $77,918. We recorded $14,280 as an unrealized gain during the nine months ended September 30, 2023 for changes in market value.

 

Computation of Loss per Share

Computation of Loss per Share

 

Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.

 

The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:

 

   2023   2022   2023   2022 
   For the Three Months Ended September 30,   For the Nine months Ended September 30, 
   2023   2022   2023   2022 
Numerator:                    
Net loss attributable to common shareholders  $(6,261,999)  $(4,893,946)  $(24,666,565)  $(12,913,826)
Denominator for basic and diluted loss per share:                    
Weighted average common stock shares outstanding   21,716,950    11,131,742    20,337,229    10,429,817 
Loss per common share - basic and diluted  $(0.29)  $(0.44)  $(1.21)  $(1.24)

 

 

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms.

 

   As of September 30, 
   2023   2022 
Stock options   3,420,754    1,307,822 
Convertible debt   7,417,906    6,471,034 
Common stock warrants   15,732,940    16,293,768 
Convertible preferred stock:          
Series D Convertible Preferred Stock   6,250    25,000 
Series G Convertible Preferred Stock   -    26,857 
Series H Convertible Preferred Stock   -    33,334 
Series H2 Convertible Preferred Stock   -    70,000 
Series J Convertible Preferred Stock   -    115,267 
Series K Convertible Preferred Stock   -    229,334 
Series AA Convertible Preferred Stock   8,601,000    8,645,000 
Series BB Convertible Preferred Stock   8,580,000    - 
Series CC Convertible Preferred Stock   4,010,000    - 
    47,768,850    33,217,416 

 

Accounting for Stock-Based Compensation Expense

Accounting for Stock-Based Compensation Expense

 

We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.

 

Determining Fair Value of Stock Option Grants

 

The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023:

 

Assumptions  CEO, other Officers and Employees 
Expected life   6.0 (yrs) 
Expected volatility   130.5%
Risk-free interest rate   3.90%
Forfeiture rate   0 to 5.00%
Expected dividend yield   0.0%

 

Valuation and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.

 

Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

 

Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.

 

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

 

Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 0% to 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense.

 

All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance.

 

The Company recognized stock-based compensation expense of $140,622 and $32,427 for the three months ended September 30, 2023 and 2022, respectively. The company recognized stock-based compensation expense of $1,706,420 and $128,984 for the nine months ended September 30, 2023 and 2022, respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations:

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Cost of sales  $11,183   $2,184   $75,724   $8,694 
Research and development   35,676    9,499    241,585    37,803 
Selling and marketing   17,150    4,583    102,675    18,166 
General and administrative   76,613    16,161    1,286,436    64,321 
Total stock-based compensation expense  $140,622   $32,427   $1,706,420   $128,984 

 

Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.

 

Fair Value Measurements

Fair Value Measurements

 

The Company follows the guidance of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”) as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.

 

The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement.

 

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.

 

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023:

 

      

Fair value measurements at

September 30, 2023 using:

 
   September 30, 2023  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities  $77,918   $77,918           -            - 
Total Financial Assets  $77,918   $77,918   $-   $- 

 

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:

 

      

Fair value measurements at

December 31, 2022 using:

 
  

December 31,

2022

  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities   63,638    63,638           -             - 
Total Financial Assets  $63,638   $63,638   $-   $- 

 

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Disaggregation of Revenue

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

 

In thousands of US dollars ($)  Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Primary geographical markets  2023   2022   2023   2022 
North America  $251   $138   $1,067   $709 
Europe   76    13    130    61 
Asia   86    (7)   468    352 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Major products/services lines  2023   2022   2023   2022 
Hardware  $273   $1   $994   $532 
Consumables   50    49    173    165 
Contract research services   -1    -    35    125 
Sample preparation accessories   31    41    113    93 
Technical support/extended service contracts   34    41    123    94 
                     
Agrochem Products   15    10    181    93 
Shipping and handling   11    2    38    20 
Other   -    -    8    - 
   $413   $144   $1,665   $1,122 

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Timing of revenue recognition  2023   2022   2023   2022 
Products transferred at a point in time  $379   $103   $1,506   $903 
Services transferred over time   34    41    159    219 
   $413   $144   $1,665   $1,122 
Schedule of Contract Balances

Contract balances

 

In thousands of US dollars ($) 

September 30,

2023

  

December 31,

2022

 
Receivables, which are included in ‘Accounts Receivable’  $329   $295 
Contract liabilities (deferred revenue)   59    60 
Schedule of Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

 

In thousands of US dollars ($)  2023   2024   Total 
Extended warranty service  $48   $11   $59 
Schedule of Customer Concentration Risk Percentage

The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.

 

   Three Months Ended
September 30,
   Nine months Ended
September 30,
 
   2023   2022   2023   2022 
Top five customers   80%   42%   49%   31%
Federal agencies   18%   4%   5%   1%

 

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.

 

   September 30,
2023
   December 31,
2022
 
Top five customers   80%   93%
Federal agencies   22%   0%
Schedule of Computation of Loss Per Share

The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:

 

   2023   2022   2023   2022 
   For the Three Months Ended September 30,   For the Nine months Ended September 30, 
   2023   2022   2023   2022 
Numerator:                    
Net loss attributable to common shareholders  $(6,261,999)  $(4,893,946)  $(24,666,565)  $(12,913,826)
Denominator for basic and diluted loss per share:                    
Weighted average common stock shares outstanding   21,716,950    11,131,742    20,337,229    10,429,817 
Loss per common share - basic and diluted  $(0.29)  $(0.44)  $(1.21)  $(1.24)
Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share

 

   As of September 30, 
   2023   2022 
Stock options   3,420,754    1,307,822 
Convertible debt   7,417,906    6,471,034 
Common stock warrants   15,732,940    16,293,768 
Convertible preferred stock:          
Series D Convertible Preferred Stock   6,250    25,000 
Series G Convertible Preferred Stock   -    26,857 
Series H Convertible Preferred Stock   -    33,334 
Series H2 Convertible Preferred Stock   -    70,000 
Series J Convertible Preferred Stock   -    115,267 
Series K Convertible Preferred Stock   -    229,334 
Series AA Convertible Preferred Stock   8,601,000    8,645,000 
Series BB Convertible Preferred Stock   8,580,000    - 
Series CC Convertible Preferred Stock   4,010,000    - 
    47,768,850    33,217,416 
Summary of Assumptions for Grants of Stock Options

The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023:

 

Assumptions  CEO, other Officers and Employees 
Expected life   6.0 (yrs) 
Expected volatility   130.5%
Risk-free interest rate   3.90%
Forfeiture rate   0 to 5.00%
Expected dividend yield   0.0%

Schedule of Stock Based Compensation Expense

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Cost of sales  $11,183   $2,184   $75,724   $8,694 
Research and development   35,676    9,499    241,585    37,803 
Selling and marketing   17,150    4,583    102,675    18,166 
General and administrative   76,613    16,161    1,286,436    64,321 
Total stock-based compensation expense  $140,622   $32,427   $1,706,420   $128,984 
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023:

 

      

Fair value measurements at

September 30, 2023 using:

 
   September 30, 2023  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities  $77,918   $77,918           -            - 
Total Financial Assets  $77,918   $77,918   $-   $- 

 

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:

 

      

Fair value measurements at

December 31, 2022 using:

 
  

December 31,

2022

  

Quoted

prices in

active

markets

(Level 1)

  

Significant

other

observable

inputs

(Level 2)

  

Significant

unobservable

inputs

(Level 3)

 
Equity Securities   63,638    63,638           -             - 
Total Financial Assets  $63,638   $63,638   $-   $- 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Rental Payments Required Under Operating Leases

Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2023:

 

Year  Total 
October 1 – December 31, 2023  $15,887 
2024   64,393 
2025   66,969 
2026   51,778 
Total future undiscounted lease payments   199,027 
Less imputed interest   (61,481)
Present value of lease liabilities  $137,546 
Schedule of Right of Use Asset and the Corresponding Lease Liability

Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:

 

Operating Leases  September 30, 2023   December 31, 2022 
Right of use asset  $159,424   $282,095 
Right of use liability, current  $66,259   $142,171 
Right of use liability, long term  $71,287   $139,924 
Total lease liability  $137,546   $282,095 
Schedule of Lease Cost for Operating Leases

The components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:

 

   September 30, 2023   September 30, 2022 
Operating lease cost  $153,290   $152,193 
Short-term lease cost   110,205    123,514 
Total lease cost  $263,495   $275,707 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Debt (Tables)
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Convertible Debts and Outstanding Balances

 

   September 30, 2023   December 31, 2022 
Holders  Interest
Rate
   Conversion
Price
   Principal   Interest
Rate
   Conversion
Price
   Principal 
Main Investor   10%  $2.50 (1)   $8,586,750    10%  $2.50 (1)  $9,393,150 
Others   0 to 24%  $2.50 (2) or $7.50    10,379,763    0 to 24%  $2.50 (2) or $7.50
   8,886,036 
Totals             -               18,279,186 
Discount             744,393              455,517 
Net            $18,222,120             $17,823,669 

 

Notes:

 

(1)Conversion price of these note is $2.50 except for a note for $189,750, which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25% discount to the 5-day average VWAP of the stock prior to default and $729,100 lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company.
   
(2)Conversion price of these notes is $2.50 but also varies with one or more of these notes having the following conversion adjustment:

 

a.Notes are convertible before maturity at $2.50 per share or mandatorily convertible when the Company up-lists to the NASDAQ at the lower of $2.50 or the up-list price.

 

 

b.Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.
c.Notes are convertible at $2.50 per share except that following an Event of Default the conversion price will be adjusted to 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.
d.Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted at lower of 1) $2.50/share; 2) 30% discount to 5-day VWAP prior to date of default.
e.Notes can be voluntary converted at lower of 1) $2.50/share; or 2) purchase price of stock sold by PBI at a price lower than $2.50/share. In the event of default, these notes can be converted at lower of 1) $2.50/share; 2) 25% discount to 5-day VWAP prior to date of default.
f.Conversion price is lower of (i) $2.50 or (ii) the price per share that the Company last sold Common Stock after the execution of an anti-dilution protection agreement.
g.Note can be converted at a Voluntary Conversion Price which is the lower of 1) $2.50/share; or 2) purchase price of stock sold by the Company at a price lower than $2.50 except that following an Event of Default, the Holder shall have the right, with no further consent from the Borrower, to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) 70% of the 5-day VWAP prior to conversion.
h.Conversion price is $2.50. If note is in default, it is $1.
i.Notes can be voluntarily converted before maturity at $2.50 per share. Lender retains the option upon an Up-list to convert at the lower of $2.50 or 10% off Up-list price.
j.Notes can be converted at the lesser of $2.5 per share or 25% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of (i) original conversion price or (ii) a 35% discount to the VWAP prior to each conversion date.
k.Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $950,000 as of September 30, 2023 is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion.
l.Some notes can be converted at the lesser of $2.50 per share or 25% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of original conversion price or the product of the VWAP of the common stock for the 5 trading dates immediately prior to the maturity date multiplied by 0.75.
Schedule of Other Debt

 

   September 30, 2023   December 31, 2022 
Holders  Interest Rate   Principal   Interest Rate   Principal 
Non-Convertible   (1)  $1,016,500    (1)  $878,809 
Merchant debt (3)        1,014,010         760,160 
SBA (2)   3.75%   162,522    3.75%   150,000 
Totals        2,193,032        $1,788,969 
Discount        -         - 
Long Term        162,522         150,000 
Short Term       $2,030,510        $1,638,969 

 

Notes:

 

(1)Interest varies from 1% to 10%. The maturity is between being past due and May 2, 2023. As of September 30, 2023, $861,500 of the non-convertible debt is past due.
(2)The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $150,000, accrues interest at 3.75% and requires monthly payments of $731 for principal and interest beginning in December 2022. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the nine months ended September 30, 2023, $14,719 interest was deferred and added to principal on EIDL loan and the Company repaid $2,197 principal on this loan. During the year ended December 31, 2020, the Company borrowed $367,039 (two-year term and 1% interest rate per annum) under the Payroll Protection program (or “2020 PPP”). During the year ended December 31, 2021, the Company borrowed $367,039 through a second Payroll Protection program (or “2021 PPP”) and extended the monthly payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven by the United States and SBA.
(3)During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1% - 100.9% per month. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. The Company’s Chief Executive Officer guarantees the Company’s performance of all representations, warranties, and covenants made by the Company in the Agreement. For loans outstanding on September 30, 2023, the maturity dates ranged from June 26, 2023 to October 15, 2023. For loan outstanding on December 31, 2022, the maturity dates ranged from April 4 to June 6, 2023.
Schedule of Related Party Debt

 

   September 30, 2023   December 31, 2022 
Holders  Interest Rate   Principal   Interest Rate   Principal   Security 
Officers & Directors   -(1)  $522,450    -(1)  $521,950    Unsecured 
Other Related Parties   12%   126,050    12%   120,850    Unsecured 
Totals        648,500         642,800      
Discount        514         7,915      
Net       $647,986        $634,885      

 

Notes:

 

(1)Interest varies from 12% to 120%.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders’ Deficit (Tables)
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Preferred Stock Outstanding

 

   September 30, 2023   December 31, 2022 
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 75 shares issued and outstanding on September 30, 2023, and 300 shares issued and outstanding on December 31, 2022 (Liquidation value of $300,000)  $-   $3 
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 80,570 shares issued and outstanding on December 31, 2022   -    806 
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 10,000 shares issued and outstanding on December 31, 2022   -    100 
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; no shares issued and outstanding on September 30, 2023 and 3,458 shares issued and outstanding on December 31, 2022   -    35 
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; no shares issued and outstanding on September 30, 2023 and 6,880 shares issued and outstanding on December 31, 2022   -    68 
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 8,601 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively   86    86 
Series BB Convertible Preferred Stock, $.01 par value; 1,000 shares authorized; 858 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022   10    - 
Series CC Convertible Preferred Stock, $.01 par value; 2,000 shares authorized; 401 shares issued and outstanding on September 30, 2023 and no shares outstanding at December 31, 2022   4    - 
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; no shares issued and outstanding on September 30, 2023 and 21 shares issued and outstanding on December 31, 2022   -    - 
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding   -    - 
Series A Convertible Preferred Stock, $.01 par value, 313,960 shares authorized, no shares outstanding   -    - 
Series B Convertible Preferred Stock, $.01 par value, 279,256 shares authorized, no shares outstanding   -    - 
Series C Convertible Preferred Stock, $.01 par value, 88,098 shares authorized, no shares outstanding   -    - 
Series E Convertible Preferred Stock, $.01 par value, 500 shares authorized, no shares outstanding   -    - 
Total Convertible Preferred Shares  $100   $1,098 
Schedule of Concerning Options and Warrants Outstanding and Exercisable

The following table summarizes information concerning options and warrants outstanding and exercisable:

 

   Stock Options   Warrants         
   Weighted Average   Weighted Average   Total 
   Shares   price per share   Shares   price per share   Shares   Exercisable 
Balance outstanding, December 31, 2022   1,307,822   $0.72    16,278,769   $3.50    17,586,591    17,570,591 
Granted   2,230,484    1.50    100,000    3.50    2,330,484      
Exercised   (117,552)   0.69    -    -    (117,552)     
Expired   -    -    (645,829)   3.50    (645,829)     
Forfeited   -    -    -    -    -      
Balance outstanding, September 30, 2023   3,420,754   $1.23    15,732,940   $3.50    19,153,694    18,289,721 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Disaggregation of Revenue (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Product Information [Line Items]        
Revenue $ 413,009 $ 144,032 $ 1,665,412 $ 1,122,169
Hardware [Member]        
Product Information [Line Items]        
Revenue 273,000 1,000 994,000 532,000
Consumables [Member]        
Product Information [Line Items]        
Revenue 50,000 49,000 173,000 165,000
Contract Research Services [Member]        
Product Information [Line Items]        
Revenue (1,000) 35,000 125,000
Sample Preparation Accessories [Member]        
Product Information [Line Items]        
Revenue 31,000 41,000 113,000 93,000
Technical Support/Extended Service Contracts [Member]        
Product Information [Line Items]        
Revenue 34,000 41,000 123,000 94,000
Agrochem Products [Member]        
Product Information [Line Items]        
Revenue 15,000 10,000 181,000 93,000
Shipping and Handling [Member]        
Product Information [Line Items]        
Revenue 11,000 2,000 38,000 20,000
Other [Member]        
Product Information [Line Items]        
Revenue 8,000
Transferred at a Point In Time [Member]        
Product Information [Line Items]        
Revenue 379,000 103,000 1,506,000 903,000
Transferred Over At Time [Member]        
Product Information [Line Items]        
Revenue 34,000 41,000 159,000 219,000
North America [Member]        
Product Information [Line Items]        
Revenue 251,000 138,000 1,067,000 709,000
Europe [Member]        
Product Information [Line Items]        
Revenue 76,000 13,000 130,000 61,000
Asia [Member]        
Product Information [Line Items]        
Revenue $ 86,000 $ (7,000) $ 468,000 $ 352,000
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Contract Balances (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Receivables, which are included in ‘Accounts Receivable’ $ 329 $ 295
Contract liabilities (deferred revenue) $ 59 $ 60
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Future Related to Performance Obligations (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Extended warranty service $ 59
2023 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Extended warranty service 48
2024 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Extended warranty service $ 11
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Top Five Customers [Member] | Revenue Benchmark [Member]          
Product Information [Line Items]          
Concentration credit risk percentage 80.00% 42.00% 49.00% 31.00%  
Top Five Customers [Member] | Accounts Receivable [Member]          
Product Information [Line Items]          
Concentration credit risk percentage     80.00%   93.00%
Federal Agencies [Member] | Revenue Benchmark [Member]          
Product Information [Line Items]          
Concentration credit risk percentage 18.00% 4.00% 5.00% 1.00%  
Federal Agencies [Member] | Accounts Receivable [Member]          
Product Information [Line Items]          
Concentration credit risk percentage     22.00%   0.00%
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Computation of Loss Per Share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Accounting Policies [Abstract]        
Net loss attributable to common shareholders $ (6,261,999) $ (4,893,946) $ (24,666,565) $ (12,913,826)
Weighted average common stock shares outstanding basic 21,716,950 11,131,742 20,337,229 10,429,817
Weighted average common stock shares outstanding diluted 21,716,950 11,131,742 20,337,229 10,429,817
Loss per common share - basic $ (0.29) $ (0.44) $ (1.21) $ (1.24)
Loss per common share - diluted $ (0.29) $ (0.44) $ (1.21) $ (1.24)
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 47,768,850 33,217,416
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 3,420,754 1,307,822
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 7,417,906 6,471,034
Common Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 15,732,940 16,293,768
Series D Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 6,250 25,000
Series G Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 26,857
Series H Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 33,334
Series H2 Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 70,000
Series J Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 115,267
Series K Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 229,334
Series AA Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 8,601,000 8,645,000
Series BB Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 8,580,000
Series CC Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total potentially dilutive shares 4,010,000
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Assumptions for Grants of Stock Options (Details) - CEO, other Officers and Employees [Member]
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Line Items]  
Expected life 6 years
Expected volatility 130.50%
Risk-free interest rate 3.90%
Expected dividend yield 0.00%
Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Forfeiture rate 0.00%
Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Forfeiture rate 5.00%
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Stock Based Compensation Expense (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total stock-based compensation expense $ 140,622 $ 32,427 $ 1,706,420 $ 128,984
Cost of Sales [Member]        
Total stock-based compensation expense 11,183 2,184 75,724 8,694
Research and Development Expense [Member]        
Total stock-based compensation expense 35,676 9,499 241,585 37,803
Selling and Marketing Expense [Member]        
Total stock-based compensation expense 17,150 4,583 102,675 18,166
General and Administrative Expense [Member]        
Total stock-based compensation expense $ 76,613 $ 16,161 $ 1,286,436 $ 64,321
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Financing Receivable, Past Due [Line Items]    
Total Financial Assets $ 77,918 $ 63,638
Fair Value, Inputs, Level 1 [Member]    
Financing Receivable, Past Due [Line Items]    
Total Financial Assets 77,918 63,638
Fair Value, Inputs, Level 2 [Member]    
Financing Receivable, Past Due [Line Items]    
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]    
Financing Receivable, Past Due [Line Items]    
Total Financial Assets
Equity Securities [Member]    
Financing Receivable, Past Due [Line Items]    
Total Financial Assets 77,918 63,638
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Financing Receivable, Past Due [Line Items]    
Total Financial Assets 77,918 63,638
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Financing Receivable, Past Due [Line Items]    
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Financing Receivable, Past Due [Line Items]    
Total Financial Assets
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Aug. 30, 2020
Property, Plant and Equipment [Line Items]            
Cumulative effect of adoption, adjustment in additional paid in capital $ 93,973,646   $ 93,973,646   $ 69,006,145 $ 2,728,243
Cumulative effect of adoption, adjustment in accumulated deficit (158,492,770)   (158,492,770)   $ (133,826,205) $ 2,255,216
Stock-based compensation expense $ 140,622 $ 32,427 $ 1,706,420 $ 128,984    
Minimum [Member]            
Property, Plant and Equipment [Line Items]            
Forfeiture rate 0.00%   0.00%      
Maximum [Member]            
Property, Plant and Equipment [Line Items]            
Forfeiture rate 5.00%   5.00%      
Nexity Global SA [Member]            
Property, Plant and Equipment [Line Items]            
Sale of stock number of shares received     100,250      
Investment owned, at fair value $ 77,918   $ 77,918      
Unrealized gain     $ 14,280      
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
October 1 – December 31, 2023 $ 15,887  
2024 64,393  
2025 66,969  
2026 51,778  
Total future undiscounted lease payments 199,027  
Less imputed interest (61,481)  
Present value of lease liabilities $ 137,546 $ 282,095
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Right of Use Asset and the Corresponding Lease Liability (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Right of use asset $ 159,424 $ 282,095
Right of use liability, current 66,259 142,171
Right of use liability, long term 71,287 139,924
Total lease liability $ 137,546 $ 282,095
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Lease Cost for Operating Leases (Details) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]    
Operating lease cost $ 153,290 $ 152,193
Short-term lease cost 110,205 123,514
Total lease cost $ 263,495 $ 275,707
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 09, 2021
Apr. 30, 2012
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2022
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]                        
Operating lease liability     $ 137,546   $ 137,546             $ 282,095
Operating lease         $ 122,671 $ 82,001            
Weighted-average remaining lease term     2 years 7 months 2 days   2 years 7 months 2 days              
Weighted-average discount rate     12.00%   12.00%              
Expenses     $ 1,705,818 $ 1,507,392 $ 7,677,487 4,473,458            
Battelle Memorial Institute [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]                        
Mimimum royalty fee             $ 5,000 $ 4,000 $ 3,000 $ 2,000 $ 1,200  
Target Discovery Inc [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]                        
Mimimum royalty fee         60,000 60,000            
Payments for fees   $ 1,400                    
Professional and contract services expense   $ 2,000                    
Expenses         55,400 $ 65,100            
Medford lease [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]                        
Annual cost of living payment         $ 7,282              
Lessee operating lease description         The lease shall be automatically extended for additional three years unless either party terminates at least nine months prior to the expiration of the current lease term              
Operating lease liability     $ 221,432   $ 221,432              
Estimated borrowing rate     12.00%   12.00%              
Sparks lease [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]                        
Lessee operating lease description On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term                      
Operating lease liability     $ 239,327   $ 239,327              
Estimated borrowing rate     12.00%   12.00%              
Corporate Office [Member]                        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]                        
Lease monthly payments         $ 7,650              
Lease expiration date         Dec. 31, 2023              
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Conversion price $ 2.50  
Totals $ 18,279,186
Debt unamortized discount 744,393 455,517
Principal amount $ 18,222,120 $ 17,823,669
Investor [Member]    
Debt Instrument [Line Items]    
Interest Rate 10.00% 10.00%
Conversion price [1] $ 2.50 $ 2.50
Totals $ 8,586,750 $ 9,393,150
Others [Member]    
Debt Instrument [Line Items]    
Totals $ 10,379,763 $ 8,886,036
Others [Member] | Minimum [Member]    
Debt Instrument [Line Items]    
Interest Rate 0.00% 0.00%
Conversion price [2] $ 2.50 $ 2.50
Others [Member] | Maximum [Member]    
Debt Instrument [Line Items]    
Interest Rate 24.00% 24.00%
Conversion price $ 7.50 $ 7.50
[1] Conversion price of these note is $2.50 except for a note for $189,750, which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25% discount to the 5-day average VWAP of the stock prior to default and $729,100 lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company.
[2] Conversion price of these notes is $2.50 but also varies with one or more of these notes having the following conversion adjustment:
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)
9 Months Ended
Sep. 30, 2023
USD ($)
Integer
$ / shares
Short-Term Debt [Line Items]  
Debt instrument, convertible price per shares $ 2.50
Debt default amount | $ $ 1
Debt instrument, convertible, conversion price $ 2.50
Debt default convertible conversion ratio 75.00%
Debt instrument, convertible, conversion price, Increase $ 2.50
Debt instrument, convertible, conversion price, decrease $ 2.50
Percentage of price 10.00%
Convertible lesser per share $ 2.5
Convertible lesser Percent 25.00%
Original debt, interest rate of debt 35.00%
Principal balance | $ $ 12,300,000
Trading day | Integer 5
Chief Executive Officer [Member]  
Short-Term Debt [Line Items]  
Principal balance | $ $ 950,000
Convertible Debt [Member]  
Short-Term Debt [Line Items]  
Debt instrument, convertible price per shares $ 2.50
Debt default amount | $ $ 189,750
Debt instrument lowest trading price 25.00%
Convertible Debt [Member] | Series AA Preferred Stock [Member]  
Short-Term Debt [Line Items]  
Debt instrument, convertible price per shares $ 2.50
Convertible Debt [Member] | 5 Day Average VWAP [Member]  
Short-Term Debt [Line Items]  
Debt default amount | $ $ 729,100
Convertible Debt One [Member]  
Short-Term Debt [Line Items]  
Debt instrument, convertible price per shares $ 2.50
Convertible Debt Two [Member]  
Short-Term Debt [Line Items]  
Debt instrument lowest trading price 30.00%
Convertible Debt Three [Member]  
Short-Term Debt [Line Items]  
Debt instrument lowest trading price 25.00%
Convertible Debt Four [Member]  
Short-Term Debt [Line Items]  
Debt instrument lowest trading price 70.00%
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Other Debt (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Short-Term Debt [Line Items]    
Totals, Principal $ 2,193,032 $ 1,788,969
Long Term, discount
Long Term, Principal 162,522 150,000
Short Term, Principal $ 2,030,510 $ 1,638,969
Non Convertible [Member]    
Short-Term Debt [Line Items]    
Interest Rate [1]
Totals, Principal $ 1,016,500 $ 878,809
Merchant Debt [Member]    
Short-Term Debt [Line Items]    
Totals, Principal [2] $ 1,014,010 $ 760,160
SBA [Member]    
Short-Term Debt [Line Items]    
Interest Rate [3] 3.75% 3.75%
Totals, Principal [3] $ 162,522 $ 150,000
[1] Interest varies from 1% to 10%. The maturity is between being past due and May 2, 2023. As of September 30, 2023, $861,500 of the non-convertible debt is past due.
[2] During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1% - 100.9% per month. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. The Company’s Chief Executive Officer guarantees the Company’s performance of all representations, warranties, and covenants made by the Company in the Agreement. For loans outstanding on September 30, 2023, the maturity dates ranged from June 26, 2023 to October 15, 2023. For loan outstanding on December 31, 2022, the maturity dates ranged from April 4 to June 6, 2023.
[3] The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $150,000, accrues interest at 3.75% and requires monthly payments of $731 for principal and interest beginning in December 2022. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the nine months ended September 30, 2023, $14,719 interest was deferred and added to principal on EIDL loan and the Company repaid $2,197 principal on this loan. During the year ended December 31, 2020, the Company borrowed $367,039 (two-year term and 1% interest rate per annum) under the Payroll Protection program (or “2020 PPP”). During the year ended December 31, 2021, the Company borrowed $367,039 through a second Payroll Protection program (or “2021 PPP”) and extended the monthly payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven by the United States and SBA.
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Other Debt (Details) (Parenthetical) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]        
Debt instrument, maturity date May 02, 2023      
Non- convertible debt amount $ 861,500      
Note payable $ 150,000      
Accrued interest rate percent 3.75%      
Debt Instrument periodic payment $ 731      
Deferred interest 14,719      
Principal amount paid $ 2,197      
Debt instrument, maturity date description July 2020 to September 2024      
Merchant Agreement [Member]        
Debt Instrument [Line Items]        
Debt instrument, maturity date description maturity dates ranged from June 26, 2023 to October 15, 2023 maturity dates ranged from April 4 to June 6, 2023    
Payroll Protection Program [Member]        
Debt Instrument [Line Items]        
Borrowed amount       $ 367,039
Debt interest rate       1.00%
Paycheck Protection Programme [Member]        
Debt Instrument [Line Items]        
Borrowed amount     $ 367,039  
Minimum [Member]        
Debt Instrument [Line Items]        
Debt interest rate 1.00%      
Minimum [Member] | Merchant Agreement [Member]        
Debt Instrument [Line Items]        
Debt interest rate 4.10%      
Maximum [Member]        
Debt Instrument [Line Items]        
Debt interest rate 10.00%      
Maximum [Member] | Merchant Agreement [Member]        
Debt Instrument [Line Items]        
Debt interest rate 100.90%      
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Related Party Debt (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]    
Totals, Principle $ 731  
Net, Principal $ 647,986 $ 634,885
Officers & Directors [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Interest Rate [1]
Totals, Principle $ 522,450 $ 521,950
Other Related Parties [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Interest Rate 12.00% 12.00%
Totals, Principle $ 126,050 $ 120,850
Related Party [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Totals, Principle 648,500 642,800
Discount, Principal 514 7,915
Net, Principal $ 647,986 $ 634,885
[1] Interest varies from 12% to 120%.
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Related Party Debt (Details) (Parenthetical)
Sep. 30, 2023
Minimum [Member]  
Debt Instrument [Line Items]  
Debt instrument, interest rate, stated percentage 1.00%
Maximum [Member]  
Debt Instrument [Line Items]  
Debt instrument, interest rate, stated percentage 10.00%
Related Party [Member] | Minimum [Member]  
Debt Instrument [Line Items]  
Debt instrument, interest rate, stated percentage 12.00%
Related Party [Member] | Maximum [Member]  
Debt Instrument [Line Items]  
Debt instrument, interest rate, stated percentage 120.00%
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Debt (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Short-Term Debt [Line Items]                  
Proceeds from Convertible Debt             $ 4,336,665 $ 3,428,249  
Fixed rate $ 2.50           $ 2.50    
Deferred Costs $ 648,470           $ 648,470    
Repayments of Senior Debt             $ 2,462,269    
Debt instrument maturity date description             July 2020 to September 2024    
Debt instrument, face amount. 12,300,000           $ 12,300,000    
Debt Instrument, Unamortized Discount 744,393           744,393   $ 455,517
Payments on convertible debt             2,462,269 1,086,946  
Losses on extinguishment of debt             $ 687,591 $ 10,000  
Preferred stock extensions 1,286,600 $ 1,397,000              
Debt instrument, convertible price per shares             $ 2.50    
Convertible Debt [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Unamortized Discount $ 744,393           $ 744,393   455,517
Debt instrument, convertible price per shares             $ 2.50    
Common Stock [Member]                  
Short-Term Debt [Line Items]                  
Number of shares issued 250,000 528,600 568,200 707,900 106,400 214,500      
Preferred stock extensions              
Preferred Stock [Member]                  
Short-Term Debt [Line Items]                  
Preferred stock extensions 6 $ 2              
Three Lenders [Member]                  
Short-Term Debt [Line Items]                  
Payments on convertible debt             $ 302,484    
Three Lenders [Member] | Forbearance Agreements [Member]                  
Short-Term Debt [Line Items]                  
Payments on convertible debt             272,500    
Four Lenders [Member] | Forbearance Agreements [Member]                  
Short-Term Debt [Line Items]                  
Interest payable 253,425           253,425    
PBI Agrochem Inc [Member]                  
Short-Term Debt [Line Items]                  
Debt instrument, face amount. $ 352,188           $ 352,188    
Minimum [Member]                  
Short-Term Debt [Line Items]                  
Debt interest rate 1.00%           1.00%    
Maximum [Member]                  
Short-Term Debt [Line Items]                  
Debt interest rate 10.00%           10.00%    
Convertible Debt [Member]                  
Short-Term Debt [Line Items]                  
Proceeds from Convertible Debt             $ 4,300,000    
Amortization of Debt Discount (Premium)             2,621,523    
Debt Instrument, Unamortized Discount $ 744,393           $ 744,393    
Convertible Debt [Member] | Convertible Common Stock [Member]                  
Short-Term Debt [Line Items]                  
Fixed rate $ 2.50           $ 2.50    
Convertible Debt, Fair Value Disclosures $ 1,832,757           $ 1,832,757    
Convertible Debt [Member] | Minimum [Member]                  
Short-Term Debt [Line Items]                  
Debt instrument term             1 month    
Debt interest rate 0.00%           0.00%    
Convertible Debt [Member] | Maximum [Member]                  
Short-Term Debt [Line Items]                  
Debt instrument term             12 months    
Debt interest rate 120.00%           120.00%    
New Loan [Member]                  
Short-Term Debt [Line Items]                  
Debt interest rate 10.00%           10.00%    
Losses on extinguishment of debt             $ 700,000    
Ten Loans [Member]                  
Short-Term Debt [Line Items]                  
Proceeds from loans             3,917,898    
Increase in principal amount             $ 4,067,898    
Ten Loans [Member] | Common Stock [Member]                  
Short-Term Debt [Line Items]                  
Number of shares issued             1,346,800    
Ten Loans [Member] | Preferred Stock [Member]                  
Short-Term Debt [Line Items]                  
Preferred stock extensions             $ 741    
Short-term Non-Convertible Loan [Member]                  
Short-Term Debt [Line Items]                  
Amortization of Debt Discount (Premium)             592,099    
Debt Instrument, Unamortized Discount $ 514           514   $ 7,915
Proceeds from Short-Term Debt             164,700    
Original issue discount             5,514    
Proceeds from (Repayments of) Related Party Debt             $ 159,000    
Short-term Non-Convertible Loan [Member] | Minimum [Member]                  
Short-Term Debt [Line Items]                  
Debt interest rate 12.00%           12.00%    
Short-term Non-Convertible Loan [Member] | Maximum [Member]                  
Short-Term Debt [Line Items]                  
Debt interest rate 120.00%           120.00%    
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Preferred Stock Outstanding (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 100 $ 1,098
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding 100 1,098
Series D Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 3
Preferred stock, shares outstanding 75 300
Series G Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 806
Preferred stock, shares outstanding 80,570 80,570
Series H Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 100
Preferred stock, shares outstanding 0 10,000
Series J Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 35
Preferred stock, shares outstanding 0 3,458
Series K Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 68
Preferred stock, shares outstanding 0 6,880
Series AA Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 86 $ 86
Preferred stock, shares outstanding 8,601 8,601
Series BB Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 10
Preferred stock, shares outstanding 858 0
Series CC Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares $ 4
Preferred stock, shares outstanding 401 0
Series H2 Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares
Preferred stock, shares outstanding 0 21
Series A Junior Participating Preferred Stock [Member]    
Class of Stock [Line Items]    
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding
Preferred stock, shares outstanding 0 0
Series A Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares
Preferred stock, shares outstanding 0 0
Series B Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares
Preferred stock, shares outstanding 0 0
Series C Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares
Preferred stock, shares outstanding 0 0
Series E Convertible Preferred Stock [Member]    
Class of Stock [Line Items]    
Total Convertible Preferred Shares
Preferred stock, shares outstanding 0 0
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) - USD ($)
Sep. 30, 2023
May 01, 2023
Dec. 31, 2022
Series D Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 850   850
Preferred stock, shares issued 75   300
Preferred stock, shares outstanding 75   300
Preferred stock, shares outstanding     $ 300,000
Series H Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 10,000   10,000
Preferred stock, shares issued 0   10,000
Preferred stock, shares outstanding 0   10,000
Series G Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 240,000   240,000
Preferred stock, shares issued 80,570   80,570
Preferred stock, shares outstanding 80,570   80,570
Series J Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 6,250   6,250
Preferred stock, shares issued 0   3,458
Preferred stock, shares outstanding 0   3,458
Series K Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 15,000   15,000
Preferred stock, shares issued 0   6,880
Preferred stock, shares outstanding 0   6,880
Series AA Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 10,000   10,000
Preferred stock, shares issued 8,601   8,601
Preferred stock, shares outstanding 8,601   8,601
Series BB Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01 $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000 1,000 1,000
Preferred stock, shares issued 858    
Preferred stock, shares outstanding 858   0
Series CC Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01 $ 0.01 $ 0.01
Preferred stock, shares authorized 2,000 2,000 2,000
Preferred stock, shares issued 401    
Preferred stock, shares outstanding 401   0
Series H2 Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 21   21
Preferred stock, shares issued 0   21
Preferred stock, shares outstanding 0   21
Series A Junior Participating Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 20,000   20,000
Preferred stock, shares outstanding 0   0
Series A Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 313,960   313,960
Preferred stock, shares outstanding 0   0
Series B Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized     279,256
Preferred stock, shares outstanding 0   0
Series C Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 88,098   88,098
Preferred stock, shares outstanding 0   0
Series E Convertible Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, par value $ 0.01   $ 0.01
Preferred stock, shares authorized 500   500
Preferred stock, shares outstanding 0   0
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details)
9 Months Ended
Sep. 30, 2023
$ / shares
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Shares, Beginning balance 17,586,591
Exercisable, Beginning balance 17,570,591
Shares, Granted 2,330,484
Shares, Exercised (117,552)
Shares, Expired (645,829)
Shares, Forfeited
Shares, Ending balance 19,153,694
Exercisable, Ending balance 18,289,721
Stock Options [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Shares, Beginning balance 1,307,822
Weighted average price per share, Beginning balance | $ / shares $ 0.72
Shares, Granted 2,230,484
Weighted average price per share, Granted | $ / shares $ 1.50
Shares, Exercised (117,552)
Weighted average price per share, Exercised | $ / shares $ 0.69
Shares, Expired
Weighted average price per share, Expired | $ / shares
Shares, Forfeited
Weighted average price per share, Forfeited | $ / shares
Shares, Ending balance 3,420,754
Weighted average price per share, Ending balance | $ / shares $ 1.23
Exercisable, Ending balance 2,556,781
Warrant [Member]  
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Shares, Beginning balance 16,278,769
Weighted average price per share, Beginning balance | $ / shares $ 3.50
Shares, Granted 100,000
Weighted average price per share, Granted | $ / shares $ 3.50
Shares, Exercised
Weighted average price per share, Exercised | $ / shares
Shares, Expired (645,829)
Weighted average price per share, Expired | $ / shares $ 3.50
Shares, Forfeited
Weighted average price per share, Forfeited | $ / shares
Shares, Ending balance 15,732,940
Weighted average price per share, Ending balance | $ / shares $ 3.50
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders’ Deficit (Details Narrative)
3 Months Ended 9 Months Ended
Apr. 13, 2023
USD ($)
shares
Sep. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
shares
Mar. 31, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
shares
Mar. 31, 2022
USD ($)
shares
Sep. 30, 2023
USD ($)
Integer
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
May 01, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Dec. 30, 2021
shares
Class of Stock [Line Items]                        
Debt instrument, convertible price per shares | $ / shares               $ 2.50        
Debt instrument, convertible, threshold trading days | Integer               5        
Number of common stock for services rendered | $   $ 325,301 $ 172,400 $ 1,419,335 $ 167,375 $ 67,800 $ 77,700          
Convertible debt issuances value | $     10,017,212 509,033     350,500          
Options outstanding, shares   19,153,694           19,153,694     17,586,591  
Number of options, exercisable   18,289,721           18,289,721     17,570,591  
Extension of warrants for series AA preferred stock | $             $ 3,626,950      
Interest expense | $   $ 4,338,759     2,034,021     $ 14,112,098 $ 6,448,771      
Fair value of dividends paid in kind | $   $ 150,000 491,634 1,029,939 1,050,475 191,303 472,900          
Shares isused for options exercised, shares               117,552        
Lender [Member]                        
Class of Stock [Line Items]                        
Shares issued, price per share | $ / shares   $ 0.69           $ 0.69        
Issued For Services Rendered [Member]                        
Class of Stock [Line Items]                        
Number of common stock for services rendered, shares                 190,500      
Number of common stock for services rendered | $               $ 1,917,036        
Conversion of Debt Extension [Member]                        
Class of Stock [Line Items]                        
Convertible debt issuances shares                 140,200      
Convertible debt issuances value | $                 $ 350,500      
Stock Issued During Period, Shares, New Issues               203,613        
Fair value of dividends paid in kind | $               $ 509,033        
Debt Settlement [Member]                        
Class of Stock [Line Items]                        
Shares isused for options exercised, shares               117,552        
Debt Extension [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues               1,346,800        
Fair value of dividends paid in kind | $               $ 1,671,573        
New Common Stock Issuances [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues               60,000        
Fair value of dividends paid in kind | $               $ 150,000        
Conversion of Preferred to Common Stock [Member]                        
Class of Stock [Line Items]                        
Convertible debt issuances shares               1,486,940        
Series AA Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Fair value of dividends paid in kind | $                 $ 1,714,678      
Payment in Kind (PIK) Note [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues                 1,172,100      
Fair value of dividends paid in kind | $                 $ 2,196,278      
Dividends Paid In Kind [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues               142,767        
Fair value of dividends paid in kind | $               $ 162,528        
Accredited Investor and Consultants [Member]                        
Class of Stock [Line Items]                        
Shares of restricted common stock               9,717,035        
Unvested Stock-Based Awards [Member]                        
Class of Stock [Line Items]                        
Unvested stock based awards | $   $ 963,322           $ 963,322        
Unrecognized compensation, period               2 years 2 months 12 days        
Closing stock price | $ / shares   $ 0.20           $ 0.20        
Options outstanding and exercisable intrinsic value | $   $ 0.00           $ 0.00        
2021 Equity Incentive Plan [Member]                        
Class of Stock [Line Items]                        
Common stock, capital shares reserved for future issuance                       3,000,000
Options outstanding, shares   3,420,754           3,420,754        
Series BB Restricted Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Shares of restricted common stock               953        
Series CC Restricted Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Shares of restricted common stock               401        
Restricted Stock [Member]                        
Class of Stock [Line Items]                        
Shares of restricted common stock                 3,100,085      
Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Preferred Stock, Shares Issued   1,000,000           1,000,000        
Number of common stock for services rendered | $            
Convertible debt issuances shares     401                  
Convertible debt issuances value | $     $ 4              
Extension of warrants for series AA preferred stock | $                      
Fair value of dividends paid in kind | $            
Common Stock [Member]                        
Class of Stock [Line Items]                        
Number of common stock for services rendered, shares   492,500 147,500 990,500 113,500 40,000 37,000          
Number of common stock for services rendered | $   $ 4,926 $ 1,475 $ 9,905 $ 1,135 $ 400 $ 370          
Convertible debt issuances shares       203,613     140,200          
Convertible debt issuances value | $     $ 2,036     $ 1,402          
Stock issued during period, value, other               95        
Extension of warrants for series AA preferred stock | $                      
Interest expense | $               $ 3,715,204 $ 634,305      
Stock Issued During Period, Shares, New Issues   250,000 528,600 568,200 707,900 106,400 214,500          
Fair value of dividends paid in kind | $   $ 2,500 $ 5,286 $ 5,682 $ 7,079 $ 1,064 $ 2,145          
Shares isused for options exercised, shares       117,552   25,279            
Common Stock [Member] | Issued For Services Rendered [Member]                        
Class of Stock [Line Items]                        
Fair value of warrants | $               $ 312,875        
Common Stock [Member] | Debt Extension [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues                 25,279      
Fair value of dividends paid in kind | $                 $ 17,433      
Common Stock [Member] | New Conversion Debt [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues                 368,500      
Fair value of dividends paid in kind | $                 $ 512,593      
Common Stock [Member] | Payment in Kind (PIK) Note [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues               170,306        
Fair value of dividends paid in kind | $                 $ 306,333      
Stock Options [Member]                        
Class of Stock [Line Items]                        
Options outstanding, shares   3,420,754           3,420,754     1,307,822  
Weighted average exercise price | $ / shares   $ 1.23           $ 1.23     $ 0.72  
Weighted average remaining term               8 years 1 month 20 days        
Number of options, exercisable   2,556,781           2,556,781        
Shares isused for options exercised, shares               117,552        
Exercisable Options [Member]                        
Class of Stock [Line Items]                        
Weighted average remaining term               7 years 9 months        
Warrant [Member]                        
Class of Stock [Line Items]                        
Number of common stock for services rendered | $            
Convertible debt issuances value | $                  
Options outstanding, shares   15,732,940           15,732,940     16,278,769  
Weighted average exercise price | $ / shares   $ 3.50           $ 3.50     $ 3.50  
Weighted average remaining term               2 years 5 months 1 day        
Class of warrant or right, outstanding 8,897,603                      
Extension of warrants for series AA preferred stock | $ $ 3,626,950   3,626,950                  
Fair value of dividends paid in kind | $            
Shares isused for options exercised, shares                      
Issuance warrants, shares   100,000     277,500     100,000 277,500      
Strike price, per share | $ / shares   $ 3.50     $ 3.50     $ 3.50 $ 3.50      
Fair value of warrants | $               $ 61,609 $ 280,608      
Common Stock and Warrant [Member] | Issued For Services Rendered [Member]                        
Class of Stock [Line Items]                        
Number of common stock for services rendered, shares               1,630,500        
Common Stock and Warrant [Member] | Conversion of Debt Extension [Member]                        
Class of Stock [Line Items]                        
Convertible debt issuances shares               1,258,742        
Convertible debt issuances value | $               $ 1,293,270        
Common Stock and Warrant [Member] | Payment in Kind (PIK) Note [Member]                        
Class of Stock [Line Items]                        
Stock Issued During Period, Shares, New Issues               4,094,121        
Fair value of dividends paid in kind | $               $ 3,715,204        
Series AA Preferred Stock [Member] | Debt Extension [Member]                        
Class of Stock [Line Items]                        
Stock issued during period, value, other                 4,400      
Stock Issued During Period, Shares, New Issues                 1,028,800      
Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Convertible preferred stock, authorized   1,000,000           1,000,000        
Convertible preferred stock, par value | $ / shares   $ 0.01           $ 0.01        
Series BB Convertible Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Convertible preferred stock, authorized   1,000           1,000   1,000 1,000  
Convertible preferred stock, par value | $ / shares   $ 0.01           $ 0.01   $ 0.01 $ 0.01  
Preferred Stock, Shares Issued   858           858        
Series CC Convertible Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Convertible preferred stock, authorized   2,000           2,000   2,000 2,000  
Convertible preferred stock, par value | $ / shares   $ 0.01           $ 0.01   $ 0.01 $ 0.01  
Preferred Stock, Shares Issued   401           401        
Series BB Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Convertible preferred stock, par value | $ / shares   $ 0.01           $ 0.01        
Preferred stock voting rights               The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held        
Number of shares converted               10,000        
Debt instrument, interest rate, stated percentage   300.00%           300.00%        
Debt instrument, convertible price per shares | $ / shares               $ 2.50        
Number of common stock for services rendered, shares               92        
Number of common stock for services rendered | $               $ 617,200        
Convertible debt issuances shares               741        
Convertible debt issuances value | $               $ 2,683,600        
Stock issued during period, value, other               62        
Series BB Preferred Stock [Member] | Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Stock issued during period, value, other               58        
Stock issued during period, value, conversion of units | $               $ 539,487        
Series CC Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Debt instrument, interest rate, stated percentage   8.00%           8.00%        
Preferred stock remain outstanding percentage               10.00%        
Preferred stock, dividend rate, percentage               75.00%        
Outstanding shares, precentage   50.00%           50.00%        
Preferred stock liquidation Preference value | $ / shares   $ 25,000.00           $ 25,000.00        
Preferred stock, convertible, conversion price | $ / shares   $ 2.50           $ 2.50        
Debt instrument, convertible, threshold percentage of stock price trigger               300.00%        
Debt instrument, convertible, threshold trading days | Integer               10        
Debt instrument convertible benefically percentage               4.99%        
Stock issued during period, shares, other               401        
Stock Issued During Period, Value, Other | $               $ 10,017,212        
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 18, 2023
Nov. 05, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Dec. 31, 2022
Subsequent Event [Line Items]                    
common stock, par value     $ 0.01           $ 0.01 $ 0.01
Stock option number of shares granted                 2,330,484  
Common Stock [Member]                    
Subsequent Event [Line Items]                    
Stock Issued During Period, Shares, Issued for Services     492,500 147,500 990,500 113,500 40,000 37,000    
Stock Issued During Period, Shares, Conversion of Units                 95  
Common stock issued for debt extension, shares     250,000 528,600 568,200 707,900 106,400 214,500    
Minimum [Member]                    
Subsequent Event [Line Items]                    
Debt interest rate     1.00%           1.00%  
Maximum [Member]                    
Subsequent Event [Line Items]                    
Debt interest rate     10.00%           10.00%  
Subsequent Event [Member]                    
Subsequent Event [Line Items]                    
Convertible Debt   $ 439,000                
Share Price   $ 2.50                
Subsequent Event [Member] | Board of Directors Chairman [Member]                    
Subsequent Event [Line Items]                    
Stock option number of shares granted 1,500,000                  
Numberof stock option exercise price $ 0.25                  
Number of years option vested 3 years                  
Subsequent Event [Member] | Board of Directors Chairman [Member] | Two Thousand Twenty One Equity Plan [Member]                    
Subsequent Event [Line Items]                    
Common stock issued for debt extension, shares 300,000                  
common stock, par value $ 0.01                  
Shares of common stock 500,000                  
Subsequent Event [Member] | Mr Schumacher [Member]                    
Subsequent Event [Line Items]                    
Number of option vested percentage 25.00%                  
Subsequent Event [Member] | Drs Ting [Member]                    
Subsequent Event [Line Items]                    
Number of option vested percentage 25.00%                  
Subsequent Event [Member] | Lazarev [Member]                    
Subsequent Event [Line Items]                    
Number of option vested percentage 25.00%                  
Number of option issuance percentage 25.00%                  
Subsequent Event [Member] | Executive Officer [Member]                    
Subsequent Event [Line Items]                    
Numberof stock option exercise price $ 0.25                  
Subsequent Event [Member] | Series BB Convertible Preferred Stock [Member]                    
Subsequent Event [Line Items]                    
Stock Issued During Period, Shares, Other   40                
Stock Issued During Period, Shares, Conversion of Units   505,000                
Subsequent Event [Member] | Common Stock [Member]                    
Subsequent Event [Line Items]                    
Stock Issued During Period, Shares, Issued for Services   278,500                
Stock Issued During Period, Shares, Other   455,350                
Stock Issued During Period, Shares, Conversion of Units   145,809                
Subsequent Event [Member] | Minimum [Member]                    
Subsequent Event [Line Items]                    
Debt interest rate   10.00%                
Subsequent Event [Member] | Minimum [Member] | Executive Officer [Member]                    
Subsequent Event [Line Items]                    
Numberof stock option exercise price 0.69                  
Subsequent Event [Member] | Maximum [Member]                    
Subsequent Event [Line Items]                    
Debt interest rate   120.00%                
Subsequent Event [Member] | Maximum [Member] | Executive Officer [Member]                    
Subsequent Event [Line Items]                    
Numberof stock option exercise price $ 1.50                  
XML 60 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000830656 2023-01-01 2023-09-30 0000830656 2023-11-10 0000830656 2023-09-30 0000830656 2022-12-31 0000830656 us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2022-12-31 0000830656 us-gaap:RelatedPartyMember 2023-09-30 0000830656 us-gaap:RelatedPartyMember 2022-12-31 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesH2ConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesH2ConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2022-12-31 0000830656 2023-07-01 2023-09-30 0000830656 2022-07-01 2022-09-30 0000830656 2022-01-01 2022-09-30 0000830656 2021-12-31 0000830656 2022-09-30 0000830656 us-gaap:PreferredStockMember 2022-12-31 0000830656 us-gaap:CommonStockMember 2022-12-31 0000830656 us-gaap:WarrantMember 2022-12-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000830656 us-gaap:RetainedEarningsMember 2022-12-31 0000830656 us-gaap:PreferredStockMember 2023-03-31 0000830656 us-gaap:CommonStockMember 2023-03-31 0000830656 us-gaap:WarrantMember 2023-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000830656 us-gaap:RetainedEarningsMember 2023-03-31 0000830656 2023-03-31 0000830656 us-gaap:PreferredStockMember 2023-06-30 0000830656 us-gaap:CommonStockMember 2023-06-30 0000830656 us-gaap:WarrantMember 2023-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000830656 us-gaap:RetainedEarningsMember 2023-06-30 0000830656 2023-06-30 0000830656 us-gaap:PreferredStockMember 2021-12-31 0000830656 us-gaap:CommonStockMember 2021-12-31 0000830656 us-gaap:WarrantMember 2021-12-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000830656 us-gaap:RetainedEarningsMember 2021-12-31 0000830656 us-gaap:PreferredStockMember 2022-03-31 0000830656 us-gaap:CommonStockMember 2022-03-31 0000830656 us-gaap:WarrantMember 2022-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000830656 us-gaap:RetainedEarningsMember 2022-03-31 0000830656 2022-03-31 0000830656 us-gaap:PreferredStockMember 2022-06-30 0000830656 us-gaap:CommonStockMember 2022-06-30 0000830656 us-gaap:WarrantMember 2022-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000830656 us-gaap:RetainedEarningsMember 2022-06-30 0000830656 2022-06-30 0000830656 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000830656 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000830656 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000830656 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000830656 2023-01-01 2023-03-31 0000830656 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000830656 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000830656 us-gaap:WarrantMember 2023-04-01 2023-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000830656 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000830656 2023-04-01 2023-06-30 0000830656 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000830656 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000830656 us-gaap:WarrantMember 2023-07-01 2023-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000830656 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000830656 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000830656 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000830656 us-gaap:WarrantMember 2022-01-01 2022-03-31 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000830656 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000830656 2022-01-01 2022-03-31 0000830656 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000830656 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000830656 us-gaap:WarrantMember 2022-04-01 2022-06-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000830656 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000830656 2022-04-01 2022-06-30 0000830656 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000830656 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000830656 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000830656 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000830656 us-gaap:PreferredStockMember 2023-09-30 0000830656 us-gaap:CommonStockMember 2023-09-30 0000830656 us-gaap:WarrantMember 2023-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000830656 us-gaap:RetainedEarningsMember 2023-09-30 0000830656 us-gaap:PreferredStockMember 2022-09-30 0000830656 us-gaap:CommonStockMember 2022-09-30 0000830656 us-gaap:WarrantMember 2022-09-30 0000830656 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000830656 us-gaap:RetainedEarningsMember 2022-09-30 0000830656 2020-08-30 0000830656 PBIO:NexityGlobalSAMember 2023-01-01 2023-09-30 0000830656 PBIO:NexityGlobalSAMember 2023-09-30 0000830656 srt:MinimumMember 2023-09-30 0000830656 srt:MaximumMember 2023-09-30 0000830656 srt:NorthAmericaMember 2023-07-01 2023-09-30 0000830656 srt:NorthAmericaMember 2022-07-01 2022-09-30 0000830656 srt:NorthAmericaMember 2023-01-01 2023-09-30 0000830656 srt:NorthAmericaMember 2022-01-01 2022-09-30 0000830656 srt:EuropeMember 2023-07-01 2023-09-30 0000830656 srt:EuropeMember 2022-07-01 2022-09-30 0000830656 srt:EuropeMember 2023-01-01 2023-09-30 0000830656 srt:EuropeMember 2022-01-01 2022-09-30 0000830656 srt:AsiaMember 2023-07-01 2023-09-30 0000830656 srt:AsiaMember 2022-07-01 2022-09-30 0000830656 srt:AsiaMember 2023-01-01 2023-09-30 0000830656 srt:AsiaMember 2022-01-01 2022-09-30 0000830656 PBIO:HardwareMember 2023-07-01 2023-09-30 0000830656 PBIO:HardwareMember 2022-07-01 2022-09-30 0000830656 PBIO:HardwareMember 2023-01-01 2023-09-30 0000830656 PBIO:HardwareMember 2022-01-01 2022-09-30 0000830656 PBIO:ConsumablesMember 2023-07-01 2023-09-30 0000830656 PBIO:ConsumablesMember 2022-07-01 2022-09-30 0000830656 PBIO:ConsumablesMember 2023-01-01 2023-09-30 0000830656 PBIO:ConsumablesMember 2022-01-01 2022-09-30 0000830656 PBIO:ContractResearchServicesMember 2023-07-01 2023-09-30 0000830656 PBIO:ContractResearchServicesMember 2022-07-01 2022-09-30 0000830656 PBIO:ContractResearchServicesMember 2023-01-01 2023-09-30 0000830656 PBIO:ContractResearchServicesMember 2022-01-01 2022-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2023-07-01 2023-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2022-07-01 2022-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2023-01-01 2023-09-30 0000830656 PBIO:SamplePreparationAccessoriesMember 2022-01-01 2022-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2023-07-01 2023-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2022-07-01 2022-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2023-01-01 2023-09-30 0000830656 PBIO:TechnicalSupportExtendedServiceContractsMember 2022-01-01 2022-09-30 0000830656 PBIO:AgrochemProductsMember 2023-07-01 2023-09-30 0000830656 PBIO:AgrochemProductsMember 2022-07-01 2022-09-30 0000830656 PBIO:AgrochemProductsMember 2023-01-01 2023-09-30 0000830656 PBIO:AgrochemProductsMember 2022-01-01 2022-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2023-07-01 2023-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2022-07-01 2022-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2023-01-01 2023-09-30 0000830656 us-gaap:ShippingAndHandlingMember 2022-01-01 2022-09-30 0000830656 PBIO:OtherMember 2023-07-01 2023-09-30 0000830656 PBIO:OtherMember 2022-07-01 2022-09-30 0000830656 PBIO:OtherMember 2023-01-01 2023-09-30 0000830656 PBIO:OtherMember 2022-01-01 2022-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2023-07-01 2023-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2022-07-01 2022-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2023-01-01 2023-09-30 0000830656 PBIO:TransferredAtAPointInTimeMember 2022-01-01 2022-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2023-07-01 2023-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2022-07-01 2022-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2023-01-01 2023-09-30 0000830656 PBIO:TransferredOverAtTimeMember 2022-01-01 2022-09-30 0000830656 PBIO:TwoThousandAndTwentyThreeMember 2023-09-30 0000830656 PBIO:TwoThousandAndTwentyFourMember 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:TopFiveCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000830656 PBIO:FederalAgenciesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000830656 PBIO:FederalAgenciesMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000830656 PBIO:EmployeeStockOptionsMember 2023-01-01 2023-09-30 0000830656 PBIO:EmployeeStockOptionsMember 2022-01-01 2022-09-30 0000830656 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0000830656 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-09-30 0000830656 PBIO:CommonStockWarrantsMember 2023-01-01 2023-09-30 0000830656 PBIO:CommonStockWarrantsMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesDConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesGConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesHConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesHTwoConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesHTwoConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesJConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesKConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesAAConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:EmployeesOfficersMember 2023-01-01 2023-09-30 0000830656 srt:MinimumMember PBIO:EmployeesOfficersMember 2023-01-01 2023-09-30 0000830656 srt:MaximumMember PBIO:EmployeesOfficersMember 2023-01-01 2023-09-30 0000830656 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000830656 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000830656 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000830656 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000830656 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2022-07-01 2022-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0000830656 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0000830656 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0000830656 us-gaap:EquitySecuritiesMember 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0000830656 us-gaap:FairValueInputsLevel1Member 2023-09-30 0000830656 us-gaap:FairValueInputsLevel2Member 2023-09-30 0000830656 us-gaap:FairValueInputsLevel3Member 2023-09-30 0000830656 us-gaap:EquitySecuritiesMember 2022-12-31 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000830656 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0000830656 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000830656 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000830656 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000830656 PBIO:CorporateOfficeMember 2023-01-01 2023-09-30 0000830656 PBIO:MedfordLeaseMember 2023-01-01 2023-09-30 0000830656 PBIO:MedfordLeaseMember 2023-09-30 0000830656 PBIO:SparksLeaseMember 2021-08-08 2021-08-09 0000830656 PBIO:SparksLeaseMember 2023-09-30 0000830656 PBIO:BattelleMemorialInstituteMember 2014-01-01 2014-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2015-01-01 2015-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2016-01-01 2016-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2017-01-01 2017-12-31 0000830656 PBIO:BattelleMemorialInstituteMember 2018-01-01 2018-12-31 0000830656 PBIO:TargetDiscoveryIncMember 2012-04-01 2012-04-30 0000830656 PBIO:TargetDiscoveryIncMember 2022-01-01 2022-09-30 0000830656 PBIO:TargetDiscoveryIncMember 2023-01-01 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 srt:MinimumMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 srt:MaximumMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 srt:MinimumMember us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 srt:MaximumMember us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember us-gaap:ConvertibleCommonStockMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 PBIO:PBIAgrochemIncMember 2023-09-30 0000830656 PBIO:ThreeLendersMember 2023-01-01 2023-09-30 0000830656 PBIO:ThreeLendersMember PBIO:ForbearanceAgreementsMember 2023-01-01 2023-09-30 0000830656 PBIO:FourLendersMember PBIO:ForbearanceAgreementsMember 2023-09-30 0000830656 PBIO:NewLoanMember 2023-09-30 0000830656 PBIO:NewLoanMember 2023-01-01 2023-09-30 0000830656 PBIO:TenLoansMember 2023-01-01 2023-09-30 0000830656 PBIO:TenLoansMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000830656 PBIO:TenLoansMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember 2023-01-01 2023-09-30 0000830656 srt:MinimumMember PBIO:ShortTermNonConvertibleLoanMember 2023-09-30 0000830656 srt:MaximumMember PBIO:ShortTermNonConvertibleLoanMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember 2023-09-30 0000830656 PBIO:ShortTermNonConvertibleLoanMember 2022-12-31 0000830656 us-gaap:InvestorMember 2023-01-01 2023-09-30 0000830656 us-gaap:InvestorMember 2023-09-30 0000830656 us-gaap:InvestorMember 2022-01-01 2022-12-31 0000830656 us-gaap:InvestorMember 2022-12-31 0000830656 srt:MinimumMember PBIO:OthersMember 2023-01-01 2023-09-30 0000830656 srt:MaximumMember PBIO:OthersMember 2023-01-01 2023-09-30 0000830656 srt:MinimumMember PBIO:OthersMember 2023-09-30 0000830656 srt:MaximumMember PBIO:OthersMember 2023-09-30 0000830656 PBIO:OthersMember 2023-09-30 0000830656 srt:MinimumMember PBIO:OthersMember 2022-01-01 2022-12-31 0000830656 srt:MaximumMember PBIO:OthersMember 2022-01-01 2022-12-31 0000830656 srt:MinimumMember PBIO:OthersMember 2022-12-31 0000830656 srt:MaximumMember PBIO:OthersMember 2022-12-31 0000830656 PBIO:OthersMember 2022-12-31 0000830656 PBIO:FiveDayAverageVWAPMember us-gaap:ConvertibleDebtMember 2023-09-30 0000830656 us-gaap:ConvertibleDebtMember PBIO:SeriesAAPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtOneMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtTwoMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtThreeMember 2023-01-01 2023-09-30 0000830656 PBIO:ConvertibleDebtFourMember 2023-01-01 2023-09-30 0000830656 srt:ChiefExecutiveOfficerMember 2023-09-30 0000830656 PBIO:NonConvertibleLoansMember 2023-09-30 0000830656 PBIO:NonConvertibleLoansMember 2022-12-31 0000830656 PBIO:MerchantDebtMember 2023-09-30 0000830656 PBIO:MerchantDebtMember 2022-12-31 0000830656 PBIO:SBAMember 2023-09-30 0000830656 PBIO:SBAMember 2022-12-31 0000830656 PBIO:PayrollProtectionProgramMember 2020-12-31 0000830656 PBIO:PaycheckProtectionProgrammeMember 2021-12-31 0000830656 srt:MinimumMember PBIO:MerchantAgreementMember 2023-09-30 0000830656 srt:MaximumMember PBIO:MerchantAgreementMember 2023-09-30 0000830656 PBIO:MerchantAgreementMember 2023-01-01 2023-09-30 0000830656 PBIO:MerchantAgreementMember 2022-01-01 2022-12-31 0000830656 PBIO:OfficersAndDirectorsMember 2023-09-30 0000830656 PBIO:OfficersAndDirectorsMember 2023-01-01 2023-09-30 0000830656 PBIO:OfficersAndDirectorsMember 2022-12-31 0000830656 PBIO:OfficersAndDirectorsMember 2022-01-01 2022-12-31 0000830656 PBIO:OtherRelatedPartiesMember 2023-09-30 0000830656 PBIO:OtherRelatedPartiesMember 2023-01-01 2023-09-30 0000830656 PBIO:OtherRelatedPartiesMember 2022-12-31 0000830656 PBIO:OtherRelatedPartiesMember 2022-01-01 2022-12-31 0000830656 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0000830656 us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0000830656 us-gaap:RelatedPartyMember 2023-09-30 0000830656 us-gaap:RelatedPartyMember 2022-12-31 0000830656 srt:MinimumMember us-gaap:RelatedPartyMember 2023-09-30 0000830656 srt:MaximumMember us-gaap:RelatedPartyMember 2023-09-30 0000830656 us-gaap:PreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember 2023-05-01 0000830656 PBIO:SeriesCCConvertiblePreferredStockMember 2023-05-01 0000830656 PBIO:SeriesBBPreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBBPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesCCPreferredStockMember 2023-09-30 0000830656 PBIO:SeriesCCPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesBBRestrictedPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesCCRestrictedPreferredStockMember 2023-01-01 2023-09-30 0000830656 PBIO:SeriesBBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-09-30 0000830656 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000830656 PBIO:TwoThousandAndTwentyOneEquityIncentivePlanMember 2021-12-30 0000830656 PBIO:TwoThousandAndTwentyOneEquityIncentivePlanMember 2023-09-30 0000830656 PBIO:UnvestedStockBasedAwardsMember 2023-09-30 0000830656 PBIO:UnvestedStockBasedAwardsMember 2023-01-01 2023-09-30 0000830656 PBIO:StockOptionsMember 2023-09-30 0000830656 PBIO:StockOptionsMember 2023-01-01 2023-09-30 0000830656 PBIO:ExercisableOptionsMember 2023-01-01 2023-09-30 0000830656 us-gaap:WarrantMember 2023-04-13 0000830656 us-gaap:WarrantMember 2023-04-11 2023-04-13 0000830656 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000830656 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000830656 PBIO:AccreditedInvestorAndConsultantsMember 2023-01-01 2023-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember PBIO:CommonStockAndWarrantMember 2023-01-01 2023-09-30 0000830656 PBIO:IssuedForServicesRenderedMember PBIO:CommonStockAndWarrantMember 2023-01-01 2023-09-30 0000830656 PBIO:IssuedForServicesRenderedMember 2023-01-01 2023-09-30 0000830656 PBIO:ConversionOfDebtMember 2023-01-01 2023-09-30 0000830656 PBIO:DebtSettlementMember 2023-01-01 2023-09-30 0000830656 PBIO:LenderMember 2023-09-30 0000830656 PBIO:DividendsPaidInKindMember 2023-01-01 2023-09-30 0000830656 PBIO:ConversionOfDebtMember PBIO:CommonStockAndWarrantMember 2023-01-01 2023-09-30 0000830656 PBIO:DebtExtensionMember 2023-01-01 2023-09-30 0000830656 PBIO:NewCommonStockIssuancesMember 2023-01-01 2023-09-30 0000830656 PBIO:ConversionOfPreferredToCommonStockMember 2023-01-01 2023-09-30 0000830656 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0000830656 PBIO:ConversionOfDebtMember 2022-01-01 2022-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember 2022-01-01 2022-09-30 0000830656 PBIO:IssuedForServicesRenderedMember 2022-01-01 2022-09-30 0000830656 PBIO:IssuedForServicesRenderedMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000830656 us-gaap:PaymentInKindPIKNoteMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000830656 PBIO:NewConversionDebtMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000830656 PBIO:DebtExtensionMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000830656 PBIO:DebtExtensionMember PBIO:SeriesAAPreferredStockMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesAAPreferredStockMember 2022-01-01 2022-09-30 0000830656 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000830656 PBIO:SeriesAJuniorParticipatingPreferredStockMember 2023-09-30 0000830656 PBIO:SeriesAJuniorParticipatingPreferredStockMember 2022-12-31 0000830656 PBIO:SeriesAConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesAConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesBConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesBConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesCConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesCConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:SeriesEConvertiblePreferredStockMember 2023-09-30 0000830656 PBIO:SeriesEConvertiblePreferredStockMember 2022-12-31 0000830656 PBIO:StockOptionsMember 2022-12-31 0000830656 us-gaap:SubsequentEventMember 2023-11-05 0000830656 srt:MinimumMember us-gaap:SubsequentEventMember 2023-11-05 0000830656 srt:MaximumMember us-gaap:SubsequentEventMember 2023-11-05 0000830656 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-10-01 2023-11-05 0000830656 PBIO:SeriesBBConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-10-01 2023-11-05 0000830656 srt:BoardOfDirectorsChairmanMember PBIO:TwoThousandTwentyOneEquityPlanMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 srt:BoardOfDirectorsChairmanMember PBIO:TwoThousandTwentyOneEquityPlanMember us-gaap:SubsequentEventMember 2023-10-18 0000830656 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2023-10-18 0000830656 PBIO:MrSchumacherMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 PBIO:DrsTingMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 PBIO:LazarevMember us-gaap:SubsequentEventMember 2023-10-18 2023-10-18 0000830656 srt:ExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-10-18 0000830656 srt:MinimumMember srt:ExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-10-18 0000830656 srt:MaximumMember srt:ExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-10-18 iso4217:USD shares iso4217:USD shares PBIO:Integer pure false --12-31 Q3 0000830656 http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember http://fasb.org/us-gaap/2023#ProductAndServiceOtherMember 10-Q true 2023-09-30 2023 false 001-38185 PRESSURE BIOSCIENCES, INC. MA 04-2652826 14 Norfolk Avenue South Easton MA 02375 (508) 230-1828 Yes Yes Non-accelerated Filer true false false 21726433 5263 3865 329263 295374 905759 982973 467155 686383 219283 257527 1020964 1243149 77918 63638 91409 103351 159424 282095 252404 317308 1602119 2009541 1062565 637238 376760 167247 2722666 2497762 4576350 10803983 253152 58242 744393 455517 455517 18222120 17823669 0 0 2030510 1638969 514 7915 647986 634885 66259 142171 29958368 34404166 162522 150000 71287 139924 10645 1822 244454 291746 30202822 34695912 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 100 1098 100 1098 0.01 0.01 100000000 100000000 23399945 23399945 13682910 13682910 234000 136829 35684321 31995762 93973646 69006145 -158492770 -133826205 -28600703 -32686371 1602119 2009541 413009 144032 1665412 1122169 413009 144032 1665412 1122169 229457 126203 844684 742707 288345 262370 1004437 716685 157773 226526 537802 422422 1030243 892293 5290564 2591644 1705818 1507392 7677487 4473458 -1292809 -1363360 -6012075 -3351289 4338759 2034021 14112098 6448771 -5965 -8675 14280 -8047 -1054122 687591 -1809249 7588 -2059 11820 -904 -4337136 -3098877 -13398407 -8266971 -5629945 -4462237 -19410482 -11618260 3626950 632054 431709 1629133 1295566 -6261999 -4893946 -24666565 -12913826 -0.29 -0.29 -0.44 -0.44 -1.21 -1.21 -1.24 -1.24 21716950 21716950 11131742 11131742 20337229 20337229 10429817 10429817 -19410482 -11618260 687591 10000 122671 82001 3715204 2196278 84341 67985 -3213622 -1777863 1809249 -1671573 2683600 1706420 128984 14280 -8047 1978645 367370 617200 33889 11568 -219228 238973 -38244 -204141 425327 80130 209513 104258 -144549 -82001 1551380 2083239 -2053823 -3051257 7495 20754 -7495 -20754 150000 81111 17443 4336665 3428249 2043681 1815000 159186 762500 2462269 1086946 159000 259600 2086658 1506066 2062716 3170580 1398 98569 3865 132311 5263 230880 1219038 938451 473027 1293270 512593 93576 162528 306333 539487 1629133 1295566 14869 44 10017212 509033 350500 6240 3626950 109874 1098 13682910 136829 31995762 69006145 -133826205 -32686371 117552 1176 79935 81111 1430244 1430244 431807 431807 990500 9905 1409430 1419335 61609 61609 203613 2036 506997 509033 73694 737 101698 102435 1111081 11111 1694123 1705234 568200 5682 1024257 1029939 783150 7832 1079919 1087751 -101154 -1012 493540 4935 -3923 40000 400 99600 100000 -6857834 -6857834 8720 86 18064240 180643 32057371 76428425 -141115846 -32449321 565272 565272 135554 135554 147500 1475 170925 172400 3626950 -3626950 528600 5286 486348 491634 -44 44400 444 -444 401 4 10017208 10017212 62 1 -624000 -6240 6239 69073 690 59403 60093 1034000 10340 1286106 1296446 302092 3021 153653 156674 20000 200 49800 50000 57 1 505699 505700 185 2 1396998 1397000 58 1 539486 539487 -6922703 -6922703 9439 95 19585905 195859 35684321 91235400 -152230771 -25115096 140622 140622 632054 632054 492500 4926 320375 325301 250000 2500 147500 150000 -95 -1 949000 9490 -9489 1949040 19490 694034 713524 173500 1735 47110 48845 35 111500 111500 556 6 1286594 1286600 -5629945 -5629945 9935 100 23399945 234000 35684321 93973646 -158492770 -28600703 109878 1099 9120526 91206 31715154 64261048 -118277468 -22208961 109878 1099 9120526 91206 31715154 64261048 -118277468 -22208961 -2728243 2255216 -473027 64483 64483 432149 432149 37000 370 77330 77700 39761 39761 132537 132537 214500 2145 470755 472900 140200 1402 349098 350500 31810 318 63938 64256 558100 5581 1167877 1173458 92000 920 141560 142480 87436 87436 -4239685 -4239685 109878 1099 10194136 101942 31974888 63867846 -120694086 -24748311 32074 32074 25279 253 17190 17443 431708 431708 40000 400 67400 67800 106400 1064 190239 191303 -4 -1 4400 44 -43 86464 865 150156 151021 224500 2245 386270 388515 22000 220 35628 35848 -2916338 -2916338 109874 1098 10703179 107033 31974888 64746760 -124042132 -27212353 32427 32427 389500 3895 630410 634305 52032 520 90536 91056 113500 1135 166240 167375 431709 431709 707900 7079 1043396 1050475 14734 14734 254500 2545 331720 334265 6140 6140 -4462237 -4462237 109874 1098 12220611 122207 31995762 67041489 -128936078 -29775522 109874 1098 12220611 122207 31995762 67041489 -128936078 -29775522 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zcvcSrbQyyTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1) <span style="text-decoration: underline"><span id="xdx_82B_zyZxedMKmmv6">Business Overview, Liquidity and Management Plans</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pressure BioSciences, Inc. (OTCQB: PBIO</i>) (the “Company”) is a leader in the development &amp; sale of innovative, enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”), (ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion-dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The UST Platform </i></b>(8 issued patents) is based on the use of intense shear forces from ultra-high-pressure discharge (greater than 20,000 psi) through a dynamically controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company first introduced the UST Platform in May 2022 through participation in several cannabis/health &amp; wellness meetings combined with a free-sample program. Executed agreements were subsequently announced with six CBD companies and one cosmeceutical/skincare company for full commercialization in Q3 202</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. The Company began shipping Nano CBD topical spray on October 2, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The BaroFold Platform</i></b> (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The PCT Platform</i></b> (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus for PCT is on making, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. We currently have over 350 PCT Systems placed in approximately 250 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific research &amp; clinical laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zAxJbBxoKNXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2) <span style="text-decoration: underline"><span id="xdx_825_zvhZwucIb9x3">Going Concern</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows from operationing business since our inception. As of September 30, 2023, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past as described in Notes 5 and 6. In addition, we raised debt and equity capital after September 30, 2023, as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zlDr9tzsYx3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3) <span style="text-decoration: underline"><span id="xdx_824_zGTPknwRd053">Summary of Significant Accounting Policies</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zA1qr4Z05bJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zRrZM1wA0w7h">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zYraWLwCbbDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zm5R37SknlC9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--RecentAccountingPronouncementPolicyTextBlock_zkiiWvgrUr9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z8Yw4tqwwvTh">Recent Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $<span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_iI_c20200830_zZOSi0z1eXng" title="Cumulative effect of adoption, adjustment in additional paid in capital">2,728,243</span> decrease in additional paid in capital and a $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20200830_zfIBRyVaToO5" title="Cumulative effect of adoption, adjustment in accumulated deficit">2,255,216</span> decrease in accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption of ASU 2020-06.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zArMK4fMgqq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zzJstJ5fFvx3">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z8qehkk4HjPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zaDwPzj0GFv3">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue in accordance with FASB ASC 606, <i>Revenue from Contracts with Customers, </i>and <i>ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers</i>. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period. We measure and allocate revenue according to ASC 606-10.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the asset or service involved is not determinable.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction lacks commercial substance.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disaggregation of revenue</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zNOIVVqdMU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B1_zf9a0OF5yTud" style="display: none">Schedule of Disaggregation of Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic">In thousands of US dollars ($)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Primary geographical markets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">North America</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zWlyjSASPQ8f" style="width: 11%; text-align: right" title="Revenue">251</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zQfT9naI4ex1" style="width: 11%; text-align: right" title="Revenue">138</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zcijXGqr14Wc" style="width: 11%; text-align: right" title="Revenue">1,067</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zwoFwaSxEMg2" style="width: 11%; text-align: right" title="Revenue">709</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Europe</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--EuropeMember_zKAwbpHPpwHe" style="text-align: right" title="Revenue">76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--EuropeMember_z1Pi82n6UVlb" style="text-align: right" title="Revenue">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--EuropeMember_zHEyiVeUQmW3" style="text-align: right" title="Revenue">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--EuropeMember_zIMnMpeBL9Wg" style="text-align: right" title="Revenue">61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Asia</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--AsiaMember_zxnfVANPqE9a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--AsiaMember_zSdiGBDfrFEh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--AsiaMember_z0Q239bMGqR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">468</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--AsiaMember_zGzwQ41CFG4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">352</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_zqtJWAFgAK06" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zTMBThimpuLg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zhaxW50ijKAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zdLfsK0QaGw3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Major products/services lines</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--HardwareMember_zAAJaTet1AN2" style="width: 11%; text-align: right" title="Revenue">273</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--HardwareMember_zfWZHpYQCBe4" style="width: 11%; text-align: right" title="Revenue">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--HardwareMember_z3pYeHZ03h06" style="width: 11%; text-align: right" title="Revenue">994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--HardwareMember_zYyW5H4wrhfe" style="width: 11%; text-align: right" title="Revenue">532</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Consumables</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zONcP1a1v481" style="text-align: right" title="Revenue">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zWMfqllKV2Kj" style="text-align: right" title="Revenue">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zqb7Dg3RWNGb" style="text-align: right" title="Revenue">173</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zx6OlOnA4t3" style="text-align: right" title="Revenue">165</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contract research services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_zwmV8esZz5bh" style="text-align: right" title="Revenue">-1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_z2A4tgcgVgEc" style="text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_z8MAwpapsON1" style="text-align: right" title="Revenue">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_zy0y2jdmcGb5" style="text-align: right" title="Revenue">125</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sample preparation accessories</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_zbtDwY0Pvnk1" style="text-align: right" title="Revenue">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_z1NmnwQExDR5" style="text-align: right" title="Revenue">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_zcOWOPDmLaec" style="text-align: right" title="Revenue">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_z5qbjQ8QNxA8" style="text-align: right" title="Revenue">93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Technical support/extended service contracts</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_z0MfNLaP5GFk" style="text-align: right" title="Revenue">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_zD9WaNRv98gd" style="text-align: right" title="Revenue">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_z1seuCVKPLYj" style="text-align: right" title="Revenue">123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_zfcJcy9S1qB7" style="text-align: right" title="Revenue">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Agrochem Products</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zPMYNOyNRlF6" style="text-align: right" title="Revenue">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zLTpj0irDCPa" style="text-align: right" title="Revenue">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zPTJkEnL9gg" style="text-align: right" title="Revenue">181</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zx9KDLIAAlL4" style="text-align: right" title="Revenue">93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shipping and handling</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z88JlCnp0FP6" style="text-align: right" title="Revenue">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zykJkD2KMeA7" style="text-align: right" title="Revenue">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zJJw8XcATuKc" style="text-align: right" title="Revenue">38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zf2bpI0ATuS7" style="text-align: right" title="Revenue">20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--OtherMember_ziwEKKG2d3M2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1350">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--OtherMember_zdH9miiSMZj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--OtherMember_zWK729ZeNCF8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--OtherMember_zX7Z4UKPqSx" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_z6mLq9XuUl7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zoVvntUu9Ex9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zv4bh9wznnza" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zB8myZ1hLiKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Timing of revenue recognition</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Products transferred at a point in time</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_znrJ5K2hsfOj" style="width: 11%; text-align: right" title="Revenue">379</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_zhPeJezQfzp9" style="width: 11%; text-align: right" title="Revenue">103</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_z9o6KJJwgTb5" style="width: 11%; text-align: right" title="Revenue">1,506</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_z4O4aG9Rqo78" style="width: 11%; text-align: right" title="Revenue">903</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Services transferred over time</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zXVLgkVBgt6d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zHcCGieDU7Ll" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">41</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zDNVTheeLQh3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zjAWJtCeCc7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">219</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_zPBomX4cuMx9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zGPRy1RjQ8I6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zblBgAYkoS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zWqvKXBsqH12" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zxJ56sERkork" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zsl4Iy9sXE2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract balances</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_z1O0wkbJ1zk7" style="display: none">Schedule of Contract Balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: justify">In thousands of US dollars ($)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230930_zOYUIQZUatw7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zyv9Loq41Fm7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_iI_pn3n3_zUeLqgjbluB6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Receivables, which are included in ‘Accounts Receivable’</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">329</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">295</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredRevenue_iI_pn3n3_zvN5jGxlIXN5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contract liabilities (deferred revenue)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zAo8h0UsjYYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transaction price allocated to the remaining performance obligations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_z7FbYa0qAKAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zzKjyi8BmDej" style="display: none">Schedule of Future Related to Performance Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic">In thousands of US dollars ($)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Extended warranty service</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandAndTwentyThreeMember_zuY91bpRacli" style="width: 14%; text-align: right" title="Extended warranty service">48</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandAndTwentyFourMember_zfUnS2jjSwui" style="width: 14%; text-align: right" title="Extended warranty service">11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930_zIaOI56aV00h" style="width: 14%; text-align: right" title="Extended warranty service">59</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zHRtVpkDCQk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All consideration from contracts with customers is included in the amounts presented above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Costs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zMl2RlXnukI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZTiEoNRkMLd">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zXPtacHaIwJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zACmltS78MG6" style="display: none">Schedule of Customer Concentration Risk Percentage</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeOV2M2NpGd9" style="width: 11%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQs8EYL9nSg6" style="width: 11%; text-align: right" title="Concentration credit risk percentage">42</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9qY1ynSdOyc" style="width: 11%; text-align: right" title="Concentration credit risk percentage">49</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3wUAEHD9Ail" style="width: 11%; text-align: right" title="Concentration credit risk percentage">31</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfbfUmA1sia5" style="text-align: right" title="Concentration credit risk percentage">18</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znLYxRJ430eh" style="text-align: right" title="Concentration credit risk percentage">4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztBRvAsF3lSb" style="text-align: right" title="Concentration credit risk percentage">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUK4GDfjvYZi" style="text-align: right" title="Concentration credit risk percentage">1</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVAFETEZyde" style="width: 16%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbIgSLLagjAi" style="width: 16%; text-align: right" title="Concentration credit risk percentage">93</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFxDHad8RHV2" style="text-align: right" title="Concentration credit risk percentage">22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAoa40X5b2Q2" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A4_zyn5ewVgcUDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_ecustom--ProductSupplyPolicyTextBlock_zVMtDKyyDhce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zcnDL6r7yrFi">Product Supply</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNC Machining</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Assembly &amp; Kitting</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Component and Subassembly Design</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory Management</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ISO certification</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--InvestmentPolicyTextBlock_zqzayEz1A5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zPrx6BI5lTr1">Investment in Equity Securities</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, we held <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230930__dei--LegalEntityAxis__custom--NexityGlobalSAMember_z55HUkuLqsrj" title="Sale of stock number of shares received">100,250</span> shares of common stock of Nexity Global SA, (a Polish publicly traded company).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $<span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20230930__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zzCoCzWdrCSj" title="Investment owned, at fair value">77,918</span>. We recorded $<span id="xdx_90A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zTNZ4ep6wjK7" title="Unrealized gain">14,280</span> as an unrealized gain during the nine months ended September 30, 2023 for changes in market value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zfTNoUH2YHSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zeuZW8DBdpwh">Computation of Loss per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zernyoySwxG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zKlrYpZv8qFa" style="display: none">Schedule of Computation of Loss Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230701__20230930_zIpZv04IxzU5" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220701__20220930_zQYvf2iomG9c" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zSd2BW7PrJs2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20220930_zcvu4Nf72DFj" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_znmtpRM8eQB9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,261,999</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(4,893,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(24,666,565</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(12,913,826</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Denominator for basic and diluted loss per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Weighted average common stock shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20230930_zu33jbbMebqa" title="Weighted average common stock shares outstanding basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20230930_zxPsATrihhb3" title="Weighted average common stock shares outstanding diluted">21,716,950</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220701__20220930_zHM521mHgJQ5" title="Weighted average common stock shares outstanding basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220701__20220930_zoqhQAtiSjB5" title="Weighted average common stock shares outstanding diluted">11,131,742</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230930_zd31G98Xlj89" title="Weighted average common stock shares outstanding basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230930_zL3P3RyPosL3" title="Weighted average common stock shares outstanding diluted">20,337,229</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20220930_zdTWfNRrNNI6" title="Weighted average common stock shares outstanding basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20220930_zWji9jEQJCxf" title="Weighted average common stock shares outstanding diluted">10,429,817</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Loss per common share - basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230701__20230930_zpeZzHOEfSsf" title="Loss per common share - basic"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230701__20230930_z3gPUh8mdNHk" title="Loss per common share - diluted">(0.29</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20220701__20220930_zLgCOkTVANB9" title="Loss per common share - basic"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20220701__20220930_z2Uur7ah0y61" title="Loss per common share - diluted">(0.44</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20230930_z87k2vwmaWYa" title="Loss per common share - basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20230101__20230930_zkeMI3loszw1" title="Loss per common share - diluted">(1.21</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20220101__20220930_zryV4cvnpk0i" title="Loss per common share - basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20220930_zdPxxHN0HTdb" title="Loss per common share - diluted">(1.24</span></span></td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8AF_z2vekmV0XDHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms.</span></p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwwZ81VsHHv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zk0t6TFJeMY8" style="display: none">Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of September 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EmployeeStockOptionsMember_zKzprQQ1al0l" style="width: 16%; text-align: right" title="Total potentially dilutive shares">3,420,754</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EmployeeStockOptionsMember_zmPBQdUMSHxb" style="width: 16%; text-align: right" title="Total potentially dilutive shares">1,307,822</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z86s91hm0x1g" style="text-align: right" title="Total potentially dilutive shares">7,417,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zoP45ZX9xIA6" style="text-align: right" title="Total potentially dilutive shares">6,471,034</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zed7LuSMv80e" style="text-align: right" title="Total potentially dilutive shares">15,732,940</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zH2vXKHcn361" style="text-align: right" title="Total potentially dilutive shares">16,293,768</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible preferred stock:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series D Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertiblePreferredStockMember_zhzzuFpwBMa5" style="text-align: right" title="Total potentially dilutive shares">6,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertiblePreferredStockMember_zZwyupFdo096" style="text-align: right" title="Total potentially dilutive shares">25,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series G Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGConvertiblePreferredStockMember_zNJiJ4zujcwh" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGConvertiblePreferredStockMember_zapzqul5w13c" style="text-align: right" title="Total potentially dilutive shares">26,857</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series H Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHConvertiblePreferredStockMember_z27PMZOx8Br6" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1507">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHConvertiblePreferredStockMember_z4yPZ6iOMcr6" style="text-align: right" title="Total potentially dilutive shares">33,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series H2 Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHTwoConvertiblePreferredStockMember_zKlxNoslUtpi" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1511">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHTwoConvertiblePreferredStockMember_zI7uDonmRMO8" style="text-align: right" title="Total potentially dilutive shares">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series J Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesJConvertiblePreferredStockMember_zErLR68jzD5a" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1515">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesJConvertiblePreferredStockMember_zIN3CyTmVzL9" style="text-align: right" title="Total potentially dilutive shares">115,267</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series K Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesKConvertiblePreferredStockMember_zJN66FqrL7e" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1519">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesKConvertiblePreferredStockMember_zMHRbw5oY1H5" style="text-align: right" title="Total potentially dilutive shares">229,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series AA Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAAConvertiblePreferredStockMember_zyLvU21YWDyd" style="text-align: right" title="Total potentially dilutive shares">8,601,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAAConvertiblePreferredStockMember_z8N1xHhM0G5b" style="text-align: right" title="Total potentially dilutive shares">8,645,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series BB Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBBConvertiblePreferredStockMember_zX0qgenRdo21" style="text-align: right" title="Total potentially dilutive shares">8,580,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBBConvertiblePreferredStockMember_zhpXsQpIN6Jf" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Series CC Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCCConvertiblePreferredStockMember_zTcnvcexCpj3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">4,010,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCCConvertiblePreferredStockMember_zKC8CAe1avKl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1533">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_zaXiQkgW5iD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">47,768,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930_zk2P153nfbT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">33,217,416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zxNSqJq0Sz2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zCeugVS9ktr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z20PgzYpcmme">Accounting for Stock-Based Compensation Expense</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Determining Fair Value of Stock Option Grants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zbRqGakyMYFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zs1Glrm3Exgj" style="display: none">Summary of Assumptions for Grants of Stock Options</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Assumptions</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">CEO, other Officers and Employees</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_zcu9lUpNlNxg" title="Expected life">6.0</span> (yrs)</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_z4qSHw8Aw3n4" style="width: 36%; text-align: right" title="Expected volatility">130.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_ziIKJGL0mtad" style="text-align: right" title="Risk-free interest rate">3.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember__srt--RangeAxis__srt--MinimumMember_zVmOcGDdusoa" title="Forfeiture rate">0</span> to <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember__srt--RangeAxis__srt--MaximumMember_z7vqDAJ1ZLv2" title="Forfeiture rate">5.00</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_zHtrE0PEduTk" style="text-align: right" title="Expected dividend yield">0.0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p> <p id="xdx_8AC_znTmr1Xi0Jrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of <span id="xdx_908_ecustom--ForfeitureRate_iI_pid_dp_c20230930__srt--RangeAxis__srt--MinimumMember_zo1I8M9UcBgf" title="Forfeiture rate">0</span>% to <span id="xdx_90E_ecustom--ForfeitureRate_iI_pid_dp_c20230930__srt--RangeAxis__srt--MaximumMember_zFFBf8rCkKgl" title="Forfeiture rate">5</span>% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930_zTc9SaXRYHic" title="Stock-based compensation expense">140,622</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930_zFuHuuPd9SJe" title="Stock-based compensation expense">32,427</span> for the three months ended September 30, 2023 and 2022, respectively. The company recognized stock-based compensation expense of $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930_zjBSbGUHhFd4" title="Stock-based compensation expense">1,706,420</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930_zTDMsnZi2Ld9" title="Stock-based compensation expense">128,984</span> for the nine months ended September 30, 2023 and 2022, respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations:</span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zcJMgq4fJlU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B5_zHRRIfdzLiqg" style="display: none">Schedule of Stock Based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cost of sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4HtMS7qVtc1" style="width: 11%; text-align: right" title="Total stock-based compensation expense">11,183</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zA239yJxgMjk" style="width: 11%; text-align: right" title="Total stock-based compensation expense">2,184</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zp0I03TMQcef" style="width: 11%; text-align: right" title="Total stock-based compensation expense">75,724</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zxpz1lWqGFh8" style="width: 11%; text-align: right" title="Total stock-based compensation expense">8,694</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zIkLxMmGV8Q7" style="text-align: right" title="Total stock-based compensation expense">35,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyU6p8aI5lX9" style="text-align: right" title="Total stock-based compensation expense">9,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDUYaIcKZhLi" style="text-align: right" title="Total stock-based compensation expense">241,585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBdUaFlMyWGg" style="text-align: right" title="Total stock-based compensation expense">37,803</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Selling and marketing</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoJRQ20jkXc" style="text-align: right" title="Total stock-based compensation expense">17,150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zBqlZm3wlPVl" style="text-align: right" title="Total stock-based compensation expense">4,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zcrnPi7SArt9" style="text-align: right" title="Total stock-based compensation expense">102,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z60h6MpCvhPc" style="text-align: right" title="Total stock-based compensation expense">18,166</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHqKaXYOTA4h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">76,613</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zROorCQQRm46" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">16,161</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJgc38c3DFV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">1,286,436</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvUJChfmTt0j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">64,321</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930_zpQyMh2wm1Ah" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">140,622</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930_zJtcMLPGhvfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">32,427</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930_zKu1pp9An08" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,706,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930_zSBXFCnGUje3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">128,984</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zba7ubpi3HR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zmq1IUVBFRZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zvfSAsUIJs27">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance of FASB ASC Topic 820, “<i>Fair Value Measurements and Disclosures</i>” (“ASC 820”) as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2uu3pYTDzCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B3_zmRr0bQw0oHl" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value measurements at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023 using:</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>active</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>markets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>observable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unobservable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Equity Securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember_z9ns0juYIqj6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">77,918</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zc77UvBGv3u7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">77,918</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPIAOZrtVI78" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">       <span style="-sec-ix-hidden: xdx2ixbrl1617">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWPSet3Rgbzb" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">        <span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Financial Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930_z4fJpCsUUUyc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">77,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zhJC7ANgNJmf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">77,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFfc4Pcy1sq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1625">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrWptIRBZMDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value measurements at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022 using:</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>active</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>markets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>observable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unobservable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Equity Securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember_zjldcxKtPLri" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">63,638</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVJDbWYbut85" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">63,638</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPt0LHbLozoa" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">       <span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbW1mUxBaHph" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">         <span style="-sec-ix-hidden: xdx2ixbrl1635">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Financial Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231_zWxrStH3qWsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">63,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjml2xuvgbRb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">63,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zycMjQwbUcpe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1641">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znlTGW2sRhbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zStUQlg4bod9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zA1qr4Z05bJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zRrZM1wA0w7h">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2022. Operating results for the nine months ended September 30, 2023 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zYraWLwCbbDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zm5R37SknlC9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--RecentAccountingPronouncementPolicyTextBlock_zkiiWvgrUr9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z8Yw4tqwwvTh">Recent Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $<span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_iI_c20200830_zZOSi0z1eXng" title="Cumulative effect of adoption, adjustment in additional paid in capital">2,728,243</span> decrease in additional paid in capital and a $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20200830_zfIBRyVaToO5" title="Cumulative effect of adoption, adjustment in accumulated deficit">2,255,216</span> decrease in accumulated deficit. There is no material impact to the Company’s statements of operations or cash flows as the result of the adoption of ASU 2020-06.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which requires measurement and recognition of expected credit losses for financial assets held. We adopted this new accounting guidance effective January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and disclosures and did not significantly impact the Company’s accounting policies or estimation methods related to the allowance for doubtful accounts. The Company does not have any reserve for doubtful accounts due to its customers being distributors, universities, research organizations and government agencies. In the past several years, all its customers have paid in full without any need for a write-down.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> 2728243 2255216 <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zArMK4fMgqq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zzJstJ5fFvx3">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84A_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z8qehkk4HjPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zaDwPzj0GFv3">Revenue Recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue in accordance with FASB ASC 606, <i>Revenue from Contracts with Customers, </i>and <i>ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers</i>. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. We enter sales contracts that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period. We measure and allocate revenue according to ASC 606-10.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues as consistent with treatment in prior periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer takes on the significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the asset or service involved is not determinable.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transaction lacks commercial substance.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disaggregation of revenue</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zNOIVVqdMU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B1_zf9a0OF5yTud" style="display: none">Schedule of Disaggregation of Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic">In thousands of US dollars ($)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Primary geographical markets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">North America</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zWlyjSASPQ8f" style="width: 11%; text-align: right" title="Revenue">251</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zQfT9naI4ex1" style="width: 11%; text-align: right" title="Revenue">138</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zcijXGqr14Wc" style="width: 11%; text-align: right" title="Revenue">1,067</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zwoFwaSxEMg2" style="width: 11%; text-align: right" title="Revenue">709</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Europe</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--EuropeMember_zKAwbpHPpwHe" style="text-align: right" title="Revenue">76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--EuropeMember_z1Pi82n6UVlb" style="text-align: right" title="Revenue">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--EuropeMember_zHEyiVeUQmW3" style="text-align: right" title="Revenue">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--EuropeMember_zIMnMpeBL9Wg" style="text-align: right" title="Revenue">61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Asia</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--AsiaMember_zxnfVANPqE9a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--AsiaMember_zSdiGBDfrFEh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--AsiaMember_z0Q239bMGqR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">468</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--AsiaMember_zGzwQ41CFG4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">352</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_zqtJWAFgAK06" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zTMBThimpuLg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zhaxW50ijKAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zdLfsK0QaGw3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Major products/services lines</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--HardwareMember_zAAJaTet1AN2" style="width: 11%; text-align: right" title="Revenue">273</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--HardwareMember_zfWZHpYQCBe4" style="width: 11%; text-align: right" title="Revenue">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--HardwareMember_z3pYeHZ03h06" style="width: 11%; text-align: right" title="Revenue">994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--HardwareMember_zYyW5H4wrhfe" style="width: 11%; text-align: right" title="Revenue">532</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Consumables</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zONcP1a1v481" style="text-align: right" title="Revenue">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zWMfqllKV2Kj" style="text-align: right" title="Revenue">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zqb7Dg3RWNGb" style="text-align: right" title="Revenue">173</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zx6OlOnA4t3" style="text-align: right" title="Revenue">165</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contract research services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_zwmV8esZz5bh" style="text-align: right" title="Revenue">-1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_z2A4tgcgVgEc" style="text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_z8MAwpapsON1" style="text-align: right" title="Revenue">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_zy0y2jdmcGb5" style="text-align: right" title="Revenue">125</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sample preparation accessories</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_zbtDwY0Pvnk1" style="text-align: right" title="Revenue">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_z1NmnwQExDR5" style="text-align: right" title="Revenue">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_zcOWOPDmLaec" style="text-align: right" title="Revenue">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_z5qbjQ8QNxA8" style="text-align: right" title="Revenue">93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Technical support/extended service contracts</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_z0MfNLaP5GFk" style="text-align: right" title="Revenue">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_zD9WaNRv98gd" style="text-align: right" title="Revenue">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_z1seuCVKPLYj" style="text-align: right" title="Revenue">123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_zfcJcy9S1qB7" style="text-align: right" title="Revenue">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Agrochem Products</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zPMYNOyNRlF6" style="text-align: right" title="Revenue">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zLTpj0irDCPa" style="text-align: right" title="Revenue">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zPTJkEnL9gg" style="text-align: right" title="Revenue">181</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zx9KDLIAAlL4" style="text-align: right" title="Revenue">93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shipping and handling</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z88JlCnp0FP6" style="text-align: right" title="Revenue">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zykJkD2KMeA7" style="text-align: right" title="Revenue">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zJJw8XcATuKc" style="text-align: right" title="Revenue">38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zf2bpI0ATuS7" style="text-align: right" title="Revenue">20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--OtherMember_ziwEKKG2d3M2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1350">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--OtherMember_zdH9miiSMZj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--OtherMember_zWK729ZeNCF8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--OtherMember_zX7Z4UKPqSx" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_z6mLq9XuUl7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zoVvntUu9Ex9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zv4bh9wznnza" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zB8myZ1hLiKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Timing of revenue recognition</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Products transferred at a point in time</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_znrJ5K2hsfOj" style="width: 11%; text-align: right" title="Revenue">379</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_zhPeJezQfzp9" style="width: 11%; text-align: right" title="Revenue">103</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_z9o6KJJwgTb5" style="width: 11%; text-align: right" title="Revenue">1,506</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_z4O4aG9Rqo78" style="width: 11%; text-align: right" title="Revenue">903</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Services transferred over time</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zXVLgkVBgt6d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zHcCGieDU7Ll" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">41</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zDNVTheeLQh3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zjAWJtCeCc7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">219</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_zPBomX4cuMx9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zGPRy1RjQ8I6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zblBgAYkoS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zWqvKXBsqH12" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zxJ56sERkork" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zsl4Iy9sXE2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract balances</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_z1O0wkbJ1zk7" style="display: none">Schedule of Contract Balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: justify">In thousands of US dollars ($)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230930_zOYUIQZUatw7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zyv9Loq41Fm7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_iI_pn3n3_zUeLqgjbluB6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Receivables, which are included in ‘Accounts Receivable’</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">329</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">295</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredRevenue_iI_pn3n3_zvN5jGxlIXN5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contract liabilities (deferred revenue)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zAo8h0UsjYYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transaction price allocated to the remaining performance obligations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_z7FbYa0qAKAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zzKjyi8BmDej" style="display: none">Schedule of Future Related to Performance Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic">In thousands of US dollars ($)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Extended warranty service</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandAndTwentyThreeMember_zuY91bpRacli" style="width: 14%; text-align: right" title="Extended warranty service">48</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandAndTwentyFourMember_zfUnS2jjSwui" style="width: 14%; text-align: right" title="Extended warranty service">11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930_zIaOI56aV00h" style="width: 14%; text-align: right" title="Extended warranty service">59</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zHRtVpkDCQk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All consideration from contracts with customers is included in the amounts presented above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract Costs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_zNOIVVqdMU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B1_zf9a0OF5yTud" style="display: none">Schedule of Disaggregation of Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic">In thousands of US dollars ($)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Primary geographical markets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">North America</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zWlyjSASPQ8f" style="width: 11%; text-align: right" title="Revenue">251</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zQfT9naI4ex1" style="width: 11%; text-align: right" title="Revenue">138</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zcijXGqr14Wc" style="width: 11%; text-align: right" title="Revenue">1,067</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--NorthAmericaMember_zwoFwaSxEMg2" style="width: 11%; text-align: right" title="Revenue">709</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Europe</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--EuropeMember_zKAwbpHPpwHe" style="text-align: right" title="Revenue">76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--EuropeMember_z1Pi82n6UVlb" style="text-align: right" title="Revenue">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--EuropeMember_zHEyiVeUQmW3" style="text-align: right" title="Revenue">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--EuropeMember_zIMnMpeBL9Wg" style="text-align: right" title="Revenue">61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Asia</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__srt--AsiaMember_zxnfVANPqE9a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__srt--AsiaMember_zSdiGBDfrFEh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__srt--AsiaMember_z0Q239bMGqR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">468</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__srt--AsiaMember_zGzwQ41CFG4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">352</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_zqtJWAFgAK06" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zTMBThimpuLg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zhaxW50ijKAi" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zdLfsK0QaGw3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Major products/services lines</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--HardwareMember_zAAJaTet1AN2" style="width: 11%; text-align: right" title="Revenue">273</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--HardwareMember_zfWZHpYQCBe4" style="width: 11%; text-align: right" title="Revenue">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--HardwareMember_z3pYeHZ03h06" style="width: 11%; text-align: right" title="Revenue">994</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--HardwareMember_zYyW5H4wrhfe" style="width: 11%; text-align: right" title="Revenue">532</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Consumables</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zONcP1a1v481" style="text-align: right" title="Revenue">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zWMfqllKV2Kj" style="text-align: right" title="Revenue">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zqb7Dg3RWNGb" style="text-align: right" title="Revenue">173</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--ConsumablesMember_zx6OlOnA4t3" style="text-align: right" title="Revenue">165</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contract research services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_zwmV8esZz5bh" style="text-align: right" title="Revenue">-1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_z2A4tgcgVgEc" style="text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_z8MAwpapsON1" style="text-align: right" title="Revenue">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--ContractResearchServicesMember_zy0y2jdmcGb5" style="text-align: right" title="Revenue">125</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sample preparation accessories</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_zbtDwY0Pvnk1" style="text-align: right" title="Revenue">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_z1NmnwQExDR5" style="text-align: right" title="Revenue">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_zcOWOPDmLaec" style="text-align: right" title="Revenue">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--SamplePreparationAccessoriesMember_z5qbjQ8QNxA8" style="text-align: right" title="Revenue">93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Technical support/extended service contracts</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_z0MfNLaP5GFk" style="text-align: right" title="Revenue">34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_zD9WaNRv98gd" style="text-align: right" title="Revenue">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_z1seuCVKPLYj" style="text-align: right" title="Revenue">123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TechnicalSupportExtendedServiceContractsMember_zfcJcy9S1qB7" style="text-align: right" title="Revenue">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Agrochem Products</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zPMYNOyNRlF6" style="text-align: right" title="Revenue">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zLTpj0irDCPa" style="text-align: right" title="Revenue">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zPTJkEnL9gg" style="text-align: right" title="Revenue">181</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--AgrochemProductsMember_zx9KDLIAAlL4" style="text-align: right" title="Revenue">93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shipping and handling</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z88JlCnp0FP6" style="text-align: right" title="Revenue">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zykJkD2KMeA7" style="text-align: right" title="Revenue">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zJJw8XcATuKc" style="text-align: right" title="Revenue">38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zf2bpI0ATuS7" style="text-align: right" title="Revenue">20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--OtherMember_ziwEKKG2d3M2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1350">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--OtherMember_zdH9miiSMZj4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1352">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--OtherMember_zWK729ZeNCF8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--OtherMember_zX7Z4UKPqSx" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_z6mLq9XuUl7d" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zoVvntUu9Ex9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zv4bh9wznnza" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zB8myZ1hLiKb" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Timing of revenue recognition</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Products transferred at a point in time</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_znrJ5K2hsfOj" style="width: 11%; text-align: right" title="Revenue">379</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_zhPeJezQfzp9" style="width: 11%; text-align: right" title="Revenue">103</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_z9o6KJJwgTb5" style="width: 11%; text-align: right" title="Revenue">1,506</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TransferredAtAPointInTimeMember_z4O4aG9Rqo78" style="width: 11%; text-align: right" title="Revenue">903</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Services transferred over time</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zXVLgkVBgt6d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zHcCGieDU7Ll" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">41</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zDNVTheeLQh3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">159</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__custom--TransferredOverAtTimeMember_zjAWJtCeCc7d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">219</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930_zPBomX4cuMx9" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930_zGPRy1RjQ8I6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930_zblBgAYkoS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,665</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930_zWqvKXBsqH12" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">1,122</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 251000 138000 1067000 709000 76000 13000 130000 61000 86000 -7000 468000 352000 413000 144000 1665000 1122000 273000 1000 994000 532000 50000 49000 173000 165000 -1000 35000 125000 31000 41000 113000 93000 34000 41000 123000 94000 15000 10000 181000 93000 11000 2000 38000 20000 8000 413000 144000 1665000 1122000 379000 103000 1506000 903000 34000 41000 159000 219000 413000 144000 1665000 1122000 <p id="xdx_896_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zsl4Iy9sXE2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contract balances</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_z1O0wkbJ1zk7" style="display: none">Schedule of Contract Balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: justify">In thousands of US dollars ($)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20230930_zOYUIQZUatw7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zyv9Loq41Fm7" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_iI_pn3n3_zUeLqgjbluB6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Receivables, which are included in ‘Accounts Receivable’</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">329</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">295</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredRevenue_iI_pn3n3_zvN5jGxlIXN5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contract liabilities (deferred revenue)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td></tr> </table> 329000 295000 59000 60000 <p id="xdx_898_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_z7FbYa0qAKAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B0_zzKjyi8BmDej" style="display: none">Schedule of Future Related to Performance Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-style: italic">In thousands of US dollars ($)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Extended warranty service</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandAndTwentyThreeMember_zuY91bpRacli" style="width: 14%; text-align: right" title="Extended warranty service">48</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930__us-gaap--AwardDateAxis__custom--TwoThousandAndTwentyFourMember_zfUnS2jjSwui" style="width: 14%; text-align: right" title="Extended warranty service">11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ExtendedWarrantyService_iI_pn3n3_c20230930_zIaOI56aV00h" style="width: 14%; text-align: right" title="Extended warranty service">59</td><td style="width: 1%; text-align: left"> </td></tr> </table> 48000 11000 59000 <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zMl2RlXnukI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zZTiEoNRkMLd">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zXPtacHaIwJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zACmltS78MG6" style="display: none">Schedule of Customer Concentration Risk Percentage</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeOV2M2NpGd9" style="width: 11%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQs8EYL9nSg6" style="width: 11%; text-align: right" title="Concentration credit risk percentage">42</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9qY1ynSdOyc" style="width: 11%; text-align: right" title="Concentration credit risk percentage">49</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3wUAEHD9Ail" style="width: 11%; text-align: right" title="Concentration credit risk percentage">31</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfbfUmA1sia5" style="text-align: right" title="Concentration credit risk percentage">18</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znLYxRJ430eh" style="text-align: right" title="Concentration credit risk percentage">4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztBRvAsF3lSb" style="text-align: right" title="Concentration credit risk percentage">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUK4GDfjvYZi" style="text-align: right" title="Concentration credit risk percentage">1</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVAFETEZyde" style="width: 16%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbIgSLLagjAi" style="width: 16%; text-align: right" title="Concentration credit risk percentage">93</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFxDHad8RHV2" style="text-align: right" title="Concentration credit risk percentage">22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAoa40X5b2Q2" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A4_zyn5ewVgcUDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--FairValueConcentrationOfRiskTextBlock_zXPtacHaIwJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B9_zACmltS78MG6" style="display: none">Schedule of Customer Concentration Risk Percentage</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine months Ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeOV2M2NpGd9" style="width: 11%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQs8EYL9nSg6" style="width: 11%; text-align: right" title="Concentration credit risk percentage">42</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9qY1ynSdOyc" style="width: 11%; text-align: right" title="Concentration credit risk percentage">49</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3wUAEHD9Ail" style="width: 11%; text-align: right" title="Concentration credit risk percentage">31</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zfbfUmA1sia5" style="text-align: right" title="Concentration credit risk percentage">18</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znLYxRJ430eh" style="text-align: right" title="Concentration credit risk percentage">4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztBRvAsF3lSb" style="text-align: right" title="Concentration credit risk percentage">5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUK4GDfjvYZi" style="text-align: right" title="Concentration credit risk percentage">1</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2023 and December 31, 2022. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Top five customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVAFETEZyde" style="width: 16%; text-align: right" title="Concentration credit risk percentage">80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbIgSLLagjAi" style="width: 16%; text-align: right" title="Concentration credit risk percentage">93</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFxDHad8RHV2" style="text-align: right" title="Concentration credit risk percentage">22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAoa40X5b2Q2" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td></tr> </table> 0.80 0.42 0.49 0.31 0.18 0.04 0.05 0.01 0.80 0.93 0.22 0 <p id="xdx_840_ecustom--ProductSupplyPolicyTextBlock_zVMtDKyyDhce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zcnDL6r7yrFi">Product Supply</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CNC Machining</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Assembly &amp; Kitting</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Component and Subassembly Design</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory Management</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ISO certification</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers (one of the largest life science instrument manufacturers in the U.S.). We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during Q3 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--InvestmentPolicyTextBlock_zqzayEz1A5f1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zPrx6BI5lTr1">Investment in Equity Securities</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, we held <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230101__20230930__dei--LegalEntityAxis__custom--NexityGlobalSAMember_z55HUkuLqsrj" title="Sale of stock number of shares received">100,250</span> shares of common stock of Nexity Global SA, (a Polish publicly traded company).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities.” ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $<span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_iI_pp0p0_c20230930__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zzCoCzWdrCSj" title="Investment owned, at fair value">77,918</span>. We recorded $<span id="xdx_90A_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--NexityGlobalSAMember_zTNZ4ep6wjK7" title="Unrealized gain">14,280</span> as an unrealized gain during the nine months ended September 30, 2023 for changes in market value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 100250 77918 14280 <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zfTNoUH2YHSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zeuZW8DBdpwh">Computation of Loss per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zernyoySwxG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zKlrYpZv8qFa" style="display: none">Schedule of Computation of Loss Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230701__20230930_zIpZv04IxzU5" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220701__20220930_zQYvf2iomG9c" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zSd2BW7PrJs2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20220930_zcvu4Nf72DFj" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_znmtpRM8eQB9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,261,999</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(4,893,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(24,666,565</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(12,913,826</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Denominator for basic and diluted loss per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Weighted average common stock shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20230930_zu33jbbMebqa" title="Weighted average common stock shares outstanding basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20230930_zxPsATrihhb3" title="Weighted average common stock shares outstanding diluted">21,716,950</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220701__20220930_zHM521mHgJQ5" title="Weighted average common stock shares outstanding basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220701__20220930_zoqhQAtiSjB5" title="Weighted average common stock shares outstanding diluted">11,131,742</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230930_zd31G98Xlj89" title="Weighted average common stock shares outstanding basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230930_zL3P3RyPosL3" title="Weighted average common stock shares outstanding diluted">20,337,229</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20220930_zdTWfNRrNNI6" title="Weighted average common stock shares outstanding basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20220930_zWji9jEQJCxf" title="Weighted average common stock shares outstanding diluted">10,429,817</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Loss per common share - basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230701__20230930_zpeZzHOEfSsf" title="Loss per common share - basic"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230701__20230930_z3gPUh8mdNHk" title="Loss per common share - diluted">(0.29</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20220701__20220930_zLgCOkTVANB9" title="Loss per common share - basic"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20220701__20220930_z2Uur7ah0y61" title="Loss per common share - diluted">(0.44</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20230930_z87k2vwmaWYa" title="Loss per common share - basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20230101__20230930_zkeMI3loszw1" title="Loss per common share - diluted">(1.21</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20220101__20220930_zryV4cvnpk0i" title="Loss per common share - basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20220930_zdPxxHN0HTdb" title="Loss per common share - diluted">(1.24</span></span></td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8AF_z2vekmV0XDHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, Series AA Convertible Preferred Stock, Series BB Convertible Stock and Series CC Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms.</span></p> <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwwZ81VsHHv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zk0t6TFJeMY8" style="display: none">Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of September 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EmployeeStockOptionsMember_zKzprQQ1al0l" style="width: 16%; text-align: right" title="Total potentially dilutive shares">3,420,754</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EmployeeStockOptionsMember_zmPBQdUMSHxb" style="width: 16%; text-align: right" title="Total potentially dilutive shares">1,307,822</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z86s91hm0x1g" style="text-align: right" title="Total potentially dilutive shares">7,417,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zoP45ZX9xIA6" style="text-align: right" title="Total potentially dilutive shares">6,471,034</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zed7LuSMv80e" style="text-align: right" title="Total potentially dilutive shares">15,732,940</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zH2vXKHcn361" style="text-align: right" title="Total potentially dilutive shares">16,293,768</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible preferred stock:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series D Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertiblePreferredStockMember_zhzzuFpwBMa5" style="text-align: right" title="Total potentially dilutive shares">6,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertiblePreferredStockMember_zZwyupFdo096" style="text-align: right" title="Total potentially dilutive shares">25,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series G Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGConvertiblePreferredStockMember_zNJiJ4zujcwh" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGConvertiblePreferredStockMember_zapzqul5w13c" style="text-align: right" title="Total potentially dilutive shares">26,857</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series H Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHConvertiblePreferredStockMember_z27PMZOx8Br6" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1507">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHConvertiblePreferredStockMember_z4yPZ6iOMcr6" style="text-align: right" title="Total potentially dilutive shares">33,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series H2 Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHTwoConvertiblePreferredStockMember_zKlxNoslUtpi" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1511">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHTwoConvertiblePreferredStockMember_zI7uDonmRMO8" style="text-align: right" title="Total potentially dilutive shares">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series J Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesJConvertiblePreferredStockMember_zErLR68jzD5a" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1515">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesJConvertiblePreferredStockMember_zIN3CyTmVzL9" style="text-align: right" title="Total potentially dilutive shares">115,267</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series K Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesKConvertiblePreferredStockMember_zJN66FqrL7e" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1519">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesKConvertiblePreferredStockMember_zMHRbw5oY1H5" style="text-align: right" title="Total potentially dilutive shares">229,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series AA Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAAConvertiblePreferredStockMember_zyLvU21YWDyd" style="text-align: right" title="Total potentially dilutive shares">8,601,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAAConvertiblePreferredStockMember_z8N1xHhM0G5b" style="text-align: right" title="Total potentially dilutive shares">8,645,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series BB Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBBConvertiblePreferredStockMember_zX0qgenRdo21" style="text-align: right" title="Total potentially dilutive shares">8,580,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBBConvertiblePreferredStockMember_zhpXsQpIN6Jf" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Series CC Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCCConvertiblePreferredStockMember_zTcnvcexCpj3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">4,010,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCCConvertiblePreferredStockMember_zKC8CAe1avKl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1533">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_zaXiQkgW5iD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">47,768,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930_zk2P153nfbT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">33,217,416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zxNSqJq0Sz2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_890_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zernyoySwxG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zKlrYpZv8qFa" style="display: none">Schedule of Computation of Loss Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230701__20230930_zIpZv04IxzU5" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220701__20220930_zQYvf2iomG9c" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230101__20230930_zSd2BW7PrJs2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20220930_zcvu4Nf72DFj" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_znmtpRM8eQB9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(6,261,999</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(4,893,946</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(24,666,565</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(12,913,826</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Denominator for basic and diluted loss per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Weighted average common stock shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20230930_zu33jbbMebqa" title="Weighted average common stock shares outstanding basic"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20230930_zxPsATrihhb3" title="Weighted average common stock shares outstanding diluted">21,716,950</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220701__20220930_zHM521mHgJQ5" title="Weighted average common stock shares outstanding basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220701__20220930_zoqhQAtiSjB5" title="Weighted average common stock shares outstanding diluted">11,131,742</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230930_zd31G98Xlj89" title="Weighted average common stock shares outstanding basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230930_zL3P3RyPosL3" title="Weighted average common stock shares outstanding diluted">20,337,229</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20220930_zdTWfNRrNNI6" title="Weighted average common stock shares outstanding basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20220930_zWji9jEQJCxf" title="Weighted average common stock shares outstanding diluted">10,429,817</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Loss per common share - basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230701__20230930_zpeZzHOEfSsf" title="Loss per common share - basic"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230701__20230930_z3gPUh8mdNHk" title="Loss per common share - diluted">(0.29</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20220701__20220930_zLgCOkTVANB9" title="Loss per common share - basic"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20220701__20220930_z2Uur7ah0y61" title="Loss per common share - diluted">(0.44</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20230930_z87k2vwmaWYa" title="Loss per common share - basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20230101__20230930_zkeMI3loszw1" title="Loss per common share - diluted">(1.21</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20220101__20220930_zryV4cvnpk0i" title="Loss per common share - basic"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20220101__20220930_zdPxxHN0HTdb" title="Loss per common share - diluted">(1.24</span></span></td><td style="text-align: left">)</td></tr> </table> -6261999 -4893946 -24666565 -12913826 21716950 21716950 11131742 11131742 20337229 20337229 10429817 10429817 -0.29 -0.29 -0.44 -0.44 -1.21 -1.21 -1.24 -1.24 <p id="xdx_897_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zwwZ81VsHHv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zk0t6TFJeMY8" style="display: none">Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">As of September 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EmployeeStockOptionsMember_zKzprQQ1al0l" style="width: 16%; text-align: right" title="Total potentially dilutive shares">3,420,754</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EmployeeStockOptionsMember_zmPBQdUMSHxb" style="width: 16%; text-align: right" title="Total potentially dilutive shares">1,307,822</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z86s91hm0x1g" style="text-align: right" title="Total potentially dilutive shares">7,417,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zoP45ZX9xIA6" style="text-align: right" title="Total potentially dilutive shares">6,471,034</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zed7LuSMv80e" style="text-align: right" title="Total potentially dilutive shares">15,732,940</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_zH2vXKHcn361" style="text-align: right" title="Total potentially dilutive shares">16,293,768</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible preferred stock:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series D Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertiblePreferredStockMember_zhzzuFpwBMa5" style="text-align: right" title="Total potentially dilutive shares">6,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesDConvertiblePreferredStockMember_zZwyupFdo096" style="text-align: right" title="Total potentially dilutive shares">25,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series G Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGConvertiblePreferredStockMember_zNJiJ4zujcwh" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesGConvertiblePreferredStockMember_zapzqul5w13c" style="text-align: right" title="Total potentially dilutive shares">26,857</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series H Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHConvertiblePreferredStockMember_z27PMZOx8Br6" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1507">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHConvertiblePreferredStockMember_z4yPZ6iOMcr6" style="text-align: right" title="Total potentially dilutive shares">33,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series H2 Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHTwoConvertiblePreferredStockMember_zKlxNoslUtpi" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1511">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesHTwoConvertiblePreferredStockMember_zI7uDonmRMO8" style="text-align: right" title="Total potentially dilutive shares">70,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series J Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesJConvertiblePreferredStockMember_zErLR68jzD5a" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1515">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesJConvertiblePreferredStockMember_zIN3CyTmVzL9" style="text-align: right" title="Total potentially dilutive shares">115,267</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series K Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesKConvertiblePreferredStockMember_zJN66FqrL7e" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1519">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesKConvertiblePreferredStockMember_zMHRbw5oY1H5" style="text-align: right" title="Total potentially dilutive shares">229,334</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series AA Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAAConvertiblePreferredStockMember_zyLvU21YWDyd" style="text-align: right" title="Total potentially dilutive shares">8,601,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAAConvertiblePreferredStockMember_z8N1xHhM0G5b" style="text-align: right" title="Total potentially dilutive shares">8,645,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series BB Convertible Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBBConvertiblePreferredStockMember_zX0qgenRdo21" style="text-align: right" title="Total potentially dilutive shares">8,580,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBBConvertiblePreferredStockMember_zhpXsQpIN6Jf" style="text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Series CC Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCCConvertiblePreferredStockMember_zTcnvcexCpj3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares">4,010,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesCCConvertiblePreferredStockMember_zKC8CAe1avKl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total potentially dilutive shares"><span style="-sec-ix-hidden: xdx2ixbrl1533">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_zaXiQkgW5iD2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">47,768,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220930_zk2P153nfbT1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive shares">33,217,416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3420754 1307822 7417906 6471034 15732940 16293768 6250 25000 26857 33334 70000 115267 229334 8601000 8645000 8580000 4010000 47768850 33217416 <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zCeugVS9ktr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z20PgzYpcmme">Accounting for Stock-Based Compensation Expense</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Determining Fair Value of Stock Option Grants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zbRqGakyMYFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zs1Glrm3Exgj" style="display: none">Summary of Assumptions for Grants of Stock Options</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Assumptions</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">CEO, other Officers and Employees</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_zcu9lUpNlNxg" title="Expected life">6.0</span> (yrs)</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_z4qSHw8Aw3n4" style="width: 36%; text-align: right" title="Expected volatility">130.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_ziIKJGL0mtad" style="text-align: right" title="Risk-free interest rate">3.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember__srt--RangeAxis__srt--MinimumMember_zVmOcGDdusoa" title="Forfeiture rate">0</span> to <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember__srt--RangeAxis__srt--MaximumMember_z7vqDAJ1ZLv2" title="Forfeiture rate">5.00</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_zHtrE0PEduTk" style="text-align: right" title="Expected dividend yield">0.0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p> <p id="xdx_8AC_znTmr1Xi0Jrk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation and Amortization Method - The fair value of each option award is estimated on the date of the grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of the expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of <span id="xdx_908_ecustom--ForfeitureRate_iI_pid_dp_c20230930__srt--RangeAxis__srt--MinimumMember_zo1I8M9UcBgf" title="Forfeiture rate">0</span>% to <span id="xdx_90E_ecustom--ForfeitureRate_iI_pid_dp_c20230930__srt--RangeAxis__srt--MaximumMember_zFFBf8rCkKgl" title="Forfeiture rate">5</span>% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price at time of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930_zTc9SaXRYHic" title="Stock-based compensation expense">140,622</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930_zFuHuuPd9SJe" title="Stock-based compensation expense">32,427</span> for the three months ended September 30, 2023 and 2022, respectively. The company recognized stock-based compensation expense of $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930_zjBSbGUHhFd4" title="Stock-based compensation expense">1,706,420</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930_zTDMsnZi2Ld9" title="Stock-based compensation expense">128,984</span> for the nine months ended September 30, 2023 and 2022, respectfully. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations:</span></p> <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zcJMgq4fJlU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B5_zHRRIfdzLiqg" style="display: none">Schedule of Stock Based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cost of sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4HtMS7qVtc1" style="width: 11%; text-align: right" title="Total stock-based compensation expense">11,183</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zA239yJxgMjk" style="width: 11%; text-align: right" title="Total stock-based compensation expense">2,184</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zp0I03TMQcef" style="width: 11%; text-align: right" title="Total stock-based compensation expense">75,724</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zxpz1lWqGFh8" style="width: 11%; text-align: right" title="Total stock-based compensation expense">8,694</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zIkLxMmGV8Q7" style="text-align: right" title="Total stock-based compensation expense">35,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyU6p8aI5lX9" style="text-align: right" title="Total stock-based compensation expense">9,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDUYaIcKZhLi" style="text-align: right" title="Total stock-based compensation expense">241,585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBdUaFlMyWGg" style="text-align: right" title="Total stock-based compensation expense">37,803</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Selling and marketing</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoJRQ20jkXc" style="text-align: right" title="Total stock-based compensation expense">17,150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zBqlZm3wlPVl" style="text-align: right" title="Total stock-based compensation expense">4,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zcrnPi7SArt9" style="text-align: right" title="Total stock-based compensation expense">102,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z60h6MpCvhPc" style="text-align: right" title="Total stock-based compensation expense">18,166</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHqKaXYOTA4h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">76,613</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zROorCQQRm46" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">16,161</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJgc38c3DFV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">1,286,436</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvUJChfmTt0j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">64,321</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930_zpQyMh2wm1Ah" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">140,622</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930_zJtcMLPGhvfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">32,427</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930_zKu1pp9An08" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,706,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930_zSBXFCnGUje3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">128,984</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zba7ubpi3HR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zbRqGakyMYFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the nine months ended September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zs1Glrm3Exgj" style="display: none">Summary of Assumptions for Grants of Stock Options</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Assumptions</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">CEO, other Officers and Employees</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_zcu9lUpNlNxg" title="Expected life">6.0</span> (yrs)</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_z4qSHw8Aw3n4" style="width: 36%; text-align: right" title="Expected volatility">130.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_ziIKJGL0mtad" style="text-align: right" title="Risk-free interest rate">3.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember__srt--RangeAxis__srt--MinimumMember_zVmOcGDdusoa" title="Forfeiture rate">0</span> to <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_dp_uPure_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember__srt--RangeAxis__srt--MaximumMember_z7vqDAJ1ZLv2" title="Forfeiture rate">5.00</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230101__20230930__us-gaap--PlanNameAxis__custom--EmployeesOfficersMember_zHtrE0PEduTk" style="text-align: right" title="Expected dividend yield">0.0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p> P6Y 1.305 0.0390 0 0.0500 0.000 0 0.05 140622 32427 1706420 128984 <p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zcJMgq4fJlU5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B5_zHRRIfdzLiqg" style="display: none">Schedule of Stock Based Compensation Expense</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Cost of sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_z4HtMS7qVtc1" style="width: 11%; text-align: right" title="Total stock-based compensation expense">11,183</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zA239yJxgMjk" style="width: 11%; text-align: right" title="Total stock-based compensation expense">2,184</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zp0I03TMQcef" style="width: 11%; text-align: right" title="Total stock-based compensation expense">75,724</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zxpz1lWqGFh8" style="width: 11%; text-align: right" title="Total stock-based compensation expense">8,694</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zIkLxMmGV8Q7" style="text-align: right" title="Total stock-based compensation expense">35,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyU6p8aI5lX9" style="text-align: right" title="Total stock-based compensation expense">9,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDUYaIcKZhLi" style="text-align: right" title="Total stock-based compensation expense">241,585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBdUaFlMyWGg" style="text-align: right" title="Total stock-based compensation expense">37,803</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Selling and marketing</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoJRQ20jkXc" style="text-align: right" title="Total stock-based compensation expense">17,150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zBqlZm3wlPVl" style="text-align: right" title="Total stock-based compensation expense">4,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zcrnPi7SArt9" style="text-align: right" title="Total stock-based compensation expense">102,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z60h6MpCvhPc" style="text-align: right" title="Total stock-based compensation expense">18,166</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHqKaXYOTA4h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">76,613</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zROorCQQRm46" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">16,161</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJgc38c3DFV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">1,286,436</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvUJChfmTt0j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stock-based compensation expense">64,321</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20230930_zpQyMh2wm1Ah" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">140,622</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20220930_zJtcMLPGhvfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">32,427</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20230930_zKu1pp9An08" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,706,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930_zSBXFCnGUje3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">128,984</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11183 2184 75724 8694 35676 9499 241585 37803 17150 4583 102675 18166 76613 16161 1286436 64321 140622 32427 1706420 128984 <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zmq1IUVBFRZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zvfSAsUIJs27">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance of FASB ASC Topic 820, “<i>Fair Value Measurements and Disclosures</i>” (“ASC 820”) as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2uu3pYTDzCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B3_zmRr0bQw0oHl" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value measurements at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023 using:</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>active</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>markets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>observable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unobservable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Equity Securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember_z9ns0juYIqj6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">77,918</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zc77UvBGv3u7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">77,918</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPIAOZrtVI78" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">       <span style="-sec-ix-hidden: xdx2ixbrl1617">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWPSet3Rgbzb" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">        <span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Financial Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930_z4fJpCsUUUyc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">77,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zhJC7ANgNJmf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">77,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFfc4Pcy1sq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1625">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrWptIRBZMDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value measurements at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022 using:</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>active</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>markets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>observable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unobservable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Equity Securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember_zjldcxKtPLri" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">63,638</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVJDbWYbut85" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">63,638</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPt0LHbLozoa" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">       <span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbW1mUxBaHph" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">         <span style="-sec-ix-hidden: xdx2ixbrl1635">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Financial Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231_zWxrStH3qWsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">63,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjml2xuvgbRb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">63,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zycMjQwbUcpe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1641">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znlTGW2sRhbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zStUQlg4bod9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2uu3pYTDzCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B3_zmRr0bQw0oHl" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value measurements at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2023 using:</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>active</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>markets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>observable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unobservable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Equity Securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember_z9ns0juYIqj6" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">77,918</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zc77UvBGv3u7" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">77,918</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPIAOZrtVI78" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">       <span style="-sec-ix-hidden: xdx2ixbrl1617">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWPSet3Rgbzb" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">        <span style="-sec-ix-hidden: xdx2ixbrl1619">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Financial Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930_z4fJpCsUUUyc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">77,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zhJC7ANgNJmf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">77,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zFfc4Pcy1sq8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1625">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zrWptIRBZMDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1627">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value measurements at</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022 using:</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quoted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>prices in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>active</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>markets</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>observable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>unobservable</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>inputs</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt">Equity Securities</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember_zjldcxKtPLri" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">63,638</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVJDbWYbut85" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">63,638</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPt0LHbLozoa" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">       <span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--CollateralAxis__us-gaap--EquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbW1mUxBaHph" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Total Financial Assets">         <span style="-sec-ix-hidden: xdx2ixbrl1635">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Financial Assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231_zWxrStH3qWsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">63,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zjml2xuvgbRb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets">63,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zycMjQwbUcpe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1641">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pdp0_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_znlTGW2sRhbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Financial Assets"><span style="-sec-ix-hidden: xdx2ixbrl1643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 77918 77918 77918 77918 63638 63638 63638 63638 <p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXBb8vk3nh39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4) <span style="text-decoration: underline"><span id="xdx_82E_zqZOviOm5Fe">Commitments and Contingencies</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating Leases</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $<span id="xdx_901_eus-gaap--PaymentsForRent_c20230101__20230930__srt--MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis__custom--CorporateOfficeMember_zSzKO6aQj0H9" title="Lease monthly payments">7,650</span> per month, on a lease extension, signed on December 5, 2022, that expires <span id="xdx_909_eus-gaap--LeaseExpirationDate1_dd_c20230101__20230930__srt--MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis__custom--CorporateOfficeMember_zH4b5sspwmSd" title="Lease expiration date">December 31, 2023</span>, for our corporate office. We expanded our space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected in the current payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023. The lease required monthly payments of $<span id="xdx_90D_ecustom--AnnualCostOfLivingPayment_c20230101__20230930__us-gaap--GeographicDistributionAxis__custom--MedfordLeaseMember_zhoh08gLnLSh" title="Annual cost of living payment">7,282</span> subject to annual cost of living increases. <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20230930__us-gaap--GeographicDistributionAxis__custom--MedfordLeaseMember_zSh3QEbiTFH9" title="Lessee operating lease description">The lease shall be automatically extended for additional three years unless either party terminates at least nine months prior to the expiration of the current lease term</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $<span id="xdx_90C_eus-gaap--OperatingLeaseLiability_iI_c20230930__us-gaap--GeographicDistributionAxis__custom--MedfordLeaseMember_zsvltyLGgwn7" title="Operating lease liability">221,432</span> based on the net present value of lease payments discounted using an estimated borrowing rate of <span id="xdx_907_ecustom--EstimatedBorrowingRate_iI_pid_dp_uPure_c20230930__us-gaap--GeographicDistributionAxis__custom--MedfordLeaseMember_zD6Z1ewzg20a" title="Estimated borrowing rate">12</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20210808__20210809__us-gaap--GeographicDistributionAxis__custom--SparksLeaseMember_zbG0JOTq6xzh" title="Lessee operating lease description">On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $<span id="xdx_901_eus-gaap--OperatingLeaseLiability_iI_c20230930__us-gaap--GeographicDistributionAxis__custom--SparksLeaseMember_zdNNUcVSl5Rk" title="Operating lease liability">239,327</span> based on the net present value of lease payments discounted using an estimated borrowing rate of <span id="xdx_90B_ecustom--EstimatedBorrowingRate_iI_pid_dp_uPure_c20230930__us-gaap--GeographicDistributionAxis__custom--SparksLeaseMember_zMJqpOWzcrfa" title="Estimated borrowing rate">12</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zJC9o4yGZBMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zjGAyckIuPC3" style="display: none">Schedule of Future Minimum Rental Payments Required Under Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Year</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230930_zl2cCsPLy7Xa" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pp0p0_maLOLLPzF2V_zaCk6CygXYA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: center">October 1 – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">15,887</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzF2V_zHMOOivQdxma" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,393</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzF2V_z2t2MUOxNs6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,969</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzF2V_zY2jk8SsdRS3" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2026</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,778</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzF2V_zBDJbR89LM1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future undiscounted lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">199,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zLR6OENJ2BC3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,481</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_zXNdM4SE6Jhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zIUIiwlr6Ksb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operating cash flows from the operating leases were $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_c20230101__20230930_zeETlU8JYSQ9" title="Operating lease">122,671</span> for the nine months ended September 30, 2023 and $<span id="xdx_904_eus-gaap--OperatingLeasePayments_c20220101__20220930_zHUTfHkLQPVa" title="Operating lease">82,001</span> for the nine months ended September 30, 2022. The weighted-average remaining lease term (years) of the above leases is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENvbW1pdG1lbnRzIGFuZCBDb250aW5nZW5jaWVzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zzVQk3p3VcUj" title="Weighted-average remaining lease term">2.59</span> year as of September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--OperatingLeasesOfLesseeTableTextBlock_zW8RwKVIucg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zF6BsdAsmcI7" style="display: none">Schedule of Right of Use Asset and the Corresponding Lease Liability</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Operating Leases</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230930_zG5ZinpEnTS" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zPqNilBk3UZ4" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zuFBt1GI7Z7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Right of use asset</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">159,424</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">282,095</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_z1muiEsRg85" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right of use liability, current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">66,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,171</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zVlpV44UffWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Right of use liability, long term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,287</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,924</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zg1Wo9YBAWhb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">282,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zux6x20t3Re8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average discount rate is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIENvbW1pdG1lbnRzIGFuZCBDb250aW5nZW5jaWVzIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230930_zG8BoU04u4E8" title="Weighted-average discount rate">12</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had no financing leases during the nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--LeaseCostTableTextBlock_znR4zbXqzeqb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_z07Z0CX3ZtO5" style="display: none">Schedule of Lease Cost for Operating Leases</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230101__20230930_zFdUc645U3R7" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20220930_zqDTOIgUlKn6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzSVZ_z9G1Ea7WKfog" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">153,290</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">152,193</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermLeaseCost_maLCzSVZ_zGXTuW304i15" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,205</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,514</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzSVZ_zn9lQ1uZR85h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">263,495</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">275,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z0sr9QpNGAv2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Battelle Memorial Institute</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“<i>Battelle</i>”). The licensed technology is the subject of a patent application filed by Battelle in 2008 and relates to a method and a system for improving the analysis of protein samples, including through an automated system utilizing pressure and a pre-selected agent to obtain a digested sample in a significantly shorter period of time than current methods, while maintaining the integrity of the sample throughout the preparatory process. In addition to royalty payments on net sales on “licensed products,” we are obligated to make minimum royalty payments for each year that we retain the rights outlined in the patent license agreement and we are required to have our first commercial sale of the licensed products within one year following the issuance of the patent covered by the licensed technology. After re-negotiating the terms of the contract in 2013, the minimum annual royalty was $<span id="xdx_90F_ecustom--MinimumRoyaltyFee_c20140101__20141231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BattelleMemorialInstituteMember_z3neM7MYCNyk" title="Minimum royalty fee">1,200</span> in 2014 and $<span id="xdx_902_ecustom--MinimumRoyaltyFee_c20150101__20151231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BattelleMemorialInstituteMember_zOptE6BLc48e" title="Minimum royalty fee">2,000</span> in 2015; the minimum royalties were $<span id="xdx_90D_ecustom--MinimumRoyaltyFee_c20160101__20161231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BattelleMemorialInstituteMember_znYCGv7LXCr3" title="Minimum royalty fee">3,000</span> in 2016, $<span id="xdx_904_ecustom--MinimumRoyaltyFee_c20170101__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BattelleMemorialInstituteMember_zRwYBCVlryn3" title="Minimum royalty fee">4,000</span> in 2017 and $<span id="xdx_903_ecustom--MinimumRoyaltyFee_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BattelleMemorialInstituteMember_ztOnvOclwAW8" title="Minimum royalty fee">5,000</span> in 2018 and each calendar year thereafter during the term of the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Target Discovery Inc</span><i>.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“<i>TDI</i>”), a related party. Under the terms of the agreement, we have been licensed by TDI to manufacture and sell an innovative line of chemicals used in the preparation of tissues for scientific analysis (“<i>TDI reagents</i>”). The TDI reagents were designed for use in combination with our pressure cycling technology. The companies believe that the combination of PCT and the TDI reagents can fill an existing need in life science research for an automated method for rapid extraction and recovery of intact, functional proteins associated with cell membranes in tissue samples. We did not incur any royalty obligation under this agreement in 2023 or 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $<span id="xdx_90B_eus-gaap--PaymentsForFees_c20120401__20120430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TargetDiscoveryIncMember_zI3FVhK3HT1k" title="Payments for fees">1,400</span> for the use of a lab bench, shared space, and other utilities, and $<span id="xdx_90F_eus-gaap--ProfessionalAndContractServicesExpense_c20120401__20120430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TargetDiscoveryIncMember_zIF6WVJ52Dt9" title="Professional and contract services expense">2,000</span> per day for technical support services as needed. The agreement requires TDI to pay the Company a minimum royalty fee of $<span id="xdx_90C_ecustom--MinimumRoyaltyFee_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TargetDiscoveryIncMember_zUkjAAITa3j4" title="Mimimum royalty fee">60,000</span> in 2022 and $<span id="xdx_901_ecustom--MinimumRoyaltyFee_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TargetDiscoveryIncMember_zdtY5tEtoYFb" title="Mimimum royalty fee">60,000</span> in 2023. For the nine months ended September 30, 2023 and September 30, 2022, the Company reported $<span id="xdx_90E_eus-gaap--CostsAndExpenses_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TargetDiscoveryIncMember_zUJM2XrQMxdi" title="Expenses">55,400</span> and $<span id="xdx_90D_eus-gaap--CostsAndExpenses_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TargetDiscoveryIncMember_zSMDHbPVLOYe" title="Expenses">65,100</span>, respectively in TDI fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Severance and Change of Control Agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by the Company without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general, and particularly in the occurrence of a change in control, as a disincentive to the control change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 7650 2023-12-31 7282 The lease shall be automatically extended for additional three years unless either party terminates at least nine months prior to the expiration of the current lease term 221432 0.12 On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term 239327 0.12 <p id="xdx_898_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zJC9o4yGZBMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zjGAyckIuPC3" style="display: none">Schedule of Future Minimum Rental Payments Required Under Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Year</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20230930_zl2cCsPLy7Xa" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pp0p0_maLOLLPzF2V_zaCk6CygXYA4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: center">October 1 – December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">15,887</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzF2V_zHMOOivQdxma" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,393</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzF2V_z2t2MUOxNs6j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,969</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzF2V_zY2jk8SsdRS3" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2026</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,778</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzF2V_zBDJbR89LM1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future undiscounted lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">199,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zLR6OENJ2BC3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,481</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_zXNdM4SE6Jhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 15887 64393 66969 51778 199027 61481 137546 122671 82001 P2Y7M2D <p id="xdx_89C_ecustom--OperatingLeasesOfLesseeTableTextBlock_zW8RwKVIucg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below is a table for the right of use asset and the corresponding lease liability in the consolidated balance sheets:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zF6BsdAsmcI7" style="display: none">Schedule of Right of Use Asset and the Corresponding Lease Liability</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Operating Leases</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230930_zG5ZinpEnTS" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20221231_zPqNilBk3UZ4" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zuFBt1GI7Z7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 2.5pt">Right of use asset</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">159,424</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 20%; text-align: right">282,095</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_iI_z1muiEsRg85" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right of use liability, current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">66,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">142,171</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zVlpV44UffWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Right of use liability, long term</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,287</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">139,924</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_zg1Wo9YBAWhb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,546</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">282,095</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 159424 282095 66259 142171 71287 139924 137546 282095 0.12 <p id="xdx_898_eus-gaap--LeaseCostTableTextBlock_znR4zbXqzeqb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease cost for operating leases for the nine months ended September 30, 2023 and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_z07Z0CX3ZtO5" style="display: none">Schedule of Lease Cost for Operating Leases</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230101__20230930_zFdUc645U3R7" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20220930_zqDTOIgUlKn6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_maLCzSVZ_z9G1Ea7WKfog" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">153,290</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">152,193</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ShortTermLeaseCost_maLCzSVZ_zGXTuW304i15" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,205</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,514</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzSVZ_zn9lQ1uZR85h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">263,495</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">275,707</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 153290 152193 110205 123514 263495 275707 1200 2000 3000 4000 5000 1400 2000 60000 60000 55400 65100 <p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zGU2TjvaYaEf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5) <span style="text-decoration: underline"><span id="xdx_829_zICy1ve2F7Fg">Debt</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Convertible Debt</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On various dates during the nine months ended September 30, 2023, the Company issued convertible notes for net proceeds of approximate total of $<span id="xdx_90F_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20230101__20230930__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_z3YARgpTl1Y7">4.3</span> million which contained varied terms and conditions as follows: a) <span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtM_c20230101__20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zg6r0WgJWvBh" title="Debt instrument term">1</span>-<span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtM_c20230101__20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zyeIrW4fyi4l" title="Debt instrument term">12</span> month maturity date; b) interest rates of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zNxpBXlep1Kk" title="Interest rates">0</span>-<span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zBe0rWiDlgN5" title="Interest rates">120</span>%; c) convertible to the Company’s common stock at issuance at a fixed rate of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertibleCommonStockMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_za72JsreVD95" title="Fixed rate">2.50</span> or at variable conversion rates upon the Company’s up-listing to NASDAQ or NYSE or an event of default. These notes were issued with shares of common stock that were fair valued at issuance date. The aggregate relative fair value of the shares of common stock and preferred stock issued with the notes of $<span id="xdx_90B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertibleCommonStockMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zbZtrT5hZ7we">1,832,757</span>  was recorded as a debt discount to be amortized over the term of the notes. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not qualify for derivative accounting treatment on September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, deferred financing costs and OID issued with the debt are $<span id="xdx_90D_eus-gaap--DeferredCostsCurrentAndNoncurrent_iI_c20230930_zPreVMrnejF4">648,470</span>  and the Company repaid $<span id="xdx_900_eus-gaap--RepaymentsOfSeniorDebt_c20230101__20230930_zel3HspTyBt7">2,462,269</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The summary of specific terms of the convertible notes and outstanding balances as of September 30, 2023, and December 31, 2022, are listed in the tables below. The convertible notes are from numerous parties and with original issue dates from July 2019 to September 2023 and maturity dates from <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20230930_zBjvJqhcHZQ1" title="Debt instrument maturity date description">July 2020 to September 2024</span>. There are approximately $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230930_z7VlS9YAUmN" title="Pay due, amount">12.3</span> million of notes that are past due as of September 30, 2023.</span></p> <p id="xdx_894_eus-gaap--ScheduleOfDebtConversionsTextBlock_zGiLurOQwLe2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zh3GTb9OsUfd" style="display: none">Schedule of Convertible Debts and Outstanding Balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest<br/> Rate</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion<br/> Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest<br/> Rate</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion<br/> Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Main Investor</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zytyF5LyvwW7" title="Interest Rate">10</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_fKDEp_zy7mkSqpSQ69" title="Conversion price">2.50</span> (1)</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z52eLX2RuHd2" style="width: 6%; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,586,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zLYnBKr32NCa" title="Interest Rate">10</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_fKDEp_ztXDgESjEBrb" title="Conversion price">2.50</span> (1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhadlNRVVjX3" style="width: 6%; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,393,150</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_z5YxMAtZjoO8" title="Interest Rate">0</span> to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_z6cbqFHXVm63" title="Interest Rate">24</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_fKDIp_zUzWKqxNpOyj" title="Conversion price">2.50</span> (2) or $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_z0DbAJztTU16" title="Conversion price">7.50</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember_zk9pJFZjsWD6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,379,763</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_zkbaX6oGyvW2" title="Interest Rate">0</span> to <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_z27fUapPzAh1" title="Interest Rate">24</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_fKDIp_zdJWltpxLWi" title="Conversion price">2.50</span> (2) or $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_zaGd1yqMu6q6" title="Conversion price">7.50</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember_zMbYozajjnU6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,886,036</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Totals</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230930_zQBqOM9DEDei" style="text-align: right" title="Totals"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1790">-</span> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231_z4wqqPqZfftg" style="text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,279,186</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230930_zwt8jgJKqfe7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt unamortized discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">744,393</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231_zZPAs0e8LQ67" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt unamortized discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">455,517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ConvertibleDebtCurrent_iI_c20230930_zMeg6skBajE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,222,120</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ConvertibleDebtCurrent_iI_c20221231_zNxQ9YKnk2Yj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,823,669</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F01_zv1r5qVC3Vhl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zXEUlSW3gkkf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price of these note is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zEapDIRIg2he" title="Debt instrument, convertible price per shares">2.50</span> except for a note for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zv0stGvs2GFa" title="Debt instrument, debt default, amount">189,750</span>, which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6FzDcQVKIs6" title="Debt instrument lowest trading price">25</span>% discount to the 5-day average VWAP of the stock prior to default and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--AwardTypeAxis__custom--FiveDayAverageVWAPMember_zlwZA1kKxrJ7" title="Debt instrument, debt default, amount">729,100</span> lower of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zPMlkmUdiQSg" title="Debt instrument, convertible price per shares">2.50</span> or (ii) the conversion price of the Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_zYeBeWeDb0d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zwsclmOp1Wv5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price of these notes is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zPopaP05SwQb" title="Debt instrument, convertible price per shares">2.50</span> but also varies with one or more of these notes having the following conversion adjustment:</span></td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes are convertible before maturity at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930_zlNUSW4tMWoe" title="Debt instrument, convertible price per shares">2.50</span> per share or mandatorily convertible when the Company up-lists to the NASDAQ at the lower of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zQtcAtNSMdp5" title="Debt instrument, convertible, conversion price">2.50</span> or the up-list price.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes are convertible upon an Event of Default at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_ecustom--DebtDefaultConvertibleConversionRatio_pid_dp_uPure_c20230101__20230930_zvw1Bevmz7l3" title="Debt default convertible conversion ratio">75</span>% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes are convertible at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930_z8LRjce2VJyg" title="Debt instrument, convertible price per shares">2.50</span> per share except that following an Event of Default the conversion price will be adjusted to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_ecustom--DebtDefaultConvertibleConversionRatio_pid_dp_uPure_c20230101__20230930_z4NwuJwV6zT9" title="Debt default convertible conversion ratio">75</span>% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be voluntary converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_znElFeVB9Fig" title="Debt instrument, convertible, conversion price">2.50</span>/share; or 2) purchase price of stock sold by PBI at a price lower than $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_c20230101__20230930_zgPTZsh014q5" title="Debt instrument, convertible, conversion price, Increase">2.50</span>/share. In the event of default, these notes can be converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zLEZweN3W8w4" title="Debt instrument, convertible, conversion price">2.50</span>/share; 2) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember_zDZB8Mv0AHq5" title="Debt instrument lowest trading price">30</span>% discount to 5-day VWAP prior to date of default.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be voluntary converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230930_zmpWEqNEXkLd" title="Debt instrument, convertible, conversion price">2.50</span>/share; or 2) purchase price of stock sold by PBI at a price lower than $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_pid_c20230101__20230930_zpkt8v5XMElk" title="Debt instrument, convertible, conversion price, increase">2.50</span>/share. In the event of default, these notes can be converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zlIBOuu62Fwh" title="Debt instrument, convertible, conversion price">2.50</span>/share; 2) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtThreeMember_z2CPXbhreHI2" title="Debt instrument lowest trading price">25</span>% discount to 5-day VWAP prior to date of default.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price is lower of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_c20230101__20230930_z2DFGKwMkwUa" title="Debt instrument, convertible, conversion price, decrease">2.50</span> or (ii) the price per share that the Company last sold Common Stock after the execution of an anti-dilution protection agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note can be converted at a Voluntary Conversion Price which is the lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zNxEwYpjXw35" title="Debt instrument, convertible, conversion price">2.50</span>/share; or 2) purchase price of stock sold by the Company at a price lower than $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_c20230101__20230930_zwkUwrANzvv7" title="Debt instrument, convertible, conversion price, Increase">2.50</span> except that following an Event of Default, the Holder shall have the right, with no further consent from the Borrower, to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFourMember_z9puy2fRkKk1" title="Debt instrument lowest trading price">70</span>% of the 5-day VWAP prior to conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230930_zWxB71oQC6ec" title="Conversion price per share">2.50</span>. If note is in default, it is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20230930_zfQelRLqC9Z9" title="Debt default amount">1</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be voluntarily converted before maturity at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zfpX4kzvq55d" title="Debt instrument, convertible, conversion price">2.50</span> per share. Lender retains the option upon an Up-list to convert at the lower of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zDKNU9gubre8" title="Debt instrument, convertible, conversion price">2.50</span> or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--PercentageOfPriceRate_iI_pid_dp_c20230930_z9Ey0I1PLsd4" title="Percentage of price">10</span>% off Up-list price.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be converted at the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--ConvertibleLesserPerShare_iI_c20230930_zdiVPhzDU5p5" title="Convertible lesser per share">2.5</span> per share or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--ConvertibleLesserDiscountPercent_iI_pid_dp_c20230930_zaTg0tVY0wye" title="Convertible lesser Percent">25</span>% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of (i) original conversion price or (ii) a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_pid_dp_c20230101__20230930_z8JQkwqF4jJa" title=" Original debt, interest rate of debt">35</span>% discount to the VWAP prior to each conversion date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zGveglLwRple" title="Principal balance">950,000</span> as of September 30, 2023 is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some notes can be converted at the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--ConvertibleLesserPerShare_iI_c20230930_zCU2qgycWnf1" title="Convertible lesser per share">2.50</span> per share or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_ecustom--ConvertibleLesserDiscountPercent_iI_pid_dp_c20230930_zqchLX4hqo9i" title="Convertible lesser Percent">25</span>% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of original conversion price or the product of the VWAP of the common stock for the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20230101__20230930_ze85Yb3Kigik" title="Trading day">5</span> trading dates immediately prior to the maturity date multiplied by 0.75.</span></td></tr></table> <p id="xdx_8A1_zWaGr0wkCHk9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, the Company recognized amortization expense related to the debt discounts indicated above of $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20230101__20230930__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zRRFazJSyJT8">2,621,523</span>. The unamortized debt discounts as of September 30, 2023 related to the convertible notes amounted to $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230930__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zwyZK3PNDov">744,393</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the principal balance that is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. is $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__dei--LegalEntityAxis__custom--PBIAgrochemIncMember_znBiExxyY97j" title="Debt instrument, face amount.">352,188</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Standstill and Forbearance Agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. During the nine months ended September 30, 2023, the Company settled one note with total principal of $<span id="xdx_901_eus-gaap--RepaymentsOfConvertibleDebt_c20230101__20230930__srt--TitleOfIndividualAxis__custom--ThreeLendersMember_zNLcGBYWhvNg">302,484</span>, leaving one final lender (three notes) with total principal of $<span id="xdx_909_eus-gaap--RepaymentsOfConvertibleDebt_c20230101__20230930__srt--TitleOfIndividualAxis__custom--ThreeLendersMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zqx7IYTEpqC2" title="Payments on convertible debt">272,500</span> outstanding and incurred interest, penalties and fees of approximately $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230930__srt--TitleOfIndividualAxis__custom--FourLendersMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementsMember_zDE8ucgtw6yh" title="Interest payable">253,425</span>  in connection with the Standstill and Forbearance Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Convertible Loan Modifications and Extinguishments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We refinanced certain convertible loans during the nine months ended September 30, 2023 at substantially the same terms for extensions ranging over a period of two to nine months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cash flows of new debt exceeded <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--NewLoanMember_zfOhM9wzhw3i" title="Debt instrument interest rate">10</span>% of the remaining cash flows of the original debt on several loans. During the nine months ended September 30, 2023 we recorded gains on extinguishment of liabilities of approximately $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--NewLoanMember_zractbDX1jMk" title="Losses on extinguishment of debt">0.7</span> million  by calculating the difference of the fair value of the new debt and the carrying value of the old debt. During the nine months ended September 30, 2023, the Company extended 17 loans totaling $<span id="xdx_90D_eus-gaap--ProceedsFromLoans_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--TenLoansMember_zLFNS5o2CWMc" title="Proceeds from loans">3,917,898</span> and increased the principal to $<span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--TenLoansMember_zDbjpVxsZE0i" title="Increase in principal amount">4,067,898</span>.  The Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TenLoansMember_zwDUShYc3Z11" title="Number of shares issued">1,346,800</span> shares of common stock and <span id="xdx_906_ecustom--StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TenLoansMember_zmjn0WfuAt97" title="Preferred stock extensions">741</span> shares of preferred stock  for these extensions and increased principal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Other Debt</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No notes in Other Debt are past due as of September 30, 2023.</span></p> <p id="xdx_896_ecustom--ScheduleOfOtherDebtTableTextBlock_zqwfwBr7Iqgk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BA_zBJ76srj5NWg" style="display: none">Schedule of Other Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Convertible</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_fKDEp_z6ngr1zFatd2" style="display: none" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1897">-</span></span>(1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--OtherLongTermDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_zrNOzdfDxXHg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,016,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_fKDEp_za0uONt8tSh6" style="display: none" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1901">-</span></span>(1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--OtherLongTermDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_zWoNLXmz32Wi" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">878,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merchant debt (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--OtherLongTermDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--MerchantDebtMember_fKDMp_zhfdQx0qVkL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,014,010</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--OtherLongTermDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--MerchantDebtMember_fKDMp_zhPjtXiDph0l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBA (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_zAHzZugMGIkl" title="Interest Rate">3.75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--OtherLongTermDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_zFfZ8SBVq7Xi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_z5dLPw9qnXg6" title="Interest Rate">3.75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--OtherLongTermDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_zi8OWQwFZ1ai" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Totals</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--OtherLongTermDebt_iI_c20230930_z2dPkHM7lF18" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,193,032</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--OtherLongTermDebt_iI_c20221231_zaf2RVoW6eDg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,788,969</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20230930_zCpluskvfRYk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1921">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20221231_zlslAmsTb5Nd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long Term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--LongTermDebt_iI_c20230930_z84bXF2c8Rqa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--LongTermDebt_iI_c20221231_z0DtUxkvF6D8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short Term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--OtherLongTermDebtCurrent_iI_c20230930_zSZ9EjKGWzT" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Short Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,030,510</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--OtherLongTermDebtCurrent_iI_c20221231_zrFYqoepmK3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Short Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,638,969</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0E_zsPrdQemUDC" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zL7fxNagBySf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest varies from <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__srt--RangeAxis__srt--MinimumMember_zAtVsHNuttIk" title="Interest Rate">1</span>% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__srt--RangeAxis__srt--MaximumMember_zlZCvS8vieA7" title="Interest Rate">10</span>%. The maturity is between being past due and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230930_zAhIjAWjeJeh" title="Debt instrument, maturity date">May 2, 2023</span>. As of September 30, 2023, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--NonConvertibleDebtInstrumentAmount_iI_c20230930_zjGx2JRUB0O6" title="Non- convertible debt amount">861,500</span> of the non-convertible debt is past due.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zm8m1JVpuhs2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zZHPcj4VOC5g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--NotesPayable_iI_c20230930_z6Gow4vFGFw7" title="Note payable">150,000</span>, accrues interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--AccruedInterestRatePercent_iI_pid_dp_c20230930_z8HDkWjvHnF1" title="Accrued interest rate percent">3.75</span>% and requires monthly payments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230930_zLMBBZ94lOpe" title="Debt Instrument periodic payment">731</span> for principal and interest beginning in December 2022. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the nine months ended September 30, 2023, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--DeferredInterest_c20230101__20230930_zaURSB2c4VKc" title="Deferred interest">14,719</span> interest was deferred and added to principal on EIDL loan and the Company repaid $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--PrincipalTransactionsRevenue_c20230101__20230930_z2tTnKokqDwc" title="Principal amount paid">2,197</span> principal on this loan. During the year ended December 31, 2020, the Company borrowed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zwQh1gpmNNeg" title="Borrowed amount">367,039</span> (two-year term and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20201231__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zfXU1nCOK5kj" title="Debt interest rate">1</span>% interest rate per annum) under the Payroll Protection program (or “2020 PPP”). During the year ended December 31, 2021, the Company borrowed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgrammeMember_z1wjcQ2mpg7h" title="Borrowed amount">367,039</span> through a second Payroll Protection program (or “2021 PPP”) and extended the monthly payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven by the United States and SBA.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0F_zvfurqtqp9a2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zL5Hp15rMn88" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230930__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember__srt--RangeAxis__srt--MinimumMember_zqDCCqJzoej9" title="Debt interest rate">4.1</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230930__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember__srt--RangeAxis__srt--MaximumMember_zGcbcTYjeCYj" title="Debt interest rate">100.9</span>% per month. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. The Company’s Chief Executive Officer guarantees the Company’s performance of all representations, warranties, and covenants made by the Company in the Agreement. For loans outstanding on September 30, 2023, the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember_zhJxj1omTdBk" title="Debt instrument, maturity date description">maturity dates ranged from June 26, 2023 to October 15, 2023</span>. For loan outstanding on December 31, 2022, the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember_z89L4htyZDZd" title="Debt instrument, maturity date description">maturity dates ranged from April 4 to June 6, 2023</span>.</span></td></tr></table> <p id="xdx_8A7_z5Ct5dBi077i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Related Party Notes</span></i></b></span></p> <p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zBsBbTP6rhch" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zSFnactlW1re" style="display: none">Schedule of Related Party Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Holders</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Principal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Principal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Security</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Officers &amp; Directors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_fKDEp_zL9FZNWf3vVh" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1970">-</span></span></span>(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zn11j2buVIkl" style="width: 9%; text-align: right" title="Totals, Principle">522,450</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_fKDEp_zrP0UvwJG1J8" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></span></span>(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_z4w2FxF5l7Xe" style="width: 9%; text-align: right" title="Totals, Principle">521,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsecured</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_zMHoSn6lj1i4" title="Interest Rate">12</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td id="xdx_989_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_zxLXsPS32TY8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals, Principle">126,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_zRX1epxZiKM8" title="Interest Rate">12</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_z6xG0aAWI6Pl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals, Principle">120,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsecured</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Totals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zAQSR8vYk3H" style="text-align: right" title="Totals, Principle">648,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zAmbbYx2Xfuj" style="text-align: right" title="Totals, Principle">642,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td id="xdx_989_ecustom--DebtInstrumentPeriodicPaymentPrincipalGross_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1Vuh4swiqQ1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Discount, Principal">514</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DebtInstrumentPeriodicPaymentPrincipalGross_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCQxXmMlq2p3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Discount, Principal">7,915</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">$</td><td id="xdx_988_eus-gaap--OtherLiabilitiesCurrent_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdkQ8v972mNf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net, Principal">647,986</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">$</td><td id="xdx_980_eus-gaap--OtherLiabilitiesCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zRH75RP2FJQi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net, Principal">634,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zkWsu6hC1mdg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zpLixo6udiNi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest varies from <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgRGVidCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--RangeAxis__srt--MinimumMember_zqQc6LkGj4uc" title="Debt instrument, interest rate, stated percentage">12</span>% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgRGVidCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--RangeAxis__srt--MaximumMember_zXh2uPC4qAAh" title="Debt instrument, interest rate, stated percentage">120</span>%.</span></td></tr></table> <p id="xdx_8A1_zR2F66TwUf68" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, we received short-term convertible loans of $<span id="xdx_90C_eus-gaap--ProceedsFromShortTermDebt_pid_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember_znxt1bgHreke">164,700</span> with $<span id="xdx_901_ecustom--DebtOriginalIssueDiscount_pid_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember_ztiZ8TPfEv96" title="Original issue discount">5,514</span> OID from related parties and repaid $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_pid_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember_zQ2HdSRoTKEl">159,000</span> of related party loans. These notes bear interest of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember__srt--RangeAxis__srt--MinimumMember_zJ1vqpGCJoUg">12</span>% to <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember__srt--RangeAxis__srt--MaximumMember_zxnRVBk0QJB4">120</span>% and are due upon demand. All related party notes are convertible at $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6n10NnHDha1" title="Debt instrument, convertible price per shares">2.50</span>/share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We amortized $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20230101__20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember_zc7Do07MatHa">592,099</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  of debt discounts during the nine months ended September 30, 2023 for all non-convertible and related party notes. The total unamortized discount for all non-convertible and related party convertible notes as of September 30, 2023, and December 31, 2022 was $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember_zYZBoWC4G2qd">514 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShortTermNonConvertibleLoanMember_zYWFtq3cX3Kh">7,915</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4300000 P1M P12M 0 1.20 2.50 1832757 648470 2462269 July 2020 to September 2024 12300000 <p id="xdx_894_eus-gaap--ScheduleOfDebtConversionsTextBlock_zGiLurOQwLe2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zh3GTb9OsUfd" style="display: none">Schedule of Convertible Debts and Outstanding Balances</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest<br/> Rate</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion<br/> Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest<br/> Rate</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion<br/> Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Main Investor</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zytyF5LyvwW7" title="Interest Rate">10</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_fKDEp_zy7mkSqpSQ69" title="Conversion price">2.50</span> (1)</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z52eLX2RuHd2" style="width: 6%; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,586,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zLYnBKr32NCa" title="Interest Rate">10</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_fKDEp_ztXDgESjEBrb" title="Conversion price">2.50</span> (1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zhadlNRVVjX3" style="width: 6%; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,393,150</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_z5YxMAtZjoO8" title="Interest Rate">0</span> to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_z6cbqFHXVm63" title="Interest Rate">24</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_fKDIp_zUzWKqxNpOyj" title="Conversion price">2.50</span> (2) or $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_z0DbAJztTU16" title="Conversion price">7.50</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember_zk9pJFZjsWD6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,379,763</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_zkbaX6oGyvW2" title="Interest Rate">0</span> to <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_z27fUapPzAh1" title="Interest Rate">24</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MinimumMember_fKDIp_zdJWltpxLWi" title="Conversion price">2.50</span> (2) or $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember__srt--RangeAxis__srt--MaximumMember_zaGd1yqMu6q6" title="Conversion price">7.50</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OthersMember_zMbYozajjnU6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,886,036</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Totals</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230930_zQBqOM9DEDei" style="text-align: right" title="Totals"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1790">-</span> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231_z4wqqPqZfftg" style="text-align: right" title="Totals"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,279,186</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230930_zwt8jgJKqfe7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt unamortized discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">744,393</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231_zZPAs0e8LQ67" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt unamortized discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">455,517</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ConvertibleDebtCurrent_iI_c20230930_zMeg6skBajE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,222,120</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ConvertibleDebtCurrent_iI_c20221231_zNxQ9YKnk2Yj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Principal amount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,823,669</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F01_zv1r5qVC3Vhl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zXEUlSW3gkkf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price of these note is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zEapDIRIg2he" title="Debt instrument, convertible price per shares">2.50</span> except for a note for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zv0stGvs2GFa" title="Debt instrument, debt default, amount">189,750</span>, which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6FzDcQVKIs6" title="Debt instrument lowest trading price">25</span>% discount to the 5-day average VWAP of the stock prior to default and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--AwardTypeAxis__custom--FiveDayAverageVWAPMember_zlwZA1kKxrJ7" title="Debt instrument, debt default, amount">729,100</span> lower of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAAPreferredStockMember_zPMlkmUdiQSg" title="Debt instrument, convertible price per shares">2.50</span> or (ii) the conversion price of the Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_zYeBeWeDb0d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zwsclmOp1Wv5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price of these notes is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zPopaP05SwQb" title="Debt instrument, convertible price per shares">2.50</span> but also varies with one or more of these notes having the following conversion adjustment:</span></td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes are convertible before maturity at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930_zlNUSW4tMWoe" title="Debt instrument, convertible price per shares">2.50</span> per share or mandatorily convertible when the Company up-lists to the NASDAQ at the lower of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zQtcAtNSMdp5" title="Debt instrument, convertible, conversion price">2.50</span> or the up-list price.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes are convertible upon an Event of Default at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_ecustom--DebtDefaultConvertibleConversionRatio_pid_dp_uPure_c20230101__20230930_zvw1Bevmz7l3" title="Debt default convertible conversion ratio">75</span>% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes are convertible at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_c20230101__20230930_z8LRjce2VJyg" title="Debt instrument, convertible price per shares">2.50</span> per share except that following an Event of Default the conversion price will be adjusted to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_ecustom--DebtDefaultConvertibleConversionRatio_pid_dp_uPure_c20230101__20230930_z4NwuJwV6zT9" title="Debt default convertible conversion ratio">75</span>% multiplied by the lowest trading price for the common stock during the five days prior to the conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be voluntary converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_znElFeVB9Fig" title="Debt instrument, convertible, conversion price">2.50</span>/share; or 2) purchase price of stock sold by PBI at a price lower than $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_c20230101__20230930_zgPTZsh014q5" title="Debt instrument, convertible, conversion price, Increase">2.50</span>/share. In the event of default, these notes can be converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zLEZweN3W8w4" title="Debt instrument, convertible, conversion price">2.50</span>/share; 2) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember_zDZB8Mv0AHq5" title="Debt instrument lowest trading price">30</span>% discount to 5-day VWAP prior to date of default.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be voluntary converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230930_zmpWEqNEXkLd" title="Debt instrument, convertible, conversion price">2.50</span>/share; or 2) purchase price of stock sold by PBI at a price lower than $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_pid_c20230101__20230930_zpkt8v5XMElk" title="Debt instrument, convertible, conversion price, increase">2.50</span>/share. In the event of default, these notes can be converted at lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zlIBOuu62Fwh" title="Debt instrument, convertible, conversion price">2.50</span>/share; 2) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtThreeMember_z2CPXbhreHI2" title="Debt instrument lowest trading price">25</span>% discount to 5-day VWAP prior to date of default.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price is lower of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_c20230101__20230930_z2DFGKwMkwUa" title="Debt instrument, convertible, conversion price, decrease">2.50</span> or (ii) the price per share that the Company last sold Common Stock after the execution of an anti-dilution protection agreement.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note can be converted at a Voluntary Conversion Price which is the lower of 1) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zNxEwYpjXw35" title="Debt instrument, convertible, conversion price">2.50</span>/share; or 2) purchase price of stock sold by the Company at a price lower than $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPriceIncrease_c20230101__20230930_zwkUwrANzvv7" title="Debt instrument, convertible, conversion price, Increase">2.50</span> except that following an Event of Default, the Holder shall have the right, with no further consent from the Borrower, to convert notes which can be the lower of 1) the Voluntary Conversion Price, or 2) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--DebtInstrumentDiscountPercentageOfStockPrice_pid_dp_uPure_c20230101__20230930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtFourMember_z9puy2fRkKk1" title="Debt instrument lowest trading price">70</span>% of the 5-day VWAP prior to conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion price is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230930_zWxB71oQC6ec" title="Conversion price per share">2.50</span>. If note is in default, it is $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20230930_zfQelRLqC9Z9" title="Debt default amount">1</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be voluntarily converted before maturity at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zfpX4kzvq55d" title="Debt instrument, convertible, conversion price">2.50</span> per share. Lender retains the option upon an Up-list to convert at the lower of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230930_zDKNU9gubre8" title="Debt instrument, convertible, conversion price">2.50</span> or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--PercentageOfPriceRate_iI_pid_dp_c20230930_z9Ey0I1PLsd4" title="Percentage of price">10</span>% off Up-list price.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes can be converted at the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--ConvertibleLesserPerShare_iI_c20230930_zdiVPhzDU5p5" title="Convertible lesser per share">2.5</span> per share or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--ConvertibleLesserDiscountPercent_iI_pid_dp_c20230930_zaTg0tVY0wye" title="Convertible lesser Percent">25</span>% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of (i) original conversion price or (ii) a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_pid_dp_c20230101__20230930_z8JQkwqF4jJa" title=" Original debt, interest rate of debt">35</span>% discount to the VWAP prior to each conversion date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some notes are not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan with a principal balance of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230930__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zGveglLwRple" title="Principal balance">950,000</span> as of September 30, 2023 is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some notes can be converted at the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--ConvertibleLesserPerShare_iI_c20230930_zCU2qgycWnf1" title="Convertible lesser per share">2.50</span> per share or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_ecustom--ConvertibleLesserDiscountPercent_iI_pid_dp_c20230930_zqchLX4hqo9i" title="Convertible lesser Percent">25</span>% discount to the opening price of the Company’s first day of trading on either Nasdaq or NYSE. In addition, if the Company fails to pay the Note in cash on maturity date, the conversion price will be adjusted to the lesser of original conversion price or the product of the VWAP of the common stock for the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIERlYnRzIGFuZCBPdXRzdGFuZGluZyBCYWxhbmNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20230101__20230930_ze85Yb3Kigik" title="Trading day">5</span> trading dates immediately prior to the maturity date multiplied by 0.75.</span></td></tr></table> 0.10 2.50 8586750 0.10 2.50 9393150 0 0.24 2.50 7.50 10379763 0 0.24 2.50 7.50 8886036 18279186 744393 455517 18222120 17823669 2.50 189750 0.25 729100 2.50 2.50 2.50 2.50 0.75 2.50 0.75 2.50 2.50 2.50 0.30 2.50 2.50 2.50 0.25 2.50 2.50 2.50 0.70 2.50 1 2.50 2.50 0.10 2.5 0.25 0.35 950000 2.50 0.25 5 2621523 744393 352188 302484 272500 253425 0.10 700000 3917898 4067898 1346800 741 <p id="xdx_896_ecustom--ScheduleOfOtherDebtTableTextBlock_zqwfwBr7Iqgk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BA_zBJ76srj5NWg" style="display: none">Schedule of Other Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest Rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Convertible</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_fKDEp_z6ngr1zFatd2" style="display: none" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1897">-</span></span>(1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--OtherLongTermDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_zrNOzdfDxXHg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,016,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_fKDEp_za0uONt8tSh6" style="display: none" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1901">-</span></span>(1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--OtherLongTermDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--NonConvertibleLoansMember_zWoNLXmz32Wi" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">878,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merchant debt (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--OtherLongTermDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--MerchantDebtMember_fKDMp_zhfdQx0qVkL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,014,010</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--OtherLongTermDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--MerchantDebtMember_fKDMp_zhPjtXiDph0l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBA (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_zAHzZugMGIkl" title="Interest Rate">3.75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--OtherLongTermDebt_iI_c20230930__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_zFfZ8SBVq7Xi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_z5dLPw9qnXg6" title="Interest Rate">3.75</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--OtherLongTermDebt_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--SBAMember_fKDIp_zi8OWQwFZ1ai" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Totals</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--OtherLongTermDebt_iI_c20230930_z2dPkHM7lF18" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,193,032</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--OtherLongTermDebt_iI_c20221231_zaf2RVoW6eDg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Totals, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,788,969</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20230930_zCpluskvfRYk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1921">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20221231_zlslAmsTb5Nd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, discount"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long Term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--LongTermDebt_iI_c20230930_z84bXF2c8Rqa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">162,522</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--LongTermDebt_iI_c20221231_z0DtUxkvF6D8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short Term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--OtherLongTermDebtCurrent_iI_c20230930_zSZ9EjKGWzT" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Short Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,030,510</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--OtherLongTermDebtCurrent_iI_c20221231_zrFYqoepmK3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Short Term, Principal"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,638,969</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0E_zsPrdQemUDC" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zL7fxNagBySf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest varies from <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__srt--RangeAxis__srt--MinimumMember_zAtVsHNuttIk" title="Interest Rate">1</span>% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__srt--RangeAxis__srt--MaximumMember_zlZCvS8vieA7" title="Interest Rate">10</span>%. The maturity is between being past due and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230930_zAhIjAWjeJeh" title="Debt instrument, maturity date">May 2, 2023</span>. As of September 30, 2023, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--NonConvertibleDebtInstrumentAmount_iI_c20230930_zjGx2JRUB0O6" title="Non- convertible debt amount">861,500</span> of the non-convertible debt is past due.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zm8m1JVpuhs2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zZHPcj4VOC5g" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--NotesPayable_iI_c20230930_z6Gow4vFGFw7" title="Note payable">150,000</span>, accrues interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--AccruedInterestRatePercent_iI_pid_dp_c20230930_z8HDkWjvHnF1" title="Accrued interest rate percent">3.75</span>% and requires monthly payments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20230930_zLMBBZ94lOpe" title="Debt Instrument periodic payment">731</span> for principal and interest beginning in December 2022. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the nine months ended September 30, 2023, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--DeferredInterest_c20230101__20230930_zaURSB2c4VKc" title="Deferred interest">14,719</span> interest was deferred and added to principal on EIDL loan and the Company repaid $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--PrincipalTransactionsRevenue_c20230101__20230930_z2tTnKokqDwc" title="Principal amount paid">2,197</span> principal on this loan. During the year ended December 31, 2020, the Company borrowed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20201231__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zwQh1gpmNNeg" title="Borrowed amount">367,039</span> (two-year term and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20201231__us-gaap--DebtInstrumentAxis__custom--PayrollProtectionProgramMember_zfXU1nCOK5kj" title="Debt interest rate">1</span>% interest rate per annum) under the Payroll Protection program (or “2020 PPP”). During the year ended December 31, 2021, the Company borrowed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgrammeMember_z1wjcQ2mpg7h" title="Borrowed amount">367,039</span> through a second Payroll Protection program (or “2021 PPP”) and extended the monthly payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven by the United States and SBA.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0F_zvfurqtqp9a2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zL5Hp15rMn88" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230930__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember__srt--RangeAxis__srt--MinimumMember_zqDCCqJzoej9" title="Debt interest rate">4.1</span>% - <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230930__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember__srt--RangeAxis__srt--MaximumMember_zGcbcTYjeCYj" title="Debt interest rate">100.9</span>% per month. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. The Company’s Chief Executive Officer guarantees the Company’s performance of all representations, warranties, and covenants made by the Company in the Agreement. For loans outstanding on September 30, 2023, the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember_zhJxj1omTdBk" title="Debt instrument, maturity date description">maturity dates ranged from June 26, 2023 to October 15, 2023</span>. For loan outstanding on December 31, 2022, the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE90aGVyIERlYnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MerchantAgreementMember_z89L4htyZDZd" title="Debt instrument, maturity date description">maturity dates ranged from April 4 to June 6, 2023</span>.</span></td></tr></table> 1016500 878809 1014010 760160 0.0375 162522 0.0375 150000 2193032 1788969 162522 150000 2030510 1638969 0.01 0.10 2023-05-02 861500 150000 0.0375 731 14719 2197 367039 0.01 367039 0.041 1.009 maturity dates ranged from June 26, 2023 to October 15, 2023 maturity dates ranged from April 4 to June 6, 2023 <p id="xdx_89E_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zBsBbTP6rhch" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_zSFnactlW1re" style="display: none">Schedule of Related Party Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Holders</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Principal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Principal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Security</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Officers &amp; Directors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_fKDEp_zL9FZNWf3vVh" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1970">-</span></span></span>(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zn11j2buVIkl" style="width: 9%; text-align: right" title="Totals, Principle">522,450</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_fKDEp_zrP0UvwJG1J8" title="Interest Rate"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></span></span>(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_z4w2FxF5l7Xe" style="width: 9%; text-align: right" title="Totals, Principle">521,950</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsecured</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_zMHoSn6lj1i4" title="Interest Rate">12</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td id="xdx_989_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_zxLXsPS32TY8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals, Principle">126,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_zRX1epxZiKM8" title="Interest Rate">12</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartiesMember_z6xG0aAWI6Pl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Totals, Principle">120,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsecured</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Totals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zAQSR8vYk3H" style="text-align: right" title="Totals, Principle">648,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zAmbbYx2Xfuj" style="text-align: right" title="Totals, Principle">642,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td id="xdx_989_ecustom--DebtInstrumentPeriodicPaymentPrincipalGross_pp0p0_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1Vuh4swiqQ1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Discount, Principal">514</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--DebtInstrumentPeriodicPaymentPrincipalGross_pp0p0_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCQxXmMlq2p3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Discount, Principal">7,915</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">$</td><td id="xdx_988_eus-gaap--OtherLiabilitiesCurrent_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdkQ8v972mNf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net, Principal">647,986</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right">$</td><td id="xdx_980_eus-gaap--OtherLiabilitiesCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zRH75RP2FJQi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net, Principal">634,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zkWsu6hC1mdg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zpLixo6udiNi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest varies from <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgRGVidCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--RangeAxis__srt--MinimumMember_zqQc6LkGj4uc" title="Debt instrument, interest rate, stated percentage">12</span>% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgRGVidCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--RangeAxis__srt--MaximumMember_zXh2uPC4qAAh" title="Debt instrument, interest rate, stated percentage">120</span>%.</span></td></tr></table> 522450 521950 0.12 126050 0.12 120850 648500 642800 514 7915 647986 634885 0.12 1.20 164700 5514 159000 0.12 1.20 2.50 592099 514 7915 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zVl2PX27gPJb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6) <span style="text-decoration: underline"><span id="xdx_827_zqqtELiL71R6">Stockholders’ Deficit</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zjmz6pBYJ0wg" title="Preferred stock, shares authorized">1,000,000</span> shares of preferred stock with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zSRIPbQDCv06" title="Preferred stock par value per share">0.01</span>. Of the <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z0puzi74EFcj">1,000,000</span> shares of preferred stock, the following is outstanding:</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zniUahqDNAQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_zIPrBapAR2pb" style="display: none">Schedule of Preferred Stock Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230930_zCCvOQWSY6s2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20221231_zaIFoF8500l7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z5K8tlCJ1Pg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Series D Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ztzk9zSL4Pe6" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z8RBTRod66Ca" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zaUA6SG55r91" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zDik73yRbKXb" title="Preferred stock, shares authorized">850</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zAZOBqtxvyz4" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zuzv3JvzwCwh" title="Preferred stock, shares outstanding">75</span></span> shares issued and outstanding on September 30, 2023, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zyuaNQTbm7Z2" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zZ27NxtfeMFd" title="Preferred stock, shares outstanding">300</span></span> shares issued and outstanding on December 31, 2022 (Liquidation value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zTdzcO3WYcO8" title="Preferred stock, shares outstanding">300,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2023">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_z8wJsGOxNEV8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series G Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_z7b22bJm1gW5" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zlsVqUCqFuw2" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zqgxn5fV5dW4" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zmSKSaB68Ua6" title="Preferred stock, shares authorized">240,000</span></span> shares authorized; no shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zVQxAbzhJsQ2" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zvZxTb8a7Tud" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zauITr3CRo4e" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_z3tLagkK7Pm8" title="Preferred stock, shares outstanding">80,570</span></span></span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">806</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zHMZLeRMwstd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series H Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zmPrFDnFlhm2" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_ztF0f5y6H4I4" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zx3ereaGJrwf" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_ztEd8SIluoG5" title="Preferred stock, shares authorized">10,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zLXEnGdKZSDg" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zcSyhRVlKcjj" title="Preferred stock, shares outstanding">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zeXE3RaVABp3" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zuJVZ5PCwNff" title="Preferred stock, shares outstanding">10,000</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2063">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_z3JPS2xaqax6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series J Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zFzvq8kX29Ac"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_z6uRF4pkN1Xh">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zKsKbXolfu08"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zPqfbi2nhoy1">6,250</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zIHq1wpb5mDj"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zMzJAyFg2qNl">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zE2VRYHjRTek"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zLC2ELKIju2e">3,458</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2082">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zFODhYJ3Dw04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series K Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zI2ArH3YV8o9" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zBCu7hc1pQab" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_z995jsshIrIg" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zkmFxVHyZTn1" title="Preferred stock, shares authorized">15,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zrmYiCKfy3Fb" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zCQPaWGyPjzk" title="Preferred stock, shares outstanding">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zLdEDiVgADZa" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zX4qw3oQKEVd" title="Preferred stock, shares outstanding">6,880</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2093">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_z07sHACL7e4b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series AA Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zGUVnQN8uUn5" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zVzN9fTjvKRf" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zL7fGaXKeNda" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zqCb0MfwkW34" title="Preferred stock, shares authorized">10,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zQHUBIttJJH1" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_ziDBHXgIXyob" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zVY4jKX0kHSc" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zOmDzrwlHZIb" title="Preferred stock, shares outstanding">8,601</span></span></span></span> shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zFVMvOjesnc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series BB Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zqbpR8RjtWG2" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_z8GkXhjTeio3" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zL1Zz16CRXv8" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_z1O7bZFDpNQ4" title="Preferred stock, shares authorized">1,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zidZJ0MbQBRg" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zBpeaH52ASW7" title="Preferred stock, shares outstanding">858</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zSreNx481AY" title="Preferred stock, shares outstanding">no</span> shares outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2132">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zEzpMbMBBfRg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series CC Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zdU92jXlLjli" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zb32QusAOLF5" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zasYCPRqizY4" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zVHjt52Pa5Dc" title="Preferred stock, shares authorized">2,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_z8So7U7xalL3" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zoRMtmIxja7a" title="Preferred stock, shares outstanding">401</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zQyQoJAWiahe" title="Preferred stock, shares outstanding">no</span> shares outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2149">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zvn7wjSmtx3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series H2 Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zCg5zJVq8JU8" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zEx3BpCE0Ne7" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zqxCB2rpmibg" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zHFQIUDO1X69" title="Preferred stock, shares authorized">21</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zRABbJ8zL6F1" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zAry9xtlRIQ9" title="Preferred stock, shares outstanding">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zeTFu3uKxKI6" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zwgcepAFVo78" title="Preferred stock, shares outstanding">21</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2165">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2166">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PreferredStockValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zTmwVVUXU6z4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series A Junior Participating Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zlkeXvRjdMT" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zW1erXIZ4Q3f" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zuxqa56BZJ52" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zcE5neWHnuA4" title="Preferred stock, shares authorized">20,000</span></span> shares authorized, <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zKgej0BawU68" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zcHhkoGGwwI1" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2184">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2185">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoNvVJS9S1ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series A Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfjBttqyeIye" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zm4ZPSUJ9xr6" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z4rmgmtWpDw5" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zyP1NFkFCKc" title="Preferred stock, shares authorized">313,960</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoNlkr9uGGI3" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOqBXhp1Wov" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2200">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zqVJBFPzPVU8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxj0MbKThPR5" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zaG6qewEOHcb" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zAPP8FXtFoP1" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zXk6HK6Z94B1" title="Preferred stock, shares authorized">279,256</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z5ybltlxxU9c" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNKjR02vkgJj" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2214">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2215">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zOVBp7RWCdMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series C Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zQKIFsPSGpL" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zSnC8OAKdpJd" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z7Rd918gjD4c" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zecWgy03MNj6" title="Preferred stock, shares authorized">88,098</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z3OBFEfzgtpk" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zeMqFRWpUxUk" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2230">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zu68g3hdyUGc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Series E Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zmz9XEkWCZB7" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zKBsEAzMK5U5" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zPHUddE0EYQh" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zJ6W1wNWJeZj" title="Preferred stock, shares authorized">500</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zPz3flJMF2X6" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_z9JcPWclYzu9" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2244">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2245">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_zSFffws6EQ27" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total Convertible Preferred Shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,098</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_ztPPjtkpnQq7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 1, 2023, Pressure Biosciences, Inc. (the “Company”) filed Articles of Amendment to Restated Articles of Organization (the “Amendment”) with the Secretary of the Commonwealth of Massachusetts to designate <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230501__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zUYop9kAqCH3" title="Convertible preferred stock, authorized">1,000</span> shares of its Preferred Stock as Series BB Convertible Preferred Stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230501__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zWkicK3tf1aa" title="Convertible preferred stock, par value">0.01</span> per share (the “Series BB Preferred Stock”) and <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230501__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_z6sq3biUnDa7" title="Convertible preferred stock, authorized">2,000</span> shares of Preferred Stock as Series CC Convertible Preferred Stock, par value $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230501__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zw4O0aA48rRi" title="Convertible preferred stock, par value">0.01</span> per share (the “Series CC Preferred Stock”). Each of the Certificate of Designation of Series BB Convertible Preferred Stock (the “Series BB COD”) and Certificate of Designation of Series CC Convertible Preferred Stock (the “Series CC COD”) filed with the Amendment set forth the terms and provisions of the Series BB Preferred Stock and Series CC Preferred Stock, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series BB Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rank</i>. The Series BB Preferred Stock ranks prior to the Company’s common stock, par value $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zObdzmlKUSz1" title="Convertible preferred stock, par value">0.01</span> per share (the “Common Stock”), and subordinate to the Series AA and Series CC Preferred Stock, and to all other classes of classes and series of equity securities of the Company, which by its terms does not rank on a parity with or senior to the Series BB Preferred, and all indebtedness of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends</i>. The holders of shares of the Series BB Preferred Stock are not entitled to receive dividends.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Rights</i>. The Series BB Preferred Stock has all of the same voting rights as the Common Stock. Each share of Series BB Preferred Stock. <span id="xdx_907_eus-gaap--PreferredStockVotingRights_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zTMV3L8TjYv4" title="Preferred stock voting rights">The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voluntary Conversion</i>. The holders of Series BB Preferred Stock have the right to convert its Series BB Preferred Stock into Common Stock at a ratio of <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zqfi7ezoZmo4" title="Number of shares converted">10,000</span> shares of Common Stock for each share of Series BB Preferred Stock held, subject to adjustment as set forth in Section 4(e) of the Series BB COD.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Company Forced Conversion</i>. The Company has the right to cause the conversion of all shares of Series BB Preferred Stock into Common Stock (“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares held by holders of the Series BB Preferred Stock, the Company may effectuate a Forced Conversion if either of the following conditions are satisfied: (i) the VWAP of the Common Stock shall equal or exceed <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zJDFcaguAh7" title="Debt instrument, convertible price per shares">300</span>% of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zyAJl9atRpG9" title="Debt instrument, convertible price per shares">2.50</span> (with such dollar figure to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction that affects the share price of the Common Stock) for either 10 consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series BB Preferred Stock that are issued pursuant to any exchange of previously issued securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series CC Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rank</i>. The Series CC Preferred Stock ranks prior to the Common Stock, pari passu to the Series AA Preferred Stock, and prior to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred Stock (the “Junior Stock”). The Series CC Preferred Stock is subordinate to and ranks junior to all indebtedness of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quarterly Dividends</i>. The holders of shares of the Series CC Preferred Stock are entitled to receive, out of funds legally available therefor, dividends at an annual rate equal to <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_ztehtV4VKHlk" title="Debt instrument, interest rate, stated percentage">8</span>% of the Liquidation Preference Amount (as defined below), calculated on the basis of a 360-day year, consisting of twelve 30-day months, and shall accrue on a daily basis from April 24, 2023. Accrued and unpaid dividends shall compound on a quarterly basis, and shall be, except as set forth in Section 2(b) of the Series CC COD, payable in cash. The first such dividend payment shall be due and payable on April 30, 2023, with subsequent dividend payments due and payable on June 30, September 30, and December 31, 2023. Each year thereafter, dividend payments shall be due and payable on March 31, June 30, September 30, and December 31.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Junior Stock Dividends</i>. The Company shall not declare or pay any cash dividends on or make any other distributions with respect to or redeem, purchase, or otherwise acquire for consideration, any shares of Junior Stock unless and until all accrued and unpaid dividends on the Series CC Preferred Stock have been paid in full, subject to restrictions as set forth in Section 3(a) of the Series CC COD.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Class Voting Rights</i>. So long as more than ten percent (<span id="xdx_905_ecustom--PreferredStockOutstandingPercentage_dp_uPure_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_z9JHKySHrKL1" title="Preferred stock remain outstanding percentage">10</span>%) of the Series CC Preferred Stock remain outstanding, the Company shall not, and shall not permit any subsidiary to, without the affirmative vote or consent of the holders of at least <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_dp_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_zTI920Byyfp5" title="Preferred stock, dividend rate, percentage">75</span>% of the shares of the Series CC Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting, in which the holders of the Series CC Preferred Stock vote separately as a class: (i) authorize, create, issue or increase the authorized or issued amount of any class or series of stock, including but not limited to the issuance of any more shares of previously authorized Preferred Stock, ranking prior to the Series CC Preferred Stock, with respect to the distribution of assets on liquidation, dissolution or winding up; (ii) amend, alter or repeal the provisions of the Series CC Preferred Stock, whether by merger, consolidation or otherwise, so as to adversely affect any right, preference, privilege or voting power of the Series CC Preferred Stock; (iii) repurchase, redeem or pay dividends on (whether in cash, in kind, or otherwise), shares of Junior Stock; (iv) amend the Articles of Incorporation or By-Laws of the Company so as to affect materially and adversely any right, preference, privilege or voting power of the Series CC Preferred Stock; (v) effect any distribution with respect to Junior Stock or parity stock; (vi) reclassify the Company’s outstanding securities; or (vii) effect a transaction with one or more persons or entities whereby such other persons or entities will own more than the <span id="xdx_902_ecustom--PercentageOfOutstandingShares_iI_dp_uPure_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_zNM5Du5XCN1l" title="Outstanding shares, precentage">50</span>% of the outstanding shares of Common Stock following such transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General Voting Rights</i>. Except with respect to transactions upon which the Series CC Preferred Stock shall be entitled to vote separately as a class as set forth in “Class Voting Rights” above and except as otherwise required by Massachusetts law, the Series CC Preferred Stock shall have no voting rights. The Common Stock into which the Series CC Preferred Stock is convertible shall, upon issuance, have all of the same voting rights as the Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidation Preference</i>. In the event of the liquidation, dissolution or winding up of the affairs of the Company, whether voluntary or involuntary, the holders of shares of the Series CC Preferred Stock then outstanding shall be entitled to receive, out of the assets of the Company whether such assets are capital or surplus of any nature, an amount equal to $<span id="xdx_90E_eus-gaap--PreferredStockLiquidationPreference_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_zidCTvIKDYRf" title="Preferred stock liquidation Preference value">25,000.00</span> per share (the “Liquidation Preference Amount”) of the Series CC Preferred Stock, on a pro rata and pari passu basis with any parity stock (the “Pari Passu Preferred Stock”), together with all accrued but unpaid dividends, before any payment shall be made or any assets distributed to the holders of the Common Stock or any other Junior Stock. If the assets of the Company are not sufficient to pay in full the Liquidation Preference Amount payable to the holders of outstanding shares of the Series CC Preferred Stock and any series of preferred stock or any other class of stock on a parity as to rights on liquidation, dissolution or winding up, with the Series CC Preferred Stock, then all of said assets will be distributed among the holders of the Series CC Preferred Stock, the Pari Passu Preferred Stock and the other classes of stock on a parity with the Series CC Preferred Stock, if any, ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voluntary Conversion</i>. The holders of Series CC Preferred Stock have the right to convert its Series CC Preferred Stock into a number of fully paid and nonassessable shares of Common Stock (the “Conversion Shares”) equal to the quotient of (i) the Liquidation Preference Amount of the shares of Series CC Preferred Stock being converted thereon divided by (ii) the Conversion Price then in effect as of the date of the delivery by such holder of its notice of election to convert. The “Conversion Price” shall mean $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_zJSGMZJWb6de" title="Preferred stock, convertible, conversion price">2.50</span> per share, subject to adjustment under Section 5(e) of the Series CC COD.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Company Forced Conversion</i>. The Company has the right to cause the conversion of all shares of Series CC Preferred Stock into Common Stock (“Forced Conversion”). Following the effectiveness of a registration statement permitting the resale of the Conversion Shares held by holders of the Series CC Preferred Stock the Company may effectuate a Forced Conversion if either of the following conditions are satisfied as of the Forced Conversion Effective Date: (i) the VWAP of the Common Stock shall equal or exceed <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_dp_uPure_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_z7av0WAn6VW3" title="Debt instrument, convertible, threshold percentage of stock price trigger">300</span>% of the Conversion Price for either <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_zZ2CutT7wHTg" title="Debt instrument, convertible, threshold trading days">10</span> consecutive trading days, or 15 of 25 consecutive trading days immediately preceding the date of the Forced Conversion Notice; or (ii) listing of the Common Stock on any national securities exchange (NYSE, NYSE American or Nasdaq). The Company shall not have an obligation to register the Conversion Shares of the shares of Series CC Preferred Stock that are issued pursuant to any exchange of previously issued securities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion Restriction</i>. At no time may a holder of shares of Series CC Preferred Stock convert shares of the Series CC Preferred Stock if the number of shares of Common Stock to be issued pursuant to such conversion would exceed, when aggregated with all other shares of Common Stock owned by such holder at such time, the number of shares of Common Stock which would result in such holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder) in excess of <span id="xdx_909_ecustom--DebtInstrumentConvertibleBeneficallyPercentage_dp_uPure_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_zNKf8MFjfr65" title="Debt instrument convertible benefically percentage">4.99</span>% of all of the Common Stock outstanding at such time (the “Conversion Restriction”); provided, however, that a holder may waive the Conversion Restriction by providing the Company with sixty-one (61) days’ notice that such holder is waiving the Conversion Restriction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023 the Company issued a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20230930__us-gaap--AwardTypeAxis__custom--SeriesBBRestrictedPreferredStockMember_znIEIzGZoXA2" title="Number of restricted shares issued">953</span> shares of Series BB restricted preferred stock and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20230930__us-gaap--AwardTypeAxis__custom--SeriesCCRestrictedPreferredStockMember_zBBIZR9WioI7" title="Number of restricted shares issued">401</span> shares of Series CC restricted preferred stock to accredited investors and consultants, with the following detail:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zLRM9hOLeIm1" title="Stock issued during period, shares, issued for services">92</span> shares of Series BB preferred stock with a fair value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zLeHdmHrbp59" title="Stock issued during period, value, issued for services">617,200</span>, for services rendered;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zgPbWXrJvvlb" title="Stock Issued uring period, shares, conversion of convertible securities">741</span> shares of Series BB preferred stock with a fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zJD5cSilW5X" title="Stock issued during period, value, conversion of convertible securities">2,683,600</span> for convertible debt extensions;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zblSmAGERHod" title="Stock issued during period, shares, conversion of units">58</span> shares of Series BB preferred stock with a fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyK7DmuVsL0d" title="Stock issued during period, value, conversion of units">539,487</span> and issued with convertible debt;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBPreferredStockMember_zgy4zuZAw3yj" title="Stock issued during period, value, other">62</span> shares of Series BB preferred stock from the conversion of common stock to preferred stock;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWffu2NDsfmk" title="Stock issued during period, value, other">95</span> shares of Series BB preferred stock was converted into common stock;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_zalrdP7D7B4j" title="Stock issued during period, shares, other">401</span> shares of Series CC preferred stock with a fair value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueOther_c20230101__20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCPreferredStockMember_z7ndC7UROTyf">10,017,212</span> for the conversion of debt/accrued interest and dividends.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Stock Options and Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20211230__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zfOaF1r586ok" title="Common stock, capital shares reserved for future issuance">3,000,000</span> shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Consistent with the Company’s existing 2013 Equity Incentive plan (the “2013 plan”), under the 2021 plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2023, options to acquire <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zeggXtMbIXf3" title="Option to acquire outstanding shares">3,420,754</span> shares were outstanding under these Plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, total unrecognized compensation cost related to the unvested stock-based awards was $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20230930__us-gaap--VestingAxis__custom--UnvestedStockBasedAwardsMember_z1ebKRLjCxy9" title="Unvested stock based awards">963,322</span> , which is expected to be recognized over weighted average period of <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230930__us-gaap--VestingAxis__custom--UnvestedStockBasedAwardsMember_zyzLZBaGWl08" title="Unrecognized compensation, period">2.2</span> years. The aggregate intrinsic value associated with the options outstanding and exercisable as of September 30, 2023, based on the September 30, 2023, closing stock price of $<span id="xdx_906_eus-gaap--SharePrice_iI_c20230930__us-gaap--VestingAxis__custom--UnvestedStockBasedAwardsMember_zkJc5zgrn5kg" title="Closing stock price">0.20</span>, was $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue_iI_c20230930__us-gaap--VestingAxis__custom--UnvestedStockBasedAwardsMember_znd7M3EKt5p7" title="Options outstanding and exercisable intrinsic value">0.00</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zKYCIzlDqeue" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information concerning options and warrants outstanding and exercisable:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span id="xdx_8B3_zXsJxk9Lm3Ig" style="display: none">Schedule of Concerning Options and Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">price per share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">price per share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercisable</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify; width: 40%">Balance outstanding, December 31, 2022</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zkFbOlUfAKxb" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Shares, beginning balance">1,307,822</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zqk5e8UdUsAk" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Weighted average price per share, Beginning balance">0.72</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zow2SSPvXNW9" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Shares, Beginning balance">16,278,769</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMOgROnJLbUc" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Weighted average price per share, Beginning balance">3.50</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zw4o5AxGF7Gi" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Shares, Beginning balance">17,586,591</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20230101__20230930_zi49Qzi5T0g6" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Exercisable, Beginning balance">17,570,591</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zhGyqumz4977" style="text-align: right" title="Shares, granted">2,230,484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z607YxQaP0ji" style="text-align: right" title="Weighted average price per share, Granted">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPTwzwW3ETO" style="text-align: right" title="Shares, Granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6BrWcVfME4h" style="text-align: right" title="Weighted average price per share, Granted">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_zInvf81fgawi" style="text-align: right" title="Shares, Granted">2,330,484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zrDvLw2ut99j" style="text-align: right" title="Shares, exercised">(117,552</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z2WAeGVb63F6" style="text-align: right" title="Weighted average price per share, Exercised">0.69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA1shTidjMm6" style="text-align: right" title="Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2361">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3DcosjLTvBd" style="text-align: right" title="Weighted average price per share, Exercised"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2363">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230930_zIOHocdZyq4d" style="text-align: right" title="Shares, Exercised">(117,552</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z4BBrTr8jr3g" style="text-align: right" title="Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl2367">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zoon7ByzXNc5" style="text-align: right" title="Weighted average price per share, Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqTJ2skpozUe" style="text-align: right" title="Shares, Expired">(645,829</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvIg5MxDlMp6" style="text-align: right" title="Weighted average price per share, Expired">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930_zuUEi6QQL0C5" style="text-align: right" title="Shares, Expired">(645,829</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_uShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z6UyytSyXTN1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2377">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zu5HjA4zyxgc" style="text-align: right" title="Weighted average price per share, forfeited"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2379">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z20IfGY9oyse" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4tCuXevuOt3" style="text-align: right" title="Weighted average price per share, Forfeited"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2383">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930_zKzfVAbpxCU9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2385">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: justify">Balance outstanding, September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zWSEZbAMfI3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Ending balance">3,420,754</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zxc9k0tZXa5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average price per share, Ending balance">1.23</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcSFoT3QZDh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Ending balance">15,732,940</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYDoXxJ8mVi3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average price per share, Ending balance">3.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zzGNwALOg58d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Ending balance">19,153,694</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zZIf9FaQM9rk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercisable, Ending balance">18,289,721</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_z5RbjAIVSU49" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zZpdjxbHI6e8" title="Options outstanding, shares">3,420,754</span> options outstanding have a $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zEzj6G8fJAL7" title="Weighted average exercise price">1.23</span> weighted average exercise price and <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zUMHgNOJeZc6" title="Weighted average remaining term">8.14</span> years of weighted average remaining life for outstanding options and <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--ExercisableOptionsMember_zEIDKbNQaNj" title="Weighted average remaining term">7.75</span> years of weighted average remaining life for exercisable options. Of these options, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zC9uiTHOh2Yf" title="Number of options, exercisable">2,556,781</span> are currently exercisable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2023, the Board authorized a 3-year extension of common stock warrants held by Series AA preferred shares holders. Therefore, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230413__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYIw5mTxBr29" title="Class of warrant or right, outstanding">8,897,603</span> warrants were extended with new expiration dates between May 2, 2026 to September 14, 2029. Based on a fair value computation, this extension resulted in net incremental expense of $<span id="xdx_90B_ecustom--ExtensionOfWarrantsForSeriesAaPreferredStock_c20230411__20230413__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRcDZEtLcTb1" title="Extension of warrants for series AA preferred stock">3,626,950</span>, which was booked as an increase in the value of warrants and an increase of the retained deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the warrants outstanding have a $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zT4K210x6jml" title="Weighted average exercise price">3.50</span> weighted average exercise price and a <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNOGE0XHc3t8" title="Weighted average remaining term">2.42</span> year weighted average remaining life.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common Stock and Warrant Issuances</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company accrued approximately $<span id="xdx_900_eus-gaap--InterestExpense_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDWYOIU5HE1c" title="Interest expense">3,715,204</span>  in interest expense for these obligations to issue common stock. During the nine months ended September 30, 2022, the Company accrued $<span id="xdx_90B_eus-gaap--InterestExpense_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkTJfud9xppf" title="Interest expense">634,305</span> in interest expense for these obligations to issue common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023 the Company issued a total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorAndConsultantsMember_zVSq9jouohSk" title="Shares of restricted common stock">9,717,035</span> shares of restricted common stock and to accredited investors and consultants, with the following detail:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--LongtermDebtTypeAxis__us-gaap--PaymentInKindPIKNoteMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndWarrantMember_zVvPolridv1g">4,094,121</span> shares of common stock with a fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--LongtermDebtTypeAxis__us-gaap--PaymentInKindPIKNoteMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndWarrantMember_zABByBLlN3Wc">3,715,204</span> to lenders for interest paid-in-kind;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__srt--StatementScenarioAxis__custom--IssuedForServicesRenderedMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndWarrantMember_zd27VwmcVCZ7" title="Number of common stock for services rendered, shares">1,630,500</span> shares with a fair value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__srt--StatementScenarioAxis__custom--IssuedForServicesRenderedMember_zW57tiCS6d" title="Number of common stock for services rendered">1,917,036</span> for services rendered;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__srt--StatementScenarioAxis__custom--ConversionOfDebtMember_zHg4rsgNcg2k">203,613</span> shares with a fair value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__srt--StatementScenarioAxis__custom--ConversionOfDebtMember_z0HZvpXYof63">509,033</span> for conversions of debt principal and interest;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930__srt--StatementScenarioAxis__custom--DebtSettlementMember_zZ1QNf6WeBsl" title="Shares isused for options exercised, shares">117,552</span> shares for stock option exercises (at an exercise price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--ClassOfWarrantOrRightAxis__custom--LenderMember_zP5RwGE7eYzi" title="Shares issued, price per share">0.69</span> per share);</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--LongtermDebtTypeAxis__custom--DividendsPaidInKindMember_zH7wxmJscig5">142,767</span> shares with a fair value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--LongtermDebtTypeAxis__custom--DividendsPaidInKindMember_zf6El59Ahj3a" title="Fair value of dividends paid in kind">162,528</span> for dividends paid-in-kind;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230930__srt--StatementScenarioAxis__custom--ConversionOfDebtMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndWarrantMember_zj2j130HeMoh" title="Convertible debt issuances shares">1,258,742</span> shares with a fair value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20230101__20230930__srt--StatementScenarioAxis__custom--ConversionOfDebtMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockAndWarrantMember_z074klRe90Fk" title="Convertible debt issuances value">1,293,270</span> for common stock issued with convertible debt;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__srt--StatementScenarioAxis__custom--DebtExtensionMember_zIaaFJHWFHlj">1,346,800</span> shares with a fair value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__srt--StatementScenarioAxis__custom--DebtExtensionMember_zujBR3sk5fJ7">1,671,573</span> for convertible debt extensions;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__srt--StatementScenarioAxis__custom--NewCommonStockIssuancesMember_zNFz8Oek6YR2">60,000</span> shares with a fair value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__srt--StatementScenarioAxis__custom--NewCommonStockIssuancesMember_zBjsoPGzK0X9" title="Fair value of dividends paid in kind">150,000</span> for sale of common, and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230930__srt--StatementScenarioAxis__custom--ConversionOfPreferredToCommonStockMember_zPjBPlarBlx8">1,486,940</span> shares for the conversion of preferred stock to common stock.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2023, the Company issued <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6evN7TGqkLh" title="Issuance warrants, shares">100,000</span> warrants (four-year term at a $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhZWRqTpcEi9" title="Strike price, per share">3.50</span> exercise price) to acquire common stock at a fair value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvd36yIc1ZC7" title="Fair value of warrants">61,609</span> to a consultant for professional services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, we issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZncJVLEPaXk">3,100,085 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock to accredited investors and consultants, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220101__20220930__srt--StatementScenarioAxis__custom--ConversionOfDebtMember_zArTJR4zFB87">140,200 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares with a fair value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220101__20220930__srt--StatementScenarioAxis__custom--ConversionOfDebtMember_zXRYvv45eZpc">350,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for conversions of debt principal and interest for common stock, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--PaymentInKindPIKNoteMember_ztWPDrmechFi">1,172,100 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the shares with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--PaymentInKindPIKNoteMember_zdaNXhXhDKIc">2,196,278 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were issued for interest paid-in-kind, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220930__srt--StatementScenarioAxis__custom--IssuedForServicesRenderedMember_zx3b9lDQutTe">190,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the shares with a fair value of $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--StatementScenarioAxis__custom--IssuedForServicesRenderedMember_zGAUBBQBGwt7">312,875 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were issued for services rendered,<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--LongtermDebtTypeAxis__us-gaap--PaymentInKindPIKNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPHbsCxIvZNj">170,306 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares with a fair value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__us-gaap--PaymentInKindPIKNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFk8jWcvV8yl">306,333 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for dividends paid-in-kind, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--StatementScenarioAxis__custom--NewConversionDebtMember_zyoLXRCPwdh4">368,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares with a fair value $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--StatementScenarioAxis__custom--NewConversionDebtMember_z4cItDndeIx">512,593 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for new convertible debt issuances, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--StatementScenarioAxis__custom--DebtExtensionMember_zIb9KCm69cUj">25,279 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares with a fair value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--StatementScenarioAxis__custom--DebtExtensionMember_zQkY6a47dTD8">17,433 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from a stock option exercise, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAPreferredStockMember__srt--StatementScenarioAxis__custom--DebtExtensionMember_zFbBeaut44x1">1,028,800 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares with a fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20220930__srt--StatementScenarioAxis__custom--SeriesAAPreferredStockMember_ziOP6z7P8Iql">1,714,678 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for debt extension and shareholders converted shares of series AA convertible preferred stock into <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--SeriesAAPreferredStockMember__srt--StatementScenarioAxis__custom--DebtExtensionMember_zcip4f1CCqed">4,400 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, we issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjqf3xXmlrh" title="Issuance warrants, shares">277,500</span> warrants (three-year to five-year terms at a $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt4HgFvcpgmc" title="Strike price, per share">3.50</span> exercise price) to acquire common stock at a total fair value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrsXs6OI3PZc" title="Fair value of warrants">280,608</span> to a lender in conjunction with the signing of new convertible loans, a vendor for services rendered and for debt extension.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000000 0.01 1000000 <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zniUahqDNAQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_zIPrBapAR2pb" style="display: none">Schedule of Preferred Stock Outstanding</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20230930_zCCvOQWSY6s2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20221231_zaIFoF8500l7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z5K8tlCJ1Pg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Series D Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_ztzk9zSL4Pe6" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_z8RBTRod66Ca" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zaUA6SG55r91" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zDik73yRbKXb" title="Preferred stock, shares authorized">850</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zAZOBqtxvyz4" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zuzv3JvzwCwh" title="Preferred stock, shares outstanding">75</span></span> shares issued and outstanding on September 30, 2023, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zyuaNQTbm7Z2" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zZ27NxtfeMFd" title="Preferred stock, shares outstanding">300</span></span> shares issued and outstanding on December 31, 2022 (Liquidation value of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zTdzcO3WYcO8" title="Preferred stock, shares outstanding">300,000</span>)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2023">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_z8wJsGOxNEV8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series G Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_z7b22bJm1gW5" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zlsVqUCqFuw2" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zqgxn5fV5dW4" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zmSKSaB68Ua6" title="Preferred stock, shares authorized">240,000</span></span> shares authorized; no shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zVQxAbzhJsQ2" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zvZxTb8a7Tud" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_zauITr3CRo4e" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_z3tLagkK7Pm8" title="Preferred stock, shares outstanding">80,570</span></span></span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">806</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zHMZLeRMwstd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series H Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zmPrFDnFlhm2" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_ztF0f5y6H4I4" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zx3ereaGJrwf" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_ztEd8SIluoG5" title="Preferred stock, shares authorized">10,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zLXEnGdKZSDg" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zcSyhRVlKcjj" title="Preferred stock, shares outstanding">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zeXE3RaVABp3" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesHConvertiblePreferredStockMember_zuJVZ5PCwNff" title="Preferred stock, shares outstanding">10,000</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2063">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_z3JPS2xaqax6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series J Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zFzvq8kX29Ac"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_z6uRF4pkN1Xh">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zKsKbXolfu08"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zPqfbi2nhoy1">6,250</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zIHq1wpb5mDj"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zMzJAyFg2qNl">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zE2VRYHjRTek"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesJConvertiblePreferredStockMember_zLC2ELKIju2e">3,458</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2082">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zFODhYJ3Dw04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series K Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zI2ArH3YV8o9" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zBCu7hc1pQab" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_z995jsshIrIg" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zkmFxVHyZTn1" title="Preferred stock, shares authorized">15,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zrmYiCKfy3Fb" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zCQPaWGyPjzk" title="Preferred stock, shares outstanding">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zLdEDiVgADZa" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesKConvertiblePreferredStockMember_zX4qw3oQKEVd" title="Preferred stock, shares outstanding">6,880</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2093">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_z07sHACL7e4b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series AA Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zGUVnQN8uUn5" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zVzN9fTjvKRf" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zL7fGaXKeNda" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zqCb0MfwkW34" title="Preferred stock, shares authorized">10,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zQHUBIttJJH1" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_ziDBHXgIXyob" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zVY4jKX0kHSc" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAConvertiblePreferredStockMember_zOmDzrwlHZIb" title="Preferred stock, shares outstanding">8,601</span></span></span></span> shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zFVMvOjesnc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series BB Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zqbpR8RjtWG2" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_z8GkXhjTeio3" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zL1Zz16CRXv8" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_z1O7bZFDpNQ4" title="Preferred stock, shares authorized">1,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zidZJ0MbQBRg" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zBpeaH52ASW7" title="Preferred stock, shares outstanding">858</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember_zSreNx481AY" title="Preferred stock, shares outstanding">no</span> shares outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2132">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zEzpMbMBBfRg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series CC Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zdU92jXlLjli" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zb32QusAOLF5" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zasYCPRqizY4" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zVHjt52Pa5Dc" title="Preferred stock, shares authorized">2,000</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_z8So7U7xalL3" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zoRMtmIxja7a" title="Preferred stock, shares outstanding">401</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCCConvertiblePreferredStockMember_zQyQoJAWiahe" title="Preferred stock, shares outstanding">no</span> shares outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2149">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zvn7wjSmtx3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series H2 Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zCg5zJVq8JU8" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zEx3BpCE0Ne7" title="Preferred stock, par value">.01</span></span> par value; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zqxCB2rpmibg" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zHFQIUDO1X69" title="Preferred stock, shares authorized">21</span></span> shares authorized; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zRABbJ8zL6F1" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zAry9xtlRIQ9" title="Preferred stock, shares outstanding">no</span></span> shares issued and outstanding on September 30, 2023 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zeTFu3uKxKI6" title="Preferred stock, shares issued"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesH2ConvertiblePreferredStockMember_zwgcepAFVo78" title="Preferred stock, shares outstanding">21</span></span> shares issued and outstanding on December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2165">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2166">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PreferredStockValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zTmwVVUXU6z4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series A Junior Participating Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zlkeXvRjdMT" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zW1erXIZ4Q3f" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zuxqa56BZJ52" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zcE5neWHnuA4" title="Preferred stock, shares authorized">20,000</span></span> shares authorized, <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zKgej0BawU68" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zcHhkoGGwwI1" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2184">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2185">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoNvVJS9S1ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series A Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfjBttqyeIye" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zm4ZPSUJ9xr6" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z4rmgmtWpDw5" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zyP1NFkFCKc" title="Preferred stock, shares authorized">313,960</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoNlkr9uGGI3" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOqBXhp1Wov" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2200">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zqVJBFPzPVU8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxj0MbKThPR5" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zaG6qewEOHcb" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zAPP8FXtFoP1" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zXk6HK6Z94B1" title="Preferred stock, shares authorized">279,256</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z5ybltlxxU9c" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNKjR02vkgJj" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2214">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2215">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zOVBp7RWCdMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series C Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zQKIFsPSGpL" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zSnC8OAKdpJd" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z7Rd918gjD4c" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zecWgy03MNj6" title="Preferred stock, shares authorized">88,098</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z3OBFEfzgtpk" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zeMqFRWpUxUk" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2230">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_hus-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zu68g3hdyUGc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Series E Convertible Preferred Stock, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zmz9XEkWCZB7" title="Preferred stock, par value"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zKBsEAzMK5U5" title="Preferred stock, par value">.01</span></span> par value, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zPHUddE0EYQh" title="Preferred stock, shares authorized"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zJ6W1wNWJeZj" title="Preferred stock, shares authorized">500</span></span> shares authorized, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_zPz3flJMF2X6" title="Preferred stock, shares outstanding"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIE9mIFByZWZlcnJlZCBTdG9jayBPdXRzdGFuZGluZyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_z9JcPWclYzu9" title="Preferred stock, shares outstanding">no</span></span> shares outstanding</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2244">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2245">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_iI_zSFffws6EQ27" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total Convertible Preferred Shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,098</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.01 0.01 850 850 75 75 300 300 300000 3 0.01 0.01 240000 240000 80570 80570 80570 80570 806 0.01 0.01 10000 10000 0 0 10000 10000 100 0.01 0.01 6250 6250 0 0 3458 3458 35 0.01 0.01 15000 15000 0 0 6880 6880 68 0.01 0.01 10000 10000 8601 8601 8601 8601 86 86 0.01 0.01 1000 1000 858 858 0 10 0.01 0.01 2000 2000 401 401 0 4 0.01 0.01 21 21 0 0 21 21 0.01 0.01 20000 20000 0 0 0.01 0.01 313960 313960 0 0 0.01 0.01 279256 279256 0 0 0.01 0.01 88098 88098 0 0 0.01 0.01 500 500 0 0 100 1098 1000 0.01 2000 0.01 0.01 The holders of Series BB Preferred Stock shall have the right to vote along with the holders of Common Stock in an amount equal to 10,000 votes for each share of Series BB Preferred Stock held 10000 3 2.50 0.08 0.10 0.75 0.50 25000.00 2.50 3 10 0.0499 953 401 92 617200 741 2683600 58 539487 62 95 401 10017212 3000000 3420754 963322 P2Y2M12D 0.20 0.00 <p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zKYCIzlDqeue" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information concerning options and warrants outstanding and exercisable:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span id="xdx_8B3_zXsJxk9Lm3Ig" style="display: none">Schedule of Concerning Options and Warrants Outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">price per share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">price per share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercisable</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify; width: 40%">Balance outstanding, December 31, 2022</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zkFbOlUfAKxb" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Shares, beginning balance">1,307,822</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zqk5e8UdUsAk" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Weighted average price per share, Beginning balance">0.72</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zow2SSPvXNW9" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Shares, Beginning balance">16,278,769</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMOgROnJLbUc" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Weighted average price per share, Beginning balance">3.50</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zw4o5AxGF7Gi" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Shares, Beginning balance">17,586,591</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right; width: 1%"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iS_c20230101__20230930_zi49Qzi5T0g6" style="border-bottom: Black 1.5pt solid; width: 6%; text-align: right" title="Exercisable, Beginning balance">17,570,591</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zhGyqumz4977" style="text-align: right" title="Shares, granted">2,230,484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z607YxQaP0ji" style="text-align: right" title="Weighted average price per share, Granted">1.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPTwzwW3ETO" style="text-align: right" title="Shares, Granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6BrWcVfME4h" style="text-align: right" title="Weighted average price per share, Granted">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_zInvf81fgawi" style="text-align: right" title="Shares, Granted">2,330,484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zrDvLw2ut99j" style="text-align: right" title="Shares, exercised">(117,552</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z2WAeGVb63F6" style="text-align: right" title="Weighted average price per share, Exercised">0.69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA1shTidjMm6" style="text-align: right" title="Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2361">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3DcosjLTvBd" style="text-align: right" title="Weighted average price per share, Exercised"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2363">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20230930_zIOHocdZyq4d" style="text-align: right" title="Shares, Exercised">(117,552</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z4BBrTr8jr3g" style="text-align: right" title="Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl2367">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zoon7ByzXNc5" style="text-align: right" title="Weighted average price per share, Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2369">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqTJ2skpozUe" style="text-align: right" title="Shares, Expired">(645,829</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvIg5MxDlMp6" style="text-align: right" title="Weighted average price per share, Expired">3.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930_zuUEi6QQL0C5" style="text-align: right" title="Shares, Expired">(645,829</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_uShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_z6UyytSyXTN1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2377">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zu5HjA4zyxgc" style="text-align: right" title="Weighted average price per share, forfeited"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2379">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z20IfGY9oyse" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2381">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4tCuXevuOt3" style="text-align: right" title="Weighted average price per share, Forfeited"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2383">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930_zKzfVAbpxCU9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl2385">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: justify">Balance outstanding, September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zWSEZbAMfI3g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Ending balance">3,420,754</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember_zxc9k0tZXa5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average price per share, Ending balance">1.23</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcSFoT3QZDh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Ending balance">15,732,940</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYDoXxJ8mVi3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average price per share, Ending balance">3.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zzGNwALOg58d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Ending balance">19,153,694</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zZIf9FaQM9rk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Exercisable, Ending balance">18,289,721</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 1307822 0.72 16278769 3.50 17586591 17570591 2230484 1.50 100000 3.50 2330484 117552 0.69 117552 645829 3.50 645829 3420754 1.23 15732940 3.50 19153694 18289721 3420754 1.23 P8Y1M20D P7Y9M 2556781 8897603 3626950 3.50 P2Y5M1D 3715204 634305 9717035 4094121 3715204 1630500 1917036 203613 509033 117552 0.69 142767 162528 1258742 1293270 1346800 1671573 60000 150000 1486940 100000 3.50 61609 3100085 140200 350500 1172100 2196278 190500 312875 170306 306333 368500 512593 25279 17433 1028800 1714678 4400 277500 3.50 280608 <p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_z8O3dDxvAuEe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7) <span style="text-decoration: underline"><span id="xdx_82A_z9mnPElBWsx1">Subsequent Events</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From October 1, 2023, through November 10, 2023, the Company issued seven (7) convertible loan with a principal balance of $<span id="xdx_906_eus-gaap--ConvertibleDebt_iI_c20231105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCetHDr73FV6">439,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The terms of the convertible notes were 15 days to 12 months with interest rates of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zI3FNZL3eTVk">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zjyzGwTBfG7a">120</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and convertible into the Company’s common stock at a fixed rate of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20231105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcimHf3nfl2e">2.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. In this time the Company also issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231001__20231105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwLC2Glk7pK2">278,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for new convertible debt loans in the third quarter, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesOther_c20231001__20231105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaSM0LmPCbDk">455,350 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for accrued interest paid-in-kind, 310,000 shares of common stock for debt extensions, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20231001__20231105__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdJVWq4FFUwa">505,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock from the conversion of Series BB preferred stock, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20231001__20231105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhe9YM7zB9Qe">145,809 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for Series AA preferred dividends and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_c20231001__20231105__us-gaap--StatementClassOfStockAxis__custom--SeriesBBConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdbtGHDzhdOh">40 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series BB preferred stock for professional services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 18, 2023, the Board of Directors (the “Board”) of Pressure BioSciences, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Pressure BioSciences, Inc. 2021 Equity Incentive Plan (the “Plan”). The Plan originally provided that no one person could be granted awards pursuant to the Plan during any one fiscal year to purchase more than <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231018__20231018__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityPlanMember_zyva5w08j02j" title="Shares of common stock">300,000 </span>shares of the Company’s common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231018__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityPlanMember_ztsS8wBOXBXk" title="common stock, par value">0.01</span> per share (the “Common Stock”). Pursuant to the amendment, the yearly limit for any one person was raised to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20231018__20231018__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityPlanMember_z5WFISZKkRze" title="Shares of common stock">500,000</span> shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the same date, the Board granted a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231018__20231018__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCOjshA70R62" title="Stock option number of shares granted">1,500,000</span> stock options to a number of employees, consultants and the four members of the Board with each option having an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20231018__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zA04k8XT9Ee2" title="Numberof stock option exercise price">0.25 </span>per share. Each award of options expires on October 18, 2033. The options for the members of the Board vest in equal amounts over twelve (12) months. The options for Mr. Schumacher and Drs. Ting and Lazarev were each vested <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20231018__20231018__srt--TitleOfIndividualAxis__custom--MrSchumacherMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwWrfvZWMIBl" title="Number of option vested percentage"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20231018__20231018__srt--TitleOfIndividualAxis__custom--DrsTingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKwecVxUs1He" title="Number of option vested percentage"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20231018__20231018__srt--TitleOfIndividualAxis__custom--LazarevMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkMRn3E5BcB" title="Number of option vested percentage">25</span></span></span>% on the date of issuance and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20231018__20231018__srt--TitleOfIndividualAxis__custom--LazarevMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKfsBLdzJVB6" title="Number of option issuance percentage">25</span>% of the options vest each year for the next three (<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231018__20231018__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBpnWi6YhlUb" title="Number of years option vested">3</span>) years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, on the same date, the Board approved the repricing of all outstanding options (including those held by the Board members and the named executive officers) to $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20231018__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsBzfyZ5qYVh" title="Numberof stock option exercise price">0.25</span>. The previous exercise prices of the outstanding stock options held by the Board members and the named executive officers ranged from $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20231018__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zoMGKk6lD7X4" title="Numberof stock option exercise price">0.69</span> to $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20231018__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zdrw5fuWr6xa" title="Numberof stock option exercise price">1.50</span>.</span></p> <p id="xdx_8A8_zAvkpY6Bk0Eg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, forward-looking statements are identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. Such statements include, without limitation, statements regarding:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient additional financing;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our belief that we will have sufficient liquidity to finance normal operations for the foreseeable future; </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the options we may pursue in light of our financial condition;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential applications for Ultra Shear Technology (<i>UST</i>);</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential applications of the BaroFold high-pressure protein refolding and disaggregation technology</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount of cash necessary to operate our business;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the anticipated uses of grant revenue and the potential for increased grant revenue in future periods;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans and expectations with respect to our continued operations;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected number of Pressure Cycling Technology (“PCT”) and Constant Pressure (“CP”) based units that we believe will be installed and the expected revenues from the sale of consumable products, extended service contracts, and biopharma contract services;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our belief that PCT has achieved initial market acceptance in the mass spectrometry and other markets;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected development and success of new instrument and consumables product offerings;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential applications for our instrument and consumables product offerings;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected expenses of, and benefits and results from, our research and development efforts;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected benefits and results from our collaboration programs, strategic alliances and joint ventures;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations of the results of our development activities funded by government research grants;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential size of the market for biological sample preparation, biopharma contract services and Ultra Shear Technology;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic conditions;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the anticipated future financial performance and business operations of our company;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reasons for resources expended in the market for genomic, proteomic, lipidomic and small molecule sample preparation;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the importance of mass spectrometry as a laboratory tool;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the advantages of PCT over other current technologies as a method of biological sample preparation and protein characterization in biomarker discovery, forensics, and histology, as well as for other applications;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the capabilities and benefits of our PCT Sample Preparation System, consumables and other products;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our belief that laboratory scientists will achieve results comparable with those reported to date by certain research scientists who have published or presented publicly on PCT and our other products and services;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to retain our core group of scientific, administrative and sales personnel; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to expand our customer base in sample preparation and for other applications of PCT, as well as for our other products and services in both the BaroFold and Ultra Shear Technology areas.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 and in this Report. We qualify all of our forward-looking statements by these cautionary statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pressure BioSciences, Inc. (OTCQB: PBIO</i>) (the “Company”) is a leader in the development &amp; sale of innovative, enabling, high pressure technology-based instruments, consumables, and services for the life sciences and other industries worldwide. Our products/services are based on three patented, high-pressure platforms: (i) Ultra Shear Technology™ (“UltraShear™” or “UST™”), (ii) BaroFold Technology™ (“BaroFold™”), and (iii) Pressure Cycling Technology™ (“PCT™”)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company was founded on the belief that its PCT platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. This premise has been well proven and PBI has been successful in installing its PCT platform in the laboratories of key opinion leaders worldwide. Although developed subsequently, the Company now assesses that the commercial potential for its UST platform across diverse multi-billion dollar markets far exceeds the potential of the PCT platform. Consequently, in January 2022, PBI made the critical strategy decision to immediately shift its primary business focus from PCT to its innovative UST Platform.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The UST Platform </i></b>(8 issued patents) is based on the use of intense shear forces from ultra-high pressure discharge (greater than 20,000 psi) through a dynamically-controlled nano-gap valve under precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based supplements (e.g., CBD, curcumin, astaxanthin), therapeutics (e.g., prednisone), and other active ingredients (e.g., retinol) into long-term stable, effectively water-soluble, highly bioavailable, oil-in-water nanoemulsion formulations. The Company began early commercial introduction of the UST Platform in May 2022, and executed agreements were subsequently announced with three CBD companies and one cosmeceutical/skincare company for commercialization in Q4 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The BaroFold Platform</i></b> (14 issued patents) can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high-pressure manipulations for the disaggregation, unfolding and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. It is scalable and practical for standard manufacturing processes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The PCT Platform</i></b> (17 issued patents) uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions safely and reproducibly in sample preparation (e.g., the critical steps performed by tens of thousands of scientists worldwide prior to analytical measurements, such as cell lysis and biomolecule extraction from tissue samples). Our focus for PCT is on making our, GMP-compliant, next generation PCT-based Barocycler EXTREME system available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. We currently have over 350 PCT Systems placed in approximately 225 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are currently over 200 independent publications highlighting the advantages of using the PCT Platform in scientific research &amp; clinical laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2023 Key Accomplishments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From January 1, 2023 to September 30, 2023, we announced the following key accomplishments:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 22: </b>PBIO’s partner Veterans Service Team increases existing purchase order by 10X for bottles of UltraShear Nano-CBD topical spray, effective immediately.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 21: </b>PBIO’s fulfillment of UltraShear Nano-CBD orders is underway; customer shipments begin first week of October</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 8: </b>PBIO’s Barofold technology achieves pivotal equipment sale and begins scale-up in service to leading global contract development and manufacturing organization.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August 30: </b>PBIO provides second progress report on UltraShear Nano-CBD Launch: “Drive to 420”.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August 22: </b>PBIO reports Q22023 financial results, provides business update, and offers guidance.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August 9: </b>PBIO reports strongly accelerating UltraShear Nano-CBD orders<b>.</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July 26: </b>PBIO and master distributor Canopy CBD Farms announce major increase in sales pipeline.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July 25: </b>PBIO to evaluate Company’s patented UltraShear process to extend shelf-life of fresh produce.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July 17: </b>Company’s UltraShear Nano-CBD commercial roll-out program enters rapid expansion phase 2.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July 10: </b>Company announces Nano-CBD topical spray distribution agreement with Crème de Canna.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July 6: </b>Key academic publication further validates PBIO’s UltraShear platforms’ impact in clean-label foods.</span></td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>July 5: </b>PBIO partners with Somalab Int’l for development &amp; distribution of UltraShear-enabled health products.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 13: </b>PBIO partners with Veterans Service Team to offer exclusive access for VST members to Nano-CBD.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 1: </b>PBIO expands on six key goals for June 2023 with expected multi-million-dollar growth potential.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 22: </b>Commercial availability of Best-in-Class Nano-CBD topical spray with lightning-fast action announced.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 16: </b>PBIO announces Q1 2023 financial results: all-time quarterly record revenue.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 9: </b>Extended consumer testing strongly validates market transforming speed and dosing efficiency of PBIO’s UltraShear processed nano-THC oral spray.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 26: </b>PBIO updates rapid progress on potential sales of exclusive THC licenses.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 21, 2023: </b>PBIO unveils powerful THC market leapfrog opportunity with exclusive licensing of UltraShear nanoemulsion processing platform.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 18: </b>PBIO announces expansion into strategic manufacturing facilities with premier process tech company.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 14: </b>PBIO reports Q4 and FY 2022 financial results – offers guidance for a strong 2023.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April 6, 2023: </b>PBIO and NutraLife Biosciences renew partnership for development and distribution of next generation nutraceuticals.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 28:</b> Company reports fresh sales momentum for PBI Agrochem.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 22: </b>PBIO receives $1.5 million contract for UltraShear nanoemulsified CBD.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 1: </b>Company announces the exchange of over $10 million of debt into equity.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>February 1:</b> Company receives record order (nearly $600,000) for 16 PCT instruments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January 27: </b>PBIO and One World Products partner to develop CBD-Nano sports performance/recovery drink.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January 19: </b>Dramatic consumer testing results confirm UltraShear nanoemulsion oral spray delivers first effects and maximization in lightning speed – simple, reliable dosing delivers profoundly improved results.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following disclosure compares the results of operations for the quarter ended September 30, 2023 (“Q2 2023”) with September 30, 2022 (“Q2 2022”) and compares the nine months ended September 30, 2023 with September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Products and Services Revenue</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognized total revenue of $413,009 for Q3 2023 compared to $144,032 for Q3 2022, a 187% increase. For the year-to-date periods ending September 30, 2023 and September 30, 2022, we recognized revenue of $1,665,412 and $1,122,169 respectively, a 48% increase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This increase in revenue was primarily attributable to a $506,828 increase in PCT instrumentation and consumable sales, a $30,295 increase in technical support services and an $87,378 increase in Agrochem products, offset by a decrease of $89,350 in scientific services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost of Products and Services</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of products and services was $229,457 for Q3 2023 compared to $126,203 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022 our cost of products and services were $844,684 and $742,707, respectively. Gross profit margin on products and services increased to 49% in the year-to-date period ended September 30, 2023 from 34% in the same period ended September 30, 2022. The increase in gross profit margin was attributable to $180,670 of Agrochem products sold in 2023 at no cost due to 2022 inventory write-off and a $79,901 instrument non-monetary exchange sale in 2022 was recorded at no profit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research and Development</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses were $288,345 for Q3 2023 compared to $262,370 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $1,004,437 and $716,685, respectively, a 40% increase. The reported increase was due to a $71,777 reclass of salaries to COGS for a non-monetary instrument exchange in 2022 and $241,585 of stock-based compensation expense for employee stock options issued in 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling and Marketing</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling and marketing expenses were $157,773 for Q3 2023 compared to $226,526 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $537,802 and $422,422, respectively a 27% increase The reported increase was primarily attributable to the hiring of a Marketing FTE in Q2 2023 and $102,675 of stock-based compensation expense for employee stock options issued in 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General and Administrative</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses were $1,030,244 for Q3 2023 compared to $892,293 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $5,290,564 and $2,591,644, respectively, a 104% increase. The increase was primarily due to approximately $2.0  million common stock and warrants issued for services, approximately $1.3 million of stock-based compensation expense for employee, BOD and financial consultant stock options issued in 2023, and approximately $132,000 of financial consulting expenses in 2023, offset by an approximately $423,000 decrease in IR expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating Loss</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss was $1,292,809 for Q3 2023 compared to $1,363,360 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, the operating loss was $6,012,075 and $3,551,289 respectively, a 79% increase. This increase was primarily due to $2.0 millions in common stock and warrants issued for services and $1.7 million of stock-based compensation expense for employee, BOD financial consultant stock options issued in 2023, offset by an approximate $423,000 decrease in IR expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest Expense, net</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense was $4,338,759 for Q3 2023 compared to $2,034,021 for Q3 2022. For the year-to-date periods ending September 30, 2023 and September 30, 2022, these expenses were $14,112,098 and $6,448,771, respectively, a 119% increase. This increase was attributable to an increase in convertible debt and merchant cash loans, in addition to stock issuances for interest paid in kind and stock issued for debt extensions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrealized gain on investment in equity securities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized loss on investments in equity securities was $5,965 for Q3 2023 compared to an unrealized loss of $8,675 for Q3 2022. For the nine months ended September 30, 2023, the unrealized gain on investment in equity securities was $14,280 as compared to an unrealized loss of $8,047 for the nine months ended September 30, 2022. The reported change was attributable to movement in the market price of the Company’s investment in Nexity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Loss on extinguishment of liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with debt extensions and forgiveness, we recognized a net gain of $0 for Q3 2023 compared to $1,054,122 of losses for Q3 2022. For the nine months ended September 30, 2023 the recognized net gain of $687,591 as compared to a net loss of $1,809,249 for the nine months ended September 30, 2022. The increase/decline in gains/losses was attributable to decreased extension and forgiveness activity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net loss attributable to common stockholders</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss attributable to common stockholders was $6,261,999 ($0.29 per share) for Q3 2023 compared to $4,893,946 ($0.44 per share) for Q3 2022. For the nine months ended September 30, 2023, the net loss attributable to common stock was $24,666,565 ($1.21 per share) as compared to $12,913,826 ($1.24 per share).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity and Financial Condition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have experienced negative cash flows from operations since our inception. As of September 30, 2023, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have substantial doubt regarding our ability to continue as a going concern. As described in Notes 5 and 6 of the accompanying consolidated financial statements, we have been successful in raising debt and equity capital. We received approximately $6.5 million  in net proceeds from loans in the nine months ended September 30, 2023. We have efforts in place to continue to raise cash through debt and equity offerings. (See Note 7 to the financial statements)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need substantial additional capital to fund our operations in future periods. If we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operations for the nine months ended September 30, 2023 was $2,053,823  as compared to $3,051,257 for the nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in investing activities for the nine months ended September 30, 2023 was $7,495 compared to $20,754 in the nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by financing activities for the nine months ended September 30, 2023 was $2,062,716 as compared to $3,170,580 for the nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Item 3 is not applicable to us as a smaller reporting company and has been omitted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM 4. CONTROLS AND PROCEDURES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 filings are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our conclusion that our disclosure controls and procedures were not effective as of September 30, 2023 is due to the continued presence of the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended December 31, 2022. These material weaknesses are the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We identified a lack of sufficient segregation of duties. Specifically, this material weakness is such that the design over these areas relies primarily on detective controls and could be strengthened by adding preventative controls to properly safeguard Company assets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training, and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles, particularly as it relates to valuation of warrants and other complex debt /equity transactions. Specifically, this material weakness resulted in audit adjustments to the annual consolidated financial statements and revisions to related disclosures, valuation of warrants and other equity transactions.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limited policies and procedures that cover recording and reporting of financial transactions.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack of multiple levels of review over the financial reporting process</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We continue to plan to remediate those material weaknesses as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve the effectiveness of the accounting group by augmenting our existing resources with additional consultants or employees to assist in the analysis and recording of complex accounting transactions, and to simultaneously achieve desired organizational structuring for improved segregation of duties. We plan to mitigate this identified deficiency by hiring an independent consultant once we generate significantly more revenue or raise significant additional working capital.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve expert review and achieve desired segregation procedures by strengthening cross approval of various functions including quarterly internal audit procedures where appropriate once we generate significantly more revenue or raise significantly more working capital.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the period covered by this Report, we implemented and performed additional substantive procedures, such as supervisory review of work papers and consistent use of financial models used in equity valuations, to ensure our consolidated financial statements as of and for the six-month period ended September 30, 2023, are fairly stated in all material respects in accordance with GAAP. We have not, however, been able to fully remediate the material weaknesses due to our limited financial resources. Our remediation efforts are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as described above, there have been no changes in our internal controls over financial reporting that occurred during the period ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>PART II. OTHER INFORMATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item 1. Legal Proceedings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Item 1A. Risk Factors</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2022 and, in this Item, 1A. The risks described in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks occur, our business, results of operations, cash flows or financial condition could suffer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no material changes to the risk factors set forth in Item 1A of our 10-K for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except where noted, all the securities discussed in this Part II, Item 2 were issued in reliance on the exemption under Section 4(a)(2) of the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On various dates in the nine months ended September 30, 2023 the Company issued a total of 9,917,035  of its common shares, 953 shares of Series BB preferred stock and 401 shares of Series CC preferred stock as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117,552 shares from option exercises;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,630,500 shares for professional services;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,346,800 shares for debt extensions;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">203,613 shares for conversion of debt and interest;</span></td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 58.5pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,767 shares for dividends paid-in-kind;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,094,121 shares for interest paid-in-kind;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,258,742 shares for shares issued with debt;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000 shares from sale of common shares;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95 shares of Series BB preferred stock was converted to common stock;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92 shares of Series BB preferred stock for professional services;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">741 shares of Series BB preferred stock for debt extensions;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58 shares of Series BB preferred stock issued with debt;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">401 shares of Series CC preferred stock for conversion of debt/accrued interest and dividends, and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62 shares of Series BB preferred stock for the conversion of common stock.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item 3. Defaults upon Senior Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Item 4. Mine Safety Disclosures</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item 5. Other Information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Item 6. Exhibits</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><a href="ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Securities Issuance and Exchange Agreement</span></a></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))</a></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))</a></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Filed herewith.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">** In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are furnished and not filed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>SIGNATURES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRESSURE BIOSCIENCES, INC.</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 20, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:  </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Richard T. Schumacher</i></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard T. Schumacher</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President &amp; Chief Executive Officer</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer and Principal Financial Officer)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p> 439000 0.10 1.20 2.50 278500 455350 505000 145809 40 300000 0.01 500000 1500000 0.25 0.25 0.25 0.25 0.25 P3Y 0.25 0.69 1.50 Conversion price of these note is $2.50 except for a note for $189,750, which will be adjusted to, upon an Event of Default, the lower of (i) the conversion price or (ii) a 25% discount to the 5-day average VWAP of the stock prior to default and $729,100 lower of (i) $2.50 or (ii) the conversion price of the Series AA Preferred Stock as adjusted. These notes are secured by all assets of the company. Conversion price of these notes is $2.50 but also varies with one or more of these notes having the following conversion adjustment: Interest varies from 1% to 10%. The maturity is between being past due and May 2, 2023. As of September 30, 2023, $861,500 of the non-convertible debt is past due. The Company entered a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $150,000, accrues interest at 3.75% and requires monthly payments of $731 for principal and interest beginning in December 2022. The balance of the principal will be due in 30 years. In connection with the EIDL loan the Company entered into a security agreement with the SBA, whereby the Company granted the SBA a security interest in all of the Company’s right, title and interest in all of the Company’s assets. During the nine months ended September 30, 2023, $14,719 interest was deferred and added to principal on EIDL loan and the Company repaid $2,197 principal on this loan. During the year ended December 31, 2020, the Company borrowed $367,039 (two-year term and 1% interest rate per annum) under the Payroll Protection program (or “2020 PPP”). During the year ended December 31, 2021, the Company borrowed $367,039 through a second Payroll Protection program (or “2021 PPP”) and extended the monthly payment date on the EIDL to December 2022. In year 2021, both 2020 PPP and 2021 PPP was forgiven by the United States and SBA. During the nine months ended September 30, 2023 and the year ended December 31, 2022 we signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 4.1% - 100.9% per month. Under the terms of these agreements, we received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the Merchant lenders at the Daily Payment Rate. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. The Company’s Chief Executive Officer guarantees the Company’s performance of all representations, warranties, and covenants made by the Company in the Agreement. For loans outstanding on September 30, 2023, the maturity dates ranged from June 26, 2023 to October 15, 2023. For loan outstanding on December 31, 2022, the maturity dates ranged from April 4 to June 6, 2023. Interest varies from 12% to 120%. EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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�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end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 391 322 1 true 128 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://pressurebiosciences.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://pressurebiosciences.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://pressurebiosciences.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://pressurebiosciences.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://pressurebiosciences.com/role/StatementsOfOperationsParenthetical Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://pressurebiosciences.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Sheet http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Business Overview, Liquidity and Management Plans Sheet http://pressurebiosciences.com/role/BusinessOverviewLiquidityAndManagementPlans Business Overview, Liquidity and Management Plans Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern Sheet http://pressurebiosciences.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Commitments and Contingencies Sheet http://pressurebiosciences.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 00000012 - Disclosure - Debt Sheet http://pressurebiosciences.com/role/Debt Debt Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders??? Deficit Sheet http://pressurebiosciences.com/role/StockholdersDeficit Stockholders??? Deficit Notes 13 false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://pressurebiosciences.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies (Tables) Sheet http://pressurebiosciences.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://pressurebiosciences.com/role/CommitmentsAndContingencies 17 false false R18.htm 00000018 - Disclosure - Debt (Tables) Sheet http://pressurebiosciences.com/role/DebtTables Debt (Tables) Tables http://pressurebiosciences.com/role/Debt 18 false false R19.htm 00000019 - Disclosure - Stockholders??? Deficit (Tables) Sheet http://pressurebiosciences.com/role/StockholdersDeficitTables Stockholders??? Deficit (Tables) Tables http://pressurebiosciences.com/role/StockholdersDeficit 19 false false R20.htm 00000020 - Disclosure - Schedule of Disaggregation of Revenue (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails Schedule of Disaggregation of Revenue (Details) Details 20 false false R21.htm 00000021 - Disclosure - Schedule of Contract Balances (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfContractBalancesDetails Schedule of Contract Balances (Details) Details 21 false false R22.htm 00000022 - Disclosure - Schedule of Future Related to Performance Obligations (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails Schedule of Future Related to Performance Obligations (Details) Details 22 false false R23.htm 00000023 - Disclosure - Schedule of Customer Concentration Risk Percentage (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails Schedule of Customer Concentration Risk Percentage (Details) Details 23 false false R24.htm 00000024 - Disclosure - Schedule of Computation of Loss Per Share (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfComputationOfLossPerShareDetails Schedule of Computation of Loss Per Share (Details) Details 24 false false R25.htm 00000025 - Disclosure - Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 25 false false R26.htm 00000026 - Disclosure - Summary of Assumptions for Grants of Stock Options (Details) Sheet http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails Summary of Assumptions for Grants of Stock Options (Details) Details 26 false false R27.htm 00000027 - Disclosure - Schedule of Stock Based Compensation Expense (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails Schedule of Stock Based Compensation Expense (Details) Details 27 false false R28.htm 00000028 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 28 false false R29.htm 00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details) Details 30 false false R31.htm 00000031 - Disclosure - Schedule of Right of Use Asset and the Corresponding Lease Liability (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfRightOfUseAssetAndCorrespondingLeaseLiabilityDetails Schedule of Right of Use Asset and the Corresponding Lease Liability (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Lease Cost for Operating Leases (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails Schedule of Lease Cost for Operating Leases (Details) Details 32 false false R33.htm 00000033 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://pressurebiosciences.com/role/CommitmentsAndContingenciesTables 33 false false R34.htm 00000034 - Disclosure - Schedule of Convertible Debts and Outstanding Balances (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails Schedule of Convertible Debts and Outstanding Balances (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical) Sheet http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Other Debt (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails Schedule of Other Debt (Details) Details 36 false false R37.htm 00000037 - Disclosure - Schedule of Other Debt (Details) (Parenthetical) Sheet http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical Schedule of Other Debt (Details) (Parenthetical) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Related Party Debt (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails Schedule of Related Party Debt (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Related Party Debt (Details) (Parenthetical) Sheet http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical Schedule of Related Party Debt (Details) (Parenthetical) Details 39 false false R40.htm 00000040 - Disclosure - Debt (Details Narrative) Sheet http://pressurebiosciences.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://pressurebiosciences.com/role/DebtTables 40 false false R41.htm 00000041 - Disclosure - Schedule of Preferred Stock Outstanding (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails Schedule of Preferred Stock Outstanding (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) Sheet http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) Details 42 false false R43.htm 00000043 - Disclosure - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) Sheet http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) Details 43 false false R44.htm 00000044 - Disclosure - Stockholders??? Deficit (Details Narrative) Sheet http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative Stockholders??? Deficit (Details Narrative) Details http://pressurebiosciences.com/role/StockholdersDeficitTables 44 false false R45.htm 00000045 - Disclosure - Subsequent Events (Details Narrative) Sheet http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://pressurebiosciences.com/role/SubsequentEvents 45 false false All Reports Book All Reports form10-q.htm pbio-20230930.xsd pbio-20230930_cal.xml pbio-20230930_def.xml pbio-20230930_lab.xml pbio-20230930_pre.xml http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "PBIO", "nsuri": "http://pressurebiosciences.com/20230930", "dts": { "inline": { "local": [ "form10-q.htm" ] }, "schema": { "local": [ "pbio-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "pbio-20230930_cal.xml" ] }, "definitionLink": { "local": [ "pbio-20230930_def.xml" ] }, "labelLink": { "local": [ "pbio-20230930_lab.xml" ] }, "presentationLink": { "local": [ "pbio-20230930_pre.xml" ] } }, "keyStandard": 257, "keyCustom": 65, "axisStandard": 28, "axisCustom": 0, "memberStandard": 33, "memberCustom": 82, "hidden": { "total": 321, "http://fasb.org/us-gaap/2023": 199, "http://pressurebiosciences.com/20230930": 118, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 391, "entityCount": 1, "segmentCount": 128, "elementCount": 578, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1202, "http://xbrl.sec.gov/dei/2023": 26, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://pressurebiosciences.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://pressurebiosciences.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "shortName": "Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R4": { "role": "http://pressurebiosciences.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "shortName": "Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://pressurebiosciences.com/role/StatementsOfOperationsParenthetical", "longName": "00000005 - Statement - Consolidated Statements of Operations (Unaudited) (Parenthetical)", "shortName": "Consolidated Statements of Operations (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://pressurebiosciences.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "PBIO:NoncashLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "longName": "00000007 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R8": { "role": "http://pressurebiosciences.com/role/BusinessOverviewLiquidityAndManagementPlans", "longName": "00000008 - Disclosure - Business Overview, Liquidity and Management Plans", "shortName": "Business Overview, Liquidity and Management Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://pressurebiosciences.com/role/GoingConcern", "longName": "00000009 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://pressurebiosciences.com/role/CommitmentsAndContingencies", "longName": "00000011 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://pressurebiosciences.com/role/Debt", "longName": "00000012 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://pressurebiosciences.com/role/StockholdersDeficit", "longName": "00000013 - Disclosure - Stockholders\u2019 Deficit", "shortName": "Stockholders\u2019 Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://pressurebiosciences.com/role/SubsequentEvents", "longName": "00000014 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://pressurebiosciences.com/role/CommitmentsAndContingenciesTables", "longName": "00000017 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://pressurebiosciences.com/role/DebtTables", "longName": "00000018 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfDebtConversionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfDebtConversionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://pressurebiosciences.com/role/StockholdersDeficitTables", "longName": "00000019 - Disclosure - Stockholders\u2019 Deficit (Tables)", "shortName": "Stockholders\u2019 Deficit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails", "longName": "00000020 - Disclosure - Schedule of Disaggregation of Revenue (Details)", "shortName": "Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_HardwareMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R21": { "role": "http://pressurebiosciences.com/role/ScheduleOfContractBalancesDetails", "longName": "00000021 - Disclosure - Schedule of Contract Balances (Details)", "shortName": "Schedule of Contract Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails", "longName": "00000022 - Disclosure - Schedule of Future Related to Performance Obligations (Details)", "shortName": "Schedule of Future Related to Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "PBIO:ExtendedWarrantyService", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "PBIO:ExtendedWarrantyService", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails", "longName": "00000023 - Disclosure - Schedule of Customer Concentration Risk Percentage (Details)", "shortName": "Schedule of Customer Concentration Risk Percentage (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_custom_TopFiveCustomersMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueConcentrationOfRiskTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_TopFiveCustomersMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueConcentrationOfRiskTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://pressurebiosciences.com/role/ScheduleOfComputationOfLossPerShareDetails", "longName": "00000024 - Disclosure - Schedule of Computation of Loss Per Share (Details)", "shortName": "Schedule of Computation of Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "00000025 - Disclosure - Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails", "longName": "00000026 - Disclosure - Summary of Assumptions for Grants of Stock Options (Details)", "shortName": "Summary of Assumptions for Grants of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2023-01-012023-09-30_custom_EmployeesOfficersMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_EmployeesOfficersMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails", "longName": "00000027 - Disclosure - Schedule of Stock Based Compensation Expense (Details)", "shortName": "Schedule of Stock Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_CostOfSalesMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R28": { "role": "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "longName": "00000028 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AdditionalPaidInCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2020-08-30", "name": "us-gaap:AdditionalPaidInCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "PBIO:RecentAccountingPronouncementPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R30": { "role": "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails", "longName": "00000030 - Disclosure - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)", "shortName": "Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://pressurebiosciences.com/role/ScheduleOfRightOfUseAssetAndCorrespondingLeaseLiabilityDetails", "longName": "00000031 - Disclosure - Schedule of Right of Use Asset and the Corresponding Lease Liability (Details)", "shortName": "Schedule of Right of Use Asset and the Corresponding Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails", "longName": "00000032 - Disclosure - Schedule of Lease Cost for Operating Leases (Details)", "shortName": "Schedule of Lease Cost for Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R33": { "role": "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000033 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R34": { "role": "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "longName": "00000034 - Disclosure - Schedule of Convertible Debts and Outstanding Balances (Details)", "shortName": "Schedule of Convertible Debts and Outstanding Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtConversionsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtConversionsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R35": { "role": "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "longName": "00000035 - Disclosure - Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)", "shortName": "Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtInstrumentConvertibleStockPriceTrigger", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtConversionsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:DebtDefaultLongtermDebtAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtConversionsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R36": { "role": "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails", "longName": "00000036 - Disclosure - Schedule of Other Debt (Details)", "shortName": "Schedule of Other Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OtherLongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "PBIO:ScheduleOfOtherDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OtherLongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "PBIO:ScheduleOfOtherDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R37": { "role": "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "longName": "00000037 - Disclosure - Schedule of Other Debt (Details) (Parenthetical)", "shortName": "Schedule of Other Debt (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "PBIO:ScheduleOfOtherDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "PBIO:ScheduleOfOtherDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R38": { "role": "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails", "longName": "00000038 - Disclosure - Schedule of Related Party Debt (Details)", "shortName": "Schedule of Related Party Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "PBIO:ScheduleOfOtherDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_OfficersAndDirectorsMember", "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R39": { "role": "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "longName": "00000039 - Disclosure - Schedule of Related Party Debt (Details) (Parenthetical)", "shortName": "Schedule of Related Party Debt (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-09-30_srt_MinimumMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "PBIO:ScheduleOfOtherDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_RelatedPartyMember_srt_MinimumMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R40": { "role": "http://pressurebiosciences.com/role/DebtDetailsNarrative", "longName": "00000040 - Disclosure - Debt (Details Narrative)", "shortName": "Debt (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RepaymentsOfSeniorDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R41": { "role": "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "longName": "00000041 - Disclosure - Schedule of Preferred Stock Outstanding (Details)", "shortName": "Schedule of Preferred Stock Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R42": { "role": "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "longName": "00000042 - Disclosure - Schedule Of Preferred Stock Outstanding (Details) (Parenthetical)", "shortName": "Schedule Of Preferred Stock Outstanding (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-09-30_custom_SeriesDConvertiblePreferredStockMember", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_SeriesDConvertiblePreferredStockMember", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R43": { "role": "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "longName": "00000043 - Disclosure - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details)", "shortName": "Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R44": { "role": "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "longName": "00000044 - Disclosure - Stockholders\u2019 Deficit (Details Narrative)", "shortName": "Stockholders\u2019 Deficit (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtInstrumentConvertibleStockPriceTrigger", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtConversionsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-09-30_custom_IssuedForServicesRenderedMember", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R45": { "role": "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative", "longName": "00000045 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-05_us-gaap_SubsequentEventMember", "name": "us-gaap:ConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of option issuance percentage", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreferenceValue", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Liquidation Preference, Value", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares." } } }, "auth_ref": [ "r192", "r303" ] }, "PBIO_MerchantDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "MerchantDebtMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Merchant Debt [Member]", "documentation": "Merchant Debt [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r197", "r268", "r269", "r270", "r271", "r272", "r274", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r292", "r406", "r625", "r626", "r627", "r628", "r629", "r694" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r88", "r89", "r126", "r127", "r197", "r268", "r269", "r270", "r271", "r272", "r274", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r406", "r625", "r626", "r627", "r628", "r629", "r694" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r22", "r55", "r58", "r73", "r74", "r76", "r80", "r118", "r119", "r197", "r268", "r269", "r270", "r271", "r272", "r274", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r292", "r406", "r625", "r626", "r627", "r628", "r629", "r694" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible debt, net of unamortized debt discounts of $744,393 and $455,517, respectively", "verboseLabel": "Principal amount", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r88" ] }, "PBIO_ExtensionOfWarrantsForSeriesAaPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ExtensionOfWarrantsForSeriesAaPreferredStock", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Extension of warrants for Series AA preferred stock", "verboseLabel": "Extension of warrants for Series AA Preferred stock", "terseLabel": "Extension of warrants for series AA preferred stock", "documentation": "Extension of warrants for series AA preferred stock." } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Preferred stock, value", "verboseLabel": "Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r91", "r450", "r639" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r115", "r268", "r269", "r279", "r280", "r281", "r285", "r286", "r287", "r288", "r289", "r625", "r626", "r627", "r628", "r629" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares of common stock", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r64" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future undiscounted lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r417" ] }, "PBIO_ThreeLendersMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ThreeLendersMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Lenders [Member]", "documentation": "Three Lenders [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Total Convertible Preferred Shares", "documentation": "Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r55", "r91" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r417" ] }, "PBIO_ForbearanceAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ForbearanceAgreementsMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Forbearance Agreements [Member]", "documentation": "Forbearance Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_PrincipalTransactionsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrincipalTransactionsRevenue", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Principal amount paid", "documentation": "Amount of realized and unrealized gain (loss) resulting from the difference between acquisition price and selling price or fair value of trading assets and trading liabilities, and from the firm's direct investment activity, conducted separately from customer trading activities, including, but not limited to, investments in private equity, alternative investment products, real estate, and exchanges and memberships." } } }, "auth_ref": [ "r77" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Conversion price", "verboseLabel": "Debt instrument, convertible, conversion price", "terseLabel": "Fixed rate", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r116", "r270" ] }, "PBIO_FourLendersMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "FourLendersMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Four Lenders [Member]", "documentation": "Four Lenders [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r417" ] }, "PBIO_TenLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TenLoansMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ten Loans [Member]", "documentation": "Ten Loans [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r417" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS SUPPLEMENTAL INFORMATION" } } }, "auth_ref": [] }, "PBIO_NewLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NewLoanMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Loan [Member]", "documentation": "New Loan [Member]" } } }, "auth_ref": [] }, "PBIO_FiveDayAverageVWAPMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "FiveDayAverageVWAPMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "5 Day Average VWAP [Member]", "documentation": "5 Day Average VWAP [Member]" } } }, "auth_ref": [] }, "PBIO_ShortTermNonConvertibleLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ShortTermNonConvertibleLoanMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-term Non-Convertible Loan [Member]", "documentation": "Short-term Non-Convertible Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r599" ] }, "PBIO_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of preferred stock for common stock", "documentation": "Conversion of preferred stock for common stock.", "label": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued professional fees and other", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18" ] }, "PBIO_OthersMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "OthersMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Others [Member]", "documentation": "Others [Member]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other (expense) income:" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid in cash", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r185", "r187", "r188" ] }, "PBIO_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of preferred stock for common stock, shares", "documentation": "Stock issued during period shares conversion of convertible securities conversion of preferred stock for common stock." } } }, "auth_ref": [] }, "PBIO_SeriesAAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesAAPreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series AA Preferred Stock [Member]", "documentation": "Series AA Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r111", "r190" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r104" ] }, "PBIO_ConvertibleDebtOneMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConvertibleDebtOneMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible Debt One [Member]", "documentation": "Convertible Debt One [Member]" } } }, "auth_ref": [] }, "PBIO_ConvertibleDebtTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConvertibleDebtTwoMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Two [Member]", "documentation": "Convertible Debt Two [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r30", "r170", "r615" ] }, "PBIO_ConvertibleDebtThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConvertibleDebtThreeMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Three [Member]", "documentation": "Convertible Debt Three [Member]" } } }, "auth_ref": [] }, "PBIO_ConvertibleDebtFourMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConvertibleDebtFourMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Four [Member]", "documentation": "Convertible Debt Four [Member]" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r22" ] }, "PBIO_NonConvertibleLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NonConvertibleLoansMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Non Convertible [Member]", "documentation": "Non Convertible [Member]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of option vested percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r722" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r281", "r327", "r328", "r329", "r330", "r331", "r332", "r396", "r426", "r427", "r428", "r626", "r627", "r634", "r635", "r636" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued employee compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r13", "r127", "r767" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r118", "r119", "r120", "r172", "r173", "r174", "r225", "r298", "r299", "r301", "r303", "r306", "r311", "r313", "r477", "r478", "r479", "r480", "r630", "r677", "r693" ] }, "PBIO_PreferredStockIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PreferredStockIssuedForServices", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Preferred stock issued for services", "documentation": "Preferred stock issued for services." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDescription", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lessee operating lease description", "documentation": "Description of lessee's operating lease." } } }, "auth_ref": [ "r410" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r670" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r35" ] }, "PBIO_DebtDefaultConvertibleConversionRatio": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DebtDefaultConvertibleConversionRatio", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt default convertible conversion ratio", "documentation": "Debt default convertible conversion ratio." } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747" ] }, "PBIO_EarlyAsu202006Adoption": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "EarlyAsu202006Adoption", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Early adoption of ASU 2020-06", "documentation": "Early Asu 202006 Adoption." } } }, "auth_ref": [] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails", "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747" ] }, "PBIO_SaleOfCommonStockForCashShares": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SaleOfCommonStockForCashShares", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock issued with debt, shares", "documentation": "Sale of common stock for cash shares.", "label": "SaleOfCommonStockForCashShares" } } }, "auth_ref": [] }, "us-gaap_PaymentInKindPIKNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentInKindPIKNoteMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment in Kind (PIK) Note [Member]", "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r670" ] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Repayments of) Related Party Debt", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "PBIO_StockIssuedDuringPeriodSharesConversionOfCommonStockToPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodSharesConversionOfCommonStockToPreferredStock", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of common stock to preferred stock, shares", "documentation": "Stock issued during period shares conversion of common stock to preferred stock." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Computation of Loss Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r703" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Total potentially dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r222" ] }, "PBIO_StockIssuedDuringPeriodValueConversionOfCommonStockToPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodValueConversionOfCommonStockToPreferredStock", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of common stock to preferred stock", "documentation": "Stock issued during period value conversion of common stock to preferred stock." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Contract liabilities (deferred revenue)", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r687" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued during period, shares, other", "verboseLabel": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r669" ] }, "PBIO_StockIssuedDuringPeriodValueIssuedPreferredStockForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodValueIssuedPreferredStockForServices", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock for services", "documentation": "Stock issued during period value issued preferred stock for services." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r658" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r669" ] }, "us-gaap_OtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebt", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Totals, Principal", "documentation": "Amount of long-term debt classified as other." } } }, "auth_ref": [ "r13", "r127", "r767" ] }, "PBIO_StockIssuedDuringPeriodValueSharesPreferredStockForServices": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodValueSharesPreferredStockForServices", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of preferred stock for services, shares", "documentation": "Stock issued during period value shares preferred stock for services." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested stock based awards", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r369" ] }, "PBIO_StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodValueIssuanceOfPreferredStockForDebtExtension", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of Preferred stock for debt extension", "verboseLabel": "Preferred stock extensions", "documentation": "Stock issued during period value issuance of preferred stock for debt extension." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r7", "r59", "r60", "r61", "r62" ] }, "PBIO_StockIssuedDuringPeriodSharesIssuanceOfPreferredStockForDebtExtension": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfPreferredStockForDebtExtension", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred stock for debt extension", "documentation": "Stock issued during period shares issuance of preferred stock for debt extension." } } }, "auth_ref": [] }, "PBIO_PreferredStockIssuedForDebtSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PreferredStockIssuedForDebtSettlement", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock issued with debt", "documentation": "Preferred stock issued for debt settlement.", "label": "PreferredStockIssuedForDebtSettlement" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r423", "r425" ] }, "PBIO_PreferredStockIssuedForDebtShares": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PreferredStockIssuedForDebtShares", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred stock issued for debt, share", "documentation": "Preferred stock issued for debt shares." } } }, "auth_ref": [] }, "PBIO_CumulativeEffectPeriodOfAdoptionAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "CumulativeEffectPeriodOfAdoptionAdjustment", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Early adoption of ASU 2020-06", "documentation": "Cumulative effect, period of adoption, adjustment.", "label": "CumulativeEffectPeriodOfAdoptionAdjustment" } } }, "auth_ref": [] }, "PBIO_WarrantsIssuedForDebtExtension": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "WarrantsIssuedForDebtExtension", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants issued for debt extension", "documentation": "Warrants issued for debt extension." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "PBIO_RecentAccountingPronouncementPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "RecentAccountingPronouncementPolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Recent Accounting Pronouncement [Policy Text Block]" } } }, "auth_ref": [] }, "PBIO_StockIssuedDuringPeriodValueWarrantsIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedDuringPeriodValueWarrantsIssuedForServices", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants issued for services", "documentation": "Stock issued during period value warrants issued for services." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued during period, value, other", "verboseLabel": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r8", "r55", "r91", "r92", "r120" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (Note 4)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r23", "r79", "r449", "r513" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued during period, value, conversion of units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r8", "r26", "r120" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares, Granted", "verboseLabel": "Stock option number of shares granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r348" ] }, "PBIO_ProductSupplyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ProductSupplyPolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Product Supply", "documentation": "Product Supply [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r395", "r396" ] }, "PBIO_ScheduleOfOtherDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ScheduleOfOtherDebtTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/DebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Debt", "documentation": "Schedule of Other Debt [Table Text Block]" } } }, "auth_ref": [] }, "PBIO_OperatingLeasesOfLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "OperatingLeasesOfLesseeTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Right of Use Asset and the Corresponding Lease Liability", "documentation": "Operating Leases of Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r250", "r251", "r538" ] }, "PBIO_PercentageOfPriceRate": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PercentageOfPriceRate", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Percentage of price", "documentation": "Percentage of price rate." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r35" ] }, "PBIO_ExtendedWarrantyService": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ExtendedWarrantyService", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Extended warranty service", "documentation": "Extended warranty service." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r35" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "auth_ref": [ "r251", "r538" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r670" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Preferred Stock Outstanding", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r351" ] }, "PBIO_ForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ForfeitureRate", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeiture rate", "documentation": "Forfeiture rate.", "label": "ForfeitureRate" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from convertible debt", "verboseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r27" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r404", "r424" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r350" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Computation of Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r35", "r36" ] }, "PBIO_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Forfeiture rate", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r37", "r39", "r70", "r71", "r243", "r599", "r682" ] }, "PBIO_AnnualCostOfLivingPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "AnnualCostOfLivingPayment", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual cost of living payment", "documentation": "Annual cost of living payment." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "NON CASH TRANSACTIONS:" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r45", "r46" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares, Beginning balance", "periodEndLabel": "Shares, Ending balance", "label": "Options outstanding, shares", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r344", "r345" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Note payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r13", "r127", "r767" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average price per share, Beginning balance", "periodEndLabel": "Weighted average price per share, Ending balance", "label": "Weighted average exercise price", "verboseLabel": "Numberof stock option exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r344", "r345" ] }, "PBIO_EstimatedBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "EstimatedBorrowingRate", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated borrowing rate", "documentation": "Estimated borrowing rate." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercisable, Beginning balance", "periodEndLabel": "Exercisable, Ending balance", "label": "Number of options, exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r346" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r98", "r110", "r129", "r167", "r177", "r178", "r181", "r194", "r201", "r203", "r204", "r205", "r206", "r209", "r210", "r217", "r227", "r233", "r237", "r239", "r247", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r394", "r397", "r455", "r534", "r552", "r553", "r620", "r653", "r713" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r366" ] }, "PBIO_MinimumRoyaltyFee": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "MinimumRoyaltyFee", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mimimum royalty fee", "documentation": "Minimum royalty fee." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfComputationOfLossPerShareDetails", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common shareholders", "label": "Net loss attributable to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r184", "r203", "r204", "r205", "r206", "r212", "r213", "r218", "r221", "r227", "r233", "r237", "r239", "r620" ] }, "PBIO_DebtInstrumentDiscountPercentageOfStockPrice": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DebtInstrumentDiscountPercentageOfStockPrice", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument lowest trading price", "documentation": "Debt instrument discount percentage of stock price." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r108", "r109", "r110" ] }, "PBIO_CommonStockAndWarrantsIssuedForDebtExtension": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "CommonStockAndWarrantsIssuedForDebtExtension", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Common stock and warrants issued for debt extension", "documentation": "Common stock and warrants issued for debt extension.", "label": "CommonStockAndWarrantsIssuedForDebtExtension" } } }, "auth_ref": [] }, "us-gaap_GeographicDistributionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicDistributionDomain", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r445", "r446" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "PBIO_PreferredStockIssuedForDebtExtension": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PreferredStockIssuedForDebtExtension", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Preferred stock issued for debt extension", "documentation": "Preferred stock issued for debt extension." } } }, "auth_ref": [] }, "PBIO_LossOnExtinguishmentOfAccruedLiabilitiesAndDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "LossOnExtinguishmentOfAccruedLiabilitiesAndDebt", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Loss on extinguishment of accrued liabilities and debt", "documentation": "Loss on extinguishment of accrued liabilities and debt." } } }, "auth_ref": [] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Inventory valuation reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r44", "r688" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long term debt", "verboseLabel": "Long Term, Principal", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r13", "r127", "r280", "r295", "r626", "r627", "r767" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r186" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r281", "r327", "r332", "r396", "r427", "r626", "r627", "r634", "r635", "r636" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r281", "r327", "r332", "r396", "r426", "r634", "r635", "r636" ] }, "PBIO_DebtSettlementMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DebtSettlementMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Settlement [Member]", "documentation": "Debt Settlement [Member]" } } }, "auth_ref": [] }, "us-gaap_GeographicDistributionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicDistributionAxis", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographic Distribution [Axis]", "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r445", "r446", "r623" ] }, "us-gaap_CollateralAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollateralAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Collateral Held [Axis]", "documentation": "Information by category of collateral or no collateral, from lender's perspective." } } }, "auth_ref": [ "r622" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r415", "r638" ] }, "PBIO_DividendsPaidInKindMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DividendsPaidInKindMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends Paid In Kind [Member]", "documentation": "Dividends Paid In Kind [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r281", "r327", "r328", "r329", "r330", "r331", "r332", "r396", "r428", "r626", "r627", "r634", "r635", "r636" ] }, "PBIO_LenderMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "LenderMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lender [Member]", "documentation": "Lender [Member]" } } }, "auth_ref": [] }, "us-gaap_CollateralDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollateralDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r642", "r643", "r646", "r647", "r648", "r649", "r770", "r774" ] }, "PBIO_IssuanceOfCommonStockForInterestPaidinkind": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "IssuanceOfCommonStockForInterestPaidinkind", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for interest paid-in-kind", "documentation": "Issuance of common stock for interest paid in kind." } } }, "auth_ref": [] }, "PBIO_DebtExtensionMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DebtExtensionMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Extension [Member]", "documentation": "Debt Extension [Member]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r17", "r194", "r247", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r382", "r383", "r384", "r397", "r512", "r619", "r655", "r713", "r756", "r757" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r721" ] }, "PBIO_NewCommonStockIssuancesMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NewCommonStockIssuancesMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Common Stock Issuances [Member]", "documentation": "New Common Stock Issuances [Member]" } } }, "auth_ref": [] }, "PBIO_NewConversionDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NewConversionDebtMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Conversion Debt [Member]", "documentation": "New Conversion Debt [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r35" ] }, "PBIO_ConversionOfPreferredToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConversionOfPreferredToCommonStockMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of Preferred to Common Stock [Member]", "documentation": "Conversion of Preferred to Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from stock option exercises", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r12" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails", "http://pressurebiosciences.com/role/StatementsOfCashFlows", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "verboseLabel": "Total stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "PBIO_SeriesAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesAConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock [Member]", "documentation": "Series A Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PBIO_SeriesAJuniorParticipatingPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesAJuniorParticipatingPreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series A Junior Participating Preferred Stock [Member]", "documentation": "Series A Junior Participating Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r380" ] }, "PBIO_SeriesBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesBConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock [Member]", "documentation": "Series B Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PBIO_SeriesCConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesCConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series C Convertible Preferred Stock [Member]", "documentation": "Series C Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PBIO_SeriesEConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesEConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series E Convertible Preferred Stock [Member]", "documentation": "Series E Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r97", "r128", "r453", "r639", "r695", "r707", "r750" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "PBIO_TwoThousandTwentyOneEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TwoThousandTwentyOneEquityPlanMember", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty One Equity Plan [Member]", "documentation": "Two Thousand Twenty One Equity Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "verboseLabel": "Cumulative effect of adoption, adjustment in accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r94", "r120", "r452", "r468", "r469", "r481", "r515", "r639" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r40", "r41", "r42", "r131", "r132", "r134", "r135" ] }, "PBIO_MrSchumacherMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "MrSchumacherMember", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mr Schumacher [Member]", "documentation": "Mr Schumacher [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "PBIO_LazarevMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "LazarevMember", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lazarev [Member]", "documentation": "Lazarev [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "PBIO_DrsTingMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DrsTingMember", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Drs Ting [Member]", "documentation": "Drs Ting [Member]" } } }, "auth_ref": [] }, "PBIO_CommonStockAndWarrantsIssuedForInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "CommonStockAndWarrantsIssuedForInterest", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock and warrants issued for interest", "documentation": "Common stock and warrants issued for interest." } } }, "auth_ref": [] }, "PBIO_WarrantsToAcquireCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "WarrantsToAcquireCommonStock", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrants to acquire common stock", "documentation": "Warrants to acquire common stock." } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment in Equity Securities", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r457", "r473", "r474", "r475", "r476", "r566", "r567" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r686" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleStockPriceTrigger", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, convertible price per shares", "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective." } } }, "auth_ref": [] }, "PBIO_LossOnExtinguishmentOfLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "LossOnExtinguishmentOfLiabilities", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gain (loss) on extinguishment of liabilities", "documentation": "Loss On Extinguishment Of Liabilities." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Deferred Revenue, Noncurrent", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r687" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r281", "r327", "r328", "r329", "r330", "r331", "r332", "r426", "r427", "r428", "r626", "r627", "r634", "r635", "r636" ] }, "PBIO_OtherDebtUnamortizedDiscountsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "OtherDebtUnamortizedDiscountsNet", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Other debt, unamortized discounts net.", "documentation": "Other debt, unamortized discounts net." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r416", "r638" ] }, "PBIO_DeemedDividendsOnExtensionOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DeemedDividendsOnExtensionOfWarrants", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Deemed dividends on extension of warrants", "documentation": "Deemed dividends on extension of warrants.", "label": "DeemedDividendsOnExtensionOfWarrants" } } }, "auth_ref": [] }, "PBIO_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Noncash Lease Expense." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r413", "r638" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r365" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": [ "r776", "r778", "r779", "r780" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r179", "r180", "r398", "r399", "r400", "r401", "r402", "r403" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ] }, "srt_NorthAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NorthAmericaMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "North America [Member]", "documentation": "Continent of North America." } } }, "auth_ref": [ "r776", "r778", "r779", "r780" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r243", "r681" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfComputationOfLossPerShareDetails", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic net loss per share attributable to common shareholders", "verboseLabel": "Loss per common share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r183", "r203", "r204", "r205", "r206", "r207", "r212", "r215", "r219", "r220", "r221", "r223", "r393", "r394", "r444", "r456", "r618" ] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment owned, at fair value", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r473", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r504", "r505", "r517", "r518", "r560", "r563", "r564", "r565", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r589", "r590", "r591", "r644", "r655", "r771" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r367" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r417" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r47" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r108" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long Term, discount", "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r73", "r76" ] }, "PBIO_TransferredOverAtTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TransferredOverAtTimeMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transferred Over At Time [Member]", "documentation": "Transferred Over At Time [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r337", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r719" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "verboseLabel": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r91", "r298" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r337", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r667", "r669", "r670" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Asia [Member]", "documentation": "Continent of Asia." } } }, "auth_ref": [ "r776", "r778", "r779", "r780" ] }, "PBIO_TwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TwoThousandAndTwentyThreeMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "2023 [Member]", "documentation": "Two Thousand And Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r30", "r108", "r189" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails", "http://pressurebiosciences.com/role/ScheduleOfRightOfUseAssetAndCorrespondingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liabilities", "label": "Total lease liability", "verboseLabel": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r408" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r668" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Contract Balances", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r718" ] }, "PBIO_TwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TwoThousandAndTwentyFourMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureRelatedToPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "2024 [Member]", "documentation": "Two Thousand And Twenty Four [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfRightOfUseAssetAndCorrespondingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Right of use operating lease liability", "verboseLabel": "Right of use liability, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r408" ] }, "PBIO_TopFiveCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TopFiveCustomersMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Top Five Customers [Member]", "documentation": "Top Five Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "verboseLabel": "Convertible preferred stock, authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r91", "r514" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r671" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r211", "r335", "r678", "r679", "r701" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r91", "r514", "r532", "r774", "r775" ] }, "us-gaap_PreferredStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockVotingRights", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock voting rights", "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r55", "r91" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "PBIO_FederalAgenciesMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "FederalAgenciesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Federal Agencies [Member]", "documentation": "Federal Agencies [Member]" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r211", "r335", "r678", "r701" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred revenue and other accrued expenses", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r692" ] }, "PBIO_EmployeeStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "EmployeeStockOptionsMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]", "documentation": "Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r5", "r73", "r105", "r289" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r669" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r78", "r766" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfRightOfUseAssetAndCorrespondingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Right of use operating lease liability long term", "verboseLabel": "Right of use liability, long term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r408" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "verboseLabel": "Convertible preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r91", "r298" ] }, "PBIO_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "CommonStockWarrantsMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Common Stock Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "PBIO_TargetDiscoveryIncMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TargetDiscoveryIncMember", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Target Discovery Inc [Member]", "documentation": "Target Discovery Inc [Member]" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r672" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants issued with debt", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r8", "r49", "r120" ] }, "PBIO_EmployeesOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "EmployeesOfficersMember", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "CEO, other Officers and Employees [Member]", "documentation": "CEO, other Officers and Employees [Member]" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r669" ] }, "PBIO_SeriesHTwoConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesHTwoConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Series H2 Convertible Preferred Stock [Member]", "documentation": "Series H2 Convertible Preferred Stock [Member]", "label": "Series H2 Convertible Preferred Stock [Member] [Default Label]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsAndOtherAdjustments", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Preferred stock dividends", "label": "Preferred Stock Dividends and Other Adjustments", "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders." } } }, "auth_ref": [ "r34", "r676", "r704" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r656" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense, net", "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r75", "r130", "r182", "r230", "r405", "r539", "r653", "r773" ] }, "PBIO_CorporateOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "CorporateOfficeMember", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Corporate Office [Member]", "documentation": "Corporate Office [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r179", "r180", "r398", "r399", "r400", "r401", "r402", "r403" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r66", "r67", "r338" ] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, convertible, threshold percentage of stock price trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r409", "r414" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Borrowed amount", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r15" ] }, "PBIO_MedfordLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "MedfordLeaseMember", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Medford lease [Member]", "documentation": "Medford lease [Member]" } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Real Estate, Type of Property [Axis]", "documentation": "Information by type of real estate property." } } }, "auth_ref": [ "r156", "r165", "r598", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r639" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Land and any structures permanently fixed to it." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r412", "r638" ] }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt default amount", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, "auth_ref": [ "r191" ] }, "PBIO_SparksLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SparksLeaseMember", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sparks lease [Member]", "documentation": "Sparks lease [Member]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r16" ] }, "PBIO_PBIAgrochemIncMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PBIAgrochemIncMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "PBI Agrochem Inc [Member]", "documentation": "PBI Agrochem Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Concentration credit risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r37", "r39", "r70", "r71", "r243" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfLeaseCostForOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r411", "r638" ] }, "PBIO_BattelleMemorialInstituteMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "BattelleMemorialInstituteMember", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Battelle Memorial Institute [Member]", "documentation": "Battelle Memorial Institute [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Trading day", "verboseLabel": "Debt instrument, convertible, threshold trading days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForFees", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments for fees", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, Past Due [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r624", "r708" ] }, "PBIO_CommonStockIssuedInLieuOfCashForDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "CommonStockIssuedInLieuOfCashForDividend", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock issued in lieu of cash for dividend", "documentation": "Common stock issued in lieu of cash for dividend" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r660" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r662" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r63" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r35" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r661" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r244", "r245" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation, period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r369" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, dividend rate, percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r299", "r562", "r569", "r571", "r582" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r198", "r199", "r200", "r224", "r431", "r473", "r493", "r504", "r506", "r507", "r508", "r509", "r510", "r514", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r533", "r536", "r537", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r554", "r645" ] }, "PBIO_PreferredStockIssuedWithDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PreferredStockIssuedWithDebt", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Preferred stock issued with debt", "documentation": "Preferred stock issued with debt." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r663" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r125", "r171", "r194", "r227", "r234", "r238", "r247", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r381", "r383", "r397", "r448", "r526", "r639", "r655", "r713", "r714", "r756" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r665" ] }, "PBIO_DiscountFromWarrantsIssuedWithDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DiscountFromWarrantsIssuedWithDebt", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Discount from warrants issued with debt", "documentation": "Discount from warrants issued with debt." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r195", "r196", "r419", "r420", "r421", "r422", "r506", "r507", "r508", "r509", "r510", "r531", "r533", "r559" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, share,issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Concerning Options and Warrants Outstanding and Exercisable", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r63" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Total Financial Assets", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r69" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfComputationOfLossPerShareDetails", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted net loss per share attributable to common shareholders", "verboseLabel": "Loss per common share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r183", "r203", "r204", "r205", "r206", "r207", "r215", "r219", "r220", "r221", "r223", "r393", "r394", "r444", "r456", "r618" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r664" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investment in equity securities", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r231", "r246", "r685", "r706" ] }, "PBIO_SeriesDConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesDConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series D Convertible Preferred Stock [Member]", "documentation": "Series D Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.01 par value; 100,000,000 shares authorized; 23,399,945 and 13,682,910 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r92", "r451", "r639" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r138", "r172", "r173", "r174", "r194", "r215", "r216", "r219", "r221", "r225", "r226", "r247", "r258", "r260", "r261", "r262", "r265", "r266", "r298", "r299", "r303", "r306", "r313", "r397", "r477", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r514", "r535", "r554", "r592", "r593", "r594", "r595", "r596", "r677", "r693", "r702" ] }, "PBIO_TransferredAtAPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TransferredAtAPointInTimeMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transferred at a Point In Time [Member]", "documentation": "Transferred At A Point In Time [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "PBIO_ConversionOfDebtIntoCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConversionOfDebtIntoCommonStock", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and interest into common stock", "documentation": "Conversion of debt into common stock." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on convertible debt", "label": "Payments on convertible debt", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r28" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r106" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r22", "r48" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r92", "r514" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": [ "r631" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r92", "r514", "r532", "r774", "r775" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseExpirationDate1", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "PBIO_SeriesHConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesHConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series H Convertible Preferred Stock [Member]", "documentation": "Series H Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtConversionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtConversionsTextBlock", "presentation": [ "http://pressurebiosciences.com/role/DebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Convertible Debts and Outstanding Balances", "documentation": "Tabular disclosure of information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The information may be presented entirely or partially in this block of text or in the associated elements." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock option exercise", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r26", "r120" ] }, "PBIO_SeriesGConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesGConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series G Convertible Preferred Stock [Member]", "documentation": "Series G Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "PBIO_SeriesH2ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesH2ConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series H2 Convertible Preferred Stock [Member]", "documentation": "Series H2 Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PBIO_SeriesJConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesJConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series J Convertible Preferred Stock [Member]", "documentation": "Series J Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PBIO_SeriesKConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesKConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series K Convertible Preferred Stock [Member]", "documentation": "Series K Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PBIO_SeriesAAConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesAAConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Series AA Convertible Preferred Stock [Member]", "documentation": "Series AA Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableBilledForLongTermContractsOrPrograms", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfContractBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Receivables, which are included in \u2018Accounts Receivable\u2019", "documentation": "Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract." } } }, "auth_ref": [ "r764" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting for Stock-Based Compensation Expense", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r336", "r343", "r362", "r363", "r364", "r365", "r368", "r373", "r374", "r375", "r376" ] }, "PBIO_SeriesBBConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesBBConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series BB Convertible Preferred Stock [Member]", "documentation": "Series BB Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "PBIO_SeriesCCConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesCCConvertiblePreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series CC Convertible Preferred Stock [Member]", "documentation": "Series CC Convertible Preferred Stock [Member]" } } }, "auth_ref": [] }, "PBIO_NexityGlobalSAMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NexityGlobalSAMember", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nexity Global SA [Member]", "documentation": "Nexity Global SA [Member]" } } }, "auth_ref": [] }, "PBIO_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConsumablesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Consumables [Member]", "documentation": "Consumables [Member]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r43", "r650", "r651", "r652", "r777" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock issued for debt extension", "verboseLabel": "Fair value of dividends paid in kind", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r91", "r92", "r120", "r482", "r554", "r593", "r654" ] }, "PBIO_HardwareMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "HardwareMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Hardware [Member]", "documentation": "Hardware [Member]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r68", "r617" ] }, "PBIO_ContractResearchServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ContractResearchServicesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract Research Services [Member]", "documentation": "Contract Research Services [Member]" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r659" ] }, "PBIO_TechnicalSupportExtendedServiceContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TechnicalSupportExtendedServiceContractsMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Technical Support/Extended Service Contracts [Member]", "documentation": "Technical Support/Extended Service Contracts [Member]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and interest for common stock", "verboseLabel": "Convertible debt issuances value", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r8", "r26", "r120" ] }, "PBIO_SamplePreparationAccessoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SamplePreparationAccessoriesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Sample Preparation Accessories [Member]", "documentation": "Sample Preparation Accessories [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Based Compensation Expense", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r65" ] }, "PBIO_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "OtherMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Other [Member]", "documentation": "Other [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "PBIO_AgrochemProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "AgrochemProductsMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Agrochem Products [Member]", "documentation": "Agrochem Products [Member]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Series AA Preferred Stock dividend", "label": "Stock Issued During Period, Value, Stock Dividend", "documentation": "Value of stock issued to shareholders as a dividend during the period." } } }, "auth_ref": [ "r8", "r26", "r120" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance warrants, shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r314" ] }, "PBIO_ConversionOfPreferredStockForCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConversionOfPreferredStockForCommonStock", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of preferred stock for common stock", "documentation": "Conversion of preferred stock for common stock." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of warrant or right, outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "PBIO_ConversionOfDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConversionOfDebtMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of Debt Extension [Member]", "documentation": "Conversion of Debt Extension [Member]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r658" ] }, "PBIO_IssuanceOfCommonStockSharesForDividendsPaidinkind": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "IssuanceOfCommonStockSharesForDividendsPaidinkind", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for dividends paid-in-kind, shares", "documentation": "Issuance of common stock shares for dividends paid in kind." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r117", "r193", "r297", "r299", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r315", "r391", "r557", "r558", "r597" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r370", "r371", "r372", "r482", "r698", "r699", "r700", "r748", "r774" ] }, "PBIO_ConversionOfDebtAccruedInterestAndAccruedDividendForPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConversionOfDebtAccruedInterestAndAccruedDividendForPreferredStock", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of debt, interest, preferred stock dividend for preferred stock", "documentation": "Conversion of debt accrued interest and accrued dividend for preferred stock." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r38", "r243" ] }, "PBIO_PayrollProtectionProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PayrollProtectionProgramMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Payroll Protection Program [Member]", "documentation": "Payroll Protection Program [Member]" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued, price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "PBIO_SBAMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SBAMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "SBA [Member]", "documentation": "SBA [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r404", "r424" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Products, services, other", "totalLabel": "Total revenue", "verboseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r228", "r229", "r232", "r235", "r236", "r240", "r241", "r243", "r324", "r325", "r431" ] }, "PBIO_NoncashPreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NoncashPreferredStockDividends", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividends", "documentation": "Noncash preferred stock dividends." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r26", "r166", "r179", "r180", "r181", "r198", "r199", "r200", "r202", "r208", "r210", "r224", "r248", "r249", "r315", "r370", "r371", "r372", "r378", "r379", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r398", "r399", "r400", "r401", "r402", "r403", "r418", "r465", "r466", "r467", "r482", "r554" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r333", "r419", "r420", "r506", "r507", "r508", "r509", "r510", "r531", "r533", "r559" ] }, "PBIO_MerchantAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "MerchantAgreementMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Merchant Agreement [Member]", "documentation": "Merchant Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "verboseLabel": "common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from debt - related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r27" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r166", "r198", "r199", "r200", "r202", "r208", "r210", "r248", "r249", "r370", "r371", "r372", "r378", "r379", "r385", "r387", "r388", "r390", "r392", "r465", "r467", "r482", "r774" ] }, "PBIO_PaycheckProtectionProgrammeMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PaycheckProtectionProgrammeMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Paycheck Protection Programme [Member]", "documentation": "Paycheck Protection Programme [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFinancingReceivablesPastDueTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, Past Due [Table]", "documentation": "Disclosure of information about aging analysis for financing receivable." } } }, "auth_ref": [ "r624", "r708" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r404", "r424" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r404", "r424" ] }, "PBIO_OfficersAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "OfficersAndDirectorsMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails" ], "lang": { "en-us": { "role": { "label": "Officers & Directors [Member]", "documentation": "Officers & Directors [Member]" } } }, "auth_ref": [] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "documentation": "Leader of board of directors." } } }, "auth_ref": [ "r705" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL STOCKHOLDERS\u2019 DEFICIT", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r92", "r95", "r96", "r112", "r516", "r532", "r555", "r556", "r639", "r655", "r695", "r707", "r750", "r774" ] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on non-convertible debt", "label": "Repayments of Other Long-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r28" ] }, "PBIO_OtherRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "OtherRelatedPartiesMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails" ], "lang": { "en-us": { "role": { "label": "Other Related Parties [Member]", "documentation": "Other Related Parties [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r404", "r424" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating costs", "label": "Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r101" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r166", "r179", "r180", "r181", "r198", "r199", "r200", "r202", "r208", "r210", "r224", "r248", "r249", "r315", "r370", "r371", "r372", "r378", "r379", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r398", "r399", "r400", "r401", "r402", "r403", "r418", "r465", "r466", "r467", "r482", "r554" ] }, "PBIO_SeriesBBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesBBPreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series BB Preferred Stock [Member]", "documentation": "Series BB Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r81", "r133" ] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ExecutiveOfficerMember", "presentation": [ "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "documentation": "Person with designation of executive officer." } } }, "auth_ref": [ "r705" ] }, "PBIO_SeriesCCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesCCPreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series CC Preferred Stock [Member]", "documentation": "Series CC Preferred Stock [Member]" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": [ "r705" ] }, "PBIO_SeriesCCRestrictedPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesCCRestrictedPreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series CC Restricted Preferred Stock [Member]", "documentation": "Series CC Restricted Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock warrants issued", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] }, "PBIO_SeriesBBRestrictedPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SeriesBBRestrictedPreferredStockMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series BB Restricted Preferred Stock [Member]", "documentation": "Series BB Restricted Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r37", "r39", "r70", "r71", "r243", "r599" ] }, "PBIO_TwoThousandAndTwentyOneEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2021 Equity Incentive Plan [Member]", "documentation": "2021 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on debt - related party", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r28" ] }, "us-gaap_FairValueConcentrationOfRiskTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueConcentrationOfRiskTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Customer Concentration Risk Percentage", "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed." } } }, "auth_ref": [ "r70", "r72", "r123", "r124" ] }, "PBIO_UnvestedStockBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "UnvestedStockBasedAwardsMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested Stock-Based Awards [Member]", "documentation": "Unvested Stock-Based Awards [Member]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments of Senior Debt", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ShippingAndHandlingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShippingAndHandlingMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Shipping and Handling [Member]", "documentation": "Packing and transport of product." } } }, "auth_ref": [ "r720" ] }, "PBIO_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockOptionsMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock Options [Member]", "documentation": "Stock Options [Member]", "label": "Stock Options [Member] [Default Label]" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrealized gain", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r100" ] }, "PBIO_SaleOfCommonStockForCash": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "SaleOfCommonStockForCash", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of Common Stock", "documentation": "Sale of common stock for cash." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r658" ] }, "PBIO_IssuanceOfCommonStockForDividendsPaidinkind": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "IssuanceOfCommonStockForDividendsPaidinkind", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for dividends paid-in-kind", "documentation": "Issuance of common stock for dividends paid in kind." } } }, "auth_ref": [] }, "PBIO_ExercisableOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ExercisableOptionsMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercisable Options [Member]", "documentation": "Exercisable Options [Member]" } } }, "auth_ref": [] }, "PBIO_CommonStockAndWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "CommonStockAndWarrantMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock and Warrant [Member]", "documentation": "Common Stock and Warrant [Member]" } } }, "auth_ref": [] }, "PBIO_AccreditedInvestorAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "AccreditedInvestorAndConsultantsMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accredited Investor and Consultants [Member]", "documentation": "Accredited Investor and Consultants [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r198", "r199", "r200", "r224", "r431", "r473", "r493", "r504", "r506", "r507", "r508", "r509", "r510", "r514", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r533", "r536", "r537", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r554", "r645" ] }, "us-gaap_ProceedsFromLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLoans", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from loans", "documentation": "Cash received from principal payments made on loans related to operating activities." } } }, "auth_ref": [ "r29" ] }, "PBIO_IssuedForServicesRenderedMember": { "xbrltype": "domainItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "IssuedForServicesRenderedMember", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issued For Services Rendered [Member]", "documentation": "Issued For Services Rendered [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r658" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock issued for debt extension, shares", "verboseLabel": "Number of shares issued", "terseLabel": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r91", "r92", "r120", "r477", "r554", "r593" ] }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Costs", "documentation": "The carrying amount of deferred costs." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r658" ] }, "PBIO_StockIssuedWithDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedWithDebt", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock issued with debt", "documentation": "Stock issued with debt." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r19", "r169", "r194", "r247", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r382", "r383", "r384", "r397", "r639", "r713", "r756", "r757" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock issued with debt", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in principal amount", "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period." } } }, "auth_ref": [ "r694" ] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, convertible, conversion price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r300" ] }, "us-gaap_ProfessionalAndContractServicesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalAndContractServicesExpense", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Professional and contract services expense", "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued employee compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r675" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Sale of common stock for cash", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestorMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Investor [Member]", "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value." } } }, "auth_ref": [ "r752", "r753" ] }, "srt_RealEstateAndAccumulatedDepreciationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationLineItems", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ] }, "srt_RealEstateAndAccumulatedDepreciationByPropertyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationByPropertyTable", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table]", "documentation": "Disclosure of information about real estate investments and accompanying accumulated depreciation for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares of restricted common stock", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r8", "r120" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r20", "r74", "r296", "r406" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest Rate", "label": "Debt interest rate", "terseLabel": "Debt instrument, interest rate, stated percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r20", "r269" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r138", "r172", "r173", "r174", "r194", "r215", "r216", "r219", "r221", "r225", "r226", "r247", "r258", "r260", "r261", "r262", "r265", "r266", "r298", "r299", "r303", "r306", "r313", "r397", "r477", "r478", "r479", "r480", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r514", "r535", "r554", "r592", "r593", "r594", "r595", "r596", "r677", "r693", "r702" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r156", "r165", "r241", "r242", "r496", "r498", "r500", "r563", "r570", "r576", "r590", "r598", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r614", "r632", "r644", "r719", "r768" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDateDescription", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument, maturity date description", "verboseLabel": "Debt instrument maturity date description", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": [ "r21" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r642", "r643", "r644", "r646", "r647", "r648", "r649", "r698", "r699", "r748", "r770", "r774" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r113", "r252", "r253", "r600", "r710" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r705", "r754" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock option exercise, shares", "negatedLabel": "Shares, Exercised", "verboseLabel": "Shares isused for options exercised, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r91", "r92", "r120", "r349" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument, maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r136", "r625", "r749" ] }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from non-convertible debt - third party", "documentation": "Amount of cash inflow from issuance of long-term debt classified as other." } } }, "auth_ref": [ "r27" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and interest for common stock, shares", "verboseLabel": "Convertible debt issuances shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r8", "r25", "r55", "r120", "r284" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r380" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r447", "r454", "r639" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Related to Performance Obligations", "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [ "r680" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventories, net of $905,759 and $982,973 reserve, respectively", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r175", "r616", "r639" ] }, "us-gaap_InterestAndDividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDividendsPayableCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued interest and dividends payable", "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://pressurebiosciences.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r84" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails" ], "lang": { "en-us": { "role": { "label": "Other debt, net of unamortized discounts of $0 and $0, respectively", "verboseLabel": "Short Term, Principal", "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r88", "r89", "r511" ] }, "us-gaap_DebtConversionConvertedInstrumentRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentRate", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Rate", "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/DebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Debt", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r22", "r197", "r268", "r269", "r270", "r271", "r272", "r274", "r279", "r280", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r406", "r625", "r626", "r627", "r628", "r629", "r694" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining term", "verboseLabel": "Number of years option vested", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r121" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionOriginalDebtInterestRateOfDebt", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Original debt, interest rate of debt", "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r31", "r33" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Geographical area." } } }, "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r241", "r242", "r496", "r498", "r500", "r563", "r570", "r576", "r590", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r614", "r632", "r644", "r719", "r768" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfRightOfUseAssetAndCorrespondingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Right of use asset operating leases", "verboseLabel": "Right of use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r407" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock liquidation Preference value", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r55", "r56", "r91", "r693", "r717" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of products and services", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r102", "r431" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r168", "r176", "r194", "r247", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r381", "r383", "r397", "r639", "r713", "r714", "r756" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected life", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r364" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "verboseLabel": "Cumulative effect of adoption, adjustment in additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r93", "r639", "r772" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument periodic payment", "verboseLabel": "Totals, Principle", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r22" ] }, "PBIO_IssuanceOfCommonStockSharesForInterestPaidinkind": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "IssuanceOfCommonStockSharesForInterestPaidinkind", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for interest paid-in-kind, shares", "documentation": "Issuance of common stock shares for interest paid in kind." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Closing stock price", "verboseLabel": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheetsParenthetical", "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Debt instrument, unamortized discount", "verboseLabel": "Debt unamortized discount", "terseLabel": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r73", "r76", "r716" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r333", "r419", "r420", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r506", "r507", "r508", "r509", "r510", "r531", "r533", "r559", "r755" ] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r99" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Assumptions for Grants of Stock Options", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r9" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r186" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetails", "http://pressurebiosciences.com/role/ScheduleOfPreferredStockOutstandingDetailsParenthetical", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r172", "r173", "r174", "r225", "r298", "r299", "r301", "r303", "r306", "r311", "r313", "r477", "r478", "r479", "r480", "r630", "r677", "r693" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r240", "r431", "r458", "r459", "r460", "r461", "r462", "r463", "r613", "r631", "r640", "r684", "r711", "r712", "r719", "r768" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LONG TERM LIABILITIES" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r326", "r334", "r365", "r366", "r367", "r429", "r430", "r464", "r502", "r503", "r561", "r568", "r572", "r573", "r581", "r610", "r611", "r621", "r630", "r637", "r641", "r644", "r709", "r715", "r759", "r760", "r761", "r762", "r763" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails", "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r642", "r643", "r646", "r647", "r648", "r649" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://pressurebiosciences.com/role/Debt" ], "lang": { "en-us": { "role": { "label": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r114", "r191", "r267", "r273", "r274", "r275", "r276", "r277", "r278", "r283", "r290", "r291", "r293" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r137", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r612" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r240", "r431", "r458", "r459", "r460", "r461", "r462", "r463", "r613", "r631", "r640", "r684", "r711", "r712", "r719", "r768" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r334", "r430", "r464", "r502", "r503", "r561", "r568", "r572", "r573", "r581", "r610", "r611", "r621", "r630", "r637", "r641", "r715", "r758", "r759", "r760", "r761", "r762", "r763" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock number of shares received", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average price per share, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r348" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r326", "r334", "r365", "r366", "r367", "r429", "r430", "r464", "r502", "r503", "r561", "r568", "r572", "r573", "r581", "r610", "r611", "r621", "r630", "r637", "r641", "r644", "r709", "r715", "r759", "r760", "r761", "r762", "r763" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "PBIO_ConvertibleLesserPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConvertibleLesserPerShare", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible lesser per share", "documentation": "Convertible lesser per share." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails", "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetailsParenthetical", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative", "http://pressurebiosciences.com/role/SummaryOfAssumptionsForGrantsOfStockOptionsDetails", "http://pressurebiosciences.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r334", "r430", "r464", "r502", "r503", "r561", "r568", "r572", "r573", "r581", "r610", "r611", "r621", "r630", "r637", "r641", "r715", "r758", "r759", "r760", "r761", "r762", "r763" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average price per share, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r349" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Totals", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r13", "r127", "r294" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets", "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails" ], "lang": { "en-us": { "role": { "label": "Related party, net of unamortized debt discount of $514 and $7,915, respectively", "verboseLabel": "Net, Principal", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r18", "r639" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r227", "r233", "r237", "r239", "r620" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "PBIO_ConversionOfCommonStockForPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConversionOfCommonStockForPreferredStock", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of common stock for preferred stock", "documentation": "Conversion of common stock for preferred stock." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LONG TERM LIABILITIES", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r13", "r85", "r86", "r87", "r90", "r194", "r247", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r382", "r383", "r384", "r397", "r713", "r756", "r757" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average price per share, Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r351" ] }, "PBIO_NonConvertibleDebtInstrumentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "NonConvertibleDebtInstrumentAmount", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Non- convertible debt amount", "documentation": "Non convertible debt instrument amount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleCommonStockMember", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Common Stock [Member]", "documentation": "Common stock securities that may be converted to another form of security." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConcerningOptionsAndWarrantsOutstandingAndExercisableDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average price per share, Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r350" ] }, "PBIO_ConvertibleLesserDiscountPercent": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ConvertibleLesserDiscountPercent", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible lesser Percent", "documentation": "Convertible lesser discount percent." } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) on extinguishment of debt", "label": "Losses on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r50", "r51" ] }, "PBIO_AccruedInterestRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "AccruedInterestRatePercent", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accrued interest rate percent", "documentation": "Accrued interest rate percent." } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, capital shares reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r24" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r103", "r537" ] }, "PBIO_DeferredInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DeferredInterest", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfOtherDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Deferred interest", "documentation": "Deferred Interest." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r243", "r633", "r719", "r768", "r769" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails", "http://pressurebiosciences.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r683", "r692" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r107" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "PBIO_DebtOriginalIssueDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DebtOriginalIssueDiscount", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original issue discount", "documentation": "Debt original issue discount." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r82", "r377", "r765" ] }, "PBIO_DebtInstrumentPeriodicPaymentPrincipalGross": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DebtInstrumentPeriodicPaymentPrincipalGross", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfRelatedPartyDebtDetails" ], "lang": { "en-us": { "role": { "label": "Discount, Principal", "documentation": "Debt instrument periodic payment principal gross." } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services", "verboseLabel": "Number of common stock for services rendered", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit", "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative", "http://pressurebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, shares", "verboseLabel": "Number of common stock for services rendered, shares", "terseLabel": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://pressurebiosciences.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r689" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r37", "r39", "r70", "r71", "r243", "r599" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r674" ] }, "PBIO_PercentageOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PercentageOfOutstandingShares", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstanding shares, precentage", "documentation": "Percentage of outstanding shares." } } }, "auth_ref": [] }, "PBIO_PreferredStockOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "PreferredStockOutstandingPercentage", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock remain outstanding percentage", "documentation": "Preferred stock outstanding percentage." } } }, "auth_ref": [] }, "PBIO_StockIssuedWithDebtShares": { "xbrltype": "sharesItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "StockIssuedWithDebtShares", "presentation": [ "http://pressurebiosciences.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Stock issued with debt, shares", "documentation": "Stock issued with debt shares." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r243", "r633", "r719", "r768", "r769" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfCustomerConcentrationRiskPercentageDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r37", "r39", "r70", "r71", "r243", "r470", "r599" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r666" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease monthly payments", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r3" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://pressurebiosciences.com/role/DebtDetailsNarrative", "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Principal balance", "verboseLabel": "Debt instrument, face amount.", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r74", "r76", "r268", "r406", "r626", "r627" ] }, "PBIO_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options outstanding and exercisable intrinsic value", "documentation": "Aggregate intrinsic value of options outstanding and exerciasable." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r673" ] }, "PBIO_DebtInstrumentConvertibleBeneficallyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://pressurebiosciences.com/20230930", "localname": "DebtInstrumentConvertibleBeneficallyPercentage", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument convertible benefically percentage", "documentation": "Debt instrument convertible benefically percentage." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock and warrants issued for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://pressurebiosciences.com/role/BusinessOverviewLiquidityAndManagementPlans" ], "lang": { "en-us": { "role": { "label": "Business Overview, Liquidity and Management Plans", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r83", "r122", "r471", "r472" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Unrealized gain (loss) on investment in equity securities", "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r546", "r547", "r586", "r587", "r588", "r690", "r691" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of interest and amortization of debt discount", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r110" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfComputationOfLossPerShareDetails", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares of common stock outstanding, diluted", "verboseLabel": "Weighted average common stock shares outstanding diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r214", "r221" ] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Rental Payments Required Under Operating Leases", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r696" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r99" ] }, "us-gaap_DebtInstrumentConvertibleConversionPriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPriceDecrease", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument, convertible, conversion price, decrease", "documentation": "Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r282", "r314" ] }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://pressurebiosciences.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain)/Loss on investment in equity securities", "label": "Debt and Equity Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt and equity securities." } } }, "auth_ref": [ "r540", "r541", "r583", "r584", "r585", "r690", "r691" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r657" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r658" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfFutureMinimumRentalPaymentsRequiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "October 1 \u2013 December 31, 2023", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r697" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfComputationOfLossPerShareDetails", "http://pressurebiosciences.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares of common stock outstanding, basic", "verboseLabel": "Weighted average common stock shares outstanding basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r212", "r221" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Strike price, per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r314" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r658" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPriceIncrease", "presentation": [ "http://pressurebiosciences.com/role/ScheduleOfConvertibleDebtsAndOutstandingBalancesDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument, convertible, conversion price, Increase", "documentation": "Per share increase in conversion price of debt instrument. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r282", "r314" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://pressurebiosciences.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lease Cost for Operating Leases", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r751" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://pressurebiosciences.com/role/StockholdersDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pressurebiosciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-22" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "940", "SubTopic": "320", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481961/940-320-45-5" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-23" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(4)", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(5)", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(1)(i)", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(1)(ii)", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Subsection": "Instruction 5", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(4)", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(5)", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(c)", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r676": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r677": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r679": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 67 0001493152-23-042131-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-042131-xbrl.zip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�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�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�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end